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Abstract 
Type 2 diabetes (T2DM) is a risk factor for periodontal disease, however the 
pathogenic links between the two disease are not completely understood. Both diseases 
are considered to be inflammatory conditions and, therefore, cytokines are likely to play 
a role in the shared susceptibility between the two diseases. Therefore, the study 
evaluated, longitudinally over 12 months, the impact of periodontal therapy on clinical 
outcomes, glycaemic control, hsCRP, lipids and local and systemic levels of IL-6, TNF-
α, IL-1β and IFN-γ in patients with T2DM.  
101 T2DM and 83 non-diabetic subjects were recruited and, of these, 
periodontitis was diagnosed in 47 T2DM and 48 non-diabetic subjects. Pre-treatment, 
subjects with T2DM had significantly higher BMI and significantly lower systolic BP 
and cholesterol compared to non-diabetic subjects. Serum levels of TNF-α, IL-1β and 
IFN-γ were significantly higher in subjects with T2DM compared to non-diabetic 
subjects. Regardless of diabetic status, GCF and salivary levels of IL-1β were 
significant predictors of the clinical periodontal condition.  
In T2DM and non-diabetic subjects, all clinical periodontal outcomes were 
significantly improved at 3, 6 and 12 months following NSM and both groups 
demonstrated significant reductions in GCF IL-1β levels at 3, 6 and 12 months. In non-
diabetic subjects, a significant reduction in non-HDL and cholesterol was seen 6 months 
after NSM. In subjects with T2DM, serum TNF-α was significantly reduced 3 and 6 
months after NSM. In subjects with T2DM, HbA1c showed 0.45% and 0.40% 
reductions at 3 and 12 months after NSM, although these reductions did not achieve 
statistical significance. 
Abstract XVII
In conclusion, periodontal therapy led to significant reductions in GCF IL-1β in 
all subjects, and also produced a significant reduction in circulating levels of TNF-α in 
subjects with T2DM. Furthermore, IL-1β in saliva and GCF appear to be good 
prognostic markers for periodontitis regardless of diabetes status. 
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1 Introduction 1
Chapter 1 Introduction 
1.1 Periodontal disease 
1.1.1 Definition and classification of periodontal disease 
Periodontal disease is a bacterially-induced chronic inflammatory disorder 
affecting the supporting structures of the teeth. Accumulation of bacterial plaque and 
the development of a dysregulated, destructive host immune-inflammatory response 
leads to pocket formation, loss of connective tissue attachment, alveolar bone 
destruction and tooth loss.  
A classification for periodontal disease is necessary in order to provide a 
framework for both the effective clinical management of patients and the 
implementation of robust research methodologies. The provision of a clinical diagnosis, 
based on a widely accepted classification system, guides the allocation of treatment. In 
this way, a classification provides the basis for the differentiation of clinical treatment, 
influencing the way in which patients are managed. Similarly, a classification system 
used for research, allocates subjects into groups based on the presence or absence of 
disease. This also affects the clinical management of the patient but importantly may 
also influence the conclusions drawn from research. In this way, the dogma relating to 
the aetiology, pathogenesis and management of periodontal disease is intimately 
influenced by the classification of periodontal disease within research studies.  
In line with developments and changes to the understanding of the aetiology and 
pathogenesis of periodontal disease, a classification system for periodontal disease must 
be revised and updated. Published classifications will at best represent a consensus view 
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of experts within the field of periodontology. Currently, well recognised criteria are 
available to assist in the clinical management of patients (Armitage, 1999).  
The current clinical classification system was formulated and published over a 
decade ago following the International Workshop for a Classification of Periodontal 
Disease and Conditions (Armitage, 1999). This extensive and detailed classification 
system, although cumbersome, provides clinicians with a way to begin to organise the 
healthcare needs of patients (Table 1.1).  
With regards to the classification of periodontal disease for research there is, 
however, a lack of consistency within the literature of what constitutes periodontal 
disease. Some studies have very low thresholds for defining the presence of 
periodontitis whereas others have much higher thresholds. The recognition of the need 
for a clear definition of what constitutes a periodontal case for research purposes is not 
new. Indeed, two separate criteria for periodontal case definition have been proposed by 
two different working groups (Table 1.2), firstly, the 5th European Workshop in 
Periodontology (Tonetti and Claffey, 2005) and secondly the American Academy of 
Periodontology (Page and Eke, 2007). However, inconsistent use ensures this continues 
to be a contentious and currently unresolved issue (Meisel and Kocher, 2009; Preshaw, 
2009). 
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Table 1.1  Overview of the classification of periodontal diseases  
I. Gingival Diseases 
A. Dental plaque-induced gingival diseases 
B. Non-plaque-induced gingival lesions 
II. Chronic Periodontitis 
III.  Aggressive Periodontitis 
IV. Periodontitis as a Manifestation of Systemic Diseases  
V. Necrotising Periodontal Diseases 
VI. Abscesses of the Periodontium 
VII. Periodontitis Associated with Endodontic Lesions 
VIII. Developmental or Acquired Deformities & Conditions 
The classification of periodontal disease and conditions provides a framework for 
management of patients and case definition for research purposes. The table shows a 
classification of periodontal disease that is modified from the International Workshop 
for a Classification of Periodontal Disease and Conditions (Armitage, 1999). 
 
Table 1.2 Case definition of periodontal disease in research  
 
 
5th European Workshop 
(Tonetti and Claffey, 2005) 
 
 
American Academy 
(Page and Eke, 2007) 
 
 
Incipient / moderate 
periodontitis 
 
Presence of proximal 
attachment loss of ≥ 3mm in ≥2 
non-adjacent teeth. 
 
Presence of ≥ 2 interproximal 
sites with attachment loss of 
≥4mm (not on same tooth) or 
≥ 2 interproximal sites with 
probing depths ≥ 5mm (not 
on same tooth). 
 
 
Substantial / severe 
periodontitis 
 
Presence of proximal 
attachment loss of ≥ 5mm in 
≥30% of teeth present. 
 
Presence of ≥ 2 interproximal 
sites with attachment loss of 
≥6mm (not on same tooth) 
and ≥ 1 interproximal site 
with probing depths ≥ 5mm 
 
Currently within the published literature a lack of consistency exists with regards to the 
definition of what constitutes a periodontal case. The table shows two different case 
definitions of periodontal disease that have been proposed for use in research (Tonetti 
and Claffey, 2005; Page and Eke, 2007). 
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Although, both these case definitions use loss of attachment (LOA) at 
interproximal sites of non-adjacent teeth as the main measurement, there is recognition 
that periodontal disease cannot be detected by measurement of a single variable. LOA, 
whilst a measure of cumulative lifetime experience of periodontitis, provides little 
information of the current condition of the periodontal tissue attachment loss and 
therefore, must be supplemented by additional measurements of bleeding on probing 
and probing depth. In addition, both criteria recognise the need to take into account the 
potential error inherent in measuring attachment loss, to avoid including cases without 
periodontitis. Thus, the threshold for interproximal LOA was set at ≥ 6 mm (Page and 
Eke, 2007) or ≥ 5 mm (Tonetti and Claffey, 2005). 
Given that the American Academy of Periodontology’s definition of ‘severe 
periodontitis’ only requires a minimum of two teeth with 6mm attachment loss and one 
tooth with a probing depth of 5 mm (Page and Eke, 2007), it would seem possible that 
based on this definition, a subject could be included into a study with only minimal 
levels of disease or attachment loss caused by overhanging restorations or the distal 
aspect of second molars where a third molar has been extracted. Obviously, having a 
high threshold of inclusion into a study must be weighed against an ethical issue of 
missing periodontal cases, however, if the main aim of a periodontal case definition is 
to provide a robust basis for research, there is a clear need to ensure that the cases that 
are included within studies have suitable levels of disease to ensure valid conclusions 
can be made. With regards to identifying subjects with substantial extent and severity of 
periodontal disease, it would appear that the 5th European Workshop in Periodontology 
(Tonetti and Claffey, 2005) provides more robust inclusion criteria, requiring subjects to 
have interproximal attachment loss of ≥ 5 mm in ≥ 30% of teeth present.  
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To supplement conventional classification of periodontal disease, studies 
investigating the links between periodontitis and systemic disease have also attempted 
to quantify the surface area of inflamed periodontal tissue using clinical attachment 
level, recession and bleeding on probing (BOP) (Hujoel et al., 2001), with previous 
studies using calculated values for periodontal epithelial surface area (PESA) and 
periodontal inflamed surface area (PISA) to investigate the condition of the periodontal 
tissues (Nesse et al., 2008; Nesse et al., 2009). In this way, quantifying periodontal 
disease on a continuous scale not only avoids the use of an arbitrary cut off point for 
periodontal case definition but also fits within the biological model that the greater the 
inflammatory burden from the periodontal tissues, the greater the contribution to 
systemic conditions beyond the oral cavity (D'Aiuto et al., 2004; Nesse et al., 2009). 
In a recent study, the accuracy of periodontitis prevalence determined by partial 
mouth periodontal examinations compared to full mouth ‘gold standard’ periodontal 
examinations was evaluated. It was found that the partial examinations substantially 
under-estimated the prevalence of periodontal disease by at least 50%, leading to high 
levels of misclassification of periodontal cases (Eke et al., 2010). Furthermore, the 
impact of using different periodontal definitions was recently investigated within a 
study that reanalysed data from a cohort study of 1296 pregnant women (Manau et al., 
2008). Within the original study, logistic regression analyses for variables influencing 
adverse pregnancy outcomes showed that after adjusting for confounding variables, a  
statistically significant association was found  between preterm birth and the presence 
of periodontal disease (odds ratio 1.77; 95% confidence interval: 1.08–2.88) (Agueda et 
al., 2008). Within the reanalysis of data, 14 different periodontitis definitions were 
applied. Using the same analysis, only 5 of the 14 tested definitions of periodontitis 
resulted in a statistically significant association with premature birth (Manau et al., 
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2008). This clearly shows that the variation in odds ratios can be attributed to the use of 
different definitions of what constitutes a periodontal case, thus, highlighting the 
importance of having a robust and widely accepted definition of periodontal disease for 
research. In addition to ensuring valid conclusions can be drawn from individual 
studies, this will also facilitate meta-analyses of studies, allowing more powerful 
conclusions to be drawn from a body of published research. 
1.1.2 Epidemiology of periodontitis 
Epidemiological studies over the past twenty years have attempted to provide 
information concerning the extent and severity to which periodontal disease affects the 
population. The most recent 2009 UK Adult Dental Health Survey (ADHS) reported 
that approximately 66% of the adults aged 55 and above have moderately advanced 
chronic periodontitis (with attachment loss ≥ 4 mm) and 25% have severe periodontitis 
(attachment loss ≥ 6 mm) (White et al., 2011). This highlights that periodontal disease 
remains common at a low level, with more severe disease concentrated in a relatively 
small proportion of the UK population (Steele and O’ Sullivan, 2011). The same study 
found that visible plaque and calculus were present in 66% and 68% of adults, 
respectively (Chadwick et al., 2011; Steele and O’ Sullivan, 2011). Similar data have 
been reported in studies in different populations. For example, a study of 7,447 dentate 
individuals in the USA found that, whilst over 90% of people aged 13 or over had 
experienced some loss of attachment, only 15% exhibited more severe destruction 
(attachment loss ≥ 5 mm) (Brown et al., 1996). A study of Tanzanian adults found that, 
whilst there were abundant plaque and calculus deposits, with ubiquitous gingivitis, 
pockets > 3 mm and attachment loss > 6 mm occurred at less than 10% of tooth 
surfaces. In addition, 75% of the tooth sites with attachment loss ≥ 7 mm were found in 
31% of subjects (Baelum et al., 1986).  
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Data from a large study of 9698 subjects in the USA, using pre-defined criteria 
for case definition, supports the view that although mild periodontitis is widespread, 
moderate to severe periodontitis affects a relatively small proportion of the population 
3.1-9.5% (Albandar et al., 1999). Interestingly, however, a different study of 853 
dentate individuals in Brazil employing full mouth probing assessments at six sites per 
tooth (Susin et al., 2004) reported a much higher prevalence of advanced periodontal 
disease, with 52% exhibiting severe destruction (attachment loss ≥ 7 mm). Also, a more 
recent epidemiological study indicates that since the 1980s, the prevalence of severe 
periodontitis in the USA may have decreased from 7.3% to 4.2% (Borrell et al., 2005). 
Despite this being lower than the prevalence estimates for advanced periodontal disease 
cited in the 1950s and 1960s (Marshall-Day et al., 1955), it still represents a significant 
number of adults who suffer from periodontal disease and who may ultimately 
experience tooth mobility and tooth loss. 
Differences between prevalence rates for periodontal disease reported over the 
last 60 years may be related to methodological differences, for example, full mouth 
versus part mouth assessments and the use of various case definitions. There have also 
been clear improvements in periodontal health awareness and improved provision of 
dental care (Steele and O’ Sullivan, 2011). In addition, within Western populations, the 
last 40 years has seen a decline in the percentage of people who smoke (Pierce, 1989; 
Molarius et al., 2001). Given the importance of smoking as a risk factor for periodontal 
disease (Kinane and Chestnutt, 2000) with 50% of periodontal disease being attributed 
to smoking (Tomar and Asma, 2000), it is likely that a reduction in the number of 
smokers will have contributed to decreasing prevalence rates of periodontitis. 
Data gathered from large cross-sectional studies have shaped our understanding 
of the prevalence of periodontal disease in the population. Notwithstanding the impact 
1 Introduction 8
of methodology and disparities in the definition of periodontitis, it would appear that 
whilst gingivitis and mild-moderate periodontitis are relatively common, severe 
periodontitis is less prevalent, usually not exceeding 10% of the population, despite 
plaque being a common finding in the majority of people.  
1.1.3 Pathogenic mechanisms in periodontitis 
Within periodontitis, the microbial dental plaque biofilm initiates a host 
inflammatory immune reaction within the periodontal tissues. The inflammatory 
reaction is not only visible clinically in the affected periodontium but the 
histopathological features have also been well described (Page and Schroeder, 1976). 
Within the periodontium, the inflammatory and immune processes primarily function to 
protect the tissues against microbes and their products, which persist on the tooth 
surface within a complex biofilm community. The host defence reactions, however, also 
cause damage within the surrounding tissue, contributing to the tissue destruction 
observed in periodontitis.  
1.1.3.1 Initiating role of dental plaque biofilm 
Dental plaque is a microbial biofilm. Biofilms are defined as “matrix-enclosed 
bacterial populations adherent to each other and/or to surfaces” (Costerton et al., 1994; 
Socransky and Haffajee, 2002). Oral bacteria bind to a pellicle formed from saliva and 
gingival crevicular fluid and to one another in a highly specific succession of species. In 
periodontally healthy sites, the dental plaque biofilm consists mostly of Gram-positive 
bacterial species, with approximately 15% Gram-negative species found and, in 
contrast, periodontally diseased sites show an increase in the proportion of Gram-
negative species to up to 50% (Tanner et al., 1996). Accompanying this compositional 
microbial transition from health to disease is an increase in total bacterial numbers from 
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approximately 102-103 bacteria during health, 104-106 during gingivitis and escalating as 
high as 105-108 during periodontitis (Tanner et al., 1996).  
It is widely accepted that bacteria in the dental plaque biofilm initiate the 
inflammatory immune response seen within the periodontal tissues. However, not all 
dental biofilms result in periodontal destruction and to highlight this a consensus report 
of the 1996 World Workshop on Clinical Periodontics concluded that Porphyromonas 
gingivalis (P.gingivalis), Aggregatibacter actinomycetemcomitans (A. 
actinomycetemcomitans) (previously known as Actinobacillus actinomycetemcomitans) 
and Tannerella forsythia (T.forsythia) (previously known as Bacteroides  forsythus) 
should be considered as major periodontal pathogens (Zambon, 1996) with the 
subsequent recognition that Fusobacterium nucleatum (F. nucleatum) is also part of this 
group (Teles et al., 2006). Indeed, molecular techniques and cluster analysis of 
subgingival plaque have demonstrated that certain species frequently occur together in 
‘complexes’ (Figure 1.1) and confirmed a strong association between P.gingivalis 
(described as a red complex microorganism) and deeper pocket depths and increased 
levels of bleeding on probing in periodontal disease (Socransky et al., 1998). In a 
further study, plaque samples from patients with periodontitis tend to contain an 
increased proportion of red and orange complex species of bacteria compared to plaque 
from periodontally healthy patients (Ximenez-Fyvie et al., 2000). In addition, the 
relationship between orange and red complex species clinical measures of periodontitis 
is also mirrored for supragingival plaque samples (Haffajee et al., 2008).  However, 
these named periodontal pathogens have also been detected in periodontally healthy 
subjects (Loomer, 2004; Sanz and Quirynen, 2005), highlighting the complex interplay 
between the bacterial challenge and the host response that is involved in periodontal 
disease.  
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Figure 1.1  Overview of microbial Complexes in subgingival plaque  
 
 
 
 
 
 
 
 
Certain microbial species in subgingival plaque have been found to frequently occur 
together in ‘complexes’ The figure shows a diagrammatical representation of these 
‘complexes’ (Socransky et al., 1998). 
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The dental plaque biofilm provides a diverse source of antigens, including 
lipopolysaccharides (LPS), leukotoxin, lipoteichoic acid and peptidoglycan, fimbriae 
and extracellular enzymes (Travis et al., 1997; Fives-Taylor et al., 1999). This bacterial 
challenge causes direct damage and stimulates the immune-inflammatory response 
within the periodontal tissues. For example, cysteine proteinases (gingipains) produced 
by P.gingivalis contribute to tissue destruction and facilitate the invasion of bacteria 
into the host tissues (Genco et al., 1999; Imamura, 2003; Andrian et al., 2004), 
additionally, LPS of gram-negative bacteria, such as P.gingivalis, stimulates the host 
response via specific host receptors (Dixon et al., 2004).  
Clearly, studies over the past 20 years have confirmed the initiating role of 
bacteria in the pathogenesis of periodontal disease, identifying a limited number of 
specific bacterial species that have been associated with severe disease (Tanner et al., 
1996; Socransky et al., 1998). However, differences in disease experience between 
individuals are not always matched with microbiological factors and individuals may 
harbour organisms without showing progressive periodontal destruction (Cullinan et al., 
2003). Therefore, although periodontitis appears to be related to the presence of certain 
pathogenic species in the subgingival microflora (Socransky et al., 1998; Haffajee et al., 
2008) the presence of a pathogenic microflora alone is insufficient to cause periodontal 
disease. The bacteria-host interaction and the nature of the subsequent host immune-
inflammatory response play a critical role in the development and progression of 
periodontal disease. 
1.1.3.2 Host response 
The histological characteristics of the inflammation that develops in the 
periodontal tissues following the formation of the dental plaque biofilm has been well 
defined (Page and Schroeder, 1976). Blood vessels within the periodontal tissues dilate, 
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become more permeable, fluid and migrating defence cells accumulate within the 
tissues at the site of infection. In an attempt to remove the bacterial challenge, large 
numbers of neutrophils and later lymphocytes accumulate in the periodontal tissues and 
migrate through the junctional epithelium into the periodontal pocket (Page and 
Schroeder, 1976). The persistence of the dental plaque biofilm, however, leads to a 
continuing cycle of microbial challenge and host inflammatory immune responses. 
Therefore, in addition to the tissue damage caused directly by bacteria, resident tissue 
cells and infiltrating host defence cells contribute to connective tissue breakdown and 
alveolar bone loss (Bartold and Narayanan, 2006).   
In vitro experiments indicate that host cells respond to bacteria by activating 
intra-cellular signalling pathways leading to cytokine secretion (Handfield et al., 2008). 
The activation of the host response to the dental plaque biofilm is dependent on the host 
cells’ ability to recognise the presence of bacteria and their products. A diverse 
collection of specific host receptors enables host cells within the periodontal tissues to 
recognise microbe-associated molecular patterns (MAMPs). Consequently, the host is 
able to orchestrate an immune-inflammatory response that reflects the bacterial 
challenge (Dixon and Darveau, 2005). Examples of MAMPs, important in periodontal 
disease pathogenesis, include bacterial LPS and fimbriae which are recognised via 
receptors such as soluble LPS binding protein, membrane-associated CD14 and Toll-
like receptors (TLRs).  
In vitro experiments have shown that whole periodontal bacteria stimulate the 
secretion of a range of pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, IL-8 and 
IL-12 (Sandros et al., 2000; Kusumoto et al., 2004). Furthermore, activation of TLRs by 
periodontal pathogens has been shown to induce the release of a similar range of 
inflammatory cytokines and antimicrobial proteins from host cells (Jotwani et al., 2003; 
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Dixon et al., 2004; Eskan et al., 2007; Eskan et al., 2008), highlighting the important 
role of host cell receptors in the inflammatory immune response within periodontal 
disease. Therefore, the activation of specific receptors by bacterial MAMPs allows the 
periodontal tissues to direct an inflammatory-immune response that is appropriate to the 
bacterial challenge present within the dental plaque biofilm. It is however paradoxical 
that these defensive processes result in the majority of tissue damage leading to the 
clinical manifestations of periodontal disease. 
Neutrophils [polymorphonuclear leukocytes (PMNs)] are critical components of 
the innate immune system and are essential to maintain periodontal health in the face of 
a constant bacterial challenge from the dental plaque biofilm. PMNs serve a protective 
function through their ability to phagocytose and kill microorganisms. The vital role of 
PMNs in innate immunity is highlighted by congenital defects such as Chediak-Higashi 
syndrome and leukocyte adhesion deficiency syndrome, in which genetic abnormalities 
alter PMN functional responses, leading to recurrent microbial infection and also severe 
periodontal disease (Lekstrom-Himes and Gallin, 2000). However, along with 
protecting the periodontium from microbial invasion, PMNs release potent lysosomal 
enzymes, cytokines and reactive oxygen species (ROS) that can be destructive to the 
periodontal tissues (Van Dyke and Vaikuntam, 1994; Johnstone et al., 2007). 
Furthermore, it has been suggested that contributing to the destructive process in 
periodontitis is neutrophil hyperactivity leading to overproduction and release of 
antimicrobial and potentially tissue-damaging reactive oxygen species (ROS) 
(Fredriksson et al., 2003). In the absence of exogenous stimulation, peripheral blood 
neutrophils from persons with chronic periodontitis demonstrate an increase in 
extracellular ROS release in vitro (Matthews et al., 2007).  
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The persistent nature of the dental plaque biofilm results in the activation of the 
adaptive immune response, leading to the recruitment T and B cells into the periodontal 
tissue (Page and Schroeder, 1976). An appropriate adaptive immune response to the 
continued microbial challenge relies on a balanced production, by the host tissues, of 
different subsets of T cells. The production of Th1 cells leads to cell mediated immune 
response, with the activation of macrophages and the induction of B cells to produce 
opsonising antibodies, which facilitates bacterial killing. On the other hand, the 
production of predominately Th2 cells provides humoural immunity, with activation of 
B cells to produce neutralising antibodies.  
Th1 and Th2 cells release different but overlapping sets of cytokines, however, 
despite extensive research, the contribution of different Th1 and Th2 cells populations 
to periodontal destruction has yet to be clearly defined. Some studies support the 
hypothesis that Th1 cells are associated with stable periodontal sites and Th2 cells are 
associated with disease progression (Gemmell and Seymour, 1994; Bartova et al., 
2000). However, other studies have reported a predominance of Th1 responses or 
reduced Th2 responses in periodontal disease (Salvi et al., 1998; Takeichi et al., 2000). 
In addition, there are studies demonstrating the involvement of both Th1 and Th2 cells 
in periodontal disease (Gemmell et al., 1999; Berglundh et al., 2002). Despite a lack of 
consensus about the role of different T cell populations in periodontal tissue destruction 
it remains clear that the balance of cytokines, produced by the innate and adaptive 
immune responses, within inflamed periodontal tissues is a contributing factor in 
whether the disease remains stable or leads to progression and tissue destruction (Okada 
and Murakami, 1998). 
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1.1.3.3 Cytokines 
Cytokines are central to the pathogenesis of many chronic inflammatory 
diseases, including periodontal disease (Seymour and Taylor, 2004). Within the 
periodontal tissue, cytokines are produced not only by infiltrating host defence cells, 
such as lymphocytes, macrophages and neutrophils but also by resident periodontal 
tissue cells, such as epithelial cells and fibroblasts (Takashiba et al., 2003). Many 
cytokines are self-regulatory, able to induce their own expression in an autocrine or 
paracrine manner and have pleiotrophic actions on a number of cell types. Cytokines act 
on their target cells by binding to specific receptors and initiating intracellular 
messengers resulting in phenotypic changes in the cell via altered gene regulation 
(Birkedal-Hansen, 1993; Taylor et al., 2004). 
In addition to their involvement in the host response against the microbial 
challenge of the dental plaque biofilm, cytokines are also able to mediate connective 
tissue and alveolar bone destruction through the induction of fibroblasts and osteoclasts 
to secrete tissue degrading enzymes (Bartold and Narayanan, 2006). Therefore, 
although primarily involved in protection, it can be seen that cytokines, for example 
interleukin-1 beta (IL-1β), tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-
6), have biological activity that underpin tissue damage in chronic inflammation, 
including periodontitis (Okada and Murakami, 1998). 
The key role that cytokines play in the host inflammatory-immune response in 
periodontal disease is supported by the analysis of human samples as well as studies in 
animals (Gemmell et al., 1997; Landi et al., 1997; Okada and Murakami, 1998). Despite 
the complex nature of the cytokine response that is involved in both the maintenance of 
periodontal health and periodontal tissue destruction, it is possible to identify cytokines 
that appear fundamental to this host response. For example, pro-inflammatory 
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cytokines, such as IL-1β and TNF-α have an important role in the initiation, regulation 
and perpetuation of innate immune responses (Birkedal-Hansen, 1993; Alexander and 
Damoulis, 1994). Early studies of human periodontal tissue biopsy samples highlight 
the importance of both IL-1β and TNF-α (Honig et al., 1989; Stashenko et al., 1991b), 
with higher levels of IL-1β and TNF-α in periodontal disease sites compared to healthy 
sites (Stashenko et al., 1991b) and higher IL-1β levels in samples from sites undergoing 
active attachment loss in comparison to stable disease sites or healthy sites (Stashenko 
et al., 1991a). Furthermore, studies have found increased levels of IL-1β in gingival 
crevicular fluid (GCF) in samples from subjects with periodontitis (Preiss and Meyle, 
1994; Figueredo et al., 1999; Engebretson et al., 2002; Zhong et al., 2007) and 
following non-surgical periodontal therapy, improvements in periodontal health are 
accompanied by statistically significant reductions in GCF levels of IL-1β (Engebretson 
et al., 2002; Thunell et al., 2010). 
As a pro-inflammatory cytokine capable of stimulating bone resorption, 
interleukin-6 (IL-6) may also play an important role in periodontal pathogenesis. In 
vitro, IL-6 stimulates bone resorption (Palmqvist et al., 2002) and concentrations of IL-
6 appear increased in inflamed periodontal tissues (Irwin and Myrillas, 1998). Studies 
have also demonstrated elevated IL-6 levels in GCF from diseased sites compared with 
control samples (Mogi et al., 1999; Lin et al., 2005). Furthermore, significantly higher 
levels of IL-6 were found systemically in patients with periodontitis compared to 
periodontally healthy controls (Marcaccini et al., 2009; Sun et al., 2009) and circulating 
levels of IL-6 were shown to decrease 3 months after non-surgical periodontal therapy 
(Marcaccini et al., 2009). The interplay between IL-6, IL-1β and TNF-α is highlighted 
by a cell culture study of primary gingival fibroblasts that demonstrated a constitutive 
mRNA expression of IL-6 and dose-dependent up-regulation of IL-6 mRNA and IL-6 
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protein levels following stimulation by IL-1β and TNF-α (Palmqvist et al., 2008). 
Conversely, IL-6 has also been shown to induce IL-1 receptor antagonist (Tilg et al., 
1994), thereby potentially providing a degree of control over upregulated inflammatory 
responses. This highlights the increasing appreciation that periodontal disease 
progression depends on the balance between pro-inflammatory and anti-inflammatory 
responses maintained by a network of cytokines (Graves and Cochran, 2003).  
 Cell culture studies have been used to investigate the production of cytokines by 
different cell types and investigate the molecular cell responses important to cytokine 
secretion. Studies have demonstrated that following stimulation with periodontal 
pathogens or their components a range of cytokines, including IL-1β, TNF-α, IL-8 and 
IL-6, are secreted by primary human gingival epithelial cells (Eskan et al., 2008; 
Stathopoulou et al., 2009). This is also highlighted by stimulation studies using 
epithelial cell lines (Bodet et al., 2006; Gursoy et al., 2008). However, given the non-
oral origin of the cell lines, caution must be used when drawing conclusions from such 
studies. 
The functioning of the adaptive immune response through the production of T 
cell populations is controlled by the cytokines that are present within the periodontal 
tissues (Gemmell et al., 1997). For example, interleukin-2 (IL-2) is essential for T cell 
proliferation and differentiation and activated T cells secrete and respond to IL-2 in an 
autocrine fashion. Early studies have demonstrated a lack of IL-2 production and 
reduced IL-2 receptor (IL-2R) expression within T cells from patients with chronic 
periodontitis, providing a possible explanation for the dysregulated T cell proliferation 
observed in these studies (Seymour et al., 1985; Kimura et al., 1991). Furthermore, IL-
1β and TNF-α, cytokines primarily involved in inflammation also have the ability to act 
on T cells as co-activators of IL-2 production (Dinarello, 2007). 
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Dysregulated cytokine networks may result in a variety of biological effects 
including up-regulation of adhesion molecules on leukocytes and endothelial cells, local 
production of chemokines, osteoclastic bone resorption and increased production and 
release of prostaglandins and matrix metalloproteinases (MMPs). Indeed, IL-1β, TNF-α, 
IL-6 have the potential to play a role in the propagation of a destructive inflammatory 
response, bone resorption and connective tissue destruction (Graves and Cochran, 
2003). Furthermore, multiple feedback loops develop; for example, cytokines induce the 
production of prostaglandins, and increased prostaglandin concentration results in 
increased cytokine secretion (Noguchi et al., 2001). 
In addition to the local immune inflammatory response within the periodontal 
tissues there is evidence that periodontal inflammation is associated with a heightened 
systemic inflammatory state. A meta-analysis of 10 cross-sectional studies (Paraskevas 
et al., 2008) provides evidence that C-reactive protein (CRP) is consistently elevated in 
patients with periodontitis compared to healthy controls. A recent cohort study, 
following patients over a 10 year period, confirms an association between advanced 
periodontitis and elevated CRP levels (Linden et al., 2008). 
Periodontal research has begun to elucidate the mediators that are important 
within periodontal tissues during health and disease. However, there are limitations 
inherent within the sampling and analytical techniques of currently published studies. 
Due to the small fluid volume available when assessing GCF, the use of conventional 
enzyme-linked immunosorbent assay (ELISA) limits the number of cytokines that can 
be analysed. Furthermore, a lack of sensitivity, particularly at the lower detection level, 
is problematic for the accurate quantification of cytokines that may play a role within 
periodontal disease pathogenesis. The recognition that individual cytokines do not act in 
isolation but rather as a complex network (Taylor et al., 2004; Preshaw and Taylor, 
1 Introduction 19 
2011) highlights a requirement for simultaneous analysis of a range of cytokines 
important within periodontal disease. 
1.1.4 Quantification of cytokines 
Sensitive methods for the precise quantification of cytokines are necessary when 
assessing cytokine levels in clinical samples, particularly when cytokine levels may be 
low and, as in the case of gingival crevicular fluid (GCF), sample volumes are very 
small. Various techniques for detecting and quantifying cytokines in biological samples 
have been used including bioassay, radioimmunoassay (RIA), ELISA, and more recent 
multiplex assays for the simultaneous quantification of multiple cytokines. 
Bioassays have been used to monitor the effects of cytokines on biological 
systems in vitro, for example the impact of adding specific cytokines on responses of 
cells in culture. For example, primary human gingival fibroblasts, cultured with various 
concentrations of IL-1β or TNF-α, demonstrated that the production of both IL-6 
messenger ribonucleic acid (mRNA) and IL-6 protein were concentration-dependently 
stimulated by IL-1β and TNF-α (Palmqvist et al., 2008). Furthermore, the impact of IL-
6 on the osteoblastic differentiation of primary human periodontal ligament cells in 
culture was assessed by quantifying alkaline phosphatase staining histochemically 
(Iwasaki et al., 2008). The advantage of bioassay is that a biological response is 
measured to confirm the potential biological relevance of a given level of a cytokine. 
However, biological samples potentially contain many cytokines and contamination by 
other more active substances will influence results. This technique is not adequately 
sensitive for cytokine quantification as part of a clinical periodontal treatment study. 
RIAs are based on the principle of competition between an antigen (in the 
clinical sample) and a radio-labelled homologous antigen for a limited number of 
specific antibody binding sites. Subsequently, a liquid scintillation counter quantifies 
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the amount of radio-labelled homologous antigen. This is inversely proportional to the 
mediator concentration in the sample, which is calculated from a standard curve 
generated from known amounts of mediator. RIAs have been developed for various 
mediators. For example, using RIA it was demonstrated that patients with periodontitis 
had significantly higher mean GCF concentrations of prostaglandin-E2 than patients 
with gingivitis (Offenbacher et al., 1981). Despite the sensitivity of this assay, the 
impractical length of RIA and the availability of more rapid assays preclude the use of 
RIA for cytokine quantification in clinical studies.   
ELISAs are non-competitive immunoassays based on the capture of test antigen 
(or standards of known quantity) by antibody coated onto the wells of microtitre plates. 
After a washing step to remove any free antigen, a second antibody is added and this 
binds to the antigen already present on the plate. The plate is then washed to remove 
unbound antibody and then, a ligand is added. The ligand is a molecule which binds to 
the antibody bound onto the plate, and itself is covalently coupled to an enzyme such as 
peroxidase. Free ligand is washed away, then bound ligand is visualised by the addition 
of a chromogen, a colourless substrate which is acted on by the enzyme portion of the 
ligand to produce a coloured end product. The colour intensity in the reaction wells is 
determined by optical density scanning of the plate, and the quantity of the test antigen 
is determined by comparison with a standard curve. ELISA have been used to quantify 
GCF levels of cytokines in patients with periodontitis (Zhong et al., 2007) and to assess 
changes in GCF cytokine levels following periodontal management (Engebretson et al., 
2002). However, the GCF volumes obtained from patients are very small and low 
cytokine levels preclude the use of dilutions. Therefore, ELISA can only be used to 
quantify a single cytokine per GCF sample. This is an important limitation given the 
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increasing recognition of the importance of cytokine networks in periodontal disease 
pathogenesis (Preshaw and Taylor, 2011). 
More recently, high-throughput multiplex immunoassays have been developed 
allowing simultaneous quantification of multiple cytokines. Using ELISA technology, 
two basic assay formats have been developed for simultaneous quantification of 
multiple cytokines; planar array assays and micro-bead assays. In planar assays, 
different capture antibodies are spotted at defined positions on a 2-dimensional array, 
such as a pre-coated microtitre plate. In the micro-bead assays the capture antibodies are 
conjugated to different populations of micro-beads, which can be distinguished by the 
fluorescence intensity in a flow cytometer. Both formats use a standard curve of known 
concentrations of cytokines to quantify unknown cytokine levels. Based on an 
assessment of the quality of the calibration curves for 5 common cytokines a 
comparison of 5 multiplex immunoassay platforms, concluded that the MULTI-
ARRAY (Meso Scale Discovery) and the Luminex-based Bio-Plex (Bio-Rad 
Laboratories) platforms were the most suitable for cytokine analysis or quantification 
(Fu et al., 2010). Using a micro-bead assay, multiple cytokines were quantified to assess 
changes in serum levels in patients with diabetes following periodontal therapy 
(O'Connell et al., 2008). Furthermore, also using micro-bead assays to quantify 16 
cytokines in GCF samples, a small study of 6 patients demonstrated a significant post 
treatment reduction in 13 cytokines in GCF samples taken from diseased sites (Thunell 
et al., 2010). The high cost of these multiplex assays could, however, limit their use in 
large clinical studies. 
1.1.5 Factors influencing the susceptibility to periodontitis 
Key to the development of periodontal disease is a chain of events involving 
microbial challenge from the plaque biofilm, stimulation of the host inflammatory 
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immune responses and destruction of connective tissue and alveolar bone breakdown 
within the periodontium leading to the clinical signs of disease. All stages within this 
chain of events are open to the influence of other factors including genetic, acquired or 
environmental factors (Page and Kornman, 1997). Such factors influence disease 
phenotype and are specific to individual patients. The relative influence of different 
factors is not yet fully understood and whilst the role of tobacco smoking is well 
defined, other factors such as genetic susceptibility remain to be fully elucidated. In 
addition, the systemic health of patients appears to influence the development of 
periodontal disease with, for example, the presence of diabetes increasing the 
prevalence, incidence and severity of periodontitis (Taylor, 2001). However, the 
mechanistic links between periodontal disease and other systemic diseases are not fully 
defined. The chronic and multi-factorial nature of both periodontal disease and diabetes 
highlights the complex nature of the interplay between systemic health and periodontal 
disease. 
 Tobacco smoking is a recognized risk factor for periodontal disease (Tomar and 
Asma, 2000). Risk calculations suggest that 40 percent of chronic periodontitis may be 
attributed to smoking (Brothwell, 2001). Smokers are up to 4 times more likely to have 
periodontal disease compared with non-smokers (Tomar and Asma, 2000; Calsina et al., 
2002) and those with a longer smoking history have an increased risk of developing 
periodontal disease (Linden and Mullally, 1994; Hyman and Reid, 2003). In addition to 
the well recognised systemic health benefits of quitting smoking, research has shown 
improved treatment outcomes, with greater reductions in probing depths, in patients 
who were supported to quit smoking as part of periodontal management (Preshaw et al., 
2005). 
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 When considering the mechanisms by which smokers are at an increased risk for 
periodontitis, numerous authors have reported the potential effects of smoking on the 
bacterial challenge, the periodontal tissues and the immune-inflammatory response. For 
example, smoking has a long term chronic effect to impair gingival circulation 
(Bergstrom and Bostrom, 2001; Dietrich et al., 2004). Smoking appears to have a 
deleterious impact on the dental plaque biofilm, increasing those bacteria commonly 
associated with periodontal disease (Zambon et al., 1996; Umeda et al., 1998; Eggert et 
al., 2001; Haffajee and Socransky, 2001). Interestingly, a recent study demonstrated 
that following non-surgical management, the microbial profile in smokers remained 
similar to baseline whereas quitters demonstrated significantly different profiles 
(Fullmer et al., 2009). Tobacco smoking affects multiple functions of PMNs, including 
migration and chemotaxis (Seow et al., 1994) and an increase in PMN elastase suggests 
enhancement of degranulation in the neutrophils of smokers (Soder et al., 2002), with 
increased concentrations of macrophage-derived TNF-α from smokers suggesting a 
more destructive inflammatory process (Fredriksson et al., 2002). Studies, however, 
have also reported lower IL-1β (Rawlinson et al., 2003) and interleukin alpha (IL-α) 
(Petropoulos et al., 2004) levels in the GCF of smokers. Thus, the effect of smoking on 
host immune-inflammatory responses, as a mechanism for increased susceptibility to 
periodontitis, remains unclear.  
A body of evidence now supports the theory that genetic factors play an 
important role in determining susceptibility to periodontitis. Periodontal disease is part 
of the phenotype of inherited conditions such as Papillon-Lefèvre syndrome (Firatli et 
al., 1996) and twin studies indicate that about 50% of the variance in attachment loss is 
due to the influence of heredity (Michalowicz et al., 2000). In order to study the precise 
genetic factors associated with susceptibility to periodontal disease, variations in 
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cytokine genes have been investigated. Based on the paradigm that cytokine gene 
polymorphisms could affect the transcription and subsequent release of cytokines, and 
because of the fundamental role of IL-1β in the pathogenesis of periodontal diseases, 
polymorphisms in the IL-1 gene have been the main focus of research (Taylor et al., 
2004). Data from Korman et al that suggested that non-smokers with periodontitis who 
were positive for a combination of two defined IL-1 single nucleotide polymorphisms 
(SNPs), known as the periodontal associated genotype (PAG), had a 7-fold increased 
chance of having severe periodontal disease compared to those who where PAG 
negative (Kornman et al., 1997). Subsequent studies confirmed that PAG correlates 
with severity of periodontitis (Kornman et al., 1999; Papapanou et al., 2001) although 
such results are not replicated in other studies (Taylor et al., 2004). In a 5 year 
longitudinal study, Cullinan et al (2001) showed that this specific IL-1 genotype was a 
contributing but nonessential factor in the progression of periodontal disease. Equally, 
they showed smokers with P. gingivalis had significantly more periodontal disease 
compared with smokers without P. gingivalis and IL-1 genotype positive smokers had 
more disease than IL-1 genotype negative smokers (Cullinan et al., 2001). This study 
clearly demonstrates the interplay between bacteria, host and environmental factors in 
the pathogenesis of periodontal disease. Furthermore, although genetic associations 
between polymorphism in the IL-1 gene and periodontal disease appear to exist, 
unambiguous results are not yet apparent and firm conclusions about the genotype of 
patients with periodontitis cannot be made. 
1.1.6 Management of periodontitis 
The main aim of NSM, including instrumentation and effective oral hygiene 
instruction (OHI),  is to prevent tooth loss via the effective and continued prevention of 
periodontal disease progression, achieved by the reduction of the microbial burden that 
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is present around the periodontal tissues. Effective periodontal therapy disrupts the 
subgingival plaque biofilm, allowing a shift in the microbial populations to those more 
commonly associated with health. For example, periodontal instrumentation resulted in 
a significant decrease in the deoxyribonucleic acid (DNA) probe counts of subgingival 
microbial species commonly associated with periodontal disease (Haffajee et al., 1997; 
Cugini et al., 2000). Given that the presence of calculus above or below the gingival 
margin impedes effective oral hygiene practices, the removal of calculus remains a 
primary aim for periodontal instrumentation. The concept of complete removal of all 
subgingival calculus is, however, viewed as unrealistic, with periodontal healing 
occurring despite the presence of residual calculus being detected microscopically 
(Nyman et al., 1986; Cobb, 2002). 
When considering the methodology used for the non-surgical approach to 
periodontal instrumentation, a recent meta-analysis concluded that, for both moderate 
pockets (5-7 mm) and deep pockets (≥ 7mm), no significant differences in probing 
depth reduction, clinical attachment gain and bleeding on probing were found when 
comparing traditional quadrant-based instrumentation with full mouth instrumentation 
(FMI) on a single visit (Farman and Joshi, 2008). Studies also highlight that the full 
mouth approach required significantly less instrumentation time to achieve similar 
results than quadrant therapy (Koshy et al., 2005; Wennstrom et al., 2005), although, a 
higher level of pain may be experienced following the full mouth approach (Apatzidou 
and Kinane, 2004; Wennstrom et al., 2005). Furthermore, studies demonstrate that, in 
patients with chronic periodontitis, sonic or ultrasonic instrumentation achieves 
treatment outcomes that are comparable with hand instrumentation (Wennstrom et al., 
2005; Aslund et al., 2008). Also, no significant difference was found in the incidence of 
recurrence of diseased periodontal pockets, defined as pockets with probing depths of 
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≥5mm and bleeding on probing, between the full-mouth ultrasonic debridement 
approach and quadrant by quadrant hand instrumentation (Tomasi et al., 2006). 
Clinical treatment outcomes for non-surgical periodontal management (NSM) 
include reduction in probing depths, gain in clinical attachment and reduction in 
bleeding on probing. The reduction in probing depths results from a combination of 
gain in clinical attachment and gingival recession. Numerous studies have shown the 
outcomes that can be expected following nonsurgical periodontal therapy are 
remarkably consistent and the magnitude of both probing depths reduction and gains in 
clinical attachment are influenced by the initial probing depth measurements. For 
example, a review of periodontal treatment outcomes showed that for those pockets 
initially 4-6 mm deep, mean probing depth reductions of approximately 1.0-1.5 mm and 
mean attachment gains of 0.5-1.0 mm are consistently seen (Cobb, 2002). For pockets 
that are 7 mm or greater, mean probing depth reductions of 2.0-2.5 mm and mean 
attachment gains of 1.0-1.5 mm can be expected (Cobb, 2002). 
The presence or absence of BOP is widely interpreted to represent the presence 
of an inflammatory infiltrate within the periodontal tissues and despite BOP being more 
reliable than other clinical signs for detection and monitoring of periodontal disease 
(Lang et al., 1996), BOP has been shown to have a low predictive value, being a poor 
predictor for periodontal disease progression (Lang et al., 1986). In contrast, the 
absence of BOP provides a high negative predictive value and is therefore an important 
indicator of periodontal health and stability (Lang et al., 1990; Joss et al., 1994).  
In research, the use of tooth loss as a marker of disease is complicated, not only 
by tooth loss due to caries but also by the long follow up time required. Therefore, a 
patient’s response to periodontal treatment is presented in terms of probing depth 
reduction, gain in attachment and change in BOP, all of which are surrogate markers of 
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periodontal disease (Hujoel, 2004). Furthermore, studies also lack predefined goals for 
periodontal treatment against which patients can be assessed (Hujoel, 2004; Armitage, 
2008). There appears to be an assumption that simply because a subject attends the 
desired number of appointments their treatment needs have been met. Obviously, within 
research trials it would be difficult to manage patients to a given endpoint, providing 
therapy until that point is reached, however, having stated treatment goals or clinical 
endpoints would allow for subjects to be categorised at the end of the study period into 
responders and non-responders (Hujoel, 2004; Armitage, 2008). 
1.2 Diabetes 
1.2.1 Definition and classification of diabetes 
The term ‘diabetes’ encompasses a group of metabolic disorders, characterised 
by hyperglycaemia, resulting from defects in insulin secretion, insulin action, or both. 
Diabetes is classified based on the underlying aetiological cause and the vast majority of 
cases of diabetes fall into two broad categories, type 1 and type 2 (Table 1.3). Type 1 
diabetes mellitus (T1DM) is caused by an absolute deficiency of insulin secretion and 
can be identified by the presence of serological markers indicating autoimmune 
destruction of the β cells of the pancreas.  In type 2 diabetes mellitus (T2DM) the main 
causal processes are insulin resistance (i.e. an inability of the body to respond normally 
to insulin) and failure of pancreatic β cells to produce sufficient insulin.  The subsequent 
hyperglycaemia has wide ranging molecular and cellular effects that predispose 
individuals to the classic diabetes complications of retinopathy, nephropathy, 
neuropathy, macrovascular disease, including cardiovascular disease. Diabetes is 
diagnosed on the basis of World Health Organisation (WHO) recommendations from 
1999, that incorporate criteria for fasting plasma glucose levels and also plasma glucose 
levels 2 hours after a 75g glucose load (WHO, 1999) (Table 1.4).  
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Conditions that predispose to overt diabetes, including impaired fasting glucose 
and impaired glucose tolerance are also defined in the WHO recommendations (WHO, 
1999) (Table 1.4). If untreated, about 7% of people with impaired fasting glucose and 
impaired glucose tolerance will progress to overt diabetes every year (Tuomilehto et al., 
2001) and impaired glucose tolerance itself carries an increased risk of macrovascular 
disease (DECODE, 1999). 
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Table 1.3  Overview of the classification of diabetes 
 
Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
Gestational diabetes 
Other Specific Types of Diabetes 
 Genetic defects 
Diseases of exocrine pancreas 
Endocrinopathies 
Drug or infection induced 
Others 
 
The table shows a classification of the main types of diabetes based on the underlying 
aetiological cause. 
 
 
Table 1.4 Overview of the diagnostic criteria of diabetes mellitus  
 
 
Glucose concentration in venous plasma (mmol/L) 
 
Diabetes mellitus 
 
Fasting ≥ 7.0 or 2-h post glucose load ≥ 11.1 
 
 
Impaired glucose tolerance 
 
Fasting < 7.0 and 2-h post glucose load ≥ 7.8 and < 11.1 
 
 
Impaired fasting glucose 
 
Fasting ≥ 6.1 and < 7.0 and 2-h post glucose load < 7.8 
 
The table shows the diagnostic criteria of diabetes mellitus and other categories of 
hyperglycaemia (WHO, 1999) 
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1.2.2 Epidemiology of diabetes 
Diabetes has reached epidemic proportions, the International Diabetes 
Federation (IDF) estimates that currently diabetes affects more than 246 million 
individuals worldwide and this is expected to rise to 380 million people by 2025 (IDF, 
2006). Between 2007 and 2025, the global predicated growth is 55%, with the greatest 
increases in the developing countries of Africa, Asia and South America (Figure 1.2) 
(IDF, 2006). Within Europe, it is estimated that diabetes affects 53.2 million or 8.4% of 
the adult population and this is predicted to rise by 21% to 64.1 million or 9.8% in 
2025, with the greatest increase being seen in the older age group (Table 1.5) (IDF, 
2006). 
In recent years, research within the UK has demonstrated a rise in the prevalence 
(Newnham et al., 2002; Fleming et al., 2005; Lusignan et al., 2005; Gonzalez et al., 
2009) and incidence (Ryan et al., 2005; Forouhi et al., 2007; Gonzalez et al., 2009) of 
diabetes cases. Furthermore, the rise of diabetes cases in the UK is largely due to 
T2DM, with the incidence of T1DM remaining relatively constant over the past decade 
and the proportion of obese individuals newly diagnosed with T2DM has increased 
from 46% to 56% (Gonzalez et al., 2009). 
In Western developed countries, the prevalence of T2DM is closely linked to 
socio-economic status (Ismail et al., 1999; Evans et al., 2000) and there are increasing 
numbers of diabetic individuals in deprived areas of affluent countries, creating 
implications for the delivery of targeted health care and prevention. 
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Figure 1.2 Estimates for 2007 & 2025 for the number of people with diabetes  
 
 
 
 
 
 
 
 
 
 
Figure shows worldwide estimates for 2007 & 2025 for the number of people with 
diabetes (IDF, 2006) 
 
 
Table 1.5 European estimates for people with diabetes 
 
2007 2025 
People with diabetes aged 20-79 (millions) 53.2 64.1 
People with diabetes aged 20-39 (millions) 3.7 3.4 
People with diabetes aged 40-59 (millions) 19.6 20.9 
People with diabetes aged 60-79 (millions) 29.8 39.8 
Prevalence (%) 8.4 9.8 
Table shows the estimates for people with diabetes in Europe (IDF, 2006) 
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1.2.3 Pathogenesis of Type 2 Diabetes 
Insulin secretion from the pancreas normally reduces glucose output by the liver, 
enhances glucose uptake by the liver and skeletal muscle, and suppresses fatty acid 
release from adipose tissue. T2DM is defined and diagnosed on the basis of 
hyperglycaemia, although the extent of the metabolic dysfunction is much broader than 
glucose metabolism (Home and Pacini, 2008). Hyperglycaemia is seen when the normal 
balanced interplay between insulin secretion and insulin action is disrupted. When 
insulin action decreases, the body usually compensates by increasing pancreatic beta-
cell (β-cell) function and insulin production. T2DM, however, develops when β-cell 
functioning is inadequately low for a specific degree of impaired insulin action 
(Stumvoll et al., 2005).  Decreased insulin secretion will reduce insulin signalling in its 
target tissues. Insulin resistance pathways affect the action of insulin in liver and 
muscle, the major target tissues, leading to increased circulating fatty acids and the 
hyperglycaemia of diabetes. Therefore, the underlying pathogenic defects in T2DM 
involve multiple pathways, each contributing to the underlying disease state (Stumvoll 
et al., 2005). Although evidence for familial clustering points to the contribution of 
genetic mechanisms, recent rapid increases in diabetes incidence and prevalence 
indicate that environmental and lifestyle factors are also of major relevance (Zimmet et 
al., 2001; Stumvoll et al., 2005). 
1.2.3.1 Insulin resistance 
Insulin resistance is seen when the effects of insulin are less than expected for 
both glucose disposal in skeletal muscle and liver and the suppression of hepatic 
endogenous glucose production.  
On a molecular level, hyperglycaemia, free fatty acids (FFA) and inflammatory 
cytokines can down-regulate intracellular insulin signalling and this contributes to 
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insulin resistance (Figure 1.3). (Griffin et al., 1999; Itani et al., 2002; Gao et al., 2004). 
Furthermore, TNF-α has been shown to enhance adipocyte lipolysis, which increases 
FFA, in addition to contributing to intracellular insulin deactivation pathways (Paz et 
al., 1997; Aguirre et al., 2000). TNF-α, IL-1β and IL-6 also have a direct inhibitory 
effect on the intracellular insulin signalling cascades (Hotamisligil, 2000; Senn et al., 
2003; Jager et al., 2007). Therefore, by targeting the insulin signalling cascade, 
inflammatory cytokines are capable of impairing insulin action, contributing to the 
development of insulin resistance (Tilg and Moschen, 2008). 
1.2.3.2 Beta-cell dysfunction 
In health, the adaptive response of pancreatic β-cells to insulin resistance 
involves an increase in insulin release that is sufficient to overcome the reduced 
efficiency of insulin action. Patients develop T2DM when β-cells are unable to 
compensate fully for decreased insulin sensitivity (Kahn et al., 2001). Indeed, 
deterioration of insulin secretion over time is the usual course in most patients, and 
many patients will have deficient insulin secretion after 10 years of diabetes (Wallace 
and Matthews, 2002). The rate of deterioration in diabetes control is around 1.5% 
HbA1c per 10 years and it thought to be a result of a decline in β-cell function (Home, 
2008b). 
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Figure 1.3 Overview of insulin signalling and insulin resistance 
 
 
 
On a molecular level, hyperglycaemia, FFA and inflammatory cytokines can down-
regulate intracellular insulin signalling and this contributes to insulin resistance. The 
figure shows and overview of insulin signalling and insulin resistance. Adapted from 
(Stumvoll et al., 2005) 
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In chronic hyperglycaemia, increased amounts of ROS are generated in β-cells 
with subsequent damage to cellular components or apoptosis (Stumvoll et al., 2005; 
Kahn et al., 2006). Elevated plasma FFA levels also contribute to progressive loss of β-
cell function (Zhou and Grill, 1994; Robertson et al., 2004; Kahn et al., 2006). In 
addition, it has long been recognised that IL-1β has the ability to damage β-cells 
(Bendtzen et al., 1986; Mandrup-Poulsen et al., 1986). Furthermore, recent clinical 
trials have highlighted the role of IL-1β in β-cell dysfunction and diabetes. In a placebo-
controlled randomised trial, administration of a competitive antagonist of IL-1β, 
interleukin-1 receptor antagonist, improved glycaemic control of patients with poorly 
controlled T2DM (Larsen et al., 2007). Furthermore, the use of neutralising antibodies 
to IL-1β, also improves glycaemic control and β-cell function in patients with T2DM 
(Donath et al., 2008). The β-cell dysfunction that contributes to T2DM therefore 
appears, at least in part, to involve IL-1β. 
1.2.3.3 Obesity 
An imbalance between nutritional intake and energy expenditure culminates in 
obesity. Obesity has long been recognised as a powerful risk factor for T2DM 
(Lundgren et al., 1989; Chan et al., 1994; Carey et al., 1997; Wang et al., 2005). 
Indeed, general obesity, as measured by body mass index (BMI), and abdominal 
adiposity strongly and independently predicts risk of T2DM (Wang et al., 2005). It has 
been said that the leading cause for developing insulin resistance is obesity (Kahn et al., 
2006).  
The classical view of adipose tissue as an energy storage depot has now been 
replaced by the perception that adipose tissue is an active endocrine organ playing a 
central role in lipid and glucose metabolism, and producing various hormones and 
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cytokines involved in the development of insulin resistance, T2DM and vascular 
diseases (Hajer et al., 2008; Taube et al., 2009).  
Due to changes in function of adipocytes and infiltrating macrophages, obesity 
is associated with the appearance of a chronic, low grade inflammatory state (Ross, 
1999). An increase in adipose tissue and adipocytes volume is accompanied by a rise in 
plasma adipokine levels, with the exception of adiponectin which is lower in obesity 
(Skurk et al., 2007; Wannamethee et al., 2007). Macrophages are more prevalent in the 
adipose tissue of obese subjects compared to lean subjects and the macrophage quantity 
correlates with measures of insulin resistance (Otto and Lane, 2005). Furthermore, the 
number of macrophages in adipose tissue is reduced by weight loss (Cancello et al., 
2005). The interplay between macrophages and adipocytes by a paracrine effect is 
proposed to be central to adipose tissue dysfunction (Hajer et al., 2008). Enlarged 
adipocytes are shown to release increased levels of FFA which bind to TLRs in 
macrophages, resulting in activation of intracellular signalling and augmented TNF-α 
production (Suganami et al., 2005; Suganami et al., 2007). In turn, TNF-α activates 
human adipocytes, thereby further inducing lipolysis and FFA production in addition to 
enhancing the expression of IL-6 and mediators that facilitate the accumulation of 
macrophages in adipose tissue (Ruan et al., 2002; Permana et al., 2006). Therefore, the 
FFA, TNF-α and IL-6 released from adipose tissue (Hotamisligil et al., 1995; Wellen 
and Hotamisligil, 2005; Scherer, 2006) have an inhibitory effect on intracellular insulin 
signalling pathways, contributing both to insulin resistance in hepatic tissue, skeletal 
muscle and adipose tissue and reduced insulin production from β-cells (Kahn et al., 
2006; Goldstein, 2008; Hajer et al., 2008).  
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1.2.3.4 Genetic factors 
Although lifestyle factors and obesity seem to be important pathogenic factors, 
genetic elements are also involved in the pathogenesis of T2DM. A positive family 
history gives a 2.4 fold increased risk for T2DM, with up to 25% of first degree 
relatives of people with T2DM developing impaired glucose tolerance or diabetes 
(Pierce et al., 1995). The lifetime risk (at age 80 years) for T2DM is calculated at 38% 
if one parent has T2DM (Pierce et al., 1995) and if both parents have T2DM, the 
prevalence of T2DM in the offspring is estimated to be around 60% by the age of 60 
years (Tattersal and Fajans, 1975). 
Research has attempted to identify causative factors among many candidate 
genes that have a plausible role in T2DM pathogenesis (Prokopenko et al., 2008). In 
most instances, initial associations were not replicated in subsequent analyses and only 
a few candidate gene associations have been confirmed by meta-analysis (Parikh and 
Groop, 2004).   
1.2.3.5 Inflammation 
Although the cellular mechanisms contributing to the pathogenesis of T2DM are 
complex and not fully elucidated, it appears inflammation plays a key role. 
Inflammatory cytokines, such as TNF-α, IL-1β and IL-6, contribute to the development 
of T2DM through insulin resistance and β-cell dysfunction (Donath et al., 2003; Pickup, 
2004). Inflammatory cytokines such as TNF-α and IL-6 have been linked to insulin 
resistance, and their expression is increased in adipose tissue in obese subjects (Kern et 
al., 2001). In response to elevated concentrations of glucose and FFA monocytes, 
macrophages, endothelial cells and adipocytes release pro-inflammatory cytokines, 
including IL-6, TNF-α and IL-1β (Morohoshi et al., 1996; Guha et al., 2000; Maedler et 
al., 2002; Donath et al., 2003; Shanmugam et al., 2003). Cytokines such as TNF-α, IL-
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1β and IL-6 contribute to insulin resistance through the down-regulation of specific 
aspects of intracellular insulin pathways (Figure1.3) (Hotamisligil et al., 1996; Stumvoll 
et al., 2005). 
Furthermore, the intracellular signalling cascades that contribute to insulin 
resistance are also involved in inflammatory signalling cascades (Shoelson et al., 2006; 
Goldstein, 2008).  Recent research has focused on modulating inflammatory pathways 
as a potential target in the management of T2DM. Studies investigating salicylates as 
potential therapeutic agents for the management of T2DM have shown that, in vivo, 
administration of salicylates improved both inflammatory parameters and glucose and 
lipid homeostasis, highlighting the involvement of the inflammatory signalling cascade 
in the pathogenesis of T2DM (Fleischman et al., 2008; Goldfine et al., 2008). IL-1β 
blockade has also been shown to improve glycaemic control and β-cell function (Larsen 
et al., 2007; Donath et al., 2008). 
1.2.4 Complications of diabetes 
Diabetes is associated with reduced life expectancy, increased morbidity and 
increased mortality. UK patients with T2DM have a mortality rate almost twice as high 
as those without diabetes (Mulnier et al., 2006). Diabetes has an irreversible and 
detrimental effect on the micro- and macro-vasculature, with cardiovascular disease 
(CVD), myocardial infarction and stroke being the leading cause of mortality in patients 
with T2DM (Dale et al., 2008). Furthermore, diabetic nephropathy, retinopathy and 
neuropathy are major causes of renal failure, blindness and sensory loss (Frank, 2004; 
Gilbertson et al., 2005). Type 2 diabetes is notable for the increased cardiovascular risk 
that it carries, clinically presenting as myocardial infarctions, angina, peripheral artery 
disease (leg claudication, gangrene), and carotid artery disease (strokes, dementia) 
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(NICE, 2008). The duration of diabetes and the degree of glycaemic control are 
important factors for all diabetic complications (UKPDS, 1998a). 
 Within the pathological processes of diabetic vascular injury, the molecular 
consequences of hyperglycaemia superimpose onto existing contributing factors for 
vascular disease, such as raised levels of serum lipids and hypertension. In patients with 
diabetes, increased oxidative stress and inflammation are recognised pathogenic 
mechanisms for vascular damage, with altered gene expression in the vasculature, 
providing a pro-inflammatory and thrombogenic environment (Feng et al., 2005; Crimi 
et al., 2007).  
The molecular pathways that contribute to diabetic complications are complex 
and incompletely understood. Hyperglycaemia leads to the formation of advanced 
glycation end products (AGEs), leading to protein cross linking and activation of the 
AGE receptor (RAGE) (Brownlee et al., 1988). Animal studies have confirmed the role 
of RAGE activation in the development of diabetic neuropathy, nephropathy and 
vascular disease (Soro-Paavonen et al., 2008). RAGE activates numerous signalling 
pathways leading to activation of pro-inflammatory and pro-coagulatory genes (Hudson 
et al., 2005) and studies in rodent models of vascular disease have shown that blockade 
of RAGE can prevent development of disease (Park et al., 1998; Bucciarelli et al., 
2002). Furthermore, activation of RAGE contributes to diabetic-induced damage 
through increased oxidative stress, with RAGE activation contributing, along with 
hyperglycaemia, to excessive production of ROS and the down-regulation of 
antioxidant activity (Calcutt et al., 2009). Increased ROS activate a range of 
intracellular signalling pathways and transcription factors thought to influence 
phenotypic changes and release of mediators that contribute to tissue damage 
(Nishikawa et al., 2000; Lambeth, 2007; Calcutt et al., 2009). 
1 Introduction 40 
1.2.5 Management of Type 2 diabetes 
The management of T2DM is focused on controlling risk factors for both 
microvascular and macrovascular diabetic complications. Therefore, current  targets for 
T2DM management include weight control, smoking, plasma glucose control, blood 
pressure control, blood lipid control, reduction of thrombogenicity, laser therapy for eye 
damage, drug therapy to delay kidney damage, foot care, and symptomatic treatments 
for nerve damage (Home et al., 2008; NICE, 2008). 
T2DM is predominately managed by the patient as part of their daily life, with 
structured education being an integral and ongoing part of diabetes care, to ensure 
patients understand diabetes and their key role in its management (Deakin et al., 2006; 
Davies et al., 2008). As part of the management of risk factors for diabetes-related 
complications it is recommended that dietary advice, following the principles of healthy 
eating, is integrated within a personalised diabetes management plan, including other 
aspects of lifestyle modification, such as increasing physical activity, losing weight and 
smoking cessation (Home et al., 2008; NICE, 2008). 
  The UK Prospective Diabetes Study (UKPDS), a large (n=3,867) randomised, 
prospective, multicenter study with a 10 year follow-up period compared the effect of 
intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) 
and conventional therapy (dietary restriction) (UKPDS, 1998a). The UKPDS 
demonstrated that the risk of microvascular and macrovascular complications of T2DM 
is strongly associated with hyperglycaemia as measured by percentage glycated 
haemoglobin (HbA1c), with a 1% reduction in HbA1c being associated with a 21% risk 
reduction in any diabetic complication clinical endpoint (Stratton et al., 2000). In the 
initial 10 year trial, intense therapy, achieving tighter glycaemic control, resulted in an 
lower incidence of microvascular complications, but not macrovascular complications 
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(UKPDS, 1998a; Stratton et al., 2000). Recently published data, however, from the 10 
year post trial follow-up of the UKPDS showed that if intensive glucose control was 
started at the time of diagnosis, a sustained legacy effect on diabetic complications was 
demonstrated. Therefore, even when between group differences in HbA1c were lost, the 
intensely managed group continued to be associated with a significant decreased risk of 
myocardial infarction and death, in addition to the well-established reduction in the risk 
of microvascular disease (Holman et al., 2008a). Consequently, national guidelines have 
therefore set an ideal target HbA1c of 6.5%, using dietary and lifestyle interventions 
with medications, as required, to achieve and maintain this target HbA1c level, with 
monitoring at a minimum of 6 monthly intervals (Home et al., 2008; NICE, 2008).  
The impact of tight blood pressure control on the risk of developing diabetic 
complications has also been extensively studied. Analysis of data from the UKPDS has 
shown the risk of complications in T2DM is associated independently and additively 
with hyperglycaemia and hypertension. Intensive treatment of both these risk factors is 
required to minimise the incidence of complications (Stratton et al., 2006). The UKPDS 
achieved a risk reduction for both micro and macro vascular disease with tight control 
of blood pressure (Turner et al., 1998a). Furthermore, the 10 year post trial follow-up 
demonstrated that good blood pressure control must be continued if the positive effect 
on diabetic complications is to be maintained (Holman et al., 2008b). consequently, 
national guidelines recommend a target blood pressure level of 140/80 mm Hg and 
lifestyle advice, anti-hypertensive medications and at least annual monitoring are 
advocated to enable this goal to be reached (Home et al., 2008; NICE, 2008).  
It is also recommended that for patients with T2DM, blood lipid control should 
be an integral part of cardiovascular risk management, including an annual 
measurement of a full lipid profile (including total cholesterol, high density lipoprotein 
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cholesterol, low density lipoprotein cholesterol and triglyceride estimations) and 
simvastatin prescribed for patients not reaching the recommended targets (total 
cholesterol < 4.0 mmol/l, high density lipoprotein cholesterol ≤ 1.4 mmol/l, serum 
triglyceride < 4.5 mmol/l) (Home et al., 2008; NICE, 2008). 
1.2.5.1 Glycaemic control 
The widespread clinical use of HbA1c to monitor long-term glycaemic control 
in patients with diabetes was established following publication of data from the UKPDS 
demonstrating the relationship between HbA1c and diabetic complications caused by 
hyperglycaemia (Stratton et al., 2000). HbA1c provides clinicians with an indication of 
a patient’s long-term glycaemic control and is used to set appropriate management goals 
to enable patients to achieve adequate plasma glucose control. HbA1c is, however, a 
surrogate marker of plasma glucose (Home, 2008a). HbA1c is formed in a non-
enzymatic pathway by haemoglobin’s normal exposure to elevated plasma levels of 
glucose. HbA1c concentrations, relative to circulating haemoglobin A concentrations, 
therefore represents the amount of glycated haemoglobin within erythrocytes, reflecting 
the average level of glucose to which the cell has been exposed during the preceding 
months. However, the relationship between HbA1c and plasma glucose is complicated 
by the fact that HbA1c taken at a specific time point is contributed to by the total 
population of erythrocytes, from the oldest (120 days) to the youngest. Additionally, 
recent plasma glucose levels have a greater impact on HbA1c than more distant plasma 
glucose levels. Therefore, HbA1c is viewed as a weighted average of plasma glucose in 
the preceding 120 days (Rohlfing et al., 2002). 
Analysis of data from a large prospective, multicenter study demonstrated a 
strong correlation between plasma glucose and HbA1c, confirming a predictable 
relationship between HbA1c and hyperglycaemia (Rohlfing et al., 2002). Understanding 
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this relationship allows clinicians and patients to set appropriate day to day plasma 
glucose targets to achieve the recommended HbA1c goal of 6.5% (NICE, 2008). 
1.2.5.2 Drug therapy in the management of Type 2 diabetes 
For those who are inadequately controlled with diet and lifestyle management, 
metformin and sulfonylureas form the mainstay of pharmacological treatment. 
Metformin can also be combined with insulin therapy, resulting in a reduction in 
required insulin dose and body weight (Douek et al., 2005). Improvements in 
hyperglycaemia coupled with unaltered plasma insulin concentrations indicate that 
metformin is an insulin-sensitizing drug, suppressing endogenous glucose production 
and improving insulin-stimulated glucose uptake, with no direct effect on β-cells in 
stimulating insulin secretion (Matthaei et al., 2000; Holstein and Beil, 2009). 
Sulfonylureas, on the other hand, act at the β-cell membrane by closing ATP-sensitive 
potassium channels, leading to enhanced insulin secretion (Holstein and Beil, 2009). 
The efficacy and safety of both metformin and sulfonylureas have been clearly 
demonstrated by large prospective studies (UKPDS, 1998b; UKPDS, 1998a; Patel et al., 
2008) and confirmed by meta-analysis of observation studies (Rao et al., 2008). 
Currently, thiazolidinediones are recommended only as a second line therapy 
when glycaemic control is inadequate and sulphonurea, metformin or insulin are not 
tolerated (NICE, 2008). This reflects the relatively modest benefits demonstrated with 
thiazolidinediones and the potential long-term side effects on the cardiovascular system 
and bone (Dormandy et al., 2005; Singh et al., 2007; Loke et al., 2009). The 
thiazolidinediones sensitise and enhance the effect of insulin in skeletal muscle, adipose 
and hepatic tissues without increasing pancreatic secretion of insulin. 
Thiazolidinediones primarily activate receptors in adipose tissue and affect adipose 
metabolism and distribution. Thiazolidinediones may also preserve β-cell function 
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(Kendall et al., 2006), an important consideration following the recognition that a 
progressive decline in glycaemic control is seen in T2DM with increasing therapy 
requirements. There is a suggestion in the literature that thiazolidinediones may 
ameliorate insulin resistance by reducing circulating concentrations of pro-
inflammatory cytokines and increasing concentrations of adiponectin (Stumvoll et al., 
2005), however, supporting evidence remains sparse. 
As part of the management of T2DM, statins are extensively used for lowering 
cholesterol and reducing cardiovascular events. Recent studies have shown that statins 
have additional beneficial anti-inflammatory effects (Ridker and Silvertown, 2008). In a 
recent randomised controlled trial, in apparently healthy subjects without 
hyperlipidemia but with elevated high sensitive C-reactive protein (hsCRP), the 
administration of statins reduced circulating hsCRP levels and also reduced the 
incidence of major cardiovascular events (Ridker et al., 2008). In vitro studies have also 
begun to demonstrate the inhibitory effect of statins on cytokine release from 
monocytes and macrophages (Krysiak et al., 2011).  
1.3 Periodontal disease & diabetes 
1.3.1 The epidemiological association between diabetes & periodontitis 
A number of case reports, cross-sectional studies, and a few longitudinal studies 
have reported an increased prevalence of periodontal disease in patients with T2DM.  
Indeed, it is accepted in the periodontal community that T2DM is an important risk 
factor for periodontal disease and, indeed, periodontal disease is viewed as a 
complication of diabetes (Loe, 1993; Salvi et al., 1997b). Epidemiological evidence 
supports associations between diabetes and increased prevalence and severity of 
periodontal disease (Taylor, 2001). Although the majority of studies have been cross-
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sectional in design, typically describing findings from small convenient samples, there 
is a smaller subset of population-based studies which strongly support associations 
between diabetes and periodontal disease (Nelson et al., 1990; Shlossman et al., 1990; 
Emrich et al., 1991; Taylor et al., 1998b). 
Several of these studies have focused on the Pima Indians, a population 
suffering from very high prevalence rates of T2DM.  In this population, diabetic 
subjects were 2.8 times and 3.4 times more likely to have periodontal disease compared 
to non-diabetic controls when periodontitis was defined by clinical attachment loss or 
radiographic bone loss, respectively (Emrich et al., 1991). In another study of the Pima 
Indians, the incidence of periodontal disease over 2.6 years was  2.6 times higher in the 
subjects with T2DM than that observed in the non-diabetic controls (Nelson et al., 
1990). It has also been reported that T2DM patients with poor glycaemic control have a 
much greater risk of progressive alveolar bone loss (odds ratio 11.4) compared to non-
diabetic subjects (odds ratio 2.2) (Taylor et al., 1998b).  Interestingly, this study also 
provided evidence to support a possible negative effect of periodontitis on glycaemic 
control, as subjects with moderate or well controlled T2DM at baseline who also had 
severe periodontitis were approximately 6 times more likely to have poor glycaemic 
control at 2-years follow-up than subjects who did not have severe periodontitis at 
baseline (Taylor et al., 1998b). 
Similar findings of increased prevalence of periodontal disease have also been 
reported in European populations with type 2 diabetes (Sandberg et al., 2000). 
Additionally, the NHANES data from the USA, found that adults with poorly controlled 
diabetes had an almost threefold increased risk of having periodontitis compared with 
adults without diabetes. Furthermore, adults with diabetes under good glycaemic control 
had no significant increase in risk for periodontal disease (Tsai et al., 2002). When 
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viewed from the wider perspective of maintaining systemic health, one study has shown 
that diabetics with severe periodontal disease are six times more likely to have poor 
glycaemic control (Taylor et al., 1996).  Furthermore, patients with severe periodontal 
disease have a significantly increased risk for microalbuminaemia and end stage renal 
disease compared to those who do not (Shultis et al., 2007). It has also been reported 
that diabetic Pima Indians with severe periodontal disease have an increased risk of 
death from diabetic nephropathy and ischemic heart disease (Saremi et al., 2005).  
Furthermore, in a large study that explored data from the NHANES study and follow-up 
evaluations for 9296 subjects, it was demonstrated that subjects with moderate levels of 
periodontal disease had a 2-fold increased odds for developing T2DM, and this 
increased risk was maintained even in those who had never smoked (Demmer et al., 
2008). 
Observations such as these lend support to the concept of a ‘bi-directional’ 
relationship between T2DM and periodontal disease, with T2DM being associated with 
increased prevalence and severity of periodontal disease, and periodontitis being 
associated with poorer glycaemic control or increased risk of diabetic complications. 
The principal findings of key studies that have investigated associations between 
periodontal disease and T2DM are summarised in Table 1.6. Taken collectively, the 
epidemiological evidence confirms that diabetes is a risk factor for periodontal disease. 
The risk for developing periodontitis is greater if diabetes control is poor and those with 
good diabetic control do not have a greater risk of periodontal disease than non-
diabetics (Tsai et al., 2002).
 Table 1.6 Principal and recent studies investigating links between periodontal disease & T2DM 
Author, Year Subjects Age Study design Principal findings 
(Nesse et al., 2009) 40 T2DM 58 ± 9.5 Cross-sectional In patients with T2DM a dose-response relationship was shown between HbA1c and 
the surface area of inflamed periodontal tissue (PISA). An increase of PISA by 
333mm2 was associated with a 1.0% increase of HbA1c. 
 
(Shultis et al., 2007) 529 T2DM 25-79 Prospective In patients with severe periodontal disease the incidence of developing end stage 
renal disease was 3.5 times as high compared to those with none/mild periodontitis. 
 
(Engebretson et al., 
2007) 
46 T2DM 54 Cross-sectional Serum TNF-α correlated with attachment loss (r=0.40, p=0.009). A dose-response 
relationship was observed between periodontitis severity and TNF-α (p=0.012). 
 
(Mattout et al., 2006) 71 T2DM, 
2073 controls 
35-65 Cross-sectional Significantly more attachment loss in T2DM patients.  More gingival inflammation 
in T2DM after controlling for plaque levels 
 
(Jansson et al., 2006) 191 T2DM 55 ± 5 Cross-sectional 20% of the T2DM patients had periodontal disease.  These subjects also had 
significantly higher HbA1c (7.1%) than periodontally healthy T2DM patients (6.5%) 
 
(Peck et al., 2006) 23 T2DM 59 ± 10 Cross-sectional Periodontal disease affected 42% of those with poor glycaemic control (HbA1c > 
8.0%) compared to 18% of those with good control (HbA1c < 8.0%) 
 
(Campus et al., 2005) 71 T2DM 
141 controls 
60 ± 10 Cross-sectional T2DM patients had significantly more missing teeth, pockets > 4 mm, bleeding on 
probing and plaque than control patients 
 
(Saremi et al., 2005) 628 ≥35 Prospective T2DM patients with severe periodontal disease had 3.2 times the risk of death from 
diabetic nephropathy and ischemic heart disease compared to those with 
none/mild/moderate periodontitis. 
 
(Lu and Yang, 2004) 72 T2DM 54 Cross-sectional Gingival inflammation and attachment loss were significantly higher in the T2DM 
 92 controls patients 
                                                                                                                                                                                                                                                
(Engebretson et al., 
2004) 
45 T2DM 32-69 Cross-sectional T2DM patients with poor glycaemic control (HbA1c > 8.0%) had significantly higher 
GCF IL-1β levels than better controlled T2DM patients 
 
(Tsai et al., 2002) 4343 T2DM 45-90 Cross-sectional Poorly controlled T2DM patients had a significantly higher prevalence of periodontal 
disease than those without T2DM (OR: 2.9, 95% CI: 1.4, 6.0) 
 
(Sandberg et al., 2000) 102 T2DM 
102 controls 
65 ± 8 Cross-sectional Significantly more T2DM patients (44.8%) had interproximal alveolar bone loss > 
1/3 root length compared to control subjects (25.5%) 
 
(Cutler et al., 1999a) 28 T2DM 
7 controls 
~28-66 Cross-sectional Probing depths, attachment loss and gingival inflammation were all significantly 
elevated in T2DM patients compared to controls 
 
(Taylor et al., 1998b) 24 T2DM 
338 controls 
15-57 Prospective Radiographic bone loss (up to 1/4 root length) was more prevalent in T2DM patients 
(67%) compared to controls (44%) 
 
(Emrich et al., 1991) 254 T2DM 
930 controls 
15-55+ Cross-sectional Prevalence of periodontal disease was higher in T2DM patients compared to non-
diabetic controls or subjects with impaired glucose tolerance 
 
(Shlossman et al., 
1990) 
736 T2DM 
2483 controls 
5-45+ Cross-sectional Periodontal disease was more prevalent in T2DM patients than controls 
 
 
(Nelson et al., 1990) 720 T2DM 
1553 controls 
15-55+ Cross-sectional 
and prospective 
83% of T2DM patients demonstrated interproximal bone loss compared to 19% of 
controls.  In follow-up appointments, the incidence of periodontitis was 60 new cases 
per 1000 person-years in T2DM patients compared to 17 new cases in controls 
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1.3.2 Mechanistic links 
The observed epidemiological associations between periodontitis and T2DM 
may arise from common pathological defects that result in increased susceptibility to 
both diseases. Furthermore, T2DM or specifically hyperglycaemia may also modify 
inflammatory processes contributing to local dysregulated immune-inflammatory 
responses, causing increased periodontal destruction.  
1.3.2.1 Inflammation 
It is increasingly recognised that inflammation plays a role in the development 
of T2DM. Low grade systemic inflammation precedes the development of T2DM 
(Freeman et al., 2002; Duncan et al., 2003; Bertoni et al., 2010) and plasma 
concentrations of IL-6 and TNF-α are increased in obese individuals and in those with 
T2DM (Ziccardi et al., 2002; Dandona et al., 2004). Further, prospective studies 
suggest that higher levels of systemic inflammation, such as serum IL-6 and CRP, 
predict future occurrence of T2DM (Pradhan et al., 2001; Bertoni et al., 2010).  
In response to hyperglycaemia, a variety of cells, including monocytes, 
macrophages, β-cells, endothelial cells and adipocytes, release pro-inflammatory 
cytokines, such as IL-6, TNF-α and IL-β (Morohoshi et al., 1996; Guha et al., 2000; 
Maedler et al., 2002; Donath et al., 2003; Shanmugam et al., 2003). Through the 
inhibition of intracellular insulin signalling cascades, TNF-α (Aguirre et al., 2000; 
Hotamisligil, 2000), IL-1β (Jager et al., 2007) and IL-6 (Senn et al., 2003) impair 
insulin action and contribute to the development of insulin resistance. Furthermore, 
blocking IL-1β has been shown to improve β-cell function and glycaemic control in 
patients with T2DM (Larsen et al., 2007; Donath et al., 2008). Also, research focusing 
on the modulation of inflammatory pathways has shown that, in patients with T2DM, 
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salsalate improved both inflammatory parameters and glucose homeostasis, highlighting 
the role of the inflammatory signalling cascade in the development of T2DM (Goldfine 
et al., 2008). Furthermore, cell culture experiments have demonstrated that in basal and 
LPS stimulated conditions, purified neutrophil cell preparations isolated from venous 
blood samples, released higher amounts of IL-1β and TNF-α in subjects with T2DM 
compared to non-diabetic controls (Hatanaka et al., 2006). 
Within the pathogenesis of periodontal disease, the importance of inflammation 
and the production of inflammatory cytokines is well recognised. A recent systematic 
review concluded that there was strong evidence from cross-sectional studies that 
plasma CRP was elevated in periodontitis-affected subjects compared with controls 
(Paraskevas et al., 2008). Cytokines, such as IL-1β, TNF-α and IL-6, are involved in the 
immune-inflammatory host reaction to the bacterial plaque biofilm with cell culture 
studies confirming that these cytokines are secreted by primary human epithelial cells 
following stimulation with periodontal pathogens (Eskan et al., 2008; Stathopoulou et 
al., 2009). Clinical research has also demonstrated elevated cytokine levels in tissue and 
GCF samples in disease compared to health (Stashenko et al., 1991b; Irwin and 
Myrillas, 1998; Engebretson et al., 2002; Lin et al., 2005; Zhong et al., 2007) with 
reductions following successful periodontal management (Engebretson et al., 2002). 
Circulating levels of IL-6 were higher in patients with periodontitis compared to 
periodontally healthy controls (Marcaccini et al., 2009; Sun et al., 2009) and systemic 
levels of IL-6 decreased following periodontal therapy (Marcaccini et al., 2009). 
Clearly, inflammatory cytokines contribute to the pathogenesis of both T2DM 
and periodontitis. Additionally, inflammation also provides a possible scientific basis 
for the increased susceptibility to periodontal disease seen in people with T2DM. 
Alterations in immunologically active molecules as a result of T2DM may alter the 
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complex cytokine network within the periodontium and thus contribute to local 
periodontal tissue destruction. 
Given the importance of inflammation, relatively few studies have, until 
recently, investigated the role of inflammatory cytokines in patients with T2DM and 
periodontitis. In one study, a trend for increasing GCF IL-1β concentrations was 
identified as diabetes control decreased (Cutler et al., 1999a).  Also, poorly controlled 
T2DM patients with untreated periodontitis have significantly higher GCF IL-1β levels 
than T2DM patients with moderate or good glycaemic control (Engebretson et al., 
2004).  A cell culture study of human monocytes, showed that the production of 
prostaglandin-E2 and IL-1β in response to challenge with LPS from P. gingivalis was 
significantly higher in monocytes from diabetic patients compared to non-diabetics with 
periodontitis (Salvi et al., 1997c). A further study demonstrated that in patients with 
T2DM, serum TNF-α correlated with attachment loss and a dose-response relationship 
was observed between periodontitis severity and circulating TNF-α (Engebretson et al., 
2007). More recently, a number of small studies have begun to document the impact of 
periodontal therapy on cytokines (see section 1.3.5 of the introduction) (Correa et al., 
2008; Dag et al., 2009; Correa et al., 2010; Kardesler et al., 2010; Santos et al., 2010; 
Kardesler et al., 2011). Table 1.7 summarises principal and recent studies investigating 
links between periodontal disease and T2DM.   
1.3.2.2 Adipokines  
Obesity is a risk factor for several chronic diseases, most notably hypertension, 
T2DM, dyslipdaemia and coronary heart disease (Gregg et al., 2005; Flegal, 2006; 
Pischon et al., 2007). Furthermore, a recent meta-analysis of data from cross-sectional 
studies demonstrate a positive association between periodontal disease and obesity 
(Chaffee and Weston, 2010) . Currently, a lack of longitudinal data limits understanding 
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of the causal relationship between obesity and periodontal disease and further studies 
would be required to clarify whether obesity is a risk factor for periodontal disease or 
that periodontitis increases the risk of weight gain (Chaffee and Weston, 2010). 
However, inflammation is described as the mechanism that links these two diseases 
(Pischon et al., 2007). 
In patients with T2DM, one potential source of cytokines is the adipose tissue, a 
recognised endocrine organ that secretes molecules involved in appetite regulation, 
metabolism and inflammation. Increased adipose mass associated with obesity is linked 
with a low-grade, chronic inflammatory response, characterised by altered production of 
adipokines and increases in biological markers of inflammation (Neels and Olefsky, 
2006; Galic et al., 2010). Furthermore, the increased mass of adipose tissue in obesity is 
associated with an increased infiltration with macrophages, capable of producing pro-
inflammatory cytokines (Coenen et al., 2007; Lumeng et al., 2007).  Indeed, expression 
of TNF-α has been shown to be increased in adipose tissue in obesity (Hotamisligil et 
al., 1993) with increased serum concentrations of both TNF-α and IL-6 seen in obese 
individuals (Ziccardi et al., 2002) and a positive correlation between IL-6 and body 
mass demonstrated in T2DM (Lazar, 2005). In addition to the contribution TNF-α and 
IL-6 have to the development of T2DM through their roles in both insulin resistance 
and β-cell dysfunction, they also have direct pro-inflammatory effects on inflammatory 
cells, including those in the periodontal tissues.  
The adipose tissue also secretes adipokines, such as leptin and adiponectin. 
Leptin is a major regulator of body weight by repressing food intake and promoting 
energy expenditure (Rabe et al., 2008). In addition to these actions, leptin is also 
involved in glucose homeostasis, modulating β-cell function (Niswender and 
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Magnuson, 2007) and improving insulin sensitivity in the liver and skeletal muscle 
(Minokoshi et al., 2002; Rabe et al., 2008).  
In addition to regulating appetite and energy storage, leptin is an important 
stimulator of inflammatory responses. It stimulates neutrophil chemotaxis and 
stimulates cytokine release by monocytes (Sanchez-Margalet et al., 2003). Furthermore, 
obesity appears to have an impact on leptin production and action. Leptin production is 
increased in obese compared to lean subjects (Fried et al., 2000). Therefore, it is 
plausible that elevated leptin levels in obese patients with T2DM may contribute to 
enhanced periodontal tissue destruction by activation of pro-inflammatory responses in 
the periodontium. However, the limited data on the role of leptin in periodontitis 
presents a confusing picture, with leptin concentrations in gingival tissue being 
inversely correlated with probing depths (Johnson and Serio, 2001) and higher GCF 
leptin levels measured in non-smokers than smokers, and higher in shallow pockets than 
deep pockets in non-smokers (Bozkurt et al., 2006).   
A further adipokine that may be relevant in the context of periodontitis and 
T2DM is adiponectin. Adiponectin regulates energy expenditure, stimulates glucose 
uptake and fatty acid oxidation in skeletal muscle and adipose tissue whilst also 
suppressing hepatic glucose output (Galic et al., 2010). Prospective and longitudinal 
studies indicate that lower levels of adiponectin are associated with a higher incidence 
of T2DM (Lindsay et al., 2002; Daimon et al., 2003; Spranger et al., 2003a; Duncan et 
al., 2004; Mather et al., 2008; Tabak et al., 2009), with a recent meta-analysis 
confirming that across diverse populations, higher adiponectin levels are associated with 
a lower risk of T2DM (Li et al., 2009). In obesity adiponectin levels are reduced and 
weight reduction leads to increases in circulating adiponectin (Ouchi et al., 1999; 
Matsubara et al., 2002). Furthermore, adiponectin is generally considered to have anti-
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inflammatory effects, and low levels of adiponectin have been associated with obesity, 
diabetes and cardiovascular disease (Kadowaki and Yamauchi, 2005). However, to date, 
there is no published research investigating the role of adiponectin in periodontitis. 
1.3.2.3 Altered neutrophil function 
Impaired or dysregulated PMN function may contribute a further mechanistic 
link between T2DM and periodontitis.  The role of PMNs in the maintenance of 
periodontal health is highlighted by studies that have reported impaired chemotaxis in 
aggressive forms of periodontitis (Sigusch et al., 2001). Reduced PMN function has also 
been found in patients with T2DM, including impaired chemotaxis (Mowat and Baum, 
1971; Gustke et al., 1998),  adherence (Bagdade et al., 1978), and phagocytosis 
(Marhoffer et al., 1992). Studies have correlated both periodontitis and diabetes with 
defective PMN chemotaxis; diabetic patients with severe periodontitis had depressed 
PMN chemotaxis compared to both diabetic patients with mild periodontitis and non-
diabetics with mild or severe periodontitis (Manouchehr-Pour et al., 1981; Bissada et 
al., 1982). 
Diabetes may also result in increased periodontal susceptibility via impaired 
PMN apoptosis (Graves et al., 2006).  Although, PMNs are key components of the 
defence mechanism against periodontal plaque bacteria in periodontitis, if apoptosis is 
delayed this may lead to increased retention of PMN in the periodontal tissues. This in 
turn could lead to increased tissue damage by the release of destructive MMPs and ROS 
by the PMNs. 
1.3.2.4 Hyperlipidaemia 
In T2DM hyperglycaemia is often accompanied by hyperlipidaemia. As part of 
the prevention of diabetes related complications, the management of hyperlipidaemia 
forms a major part of the management of T2DM (NICE, 2008).  
1 Introduction 55 
Research demonstrates an association between raised serum lipids and 
periodontitis. Studies have found that subjects with periodontal disease have 
hyperlipidaemia when compared with subjects with a healthy periodontium (Cutler et 
al., 1999b; Losche et al., 2000) and patients diagnosed with hyperlipidaemia have 
significantly higher values of periodontal parameters than control subjects with a 
normal metabolic status (Noack et al., 2000; Fentoglu et al., 2009). Recently, a small 
interventional study also demonstrated that improved periodontal health, following 
periodontal treatment, produced a positive effect on lipid parameters in patients with 
hyperlipidaemia and periodontitis (Fentoglu et al., 2010).  
Hyperlipidaemia is described as one of the factors associated with diabetes-
induced immune cell alterations (Iacopino and Cutler, 2000), however, only a few 
studies have investigated the effect of improved periodontal health on serum lipid 
profiles in subjects with T2DM (Kiran et al., 2005; Kardesler et al., 2010) . 
1.3.2.5 Advanced glycation endproducts 
In a hyperglycaemic environment, numerous proteins including collagen 
undergo a non-enzymatic glycosylation process to form AGEs. There is evidence that 
supports a role for AGEs via their interaction with cellular AGE receptor (RAGE) in 
exacerbating diabetic complications including periodontal disease (Jakus and Rietbrock, 
2004; Takeda et al., 2006). 
Binding of AGE to RAGE on monocytes and macrophages has been associated 
with an up-regulation of pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6 
(Lalla et al., 2001). Monocytes from patients with diabetes also produce significantly 
greater amounts of TNF-α, IL-1β and PGE2 in vitro than non-diabetic controls (Salvi et 
al., 1997a; Salvi et al., 1997c). The presence of RAGE in the gingival tissues has been 
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confirmed by immunohistochemistry in both diabetic and non-diabetic subjects (Katz et 
al., 2005). 
AGE formation also results in the production of ROS, and AGEs detected in the 
gingival tissues of diabetic patients have been shown to increase oxidant stress in these 
tissues when compared to non-diabetic individuals (Schmidt et al., 1996). Enhanced 
oxidant stress and the subsequent endothelial cell changes that occur may lead to 
vascular injury common to diabetic complications, including periodontal disease 
(Schmidt et al., 1994; Vlassara, 2001). AGEs also enhance the respiratory burst of 
PMNs (Wong et al., 2003).  This mechanism may contribute to local tissue damage in 
the periodontium of patients with T2DM, given the known importance of PMNs in 
periodontal tissue breakdown resulting from extracellular release of lysosomal contents.   
The irreversible nature of AGE formation and the interaction with RAGE creates 
environments in which cells are constantly exposed to these products, thereby creating 
heightened inflammatory responses. Studies support the view that AGE-mediated 
events are of primary importance in the pathogenesis of diabetic complications such as 
retinopathy, nephropathy, neuropathy and atherosclerosis. They may also be involved in 
changes within the periodontium, rendering T2DM patients with poor glycaemic control 
and elevated AGE production more susceptible to periodontal disease.  Thus, increased 
susceptibility to periodontal disease in patients with poorly controlled T2DM may be 
partly attributed to increased AGE deposition as a result of hyperglycaemia and 
subsequent increased activation of immune-inflammatory events via RAGE, and also 
the enhanced respiratory burst in PMNs.  This lends further support to the concept of 
the diabetic hyper-responder who mounts an upregulated periodontal immune-
inflammatory response to plaque bacteria, leading to increased tissue destruction.   
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1.3.3 Association between periodontal health and glycaemic control 
In a cross-sectional study, 46 patients with T2DM and chronic periodontitis 
were studied to determine the relationship between plasma TNF-α levels and clinical 
periodontal status, GCF levels of IL-1β and HbA1c levels (Engebretson et al., 2007). 
Plasma TNF-α showed a significant positive correlation with attachment loss (r=0.40, 
p=0.009) and GCF IL-1β (r=0.33, p=0.035). A dose-response relationship was observed 
between periodontitis severity and plasma TNF-α (p=0.012) (Engebretson et al., 2007). 
This study highlighted that chronic periodontitis is associated with TNF-α levels in 
subjects with T2DM, supporting the hypothesis that periodontal inflammation may 
contribute to systemic inflammation and insulin resistance seen in patients with T2DM. 
 To explore the possible dose-response relationship between periodontitis and 
HbA1c levels, a cross-sectional study assessed HbA1c and the clinical periodontal 
status in 40 patients with T2DM using PISA (Nesse et al., 2008; Nesse et al., 2009). 
Traditional definitions of periodontal disease are categorical and the calculation of PISA 
provides a composite numerical score to define periodontitis whilst also attempting to 
quantify the inflammatory burden from the periodontal tissues. Multiple linear 
regression analysis demonstrated a dose-response relationship between PISA and 
HbA1c in patients with T2DM and a PISA increase of 333 mm2 was associated with a 
clinically significant increase in HbA1c level of 1% (Nesse et al., 2009). A prospective 
treatment study will be required to further explore the impact of periodontal 
management on PISA and HbA1c. 
1.3.4 Periodontal treatment outcomes in people with diabetes 
In recent years, a number of studies have published clinical periodontal 
treatment outcomes in patients with T2DM (Stewart et al., 2001; Kiran et al., 2005; 
Promsudthi et al., 2005; Jones et al., 2007; Correa et al., 2008; O'Connell et al., 2008; 
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Dag et al., 2009; Kardesler et al., 2010; Kardesler et al., 2011) (Table 1.7). The clinical 
treatment outcomes assessed in these studies include reduction in probing depths, gain 
in clinical attachment and reduction in bleeding on probing and overall, these studies 
have confirmed that positive clinical periodontal treatment outcomes to non-surgical 
periodontal management in patients with T2DM (Stewart et al., 2001; Kiran et al., 
2005; Promsudthi et al., 2005; Jones et al., 2007; Correa et al., 2008; O'Connell et al., 
2008; Dag et al., 2009; Kardesler et al., 2010; Kardesler et al., 2011). Furthermore, 
studies that evaluated periodontal treatment outcomes in subjects with and without 
T2DM have confirmed similar improvements in periodontal health for both T2DM and 
non-diabetic subjects (Correa et al., 2008; Dag et al., 2009; Kardesler et al., 2010; 
Santos et al., 2010; Kardesler et al., 2011) (Table 1.7). 
More recently, composite assessments have also been used to evaluate the 
periodontal condition of patients with T2DM, incorporating within a numerical score, 
both periodontal epithelial surface area and BOP (Nesse et al., 2008; Nesse et al., 2009) 
and thus providing an evaluation of the inflammatory burden produced from the 
periodontium. However, to date, there are no published data exploring the impact of 
periodontal therapy on such composite measures. 
1.3.5 Impact of periodontal treatment on inflammation in T2DM 
Periodontal inflammation may contribute to the systemic inflammatory 
component of insulin resistance and T2DM. Furthermore, alterations in 
immunologically active molecules as a result of T2DM may alter the cytokine network 
within the periodontium and thus contribute to local periodontal tissue destruction 
(Preshaw et al., 2007).  
Recently, a number of small prospective treatment studies have begun to 
document the impact of periodontal therapy on markers of inflammation, with some 
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studies evaluating local cytokine levels (Correa et al., 2008; Santos et al., 2010; 
Kardesler et al., 2011) and other studies evaluating circulating cytokine levels (Dag et 
al., 2009; Correa et al., 2010; Kardesler et al., 2010) (Table 1.7). However, to date, the 
impact of periodontal therapy on both local and systemic cytokines has not been 
investigated within a study (Table 1.7). 
The impact of periodontal management on serum levels of multiple mediators 
was assessed in a prospective treatment study of patients with T2DM (n=30), with a 
significant reduction in IL-6 levels were demonstrated following treatment, but not for 
other relevant mediators, such as TNF-α, IL-1β (O'Connell et al., 2008). As part of a 
small prospective treatment study, 13 subjects with T2DM were provided with 
mechanical periodontal debridement and local delivery of minocycline for 4 weeks. 
Serum TNF-α levels pre- and post-treatment were then assessed. Following treatment a 
significant reduction in serum TNF-α was demonstrated (p<0.015) (Iwamoto et al., 
2001). This study also showed a strong correlation between reduction in serum TNF-α 
concentration and in the reduction in HbA1c following periodontal treatment, with the 
authors concluding the improvements in metabolic control following the periodontal 
treatment may possibly be mediated by reduced serum TNF-α (Iwamoto et al., 2001). 
Recently, a small prospective treatment study assessed the impact of periodontal 
therapy on systemic inflammatory mediators. In 13 well controlled (HbA1c <7%)  and 
12 poorly controlled (HbA1c ≥7%) patients with T2DM and 15 non-diabetic subjects, 
serum levels of TNF-α, IL-6 and CRP were quantified by ELISA before and then 1and 
3 months after non-surgical periodontal management (Kardesler et al., 2010). At 3 
months post-treatment, the only significant reduction was in the serum IL-6 levels in 
well controlled patients with diabetes and non-diabetics. Interestingly, this was also the 
first study to publish the impact of periodontal management on serum levels of 2 
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adipokines, leptin and adiponectin. Compared to pre-treatment levels, the non-diabetic 
group had increased adiponectin levels at month 3 (p<0.05) and leptin levels were 
increased in well-controlled patients with diabetes at month 1 (p<0.05) (Kardesler et al., 
2010). In a similar study, the impact of periodontal therapy on serum TNF-α levels was 
assessed in T2DM and non-diabetic subjects, and a significant reduction in serum TNF-
α was demonstrated in both groups at 3 months post periodontal treatment compared to 
baseline levels (Dag et al., 2009). 
The impact of non-surgical periodontal therapy on levels of IL-1β and MMP-8 
and -9 was assessed in patients with (n=23) and without (n=26) T2DM. Following 
periodontal therapy, a significant reduction in GCF volume and the total amount of IL-
1β and MMP-8 and -9 was seen in deep sites and significant reductions in GCF volume 
and the total amount of IL-1β were seen in shallow sites. No significant differences in 
total amount of the mediators in both deep and shallow sites were found between 
diabetes and non-diabetic controls at baseline and follow-up (Correa et al., 2008). The 
reduction in GCF IL-1β levels following periodontal treatment would confirm data from 
earlier studies investigating non-diabetics (Engebretson et al., 2002). 
Given the wide clinical use of CRP to quantify systemic inflammatory state and 
assess the related cardiovascular risk, it is surprising that few studies document the 
impact of periodontal therapy on CRP levels in patients with T2DM. In a small pilot 
study hsCRP levels were assessed before and 4 weeks after non-surgical periodontal 
therapy in subjects with diabetes (n=10) and showed that following treatment, mean 
hsCRP levels were significantly decreased from 2.3 to 1.5 mg/L (p<0.01) (Lalla et al., 
2007). Unfortunately, a lack of non-diabetic control group precludes conclusions being 
drawn about the importance of diabetes.  In a further study of 33 patients with diabetes 
and 20 non-diabetic controls, there were no significant differences found in the median 
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CRP values either before or 4 months after periodontal management (Christgau et al., 
1998). Both of these studies are limited by the inclusion of both T2DM and T1DM 
patients, given their differing pathology. In a more recent study of 23 patients with 
T2DM, a non-significant decrease in hsCRP was found following improved periodontal 
health (Correa et al., 2010) however, interpretation of this result is difficult given the 
lack of a non-diabetic control group. 
Among the prospective treatment studies investigating the impact of periodontal 
therapy on cytokine levels, there is considerable heterogeneity in terms of the 
methodology. For example, the inclusion criteria for periodontal case definition and the 
choice of cytokines studied lacks consistency and varying sampling and elution methods 
are used for GCF.  Drawing simple, clear conclusions from these studies is therefore 
difficult.  As a general rule, many of these studies have used very small numbers of 
subjects, and focussed on one or two mediators at a time which limits our understanding 
of the complexity of cytokine networks is important in both T2DM and periodontitis. 
Furthermore, none of the studies have simultaneously assessed local and systemic 
inflammatory cytokine levels following periodontal therapy and thus the conclusions 
that can be drawn from the literature are compromised.  
The interplay between local inflammation within the periodontal tissues, 
systemic inflammation and glycaemic control is complex and not fully understood. To 
clarify the impact of periodontal treatment on systemic inflammation in patients with 
T2DM, further studies are required to assess glycaemic control, CRP and explore the 
relevance of relevant cytokines and adipokines both locally within the GCF and 
systemically. 
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1.3.6 The impact of periodontal treatment on glycaemic control and lipid 
profiles 
In addition to the observational evidence highlighting the relationship between 
periodontal disease and T2DM, increasing numbers of interventional studies have been 
conducted to explore the effects of periodontal disease on glycaemic control in patients 
with diabetes. In patients with T2DM the impact of periodontal management on 
glycaemic control, as measured by HbA1c, has been investigated using controlled and 
non-controlled interventional studies (Table 1.7). 
A randomized clinical trial was carried out in the USA to study the efficacy of 
periodontal management on glycaemic control of 165 veterans over 4 months (Jones et 
al., 2007). HbA1c was the main outcome measure when comparing the treatment group 
(n=82), that received periodontal instrumentation, a 2 week course of systemic 
doxycycline and daily chlorhexidine rinse, against the control group (n=83) that 
received no periodontal management as part of the research. To enable improvements in 
glycaemic control to be studied, only subjects with poorly controlled diabetes, indicated 
by a HbA1c score of ≥8.5%, were included. Mean baseline HbA1c levels were 10.2% 
and 9.9% for control and treatment group respectively. However, 4 month mean HbA1c 
data for each group were not published. Between group differences in the mean change 
in HbA1c of the study period were not significant, even after controlling for baseline 
HbA1c, duration of diabetes and age. The number of subjects achieving clinically 
significant reductions in HbA1c of 0.5% and 1% (Stratton et al., 2000) was not 
significantly different between groups. Therefore, the study concluded that no 
significant benefit in glycaemic control was found at 4 months post-periodontal therapy. 
Unfortunately, the inclusion criteria were based on subjects having a community 
periodontal index of treatment need (CPITN) score of ≥3 in at least two sextants. 
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Furthermore, despite the central role of periodontal inflammation in the biological 
rationale supporting periodontal management and glycaemic control, data to clarify the 
periodontal status of each group were not published. This precludes conclusions being 
made about the relative success of periodontal management and its influence on 
glycaemic control.   
In a smaller randomised control trial (RCT), the effect of improved periodontal 
health on metabolic control was investigated in 44 subjects with T2DM (Kiran et al., 
2005). Between baseline and the 3 month review, HbA1c levels in the treatment group 
showed a significant decrease whereas the control group had a non-significant increase 
in HbA1c. Caution on the interpretation of this result must be used since only subjects 
with HbA1c values of 6-8% were included. Therefore, excluding subjects with poor 
glycaemic control and artificially restricting the standard deviations of the mean values 
for each group, could potentially have enabled significant differences to be achieved 
more easily. Additional metabolic data including triglyceride, total cholesterol, high 
density lipoproteins and low density lipoproteins showed no significant changes 
following periodontal treatment. The study also describes significant improvement in 
plaque index (PI), gingival index (GI), probing depths (PD), LOA and BOP in the 
treatment group but not in the control group. However, only mean periodontal data were 
presented, thus simplifying and missing valuable PD, recession or LOA data and failing 
to adequately describe the tissue response occurring following periodontal treatment. 
Therefore, although the study concludes that non-surgical periodontal treatment is 
associated with improved glycaemic control in patients with T2DM, the limitations of 
the study in reporting periodontal data and using restricted HbA1c values as inclusion 
criteria weaken this conclusion (Kiran et al., 2005). 
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Consideration of additional intervention studies both controlled (Stewart et al., 
2001; Promsudthi et al., 2005; O'Connell et al., 2008) and non-controlled (Grossi et al., 
1997; Iwamoto et al., 2001) also demonstrate inconsistent results regarding the impact 
of periodontal management on HbA1c. More recently, meta-analyses have been 
conducted in an attempt to clarify whether periodontal treatment has an effect on 
glycaemic control (Janket et al., 2005; Darre et al., 2008; Simpson et al., 2010). In the 
earlier meta-analysis of 10 intervention studies to quantify the effects of periodontal 
therapy on HbA1c, a weighted mean HbA1c decrease of 0.66% was observed, though 
this did not achieve statistical significance (Janket et al., 2005). Darré et al used a 
systematic review to identify 9 controlled interventional studies, providing a total of 485 
patients, to be included into the meta-analysis (Darre et al., 2008). This meta-analysis 
indicated that periodontal treatment effectively reduced HbA1c levels with a calculated 
standardised mean difference (SMD) in HbA1c of 0.46 which was found to be 
significant (95% confidence interval (CI), 0.11, 0.82; p=0.01). Additionally, when the 
SDM was back-transformed, by multiplying by it by a ‘typical’ standard deviation (SD), 
into the original HbA1c units, the findings suggested that periodontal treatment could 
lead to a clinically significant 0.79% reduction in HbA1c values. However, the authors 
expressed caution regarding the interpretation of this result following the finding that 
exclusion of a single study (Stewart et al., 2001) decreased the SMD to a non-
significant value of 0.27 (95% CI, -0.01, 0.60).  
In the most recent, meta-analysis, the effect of the mean % difference in HbA1c 
for NSM, with or without antibiotic therapy, against no treatment or usual treatment was 
-0.40% (95% CI, -0.78, 0.01), representing a statistically significant reduction in HbA1c 
(p=0.04) for NSM and the authors concluded that some evidence exists for 
improvements in metabolic control in people with di
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although larger studies are required to fully understand the potential of periodontal 
therapy to improve glycaemic control in people with diabetes (Simpson et al., 2010). 
Clearly, there is a lack of conclusive evidence to recommend periodontal 
management as an effective means to reduce HbA1c levels in people with diabetes. 
Darré and co-workers highlighted that a RCT with sufficient statistical power would be 
invaluable, and their post-hoc calculation showed that a minimum sample size of 150 
participants would be required (Darre et al., 2008; Garcia, 2009). Subsequently, a study 
protocol for a randomised, controlled trial has recently been published (Vergnes et al., 
2009). This study aims to assess whether periodontal treatment could lead to a decrease 
in HbA1c in diabetic patients with periodontitis. The target sample size is 150 
participants, with half in the immediate treatment group and half in a delayed treatment 
group. Periodontal treatment will include NSM with systemic antibiotic therapy and 
chlorhexidine mouthwash. The difference in change of HbA1c and quality of life 
between the two groups will be assessed at a 13 week follow-up appointment.  
 In patients with T2DM, the effective management of dyslipidaemia, including 
raised serum levels of total cholesterol, low density lipoproteins (LDL) and triglycerides 
(TG) is an integral part of diabetic management. It has been proposed that dyslipdaemia 
plays an integral part, along with systemic inflammation, in the relationship between 
periodontal tissue inflammation and diabetes (Iacopino and Cutler, 2000). However, 
studies that investigated the impact of periodontal management on lipid profiles in 
patients with periodontitis and T2DM have failed to demonstrate significant changes in 
lipid levels (Kiran et al., 2005; Kardesler et al., 2010). 
 Table 1.7  Studies investigating the impact of periodontal therapy on periodontal health, glycaemic control and cytokine levels  
Author, Year Sample size        
(n) 
Duration 
(weeks) 
Treatment 
provided 
Changes in periodontal 
health  
Changes in cytokines  Changes in HbA1c  
(Kardesler et al., 
2011) 
T2DM: 20 
non-diabetic: 22 
 
12 NSM 
 
Significant improvement 
in PI, GI, PD, CAL and 
BOP for both groups.  
 
A non-significant significant reduction in 
total amount of IL-6 in GCF in T2DM 
and non-diabetic subjects (data values not 
published) 
 
T2DM reported a significant 
reduction in HbA1c in T2DM 
subjects (data values not published) 
(Santos et al., 2010) Well controlled 
T2DM: 18 
Poorly controlled 
T2DM: 20 
 
24 NSM Significant improvement 
in PI, GI, PD, CAL and 
BOP for both groups. 
No significant change in total amount of 
TNF-α, IL-4, IL-17 and IL-23 in GCF in 
both well and poorly controlled T2DM 
subjects. Total amount of INF-γ in GCF 
showed a significant increased in well 
controlled T2DM but no change in poorly 
controlled T2DM subjects (data values 
not published) 
Mean HbA1c showed a non-
significant increase of 0.3% and 1.3 
% in poorly and well controlled 
T2DM subjects  respectively 
(Correa et al., 2010) T2DM: 23 
 
12 NSM 
 
Significant improvement 
in PI, GI, PD, CAL and 
BOP for both groups 
 
Median plasma TNF-α levels showed a 
significant reduction of 1.1pg/ml. Plasma 
IL-4, IL-6, IL-8 & Il-10 levels showed 
non-significant reductions of 3.7, 0.8, 0.6, 
3.3pg/ml respectively. 
Non significant reduction in median 
HbA1c of 0.4% 
(Kardesler et al., 
2010) 
Well controlled 
T2DM: 13 
Poorly controlled 
T2DM: 12 
Non-diabetic: 15 
12 NSM 
 
Similar improvements in 
PI, PD, CAL and BOP 
for all groups for 
Serum TNF-α levels showed non-
significant reductions in all groups. Serum 
IL-6 levels showed a significant reduction 
in well controlled T2DM and non-diabetic 
subjects and a non-significant reduction in 
poorly controlled T2DM subjects. (data 
values not published) 
Poorly controlled T2DM showed a 
significant reduction in HbA1c 3 
months after periodontal treatment 
(P<0.05) 
 (Dag et al., 2009) 
 
Well controlled 
T2DM: 15 
Poorly controlled 
T2DM: 15 
Non-diabetic: 15 
12 NSM Significant improvement 
in PI, GI, PD, CAL and 
BOP for all groups 
Mean serum TNF-α levels showed a 
significant reduction of 2.1, 2.17 and 
2.70pg/ml in well controlled T2DM, 
poorly controlled T2DM and non-
diabetic subjects respectively 
Mean HbA1c showed a significant 
reduction of 0.21% in well 
controlled T2DM subjects and a 
non-significant reduction of 0.19% 
in poorly controlled T2DM subjects 
(Correa et al., 2008) T2DM: 23 
non-diabetic: 26 
 
13 NSM 
 
Significant improvement 
in PI, GI, PD, CAL and 
BOP for both groups. 
Median total amount of IL-1β showed 
significant reduction of 83.4 and 
38.7pg/ml in T2DM and non-diabetic 
subjects respectively 
In T2DM group, following 
periodontal treatment the mean 
HbA1c showed a non significant 
reduction of 0.31± 1.81% 
(O'Connell et al., 
2008) 
treatment A: 15 
treatment B: 15 
 
12 NSM +/-
doxycycline 
 
At follow-up significant 
improvement in PI, GI, 
PD, CAL and BOP for 
both treatment groups. 
No significant difference 
between groups. 
Multiple serum cytokines levels assessed 
(n=30). Significant reduction in mean 
serum IL-6 levels of 1pg/ml. No change 
in serum TNF-α and IL-1β levels and a 
non-significant increase in serum IFN-γ. 
Following treatment a significant 
reduction in HbA1c of 1.5% for the 
group with doxycycline. No 
significant difference between 
groups. 
(Jones et al., 2007) treatment: 82 
usual care: 83 
16 NSM + 
doxycycline   
 Data not published Data not published Both groups had mean HbA1c 
reduction that was not significant. 
Between group difference in HbA1c 
was clinically and statistically not 
significant. Number of subjects 
achieving reductions in HbA1c of 
0.5% and 1% was not significantly 
different between groups. 
(Kiran et al., 2005) treatment: 22 
no treatment: 22 
12 NSM At follow-up significant 
improvement in PI, GI, 
PD, CAL and BOP for 
treatment group 
Data not published HbA1c levels in the treatment 
group decreased significantly from 
7.31 ± 0.74 to 6.51 ± 0.80, whereas 
the control group showed a slight 
but insignificant increase in HbA1c. 
 (Promsudthi et al., 
2005) 
treatment: 27 
no treatment: 25 
12 NSM+ 
doxycycline 
At follow-up significant 
improvements in PI, PD, 
CAL and BOP for 
treatment group with 
shallower  PD and less 
CAL compared to the  
control group 
Data not published Following treatment, the reduction 
in HbA1c did not reach 
significance. Although more 
patients in the treatment group had 
a decrease in HbA1c this difference 
was not significant. 
(Rodrigues et al., 
2003) 
treatment A: 15 
treatment B: 15 
12 NSM+/- 
amoxicillin 
 
Following treatment a 
significant reduction in 
PD, BOP and PI was 
recorded in both groups. 
No significant changes in 
CAL. 
Data not published HbA1c reduced in both groups, 
although only changes in group 
receiving instrumentation without 
antibiotics reached significance 
(Stewart et al., 2001) treatment: 36 
control: 36 
43.5 NSM 
 
Periodontal treatment 
outcomes not published 
and periodontal status of 
control group not known 
Data not published Statistically significant reductions 
in HbA1c in both the treatment 
group (from 9.5% to 7.6%) and 
control group (from 8.5% to 7.7%). 
 
(Iwamoto et al., 
2001) 
treatment: 13 4 NSM +local 
minocycline 
No significant change in 
mean PD following 
treatment. Further 
periodontal data not 
published. 
 
Data not published Following periodontal treatment 
HbA1c levels reduced significantly 
7.96 ± 1.94 to 7.12 ± 1.48 
 
Table shows and overview of interventional studies investigating changes in glycaemic control, periodontal health and cytokine levels following 
periodontal management in patients with T2DM
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1.4 Aims of the study 
1. To clinically characterise the periodontal status of a local North East population of 
patients with T2DM by measuring the extent and severity of periodontal disease. 
2. To explore the local levels in GCF and saliva of pro-inflammatory cytokines (IL-1β, 
TNF-α and IL-6) in patients with T2DM compared to non-diabetic patients. 
3. To explore the systemic levels in serum of pro-inflammatory cytokines (IL-1β, TNF-
α and IL-6) in patients with T2DM compared to non-diabetic patients. 
4. To investigate associations between clinical periodontal status, inflammatory 
cytokine levels and markers of diabetes control. 
5. To investigate the clinical periodontal healing in patients with T2DM and 
periodontitis following NSM and evaluate the impact of improved periodontal health 
on markers of diabetes control and local and systemic inflammatory cytokine levels. 
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Chapter 2 Materials and methods 
2.1 Ethical approval 
Ethical approval for this research was obtained from Sunderland Local Research 
Ethics Committee (ref 06/Q0904/8). The application included a protocol of the study 
that highlighted particular ethical issues pertaining to the study, with the main ethical 
problems being related to the samples that were collected (GCF, saliva, blood) which 
were purely for research purposes and would otherwise not be collected.  This was 
made clear to prospective participants in the information sheet.  Whereas collection of 
GCF and saliva samples was non-invasive, quick and painless, collection of blood 
samples could be associated with discomfort and there was the potential for unwanted 
events (e.g. bruising). The risks of venepuncture were minimised by the use of trained, 
experienced clinicians to obtain the blood samples. The periodontal examinations and 
treatment that was provided as part of the study constituted routine clinical care and one 
positive aspect of the study was that the T2DM patients received an oral and periodontal 
examination, and if they are found to have periodontal disease, treatment was offered. 
Patients were also given information and instruction on how to better maintain good 
oral and periodontal health. All samples collected and all data recorded were stored 
anonymously, using a coding system. No information that was generated as part of this 
research had an impact on the patients’ clinical care and no feedback of the results of 
analysis of individual samples was given to individual patients. 
2.2 Patient recruitment and discharge 
T2DM patients were recruited from both secondary care databases, held by Dr. 
Weaver at the Queen Elizabeth Hospital in Gateshead and Professor Roy Taylor at 
Newcastle University, and databases held within primary care settings, such as general 
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medical practices that are part of the North East Diabetes Research Network. The 
information held on the databases in both primary and secondary care settings, allowed 
T2DM patients matching the age criteria to be identified. These patients were sent a 
letter informing them about the research and inviting them to participate. Patient 
participation was on an ‘opt-in’ basis.  If patients then contacted the research team to 
indicate that they would like to participate, a short telephone screening took place to 
ensure they fitted within the inclusion and exclusion criteria. Patients were then sent the 
full information sheet to read, and arrangements were made for them to attend the 
Dental Hospital for the pre-treatment screening appointment. Recruitment of non-
diabetic patients involved the identification of suitable patients from either those 
referred from general dental practice into the restorative department within the School 
of Dental Sciences or patients seen on student treatment clinics within the School of 
Dental Sciences. Each non-diabetic subject was matched to a previously recruited 
T2DM subject. Subjects were matched based on age (within 5 years), gender, smoking 
status and periodontal diagnosis. Suitable non-diabetic subjects were approached during 
an appointment at the dental hospital, informed about the study and given the 
opportunity to decide whether to participate. 
 Patients recruited fulfilled the following inclusion criteria: 30-55 years old, male 
or female, with a minimum of 20 natural teeth.  Exclusion criteria included pregnancy, 
immunosuppression, any condition requiring prophylactic antibiotics prior to dental 
treatment, bleeding disorders, prolonged bleeding as a result of medication, drug-
induced gingival overgrowth, any medical condition that could compromise safe 
participation in the study, or any patient who had undergone non-surgical therapy for 
periodontal disease in the last 6 weeks. 
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At the pre-treatment screening appointment, patients who were identified as 
having periodontal disease were offered the necessary treatment and these patients were 
monitored as part of the longitudinal component of the study.  The patient’s general 
medical practitioner (GMP) and general dental practitioner (GDP) were informed via 
letter of their involvement in the research. Following completion of the study, patients 
were discharged back to their GDP for long-term periodontal maintenance care, with a 
written discharge letter that detailed the maintenance plan that the GDP should follow. 
For those patients identified at the screening appointment as not having periodontal 
disease, their participation in the study was limited to the screening visit only. For these 
patients without periodontal disease they were offered oral hygiene advice and a 
prophylaxis and this was provided at the screening appointment. If the clinical 
examination identified other dental or oral problems, such as caries, appropriate 
management was arranged within general dental practice or in the dental hospital, for 
patients not registered with a GDP.  
2.3 Consent 
Written informed consent was obtained when the patient first attended, at the 
start of the pre-treatment screening appointment. This process involved a clinician 
confirming that the patient had received and understood the written information about 
the study. The clinician then verbally confirmed the background and aims of the study 
as well as the potential benefits and risks of participation in the study. Each subject had 
the opportunity to ask questions and not to participate in the study. Subjects wishing to 
participate in the study then signed two copies of the consent forms, one copy was 
retained within the patient’s individual case report form and one copy was given to the 
patient. 
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2.4 Power calculation and estimation of sample size 
Providing a definitive power calculation at the planning stage of the study was 
difficult given the paucity of studies that had investigated this area at that time. Using 
data (Kiran et al., 2005) from a study published at the time of planning, a power 
calculation provided an estimate of the number of patients required with periodontitis 
for detecting significant changes in HbA1c over 12 months. Therefore, to provide a 
85% power for detecting significant changes in HbA1c over 12 months, assuming 
α=0.05, δ=0.6% and σ=1.0%, it was estimated that 30 patients with periodontitis and 
diabetes would be required to be followed for the duration of the study. To compensate 
for an estimated 20 % drop out of subjects, the aim was to recruit 36 T2DM subjects 
with periodontitis into the study. Using an estimate of the prevalence of periodontitis in 
diabetic populations of approximately 30% (Nelson et al., 1990), it was estimated that 
140 T2DM subjects would be required to be screened in order to identify 36 T2DM 
patients with periodontitis. 
2.5 Periodontal disease case definition 
At the first visit (pre-treatment screening), all subjects received a full periodontal 
examination, including PI, modified Gingival Index (mGI), PD, recession and BOP. 
Radiographs were obtained as clinically indicated, and clinical and radiographic 
examinations were used to confirm the periodontal diagnosis based on diagnostic 
criteria (Table 2.1). Difficult diagnoses were resolved by discussion between two 
clinicians. 
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Table 2.1  Periodontal Diagnostic Criteria   
 
Healthy 
Periodontium 
 
BOP ≤ 15% 
No probing depth sites >4mm 
No attachment loss – disregard localised recession (e.g. due to 
tooth brush trauma) 
No bone loss 
 
 
Gingivitis 
 
 
BOP > 15% 
No sites with probing depths > 4mm, except for up to 5 sites 
with 5mm probing depths (e.g. at distal surface of last standing 
molars) 
No attachment loss - disregard localised recession (e.g. due to 
tooth brush trauma) 
No bone loss 
 
 
Periodontitis 
 
 
≥ 6 sites with probing depths of ≥ 5mm 
Loss of attachment and / or bone loss 
 
Robust case definitions for periodontal status are required to avoid misclassification of 
subjects. Table shows the case definitions used in the current study to define 
periodontitis, gingivitis and healthy periodontium. 
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2.6 Clinical protocol 
2.6.1 Plaque scores 
The plaque index (PI) of Silness and Loe was used (Silness and Loe, 1964) as follows: 
0 No plaque. 
1 A film of plaque adhering to the free gingival margin and the adjacent area of 
the tooth. The plaque may be seen in situ only after application of disclosing 
solution or by using the probe on the tooth surface. 
2 Moderate accumulation of soft deposits within the gingival pocket, or the tooth 
and gingival margin which can be seen with the naked eye. 
3 Abundance of soft matter within the gingival pocket and/or on the tooth and 
gingival margin.  
The tooth was dried with a gentle stream of air and disclosing solution was not 
used. Visual examination was sufficient to identify sites with a score of 2 or 3. If no 
plaque could be seen with the unaided eye, the probe was swept along the gingival 
margin to differentiate between a score of 1 (if plaque was present on the probe tip) or 0 
(with no plaque present). The presence or absence of plaque was recorded at 6 sites per 
tooth on the four target teeth from which GCF samples were taken. The scores were 
recorded immediately by an assistant (as were gingival scores, probing depths, recession 
and bleeding scores). 
2.6.2 Modified Gingival Index 
The modified gingival index (mGI) (Lobene et al., 1986) was used to clinically 
assess gingival inflammation as follows: 
0 Absence of inflammation. 
2  Materials and methods 76 
1 Mild inflammation; slight change in colour, little change in texture of any 
portion but not the entire gingival margin or papillary gingival unit. 
2 Mild inflammation; criteria as above but involving the entire marginal or 
papillary gingival unit. 
3 Moderate inflammation; glazing, redness, oedema and/or hypertrophy of the 
marginal or papillary gingival unit. 
4 Severe inflammation; marked redness, oedema and/or hypertrophy of the 
marginal or papillary gingival unit, spontaneous bleeding, congestion or 
ulceration.  
The gingival tissue was dried with a gentle stream of air. Visual examination 
was used to allocate a score at 6 sites per tooth on the four target teeth, from which GCF 
samples were taken. A score of 0 was allocated if no inflammation was seen and a score 
of 4 was given if the tissues were severely inflamed displaying spontaneous bleeding, 
ulceration or marked swelling/redness. A score of 1 was given if only part of the area 
was inflamed. Scores 2 and 3 indicated mild and moderate inflammation that affected 
the entire area. 
2.6.3 Probing depth 
The University of North Carolina (UNC) 15 probe (Dentsply, Addlestone, UK) 
was used to measure probing depths (PD), taken as the distance from the gingival 
margin to the base of the pocket. The probe was inserted into the pocket and advanced 
apically, along the long axis of the tooth, until the resistance of the gingival tissue at the 
base of the pocket was felt. The probing depth recording was made in mm by direct 
visualisation of the probe markings. Probing depths were recorded at 6 sites per tooth 
for all teeth present, excluding the 3rd molars. 
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2.6.4 Bleeding on probing 
Following the completion of probing depths within one aspect of a quadrant (for 
example, buccal aspect of the upper right quadrant) the probing sites were re-examined 
to determine whether post-probing bleeding occurred. Bleeding status was recorded 
dichotomously at 6 sites per tooth depending on the presence or absence of bleeding 
from the base of the pocket following probing. 
2.6.5 Recession 
The UNC 15 probe was used to measure recession, taken as the distance from 
the cemento-enamel junction (CEJ) to the gingival margin. Recession was measured 
whilst the probe was inserted into the pocket during the probing depth assessment. 
When the CEJ could be seen above the gingival margin, the recession recording was 
made in mm by direct visualisation of the probing markings. When the CEJ was below 
the gingival margin, the trained clinician estimated the position of the CEJ in relation to 
the gingival margin and made a negative recording in mm. Recession was recorded at 6 
sites per tooth for all teeth present, excluding the 3rd molars. 
2.6.6 Loss of attachment  
The value for loss of attachment (LOA) was the sum of probing depth and 
recession, and is therefore, the distance from the CEJ to the base of the pocket.  LOA 
was calculated at 6 sites per tooth for all teeth present, excluding the 3rd molars. 
2.6.7  Periodontal epithelium surface area and periodontal inflamed 
surface area  
Using a previously published Excel spread sheet, PESA (mm2) and PISA (mm2) 
were calculated for each subject (Nesse et al., 2008). Firstly, LOA and recession values 
at 6 sites per tooth were entered, allowing PESA for each tooth to be calculated. The 
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PESA for each tooth was multiplied by the proportion of sites around the tooth that was 
affected by BOP to calculate the PISA for each tooth. The sum of all individual PISAs 
around individual teeth gave the total PISA (mm2) within each subject’s mouth and 
similarly the sum of all individual PESA gave total PESA (mm2). 
2.6.8 Smoking status 
Pre-treatment and at month 12 smoking habits were assessed, according to 
whether the subjects were current, non, or ex-smokers and the smoking extent of the 
current and ex-smokers further quantified according to the standardised measure of pack 
years.  This equates the number of cigarettes smoked by each patient to the number of 
pack years smoked, a pack year being equal to smoking 1 pack of 20 cigarettes per day 
for 1 year.   
2.6.9 Demographic data 
At the pre-treatment screening visit, demographic data including age and gender 
was recorded. Socio-economic status was assessed using index of multiple deprivation 
(IMD).  A number of indicators, covering a range of economic, social and housing 
issues are combined to produce a single IMD each small area in England. Each area can 
also be ranked relative to another according to their level of deprivation. The Office of 
National Statistics’ online neighbourhood statistics tool was used to calculate IMD from 
a subject’s 6 digit postcode.  
2.6.10  Diabetes history 
For all subjects with T2DM a diabetes history was taken at the screening visit. 
This included years since diagnosis, age at diagnosis, family history of diabetes, method 
of diabetes control, level of glycaemic control in the last year (good/moderate/poor), 
presence of macro- and microvascular diabetes complications and medications. 
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2.6.11  Physical examination 
At the pre-treatment screening, month 6 and month 12 visits, subject’s blood 
pressure was recorded using the subject’s right upper arm, with the patient seated using 
an automated machine. Height and weight were also recorded allowing body mass index 
(BMI) to be calculated by dividing the weight (in kilograms) by the square of the height 
(in metres). 
2.6.12  Oral examination 
At the pre-treatment screening visit, oral soft tissues were examined to identify 
any lesions, oral candidosis or xerostomia. Denture use was also recorded. The dentition 
was then examined, teeth were assessed on a pre-defined dental examination criteria 
(Kelly, 2000), recording the number of teeth in each category (Table 2.2). 
2.6.13   Oral health behaviour 
At the pre-treatment screening appointment, subjects were asked closed 
questions regarding oral health behaviour. Questions included frequency of tooth 
brushing and interproximal cleaning as well as timing and reason for last dental visit. 
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Table 2.2  Diagnostic criteria for hard tissue examination 
 
Sound & Untreated  
 
No evidence of caries into dentine or restorations 
Including caries restricted to enamel 
 
 
 
Restored (1 to 3 
surfaces) 
 
 
Amalgam, composite, GIC, F/S, onlays, inlays and ¾ crowns – 
up to and including 3 surfaces 
Including veneers, shims and adhesive retainers for resin 
retained bridges 
 
 
Extensively Restored 
(4 or more surfaces) 
 
 
Amalgam, composite, GIC, onlays or inlays – 4 surfaces or 
more 
Permanent or temporary crowns, including full coverage 
crowns and conventional bridge abutments  
 
 
Carious 
 
 
Visual – usually manifests as shadowing under an occlusal 
surface or marginal ridge 
Cavitated – but no pulpal involvement 
Includes temporary dressing placed for treatment of caries 
 
 
Broken down / 
pulpal involvement 
 
 
Teeth so broken down that it is inconceivable that there is not 
pulpal involvement 
 
The hard tissues were examined and assessed against on a pre-defined dental 
examination criteria (Kelly, 2000) 
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2.6.14   Non-surgical periodontal management and follow-up 
Following pre-treatment screening, comprehensive targeted non-surgical 
periodontal therapy was provided for subjects with periodontitis (the treatment day 
constituted the baseline time point, and was within 2 months of the pre-treatment 
screening appointment), using oral hygiene instruction (OHI) and a full mouth 
instrumentation (FMI) approach (Quirynen et al., 2000). A combination of ultrasonic 
instrumentation, using a Cavitron Select machine (Dentsply, Addlestone, UK), and hand 
instrumentation, using flexichange scalers and gracey curettes (Dentsply, Addlestone, 
UK), was used. Pockets were irrigated with 0.2% chlorhexidine gluconate (Kent 
express, Kent, UK). Effective tooth brushing and interproximal cleaning was 
demonstrated to the patient. 
  The subjects were then seen at week 3 and week 6 after initial treatment for OHI 
and further prophylaxes to disrupt reforming plaque deposits. For these subjects, a 
periodontal examination was subsequently undertaken at 3, 6 and 12 months after the 
initial instrumentation to evaluate periodontal healing following the treatment.  
Additional periodontal treatment to eliminate periodontal inflammation was undertaken 
at months 3, 6 and 12 months as clinically indicated (Figure 2.1). Pre-treatment 
screening was undertaken on all participants, however, only those subjects with 
periodontitis proceeded beyond screening. At the pre-treatment screening appointment, 
subjects with gingivitis received oral hygiene instruction and full mouth instrumentation 
and prophylaxis, as required. Patients with gingivitis or healthy periodontal tissues were 
not followed up after the screening visit. 
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2.6.15   Data collection & storage 
Patients were allocated a subject identification number and each patient had a 
case report form (CRF) in which all clinical periodontal data were recorded at the time 
of examination by the clinician or an assistant. The results from the clinical 
biochemistry laboratory were also recorded within the patient’s CRF.  
2.7 Statistical analysis 
Statistical analyses were conducted using the statistical software SPSS 15.  All 
variables were assessed for normality using the Kolmogorov-Smirnov test, 
supplemented with histograms.  Where there was no evidence to reject normality, 
means and standard deviations (SD) of these parametric variables were calculated.  
Where the assumption of normality was rejected, medians and interquartile ranges 
(IQR) of these non-parametric variables were calculated.  Discrete variables were 
analysed using chi-squared tests. The significance of all tests was assessed at the 5%. 
Cross-sectional pre-treatment data (categorised based on diabetes status) were 
analysed with independent samples t-tests or Mann-Whitney tests for parametric or non-
parametric variables, respectively. Cross-sectional data (categorised based on 
periodontal status and diabetes status) were analysed with one-way analysis of variance 
(ANOVA) or the Kruskal-Wallis test for parametric and non-parametric variables, 
respectively. Independent samples t-tests or Mann-Whitney tests were applied for post 
hoc analysis of parametric or non-parametric data, respectively. A P-value of <0.05 was 
considered significant. P-values were corrected for multiple comparisons with the 
Bonferroni-Holm test. The associations between cytokine levels and clinical data were 
assessed using Pearson’s correlation coefficients (r), if both variables were normally 
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distributed, or Spearman’s correlation coefficients (rho), if both variables were not 
normally distributed.  Scatter diagrams were constructed to illustrate these associations. 
Longitudinal non-parametric data were analysed with the Friedman test, with the 
Wilcoxon Mann-Whitney test applied for post hoc analyses. Longitudinal parametric 
data were analysed with repeated measures ANOVA and paired samples t-tests for post 
hoc analyses. A p-value of <0.05 was considered significant. P-values were corrected 
for multiple comparisons with the Bonferroni-Holm test.  At each time-point, for 
subjects with periodontitis only, cross-sectional data were analysed using independent 
samples t-tests or Mann-Whitney tests for parametric or non-parametric data, 
respectively. Also, to evaluate the impact of any pre-treatment differences between 
subjects with T2DM and non-diabetic subjects, analysis of covariance (ANCOVA) was 
performed, using diabetes status as a factor and pre-treatment parameter as covariate to 
reveal whether adjusted month 3, month 6 and month 12 parameters still differed 
significantly between subjects with and without diabetes. 
Multinominal logistic regression analyses were applied to test the value of PISA 
as a predictor of periodontal status categorised as periodontal health, gingivitis or 
periodontitis. Linear regression analyses were used to determine the ability of cytokine 
levels in GCF and saliva to predict PISA. 
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Figure 2.1 Overview of study protocol 
  Pre-
treatment 
screening 
Treatment* 
(month 0) 
Week 
3* 
Week 
6* 
Month 
3* 
Month 
6* 
Month 
12* 
Informed consent  ●       
Demographic 
data 
 ●       
Medical history  ●     ● ● 
Diabetes history #  ●       
Smoking status  ●       
Physical exam  ●     ● ● 
Oral health 
history 
 ●       
Oral examination  ●  ● ● ● ● ● 
GCF samples  ●    ● ● ● 
 Saliva samples  ●    ● ● ● 
Periodontal 
examination 
PI ●    ● ● ● 
mGI ●    ● ● ● 
PD ●    ● ● ● 
Recession ●    ● ● ● 
BOP ●    ● ● ● 
Blood samples 
 
 
HbA1c ●    ● ● ● 
hsCRP ●    ● ● ● 
Lipids ●    ● ● ● 
Initial 
periodontal 
therapy  
OHI & 
FMI 
 ●      
Prophylaxis    ● ● ● ● ● 
Additional 
periodontal 
therapy  
(As 
required) 
    ● ● ● 
Table shows an overview of the study protocol to highlight the procedures undertaken at each time point 
#
 not used in non-diabetic subjects 
*
 only in subjects with periodontitis 
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2.8 Sampling, elution and storage of GCF 
GCF was sampled with Periopaper strips (Oraflow Inc, New York) and the 
volume quantified using a calibrated Periotron 6000 (Preshaw et al., 1996). Prior to use, 
the Periotron was allowed to ‘warm up’ according to the manufacturers’ instructions, 
and then zeroed with a blank (dry) Periopaper. The reading dial was adjusted until the 
digital display indicated zero.  
To minimise contamination by blood, GCF samples were collected prior to 
periodontal probing.  At screening, 4 GCF samples were collected from each patient, 
from the mesio-buccal aspects of the four 1st molars.  If the 1st molar was absent in a 
quadrant, the 2nd molar was used, then the 2nd premolar, then the 1st premolar, then the 
canine or incisor teeth (the sampled teeth were designated target teeth). The site was 
isolated with cotton rolls and a saliva ejector, and dried with a gentle stream of air. 
Supragingival plaque, if present, was carefully removed with a curette prior to 
sampling. A Periopaper was placed carefully into the sulcus until mild resistance was 
felt and was held there for 30 seconds.   
The paper was transferred immediately to the jaws of the Periotron to minimise 
evaporation errors. Care was taken to ensure that Periopapers were positioned in a 
standardised position between the jaws, so that the black line on the paper was at the 
outer rim of the jaw plate. After ‘mode II’ illuminated on the Periotron display, the GCF 
volume (in Periotron units) was recorded by an assistant. The Periopaper was then 
placed into a sterile plastic 0.5ml micro-tube (Sarstedt, Leicester, UK) containing 150µl 
autoclaved and filtered phosphate buffered saline (PBS). Each GCF sample was stored 
in a separate micro tube and each tube was labelled with the patient’s study number, 
tooth number and date. Between samples, the jaws of the Periotron were cleaned with 
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an alcohol swab and allowed to dry. The GCF samples were kept on ice at the chair side 
and transferred, within 20 minutes of sampling, to the laboratory and frozen at -80oC 
(Cutler et al., 1999a) to await subsequent elution & analysis.  
This process was used to collect GCF samples from the same 4 sites at months 3, 
6 and 12 in those patients who were diagnosed with periodontal disease and who were 
entered into the longitudinal phase of the study.  
Elution of GCF from the Periopaper was carried out on the same day the samples 
were analysed used the Multi-spot cytokine assay. All samples were thawed on ice for 
15 minutes and then 50µl of 1% bovine serum albumin (BSA) was added. GCF samples 
were centrifuged (Sigma 3K10 centrifuge) at 300rpm for 60 minutes at 4oC and then at 
12000rpm for 2 minutes at 4oC. The Periopapers were then removed with college 
tweezers, with the ends of the tweezers being rinsed with phosphate buffered saline PBS 
between samples. 
2.9 Collection of venous blood sample 
A tourniquet was applied 8 cm above either the antecubital fossa or the hand, and 
the veins were allowed to engorge with blood. Using a 21 gauge and 1.5 inch 
Vacutainer needle (NHS Supply Chain, Derbyshire, UK) and a needle holder for 16mm 
diameter tubes (NHS Supply Chain, Derbyshire, UK), venous access was achieved and 
a venous blood sample was taken to fill the following three plastic, Vacutainer tubes 
(BD, Oxford, UK): 3ml EDTA (lavender top), 5ml serum separation (gold top) and 9ml 
serum separation tube (gold top). Once all blood was sampled, the tourniquet was 
loosened, the needle removed and pressure applied to the sample site with cotton wool 
until haemostasis was achieved. All tubes containing the blood samples were slowly 
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inverted at least five times and, keeping the tubes upright, the samples were left to stand 
for 30 minutes prior to transferring to the appropriate laboratory. 
2.10   Clinical biochemistry analysis 
The 3ml EDTA (lavender top) and 5ml serum separation (gold top) tubes were 
labelled with a adhesive labels from the patient’s hospital notes and these samples were 
subsequently sent to the Clinical Biochemistry Department of the Newcastle Royal 
Victoria Infirmary for analysis of the HbA1c, hsCRP, triglyceride, cholesterol, high 
density lipoprotein (HDL) and non-high density lipoproteins (non-HDL) levels 
according to the standard operating procedure of the Newcastle Hospital NHS Trust 
Clinical Biochemistry Laboratory. 
2.11    Serum separation and storage 
 The 9ml serum separation tube (gold top) was kept on ice at the chair side and 
transferred, within 2 hours of sampling, to the laboratory. The sample was centrifuged 
at 1500 x g for 15 minutes at 4oC to separate the serum to the top of the tube via the 
formation of a polymer barrier. A Pasteur pipette was used to transfer the serum into six 
0.5ml micro tubes, labelled with subject number and date and samples were then frozen 
at -80oC to await subsequent elution & analysis. 
2.12    Collection and storage of saliva 
 10ml of sterile saline was syringed onto the upper gingival margins, with the 
patient sat upright in the dental chair. The patient was asked to rinse around for 30 
seconds and then expectorate into a polystyrene cup. This expectorated saliva wash was 
transferred into sterile 15ml centrifuge tubes (Sarstedt, Leicester, UK) The saliva wash 
sample was kept on ice at the chair side and transferred, within 20 minutes of sampling, 
to the laboratory. The sample was centrifuged at 1500 x g for 15 minutes at 4oC to 
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separate any particulate matter to the bottom of the tube. A Pasteur pipette was used to 
transfer the fluid into four 0.5ml micro tubes, labelled with subject number and date and 
samples were then frozen at -80oC to await subsequent elution & analysis.  
2.13    Calculating GCF volume 
Firstly, a quadratic equation was generated as part of the calibration of the 
Periotron 6000 which was undertaken every 12 weeks during this study. Then the 
software package Excel was used to solve the quadratic equations in order to calculate 
GCF volume from the Periotron units. 
2.14    Multi-spot cytokine assay 
IL-6, TNF-α, INF-γ and IL-1β concentrations in serum, saliva and GCF samples 
were determined with a commercially available human pro-inflammatory 4-plex I 
Ultrasensitive kit (Meso Scale Discovery, Maryland, USA).  All assays were performed 
at room temperature. Details of sensitivity ranges for each cytokine are listed in table 
2.3. The multi-spot assay employs a sandwich immunoassay format within a 96 well 
plate, in which 4 specific capture antibodies are immobilized on 4 different spots at the 
base of each well. The standard solution or samples are incubated in the plate, and each 
cytokine binds to its corresponding capture antibody spot. Cytokine levels are 
quantified using a cytokine-specific detection antibody labelled with MSD SULFO-
TAG reagent (Figure 2.2). 
Nonspecific binding, on the pre-coated 96-well multi-spot assay plate (Meso 
Scale Discovery, Maryland, USA) was blocked with 25 µl of Human Serum Cytokine 
Assay Diluent (Meso Scale Discovery, Maryland, USA). The plate was sealed with an 
adhesive plate seal and incubated for 30 minutes at room temperature on a plate shaker 
at 300 rpm. The Human Serum Cytokine Assay Diluent was aspirated out of each well 
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and 25 µl of the sample (in duplicate) or 25 µl of standard (in duplicate, serial dilution 
prepared in Human Serum Cytokine Assay Diluent) were added in accordance with a 
pre-defined plate map. A duplicate Human Serum Cytokine Assay Diluent sample was 
included as a negative control. Standard and samples were sealed and incubated for 2 
hours on a plate shaker at 300 rpm. The sample or standard was aspirated off and the 
plate was washed three times with wash buffer (0.05% Tween 20 in PBS), aspirating the 
contents of each well between each wash. 25 µl of the prepared detection antibody 
solution (60 µl detection antibody blend, Meso Scale Discovery, diluted into 2.94 ml of 
Human Serum Cytokine Assay Diluent) was added to each well. The plate was sealed 
and incubated for 2 hours on a plate shaker at 300 rpm, avoiding direct light. The 
detection antibody solution was aspirated off and the washing step was repeated. 150 µl 
of the prepared read buffer (8ml read buffer solution, Meso Scale Discovery, in 8ml of 
de-ionized water) was added using reverse pipetting technique, to avoid air bubbles. 
The plate was immediately analysed using the SECTOR imager. 
 To utilize the quantitative value of the electrochemiluminescent detection, a 
titration curve was produced for each plate using a known standard. Using the software 
provided with the SECTOR instrument, a 4-parameter logistic model was used to fit the 
data generated from the known standards. The algorithms used by the SECTOR 
instrument allowed signals from standard samples with known levels of the cytokine to 
calculate the concentration of the cytokine in the sample. The SECTOR instrument 
calculates the lower detection limit for each plate, based on 2.5 standard deviations 
above the value for the negative control (0 pg/ml standard) (Table 2.3). 
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Table 2.3 Sensitivity range for multi
Multi-spot cytokine assay
IL-1β 
IL-6 
TNF-α 
INF-γ 
 
 
Figure 2.2 Diagram of m
The diagram represents the multi
immunoassay format within a 96 well plate. At the base of each well, 4 specific 
antibodies are immobilized on 4 different spots enabling the simultaneous quantification 
of IL-6, TNF-α, IL-1β and IFN
 
 
-spot cytokine assay 
 Sensitivity range [pg/ml]
2500 – 0.78 
2500 – 0.76 
2500 – 0.96 
2500 – 1.8 
ulti-spot cytokine assay 
-spot cytokine assay which employs a sandwich 
-γ from a 25 µl clinical sample. 
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Chapter 3 Calibration and verification studies 
3.1 Clinical Calibration 
3.1.1 Background 
In clinical periodontal research, periodontal probes are used to make direct, site-
specific measurements of PD and recession. LOA is then calculated with LOA= PD + 
recession. LOA has been described as the gold standard measurement for assessing 
periodontal disease progression and therapeutic outcomes (Jeffcoat, 1992; Pihlstrom, 
1992; Reddy, 1997).  
Manual probing has been shown to accurately assess LOA (Hull et al., 1995). 
However, the validity of periodontal probing to assess PD is dependent upon the 
accuracy and reproducibility of probing measurements. Factors, including probing 
pressure, probe tip diameter, variations in probe markings and probe insertion angle 
may contribute to increased variability and decreased reproducibility in PD 
measurements (Pihlstrom, 1992; Reddy, 1997). 
A low level of examiner reproducibility in periodontal probing assessments 
leads to higher measurement variance independent of the actual biological component 
of the probing variance (Jeffcoat, 1992). This would potentially increase the need for 
larger sample size to demonstrate statistical significance between outcomes variables 
and would raise the minimum threshold of clinical change needed to reliably identify 
periodontal sites that experience progression or healing in longitudinal analysis. 
Assessment of examiner reproducibility and calibration training are used to identify and 
minimise sources of examiner variation (Polson, 1997). 
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3.1.2 Aim 
The aim of this phase of the research was to examine inter- and intra-examiner 
reproducibility for the measurement of PD, recession, plaque and gingival 
inflammation. 
3.1.3 Methods 
The clinicians responsible for performing the periodontal examinations 
underwent calibration training, including a discussion of the principles of periodontal 
data collection and procedures focused on the use of manual probing forces, 
identification of interproximal sites and appropriate reference points, LOA calculation 
and the use the PI and mGI to score plaque and gingival inflammation. Following this, 
both slides (PI and mGI) and patients (mGI, PD and recession) were examined to assess 
examiner reproducibility. Each clinician independently made an initial evaluation to 
provide measurements of mGI, PI, PD and recession at 6 sites per tooth. Following a 30 
minute break, measurements were repeated by each examiner. During the repeat 
assessment, the examiners were blind to both the initial measurements and the 
measurements of the other examiner. To reflect the diversity of patients, a variety of 
patients were used to assess reproducibility, including those with healthy periodontal 
tissues, gingivitis and periodontitis.  
The percent exact agreement and agreement with ±1.0 mm were determined 
between initial and replicate assessments of PD, recession, PI and mGI. Kappa statistics 
(Hunt, 1986) were used to quantify inter- and intra-examiner agreement beyond chance 
for site-based replicate assessments of PD, recession, PI and mGI by employing all 
examined sites and ignoring the contribution of subjects. A ≥ 80% level of exact 
agreement and a ≥ 90% level of within 1 agreement was considered satisfactory and 
kappa values between 0.40 and 0.75 were considered to represent fair to good 
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agreement, with kappa > 0.75 indicating excellent agreement (Landis and Koch, 1977; 
Petrie, 2009). 
3.1.4 Results 
Table 3.1 reveals that in Nov 2006, at the start of the study, the exact agreement 
for mGI, PI, PD and recession was found to be above the 80% level and the within 1 
agreement was above the 90% level for both examiners. The kappa values for exact 
intra-examiner agreement all exceeded the threshold required (> 0.75) to indicate 
excellent intra-examiner agreement except for mGI in examiner 2 with a kappa value of 
0.68 indicated good intra-examiner agreement (Table 3.1).  
Table 3.1 demonstrates that at this same time point, the kappa values for exact 
inter-examiner agreement for PI and recession were 0.61 and 0.50, indicating fair inter-
examiner agreement. However, for PD inadequate inter-examiner agreement was 
indicated by a kappa value of 0.30. The kappa value for mGI could not be computed 
due to the lack of symmetry in the categories of the 2-way table from which kappa 
value is calculated. The exact agreement was found to be above the 80% level for PI, 
but not for mGI, PD and recession and the within 1 agreement was above the 90% level 
for mGI, PI and recession. Inter-examiner agreement could be considered adequate for 
mGI, PI and recession but not PD (Table 3.1) 
Table 3.1 reveals that in Dec 2006, following further calibration training, the 
exact agreement (within 1) for PD was found to be 82.9% (97.6%) between examiners 
and the kappa value for exact inter-examiner agreement for PD of 0.75 indicated 
excellent inter-examiner agreement (Table 3.1). 
Table 3.1 also presents data at a further 3 time points carried out within the 
timeframe of the clinical trial. Despite variation in kappa values, all the measurements 
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demonstrated kappa values that indicated fair to good (0.40 and 0.75) or excellent (> 
0.75) agreement. Furthermore, ≥ 90% level of within 1 agreement was seen for all 
measurements demonstrating good intra-examiner agreement with variations mostly 
occurring within 1 (Table 3.1). 
3.1.5 Conclusion 
The findings demonstrate that, using a manual probe, appropriately trained 
examiners produce kappa values for exact agreement that indicate acceptable inter- and 
intra-examiner agreement. Furthermore, a high (≥ 90%) level of within 1 agreement 
confirms that when agreement is not seen the magnitude of differences is small.
    
Table 3.1  Intra- and inter-examiner reproducibility data 
κ:   kappa statistic 
Exact agreement: exact agreement between replicates on measurement scale 
Within 1:  agreement between replicates to within 1 unit on measurement scale 
Mean bias:  mean of differences between replicates 
Measurement error: standard deviation of differences between replicates 
 Nov 2006 Dec 
2006 
June 2007 May 2008 Sept 2009 
 mGI PI PD Rec PD mGI PI PD Rec mGI PI PD Rec mGI PD Rec 
Examiner 
1 (PG) 
 
κ 0.86 0.83 0.80 0.90             
Exact 
agreement 
90.6% 88.9% 85.5% 93.6%             
Within 1 100% 100% 98.8% 98.8%             
Mean bias -0.04 0.03 0.02 -0.01             
Measurement 
error 
0.03 0.01 -0.004 0.01             
Examiner 
2 (HF) 
 
κ 0.68 0.77 0.79 0.82  0.46 0.69 0.55 0.65 0.77 0.82 0.54 0.54 0.45 0.63 0.65 
Exact 
agreement 
81.3% 89.2% 83.7% 86.6%  64.9% 77.1% 75.0% 95.8% 85.4% 90.0% 70.5% 76.3% 69.0% 79.5% 80.8% 
Within 1 100% 100% 97.1% 99.4%  93.5% 100% 98.6% 100% 99.3% 96.3% 97.4% 94.2 99.4 100 98.1 
Mean bias -0.02 0.05 -0.12 0.01  -0.39 -0.15 -0.04 -0.01 -0.10 0.01 0.10 -0.02 -0.17 -0.03 -0.04 
Measurement 
error 
0.04 0.02 -0.04 0.02  0.27 -0.03 -0.03 -0.01 0.05 -0.001 0.10 -0.03 0.12 -0.03 0.07 
Inter-
examiner  
κ - 0.61 0.30 0.50 0.75            
Exact 
agreement 
74.5% 83.1% 47.7% 65.4% 82.9%            
Within 1 100% 100% 86.9% 93.3% 97.6%            
Mean bias -0.06 0.03 0.02 -0.18 -0.04            
Measurement 
error 
0.02 0.01 -0.27 -0.001 -0.02            
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3.2 Periotron calibration 
3.2.1 Background 
The Periotron 6000 (ProFlow Inc., Amityville NY, USA) is used to determine 
GCF volumes sampled on Periopaper strips, and has been shown to be reproducible and 
accurate when operated correctly (Chapple et al., 1995). The Periotron 6000 quantifies 
the volume of GCF collected on a filter paper by measuring the electrical capacitance of 
the wet paper strip. The Periotron must be calibrated prior to use by the placement of 
known volumes of test fluid onto Periopapers and recording the digital output to 
produce a calibration curve. In the present study, the Periotron was calibrated every 12 
weeks. Previous research has demonstrated that the calibration curve for the Periotron 
6000 is quadratic in nature (Preshaw et al., 1996). Thus, by solving a quadratic 
equation, a Periotron unit can be converted into a GCF fluid volume. 
3.2.2 Methods 
The Periotron 600 fluid analyser was allowed to warm up for 10 minutes prior to 
use, then zeroed with a dry Periopaper. A Hamilton 7000 series microlitre syringe 
(maximum volume 2 µl with 0.02 µl gradations) was used to dispense known volumes 
of calibration liquid (human serum) onto Periopapers. Ideally, GCF should be used for 
calibration purposes, although it would be probably impossible to collect sufficient 
volumes. It is generally agreed that serum is the most appropriate alternative, being 
similar to GCF in both viscosity and composition (Cimasoni, 1974). 
Whole human venous blood samples were collected in a 9 ml serum separation 
tube (gold top). After 30 minutes standing at room temperature, the sample was 
centrifuged at 1500 x g for 15 minutes at 4 oC to separate the serum to the top of the 
tube via the formation of a polymer barrier. The Hamilton syringe was mounted in a 
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retort stand positioned at eye level to minimise parallax errors. A piece of lightly 
coloured card placed behind the syringe facilitated visualisation of the meniscus. Serum 
was repeatedly drawn into the syringe then dispensed to ensure that the inner walls of 
the syringe barrel were coated prior to calibration. 16 different volumes of serum 
(ranging from 0.1 to 1.6 µl) were used, and each volume was measured in triplicate. 
Serum was dispensed from the syringe onto the Periopaper strip which was transferred 
rapidly to the jaws of the Periotron to minimise evaporation errors. Between each 
sample the jaws of the Periotron were cleaned with an alcohol swab and allowed to dry. 
The Periotron was then re-zeroed with a dry Periopaper strip. 
3.2.3 Results 
The calibration curve generated for the Periotron 600 using serum is shown in 
Figure 3.1. The quadratic regression equation is P = AV2 + BV + C (where P = 
Periotron units, V = fluid volume and A, B and C are constants determined by the 
regression). In this case, P = -59.49V2 + 193.41V – 16.719 (Figure 3.1). 
3.2.4 Discussion 
Ensuring accuracy is important when evaluating and presenting cytokine levels 
in GCF.  Within the literature, cytokine levels are presented as ‘total amount of cytokine 
protein’ per 30 second GCF sample and/or concentration of cytokine, in which the total 
amount of cytokine is divided by the GCF volume (Correa et al., 2008; Santos et al., 
2010; Kardesler et al., 2011). However, when presenting GCF levels as a concentration 
there should be an appreciation that very low GCF volumes could have a dramatic 
affect on a calculated GCF cytokine concentration. This would have particular 
consequences in prospective treatment studies that are evaluating the impact of 
improved periodontal health, following periodontal therapy, on GCF cytokine levels. 
For example, in recent studies, reductions in both GCF volume and total amounts of IL-
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6, IL-1β and IFN-γ in GCF have been shown to accompany improvements in 
periodontal health following periodontal treatment in T2DM subjects, however, when 
the same changes in cytokine levels are presented as concentrations they appear to 
demonstrate increases in cytokine levels following periodontal treatment (Correa et al., 
2008; Santos et al., 2010; Kardesler et al., 2011). It is possible that this apparent 
increase in GCF cytokine levels is an artefact of the reductions in GCF volume. To aid 
interpretation of results and improve the clarity of conclusions drawn from prospective 
studies such as these, it would seem more appropriate to present changes in GCF 
volume and changes in total amount of GCF cytokine as separate treatment outcomes. 
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Figure 3.1  Example Periotron 6000 calibration curve 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot for Periotron units generated for 16 different volumes of serum (ranging 
from 0.1 to 1.6 µl) undertaken in triplicate with quadratic trend line. This was 
undertaken as part of the Periotron 6000 calibration studies. 
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3.3 Verification of methods for GCF elution 
3.3.1 Background 
The clinical GCF sampling technique, using filter paper strips placed within the 
gingival crevice for 30 seconds is consistently described within the literature 
(Engebretson et al., 2007). However, the method used to elute mediators from the filter 
paper strips into supernatant for analyses is rarely described, with variations in elution 
method having a potential impact on mediator levels. In an attempt to devise a standard 
methodology that maximised cytokine protein elution, verification studies were 
conducted to compare 4 different elution methods.  
3.3.2 Methods 
1µl of known concentration of IL-6 was spiked onto a Periopaper strip and then 
placed into 150 µl PBS. The chosen elution method was used (A, B, C or D). The 
Periopaper was removed and the recovered IL-6 concentration quantified using an IL-6 
ELISA (DuoSet human IL-6, R&D systems). 
A: Centrifuge 60 minutes at 300 rpm (8 g) and then 2 minutes at 12000 rpm (13201 g), 
4 oC. 
B: Centrifuge 2 minutes at 12000 rpm (13201 g), 4 oC. 
C: Addition of 50µl 1% BSA, centrifuge 60 minutes at 300 rpm (8g) and then 2 minutes 
at 12000 rpm (13201 g), 4 oC. 
D: Addition of 50 µl 1% BSA, centrifuge 2 minutes at 12000 rpm (13201 g), 4 oC. 
3.3.3 Results 
Table 3.2 shows the mean recovered IL-6 concentrations and the % recoverability for 
the 4 methods, based on 2 independent experiments assayed in triplicate. Both the 
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addition of 50 µl 1% BSA, to reduce non-specific binding, and centrifugation of 
samples for 60 minutes at low speed, improved the recoverability of IL-6 from 
Periopapers, particularly at lower concentrations (Table 3.2).  
3.3.4 Conclusion 
The elution protocol for clinical GCF samples was informed by these results. 
This will ensure maximal recoverability of cytokines present at low physiological levels 
within GCF samples. Therefore, prior to quantification of cytokines, GCF samples were 
taken out of storage in the -80 oC freezer and defrosted on ice. 50µl 1% BSA was then 
added and samples were centrifuged for 60 minutes at 300 rpm (8 g) and then for 2 
minutes at 12000 rpm (13201 g) at 4oC (method C). 
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Table 3.2 Recoverability of IL-6 following elution from Periopapers 
Total IL-6 
Conc (pg/ml) 
Method A Method B 
Mean 
recovered IL-6 
Conc (pg/ml)* 
% 
Recoverability 
Mean 
recovered IL-6 
Conc (pg/ml)* 
% 
Recoverability 
     
233.33 146.59 62.83 123.97 53.13 
116.67 26.89 23.05 26.09 22.36 
58.33 8.07 13.83 6.05 10.37 
   
Total IL-6 
Conc (pg/ml) 
Method C Method D 
Mean recovered 
IL-6 Conc 
(pg/ml)* 
% 
Recoverability 
Mean recovered 
IL-6 Conc 
(pg/ml)* 
% 
Recoverability 
     
175 92.88 53.07 78.76 45.01 
87.5 34.63 39.57 17.28 19.75 
43.75 14.17 32.39 8.11 18.53 
The method used to elute mediators from the filter paper strips into supernatant for 
analyses is rarely described in the literature, with variations in elution method having a 
potential impact on mediator levels. The table shows the mean recovered IL-6 
concentration and % recoverability for 4 elution methods. Results are based on 2 
independent experiments assayed in triplicate. The initial total concentration of IL-6 is 
lower for methods C & D because these samples were diluted, as part of the method, by 
the addition of 50 µl 1% BSA. 
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3.4 Verification of multi-spot cytokine assay for clinical GCF 
samples 
3.4.1 Background 
The accurate quantification of cytokines in biological samples is dependent on 
the accuracy of the analytical technique. In an attempt to assess the suitability of the 
multiplex cytokine assay to analyse GCF samples the lower limit of detection (LLOD) 
and inter-plate variation was assessed. 
3.4.2 Method 
The multi-spot assay was performed according to the previously described 
method and the LLOD, which is the calculated concentration of the signal that is 2.5 
standard deviations over the zero standard, was recorded for IL-6, IL-1β, TNF-α and 
IFN-γ on 4 plates undertaken on different days (Table 3.3). Additionally, GCF was 
sampled and immediately eluted according to the previously described methods. To 
avoid repeated freeze-thaw cycles the supernatant was aliquoted into 3 separate 500µl 
microtubes prior to being stored in the -80 freezer until analysis. The assay was 
performed according to the previously described method on 3 plates undertaken on 
different days (Table 3.4). All GCF samples were thawed once. The inter-plate variation 
was calculated as follows: 


× 100 
3.4.3 Results 
The inter-plate variation for the calculated LLOD for IL-6, IL-1β and TNF-α 
was 14.8 %, 10.8 % and 16.0 % respectively. The inter-plate variation for the LLOD for 
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IFN-γ was 51.4% (Table 3.3). The inter-plate variation for GCF IL-6, IL-1β, TNF-α and 
IFN-γ was 19%, 17.5%, 23.8% and 67.8 % respectively (Table 3.4). 
3.4.4 Conclusion 
In summary, for the calculated LLOD the inter-plate variation was less than 20% 
for IL-6, IL-1β and TNF-α. Similarly for GCF samples the inter-plate variation was less 
than 25% for IL-6, IL-1β and TNF-α. These data indicate a reasonable level of 
reproducibility and increases the confidence of using this multi-spot assay to quantify 
IL-6, IL-1β and TNF-α in GCF, particularly as the calculated LLOD values were all 
very low (typically < 1 pg/ml). However, for IFN-γ, the inter-plate variation for the 
calculated LLOD and GCF samples was 51.4% and 67.8% respectively. This indicates a 
low level of reproducibility for IFN-γ and reduces the confidence for using the 
multiplex assay to quantify IFN-γ in GCF. 
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Table 3.3 Inter-plate variation of LLOD for multi-spot cytokine assay 
Plate number IL-6  
(pg/ml) 
IL-1β 
(pg/ml) 
TNF-α 
(pg/ml) 
IFN-γ 
(pg/ml) 
 I 0.818 0.885 1.06 2.68 
II 0.656 0.808 0.779 1.26 
III 0.673 0.697 1.13 2.69 
IV 0.885 0.729 0.936 0.936 
Mean 0.758 0.780 0.963 1.8 
SD 0.112 0.084 0.154 0.926 
%CV 14.8 10.8 16.0 51.4 
Results are based on 4 plates (assayed on separate days) in duplicate 
 
 
Table 3.4 Inter-plate variation of multi-spot cytokine assay for GCF samples 
Results are based on 3 plates (assayed on separate days) in duplicate 
 
  
Plate number IL-6 
(pg/ml) 
IL-1β 
(pg/ml) 
TNF-α 
(pg/ml) 
IFN-γ 
(pg/ml) 
I 4.54 211 1.06 2.6 
 
5.16 229 0.96 2.49 
II 4.76 263 1.68 4.82 
 
5.4 286 1.56 5.11 
III 3.43 186 1.09 0.76 
 
3.46 192 1.13 0.82 
Mean 4.45 227.8 1.25 2.77 
SD 0.85 39.85 0.30 1.88 
Inter-plate variation 19.0 17.5 23.8 67.8 
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3.5 Verification of stability of samples within -80 oC freezer 
3.5.1 Background 
Within biological samples, the degradation of cytokine proteins during storage 
and prior to analysis could negatively impact on the accuracy of results for the 
quantification of cytokine levels in clinical samples. In an attempt to evaluate the 
stability of cytokines within clinical samples, variations in GCF, saliva and serum 
cytokine levels following storage for 6 months at -80oC was assessed.  
3.5.2 Method 
GCF was obtained and eluted according to the previously described method. To 
avoid repeated freeze-thaws, the supernatant was aliquoted into 2 separate 500 µl 
microtubes. Samples were then stored at -80 oC for either 0 or 6 months. The multi-spot 
assay was performed according to the previously described method. All samples were 
freeze-thawed only once. The inter-plate variation was calculated as follows: 


× 100 
3.5.3 Results 
For GCF sample A, the inter-plate variation, between month 0 and month 6, for 
GCF IL-6, IL-1β, TNF-α and IFN-γ was 44.8%, 26.8%, 15.6% and 52.5% respectively 
(Table 3.5). At both month 0 and month 6, the levels for IL-6 were below the mean 
LLOD and the IFN-γ cytokine levels at month 0 was below the mean LLOD (the mean 
LLOD was previously demonstrated in Table 3.3). For all cytokines, the month 6 
analysis produced higher levels for all 4 cytokines in comparison to the analysis at 
month 0.  
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For GCF sample B, the inter-plate variation, between month 0 and month 6, for 
GCF IL-6, IL-1β, TNF-α and IFN-γ was 21.5%, 29.3%, 33.68% and 30.8% respectively 
(Table 3.4). At month 6, the differences between the duplicates, for all 4 cytokines, 
appear higher than previous verification data (Table 3.4). For all cytokines, the month 6 
analysis produced higher levels for all 4 cytokines in comparison to the analysis at 
month 0. 
The mean inter-plate variation (for samples A and B), between month 0 and 
month 6, for GCF IL-6, IL-1β, TNF-α and IFN-γ  was 33.1%, 28.0%, 24.7% and 41.7 % 
respectively. 
3.5.4 Conclusions 
In summary, for GCF samples stored for 6 months in a -80 oC freezer, the inter-
plate variation for IL-6, TNF-α and IL-1β appears higher than the inter-plate variation 
seen previously without the extended storage time (see Table 3.4). The apparent lower 
levels of reproducibility for GCF IL-6, TNF-α and IL-1β following storage for 6 months 
in a -80 oC freezer should, however, be interpreted with caution. The levels for IL-6 
were below the level of detection in sample A, explaining the larger inter-plate 
variations seen for this sample. Additionally, at month 6 increased variations between 
duplicates in sample B for all cytokines also contributed to higher inter-plate variations. 
Also, for all cytokines, the month 6 analysis produced higher levels for all 4 cytokines 
in comparison to the analysis at month 0. This suggests protein degradation is not a 
significant issue. These data indicate that storage of GCF samples in a -80 oC freezer for 
6 months may lead to an increase in inter-plate variation but the effect that such storage 
has on the level of cytokines present in samples is not clear. Therefore, to minimise 
such variations the time between sampling and analysis was minimised by analysing 
samples through-out the study time-frame. 
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Table 3.5  Inter-plate variation of multi-spot cytokine assay for GCF samples 
stored for 6 months in a -80 oC freezer 
Sample Time 
(months) 
IL-6 
(pg/ml) 
IL-1β 
(pg/ml) 
TNF-α 
(pg/ml) 
IFN-γ 
(pg/ml) 
A 0 0.16 167 2.11 0.99 
  
0.29 161 1.73 1.03 
A 6 0.46 203 2.43 2.9 
  
0.51 279 1.82 2.0 
 Mean 0.35 202.5 2.02 1.73 
 SD 0.16 54.27 0.32 0.91 
  Inter-plate variation 44.8 26.8 15.6 52.5 
B 0 2.51 
2.55 
512 
560 
2.77 
3 
3.2 
2.81 
B 6 2.84 
3.86 
843 
936 
3.94 
5.61 
3.48 
5.39 
 Mean 2.94 712.75 3.83 3.72 
 SD 0.63 208.52 1.29 1.15 
  Inter-plate variation 21.5 29.255 33.68 30.83 
Mean inter-plate variation 33.1 28.0 24.7 41.7 
SD inter-plate variation 16.5 1.7 12.8 15.3 
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Chapter 4 Investigation of the general and oral health 
status of patients with T2DM 
4.1 Introduction 
The epidemiological evidence from association studies confirms that diabetes is 
a risk factor for periodontal disease. The risk for developing periodontitis is greater if 
diabetes control is poor and those with good diabetic control do not have a greater risk 
of periodontal disease than non-diabetic patients (Nelson et al., 1990; Emrich et al., 
1991; Taylor et al., 1998a; Tsai et al., 2002). Furthermore, evidence suggests that those 
with moderate levels of periodontal disease have a 2-fold increased risk for developing 
T2DM (Demmer et al., 2008) and diabetics with severe periodontal disease are six times 
more likely to have poor glycaemic control (Taylor et al., 1996). This highlights a bi-
directional relationship between these two diseases. Furthermore, a recent meta-analysis 
of cross-sectional data has demonstrated a positive association between periodontal 
disease and obesity, a known risk factor for T2DM (Chaffee and Weston, 2010). This 
highlights the importance of considering oral health within a wider perspective of 
maintaining systemic health, however, previous research has demonstrated that the 
attitudes towards oral health of patients with diabetes are poor in comparison to the 
general population (Allen et al., 2008). 
Recently, a small number of interventional studies have used data from full-
mouth clinical periodontal measurements to describe the periodontal status of patients 
with T2DM and periodontal disease prior to the provision of periodontal management 
(Correa et al., 2008; Dag et al., 2009; Correa et al., 2010; Kardesler et al., 2010; Santos 
et al., 2010). Some studies demonstrated no significant differences in the clinical 
periodontal status at baseline (Dag et al., 2009; Kardesler et al., 2010), whilst another 
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demonstrated that the diabetic group had higher levels of periodontal disease compared 
to non-diabetic subjects (Correa et al., 2008). 
4.2 Results 
4.2.1 Demographic data 
Demographic findings for the diabetic and non-diabetic subjects are summarised 
in Table 4.1. Of note, no significant differences between the T2DM and non-diabetic 
groups were found for gender, age, ethnicity, smoking status and pack years. This 
demonstrates that the non-diabetic and T2DM groups were appropriately matched for 
gender, age, and ethnicity and were balanced for smoking status. There was a 9% 
prevalence of current smokers in the present study in both the T2DM and non-diabetic 
groups.  
The demographic findings did, however, highlight some important differences 
between diabetic and non-diabetic patients. The IMD rank differed significantly 
between the T2DM subjects [9198 (3384-21930)] and the non-diabetic subjects [18213 
(7658-25035)], demonstrating that diabetic subjects lived in more deprived areas. The 
subjects with T2DM had significantly higher systolic blood pressure [146.9 (±21.2)] 
compared to the non-diabetic group [136.6 (±18.9)]. Similarly, patients with T2DM had 
significantly higher BMI [32.6 (29.8-36.0)] compared to the non-diabetic patients [27.3 
(25.0-29.5)]. Furthermore, Table 4.1 and Figure 4.1 show that proportions of T2DM and 
non-diabetic patients in each BMI category were significantly different, with the T2DM 
group containing a higher proportion of obese (42.6%) and morbidly obese (30.7%) 
subjects compared to 10.8% and 13.3%, respectively, in the non-diabetic group (Table 
4.1 and Figure 4.1). 
Table 4.2 summarises subject demographic data following further categorisation 
of subjects based on their periodontal diagnosis. When demographic data for these six 
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categories (diabetic subjects with healthy periodontal tissues; diabetic subjects with 
gingivitis; diabetic subjects with periodontitis; non-diabetic subjects with healthy 
periodontal tissues; non-diabetic subjects with gingivitis and non-diabetic subjects with 
periodontitis) were analysed, there were no significant differences found between the 
groups for gender or age. However, there were significant differences in the proportions 
in the ethnicity categories with a higher proportion of Black and Asian subjects within 
the T2DM groups. The clinical significance of this, however, is likely to be limited, 
given to the very low numbers of Black and Asian subjects recruited (5 out of a total of 
184 subjects). The IMD rank differed significantly between T2DM subjects with 
gingivitis [7046 (2320-17948)] and non-diabetic subjects with gingivitis [21195 (16093-
26175)], showing subjects with T2DM living in more deprived areas.  
For subjects with healthy periodontal tissues and gingivitis, the systolic blood 
pressure was significantly higher in subjects with T2DM [146.1 (±20.6) mmHg and 150.1 
(±21.2) mmHg] compared to non-diabetic subjects [122.2 (±11.0) mmHg and 135 (±18.3) 
mmHg]. Additionally, within the non-diabetic group, systolic blood pressure was 
significantly lower in those with healthy periodontal tissues [122.2 (±11.0) mmHg] 
compared to those with either gingivitis [135 (±18.3) mmHg] or periodontitis [141.0 
(±19.1) mmHg].  
When considering BMI, subjects with healthy periodontal tissues, gingivitis or 
periodontitis, the BMI was significantly higher in subjects with T2DM [31.2 (24.5-34.6) 
kg/m2, 32.9 (30.7-36.7) kg/m2 and 33.0 (29.9-36.5) kg/m2] compared to non-diabetic 
subjects [24.7 (23.1-27.7) kg/m2, 27.3 (26.3-30.9) kg/m2 and 28.1 (25.2-32.0) kg/m2]. 
Furthermore, Figure 4.2 highlights there were significant differences in the proportions 
of subjects in each of the BMI categories with a higher proportion of obese and 
morbidly obese subjects in the diabetic group compared to the non-diabetic group. 
Interestingly, BMI was significantly higher in non-diabetic subjects with periodontitis 
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[28.1 (25.2-32.0) kg/m2] compared to non-diabetic subjects with healthy periodontal 
tissues [24.7 (23.1-27.7) kg/m2]. Similarly, in subjects with T2DM, the BMI appeared 
higher in the periodontitis group [33.0 (29.9-36.5) kg/m2] compared to the group with 
healthy periodontal tissues [31.2 (24.5-34.6) kg/m2], although the difference failed to 
reach significance (Table 4.3 and Figure 4.2).  
When considering smoking status, Figure 4.3 shows, that for both diabetic and 
non-diabetic subjects, there was a tendency towards a higher proportion of current or 
ex-smokers in those with periodontitis compared to those with gingivitis or healthy 
periodontal tissue, although, this difference failed to reach significance. Interestingly, 
pack years was lowest in subjects with healthy periodontal tissues [5.0 (4.0-15.0) in 
T2DM subjects and 10.9 (4.4-23.0) in non-diabetic subjects] and highest in subjects 
with periodontitis [30 (10.6-40.0) in T2DM subjects and 15.0 (5.2-30.0) in non-diabetic 
subjects], although the difference failed to reach significance (Table 4.3 and Figure 4.3). 
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Table 4.1  Demographic data from the T2DM and non-diabetic groups 
 
 
T2DM patients 
(n=101) 
Non-diabetic patients 
(n=83) p-value 
Gender (n (%)) 
   
Male 67 (66.3) 50 (60.2) NS 
Age (years) 49 (45-53) 48 (43-54) NS 
Ethnicity (n (%)) 
   
Caucasian 96 (95.1) 83(100.0) 
NS Black 1 (1.0)  
Asian 4(4.0) 
 
IMD  rank 9198 (3384-21930) 18213 (7658-25035) < 0.001 
Smoking 
   
Status (n (%)) 
   
Current 9 (8.9) 9 (10.8) 
NS Ex 37 (36.6) 25 (30.1) 
Never 55 (54.5) 49 (59.0) 
Pack years * 16 (10.0-38.8) 15 (4.9-23.8) NS 
Systolic blood pressure (mmHg) 146.9 (±21.2) 136.6 (±18.9) < 0.001 
Diastolic blood pressure (mmHg) 81.0 (74.0-90.0) 81.0 (74.0-88.0) NS 
 BMI (kg/m2) 32.6 (29.8-36.0) 27.3 (25.0-29.5) < 0.001 
Status (n(%)) 
   
normal weight 7 (6.9) 20 (24.1) 
< 0.001 
overweight 19 (18.8) 43 (51.8) 
obese 43 (42.6) 9 (10.8) 
morbidly  obese 31(30.7) 11 (13.3) 
P-values determined using chi-squared test for discrete variables, Mann-Whitney U tests 
for continuous non-parametric variables (age, pack years, IMD rank, diastolic blood 
pressure and BMI) and independent t-test for continuous parametric variables (systolic 
blood pressure). * Applicable only to current and ex-smokers (n=46 diabetic subjects, 
n=34 non-diabetics subjects). Means (±SD) are presented for parametric data and 
medians (IQR) are presented for non-parametric data. 
  
4  Results 114
 
Figure 4.1 Categorisation of T2DM and non-diabetic patients based on BMI 
 
Stacked bar chart of subjects categorised based on BMI for T2DM patients (normal 
weight n=7, overweight n=17, obese n=43, morbidly obese n=31) and non-diabetic 
patients (normal weight n=20, overweight n=42, obese n=9, morbidly obese n=10). 
    normal weight 18.5-24.9 kg/m2,     overweight 25.0-29.9 kg/m2,     obese 30-34.9 
kg/m2,      morbidly obese >35 kg/m2. 
 
  
 Table 4.2  Subject demographic data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 
Health  
(n=14) 
Gingivitis  
(n=39) 
Periodontitis 
(n=48) 
Health  
(n=16) 
Gingivitis  
(n=19) 
Periodontitis 
(n=48) 
 
Male (n(%)) 5 (35.7) 26 (66.7) 36 (75.0) 4 (25.0) 11 (57.9) 35 (72.9) NS 
Age (years) 49.0 (±7.8) 47.3 (±6.8) 50.1 (±5.8) 48.0 (±7.5) 46.6 (±8.1) 48.8 (±6.7) NS 
Ethnicity (n(%)) 
       
Caucasian 13 (92.9) 38 (97.4) 45 (93.8) 16 (100) 19 (100) 48 (100) 
< 0.05 Black 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Asian 0 (0) 1 (7.1) 3 (6.3) 0 (0) 0 (0) 0 (0) 
IMD rank 10718 (2133-
20143) 
7046 (2320-
17948)$ 
15579 (3865-
24013) 
19357 (11702-
26868) 
21195 (16093-
26175) 
16024 (5090-
23060) 
$< 0.001 
Smoking status (n(%)) 
       
Current 0 (0) 3 (7.7) 6 (12.5) 0 (0) 2 (10.5) 7 (14.6) 
 
NS Ex 3 (21.4) 10 (25.6) 24 (50.0) 4 (25.0) 4 (21.1) 17 (35.4) 
Never 11 (78.6) 26 (66.7) 18 (37.5) 12 (75.0) 13 (68.4) 24 (50.0) 
Pack years * 5.0 (4.0-15.0) 15.0 (10.0-24.0) 30.0 (10.6-40.0) 10.9 (4.4-23.0) 11.1 (2.51-26.3) 15.0 (5.2-30.0) NS 
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Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 
Health  
(n=14) 
Gingivitis  
(n=39) 
Periodontitis 
(n=48) 
Health  
(n=16) 
Gingivitis  
(n=19) 
Periodontitis 
(n=48) 
 
 
Systolic BP (mmHg) 
 
146.1 (±20.6)$ 
 
150.1 (±21.2) $ 
 
144.8 (±21.5) 
 
122.2 (±11.0) ¶, # 
 
135 (±18.3) 
 
141.0 (±19.1) 
 
$,¶, #< 0.05  
Diastolic BP (mmHg) 80.0 (71.8-90.0) 87.4 (76.0-92.0) 79.5 (74.0-88.8) 79.0 (69.8-82.5) 80.0 (73.0-88.0) 83.0 (76.0-93.5) NS 
BMI (kg/m2) 31.2 (24.5-34.6) $ 32.9 (30.7-36.7) $ 33.0 (29.9-36.5) $ 24.7 (23.1-27.7) ¶ 27.3 (26.3-30.9)  28.1 (25.2-32.0)  $, ¶ < 0.05 
BMI status (n(%))** 
       
Normal weight 3 (23.1) 1 (2.7) 3 (6.3) 8 (50.0) 2 (10.5) 10 (21.7) 
< 0.001 
overweight 2 (15.4) 6 (16.2) 9 (18.8) 7 (43.8) 12 (63.2) 23 (50.0) 
obese 5 (38.5) 18 (48.6) 20 (41.7) 1 (6.3) 3 (15.8) 5 (10.9) 
morbidly  obese 3 (14.3) 12 (32.4) 16 (33.3) 0 (0) 2 (10.5) 8 (17.4) 
P-values were determined using chi-squared test for discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables (pack years, IMD rank, diastolic blood pressure and BMI) and one way ANOVA test with post-hoc independent t-test for 
continuous parametric variables (age and systolic blood pressure). * Applicable only to current and ex-smokers (n=3 diabetic with healthy perio, n=13 
diabetic with gingivitis, n=29 diabetic with periodontitis, n=4 non-diabetic with healthy perio, n=6 non-diabetic with gingivitis, n=23 non-diabetic with 
periodontitis). Mean (±SD) is presented for parametric data and median (IQR) is presented for non-parametric data. ** Missing data for 2 non-diabetic 
subjects with periodontitis. 
 
$
 indicates a comparison within rows between diabetic and non-diabetic groups with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes groups 
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Figure 4.2  Categorisation using BMI of subjects within groups based on 
periodontal and diabetes status  
 
Stacked bar chart of subjects categorised based on BMI for D/H patients (normal weight 
n=3, overweight n=2, obese n=5, morbidly obese n=3), D/G patients (normal weight 
n=1, overweight n=6, obese n=18, morbidly obese n=12), D/P patients (normal weight 
n=3, overweight n=9, obese n=20, morbidly obese n=16), ND/H patients (normal 
weight n=8, overweight n=7, obese n=1), ND/G patients (normal weight n=2, 
overweight n=12, obese n=3, morbidly obese n=2), ND/P patients (normal weight n=10, 
overweight n=23, obese n=5, morbidly obese n=8) 
 
normal weight 18.5-24.9 kg/m2,      overweight 25.0-29.9 kg/m2,     obese 30-34.9 
kg/m2,      morbidly obese >35 kg/m2. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H:  Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.3  Categorisation using smoking status of subjects within groups based 
on periodontal and diabetes status 
 
Stacked bar chart of subjects categorised based on smoking status for D/H patients 
(never smoked n=11, ex-smoker n=3), D/G patients (current smoker n=3, never smoked 
n=26, ex-smoker n=10), D/P patients (current smoker n=6, never smoked n=18, ex-
smoker n=24), ND/H patients (never smoked n=12, ex-smoker n=4), ND/G patients 
(current smoker n=2, never smoked n=13, ex-smoker n=4) ND/P patients (current 
smoker n=7, never smoked n=24, ex-smoker n=17). 
 
 current smoker,       ex-smoker,   never smoked 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis  
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4.2.2 Diabetes Care data 
Table 4.3 summarises data regarding diabetes care for the subjects with T2DM 
and demonstrates that of the 101 subjects with T2DM that were assessed at baseline, 
60.4% gave a family history of diabetes and 32.7% presented with at least one diabetic 
complication, not including periodontitis. 94.9% of subjects with T2DM had received 
examinations of their feet and eyes within the past 12 months. Based on HbA1c values, 
46.5% of subjects with diabetes could be categorised as having good glycaemic control 
(HbA1c <7.0%) (WHO, 1999). However, only 26.3% of subjects met the more stringent 
HbA1c target of 6.5% set out in more recent national T2DM management guidelines for 
the UK (NICE, 2008) (Table 4.3).  
Table 4.4 presents data following categorisation of subjects based on their 
periodontal diagnosis and demonstrates that subjects with gingivitis [6.0 (3.0-13.0 
years] or periodontitis [7.0 (3.0-10.0) years] presented with a longer history of diabetes 
compared to those with healthy periodontal tissues [2.5 (1.0-5.0) years]. Furthermore, 
Table 4.5 and Figure 4.4 highlight significant differences in the proportions of subjects 
meeting the UK target for glycaemic control of HbA1c ≤ 6.5 %, with a higher 
proportion of subjects with healthy periodontal tissues meeting the target (64.3%) and 
progressively fewer subjects reaching this target in the gingivitis (26.3%) and 
periodontitis groups (14.9%) respectively (Table 4.4 and Figure 4.4). Table 4.5 also 
shows there were significant differences in the proportions of subjects with specific 
management regimes with a higher proportion of subjects with healthy periodontal 
tissues being managed by dietary intervention alone (42.9%) and progressively fewer 
subjects being managed by diet alone in the gingivitis (12.8%) and periodontitis (8.5%) 
groups, respectively. Conversely, a higher proportion of subjects with periodontitis 
(29.8%) required insulin and there were progressively fewer subjects requiring insulin 
in the gingivitis (17.9%) and healthy periodontal tissues (0.0%) groups respectively. 
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Table 4.4 also shows a higher proportion of subjects reporting a diabetic complication 
was seen in subjects with periodontitis [35.4%] and gingivitis [35.9%] compared to 
subjects with healthy periodontal tissues [14.3%], although the difference failed to reach 
statistical significance (Table 4.4). 
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Table 4.3 Diabetes care data for patients with T2DM 
 
 
Diabetic patients 
(n=101) 
 
 
Years since diabetes diagnosis (years) 5 (2-10) 
Family history (n (%))  
Positive finding 61 (60.4) 
Diabetes Management (n (%)) *  
Diet only 15 (15.0) 
Oral hypoglycaemic drugs 64 (64.0) 
With insulin 21 (21.0) 
Glycaemic control categories (n (%)) **  
Good (<7.0%) 46 (46.5) 
Moderate (7.0-8.5%) 25 (25.3) 
Poor (>8.5%) 28 (28.3) 
Glycaemic control target met (≤6.5%) (n (%)) 26 (26.3) 
Patient perception of glycaemic control (n (%)) *  
Good 44 (44.0) 
Moderate 36 (36.0) 
Poor 20 (20.0) 
Diabetic complications (n (%))  
Positive finding 33 (32.7) 
Screening for complications (n(%))***  
Eye examination 93 (94.9) 
Foot examination 93 (94.9) 
Taking lipid lowering medication (n(%)) 73 (72.3) 
 
 
Means (±SD) are presented for parametric data and medians (IQR) are presented for 
non-parametric data. * Applicable to n=100. ** Applicable to n=99. *** Applicable to 
n=98. 
 
   
Table 4.4  Diabetes care data for patients with T2DM within groups based on periodontal diagnosis 
 
 
Diabetic subjects (n=101) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
 
 
    
Years since diabetes diagnosis (years) 2.5 (1.0-5.0) #,¶ 6.0 (3.0-13.0) 7.0 (3.0-10.0) #,¶ < 0.05 
Family history – positive finding (n(%)) 10 (71.4) 26 (66.7) 25 (52.1) NS 
Diabetes Management (n(%)) *     
Diet only 5 (42.9) 5 (12.8) 5 (10.4)  
Oral hypoglycaemic drugs 8 (57.1) 27 (69.2) 29 (60.4) < 0.01 
With insulin 0 (0) 7 (17.9) 14 (29.2)  
Glycaemic control target met (≤6.5%) (n(%)) 9 (64.3) 10 (26.3) 7 (14.9) < 0.001 
Glycaemic control categories (n(%)) **     
Good (<7.0%) 9 (64.3) 19 (50.0) 18 (38.3)  
Moderate (7.0-8.5%) 1 (7.1) 12 (31.6) 12 (25.5) NS 
Poor (>8.5%) 4 (28.6) 7 (18.4) 17 (36.2) 
 
Glycaemic control target met (≤6.5%) (n (%)) 9 (64.3) 10 (26.3) 7 (14.9)  
Continued over page 
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Diabetic subjects (n=101) 
p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Patient perception of glycaemic control (n(%)) ***     
Good 9 (64.3) 16 (41.0) 19 (40.4) 
 
Moderate 4 (28.6) 15 (38.5) 17 (36.2) NS 
Poor 1 (7.1) 8 (20.5) 11 (23.4)  
Diabetic complications (n(%))     
Positive finding 2 (14.3) 14 (35.9) 17 (35.4) NS 
Eye screening for complications (n(%))**** 13 (92.9) 38 (97.4) 41 (93.2) NS 
Foot screening for complications (n(%))**** 13 (92.9) 37 (94.9) 42 (95.5) NS 
Taking lipid lowering medication (n(%)) 10 (71.4) 26 (66.7) 37 (77.1) NS 
P-values were determined using chi-squared test for discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables (years since diabetes diagnosed) and one way ANOVA test with post-hoc independent t-test for continuous parametric variables 
(age at diagnosis). Mean (±SD) is presented for parametric data and median (IQR) is presented for non-parametric data. * Applicable to n=13 diabetic 
with healthy perio, n=39 diabetic with gingivitis, n=48 diabetic with periodontitis. ** Applicable to n=14 diabetic with healthy perio, n=38 diabetic 
with gingivitis, n=47 diabetic with periodontitis. *** Applicable to n=14 diabetic with healthy perio, n=39 diabetic with gingivitis, n=47 diabetic with 
periodontitis. **** Applicable to n=14 diabetic with healthy perio, n=39 diabetic with gingivitis, n=44 diabetic with periodontitis. 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                       
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within diabetic subjects 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within diabetic subjects 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within diabetic subjects
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Figure 4.4  Categorisation of T2DM subjects achieving national UK target of 
HbA1c ≤ 6.5% within groups based on periodontal  
 
Stacked bar chart of T2DM subjects categorised based achievement of national UK 
target of HbA1c ≤6.5% for subjects with healthy periodontal tissues (>6.5% n=7, 
≤HbA1c n=17), gingivitis (>6.5% n=7, ≤HbA1c n=17) and periodontitis (>6.5% n=7, 
≤HbA1c n=17). 
 
    >6.5% HbA1c (target not achieved),       ≤6.5% HbA1c target (target achieved) 
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4.2.3 Oral and dental data 
Oral and dental findings are summarised in Table 4.5. Of note when comparing 
the T2DM and the non-diabetic groups, significant differences were found relating to 
dry mouth and caries into dentine. Dry mouth was reported more frequently by subjects 
with T2DM [14.9%] compared to non-diabetics [2.4%]. Furthermore, dry mouth was 
clinically present more often in subjects with T2DM [7.9%] compared to non-diabetic 
subjects [1.2%]. Caries into dentine was clinically present more often in subjects with 
T2DM [20.8%] compared to subjects without diabetes [4.9%] (Table 4.5). 
Table 4.6 presents data following further categorisation of subjects based on 
their periodontal diagnosis and demonstrates a lack of significant differences between 
groups apart from teeth restored involving 1-3 surfaces in which subjects with T2DM 
and healthy periodontal tissues [9.9±3.9] had significantly more restored teeth than 
diabetic subjects with either gingivitis [6.5±3.6] or periodontitis [7.0±3.6]. Subjects 
with T2DM and gingivitis [6.5±3.6] had significantly less restored teeth than non-
diabetic subjects with gingivitis [9.0±4.2]. There were also differences in the 
proportions of subjects with at least one tooth with caries into dentine, with subjects 
with T2DM and either gingivitis or periodontitis being more likely to have at least one 
carious tooth, although this difference failed to reach statistical significance and was 
detected as a trend (p=0.075) (Table 4.6). 
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Table 4.5 Oral and dental data comparing subjects with and without T2DM 
 
 
Diabetic subjects 
(n=101) 
Non-diabetic subjects 
(n=83) p-value 
Abnormal Soft Tissue findings (n(%)) 
  
NS Positive finding 7 (6.8) 3 (3.6) 
Clinician assessed dry mouth (n(%)) 
  
< 0.05 Positive finding 8(7.9) 1(1.2) 
Patient reported dry mouth (n(%)) 
  
< 0.01 Positive finding 15 (14.9) 2 (2.4) 
Pain in previous month 
  
NS Positive finding 13 (12.9) 6 (7.2) 
Removable Prosthesis (n(%)) 
   
None 92 (91.1) 79 (95.2) 
NS Acrylic 6 (5.9) 4 (4.8) 
Chrome 3 (3.0) 
 
Teeth present 25.0 (22.0-28.0) 26.0 (24.0-27.0) NS 
Sound & unrestored teeth 16.0 (6.2) 16.1 (4.8) NS 
Restored teeth (1-3 surfaces) 8.0 (5.0-10.0)  7.0 (5.0-11.5) NS 
n (%) with at least one 96.0 (93.2) 82 (98.8) NS 
Restored teeth (+4 surfaces) 0.0 (0.0-2.0) 0.0 (0.0-2.0) NS 
n (%) with at least one 46 (45.5) 32 (38.5) NS 
Teeth with caries into dentine 0.0 (0.0-0.0) 0.0 (0.0-0.0) < 0.001 
n (%) with at least one 21 (20.8) 4 (4.9) < 0.05 
Broken down teeth 0.0 (0.0-0.0) 0.0 (0.0-0.0) NS 
n (%) with at least one 7 (6.9) 2 (2.4) NS 
Endodontically treated teeth* 0.0 (0.0-0.0) 0.0 (0.0-1.0) NS 
n (%) with at least one 9 (20.9) 12 (33.3) NS 
Periapical radiolucencies* 0.0 (0.0-0.0) 0.0 (0.0-0.8) NS 
n (%) with at least one 7 (16.3) 8 (22.2) NS 
P-values determined using chi-squared test for discrete variables, Mann-Whitney U tests 
for continuous non-parametric variables and independent t-test for continuous 
parametric variables. *(n=43 diabetic subjects, n=36 non-diabetics subjects). 
  
Table 4.6  Oral and Dental data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 
Healthy  
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
 
       
Abnormal soft tissue -positive finding (n(%)) 1 (7.1) 3 (7.7) 3 (6.35) 0 (0) 1 (5.2) 2 (4.2) NS 
Clinically dry mouth -positive finding (n(%)) 2 (14.3) 3 (7.7) 3 (6.3) 0 (0) 1 (5.2) 0 (0) NS 
Reported dry mouth - positive finding (n(%)) 3 (21.4) 5 (12.8) 7 (14.6) 0 (0) 1 (5.2) 1 (2.1) NS 
Pain – positive finding (n(%)) 1 (7.1) 5 (12.8) 7 (14.6) 0 (0) 3 (15.7) 3 (6.3) NS 
Removable Prosthesis (n(%)) 
       
None 14 (100) 35 (89.7) 43 (89.6) 15 (93.8) 18 (94.7) 46 (95.8) 
NS Acrylic 0 (0) 2 (5.1) 4 (8.3) 1 (6.3) 1 (5.2) 2 (4.2) 
Chrome 0 (0) 2 (5.1) 1 (2.1) 0 (0) 0 (0) 0 (0) 
Teeth present 25.0 (23.5-28.0) 26.0 (22.0-27.0) 25.0 (22.0-29.0) 27.0 (24.5-28.0) 25.0 (23.0-27) 26.0 (23.0-27.0) NS  
Sound & unrestored teeth 13.2 (±5.6) 16.3 (±5.8) 16.6 (±6.5) 17.1 (±5.0) 14.8 (±5.2) 17.0 (±4.5) NS 
Restored teeth (1-3 surfaces) 9.9 (±3.9)#,¶ 6.5 (±3.6)$ 7.0 (±3.6) 8.4 (±4.4) 9.0 (±4.2) 7.5 (±3.8) #,¶,$< 0.05 
n (%) with at least one 14 (100.0) 36 (92.3) 43 (89.6) 14 (87.5) 19 (100.0) 46 (95.8) NS 
Restored teeth (+4 surfaces) 1.0 (0.0-3.0) 0.0 (0.0-2.0) 0.0 (0.0-2.0) 0.0 (0.0-2.3) 0.0 (0.0-1.0) 0.0 (0.0-2.0) NS 
n (%) with at least one 7 (50.0) 18 (46.2) 21(43.8) 5 (31.3) 6 (31.6) 21 (43.8) NS 
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Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 Healthy  
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
 
      
 
Teeth with caries into dentine 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0)$ 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) $< 0.05 
n (%) with at least one 1(7.1) 9 (23.1) 11 (22.9) 2 (12.5) 2 (10.5) 2 (4.2) 0.075 
Broken down teeth 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) NS 
n (%) with at least one 0 (0.0) 3 (7.7) 4 (8.3) 0 (0.0) 1 (5.3) 1 (2.0) NS 
Endodontically treated teeth* 0 0.0 (0.0-0.0) 0.0 (0.0-0.25) 0 2.0 (1.0-3.0) 0.0 (0.0-1.0) NS 
Periapical radiolucencies * 0 0.0 (0.0-0.75) 0.0 (0.0-0.0) 0 0.0 (0.0-0.0) 0.0 (0.0-1.0) NS 
P-values were determined using chi-squared test for discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables (years since diabetes diagnosed) and one way ANOVA test with post-hoc independent t-test for continuous parametric variables 
(age at diagnosis). Means (±SD) are presented for parametric data and medians (IQR) are presented for non-parametric data. *(n=5 diabetic subjects 
with gingivitis, n=38 diabetic subjects with periodontitis, n=2 non-diabetic subjects with gingivitis, n=34 non-diabetic subjects with periodontitis). 
 
$
 indicates a comparison within rows between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes group
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4.2.4 Oral health behaviour data 
Table 4.7 summarises oral health behaviour data for diabetic patients and non-
diabetic patients. Of note, when comparing the T2DM and the non-diabetic groups, 
there were significant differences in the proportions of subjects for each of the oral 
health behaviours, with a higher proportion of non-diabetic subjects reporting that they 
attend a GDP regularly, or reporting that they had attended at GDP in the last 12 
months. Additionally, there were significant differences in the reason for the last visit to 
a GDP, with a higher proportion of non-diabetics attending for a check-up and a higher 
proportion of diabetics making emergency attendances. There were also significant 
differences in the frequency of tooth-brushing and interproximal cleaning, with a higher 
proportion of non-diabetics tooth-brushing at least twice a day and performing 
interproximal cleaning at least 3 times weekly (Table 4.7). 
Table 4.8 presents data following further categorisation of subjects based on 
their periodontal diagnosis and demonstrates that there were significant differences in 
the proportions of subjects for each of the oral health behaviours. Figure 4.5 and 4.6 
highlight that non-diabetic groups appeared to have a higher proportion of subjects 
tooth-brushing at least twice daily and attending a GDP regularly compared to diabetic 
subjects with the same periodontal condition (Table 4.8 and Figures 4.5 and 4.6). 
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Table 4.7    Oral health behaviour data comparing subjects with and without T2DM 
 
 
Diabetic subjects 
(n=101) 
Non-diabetic subjects 
(n=83) p-value 
Attends GDP regularly 
positive finding (n(%)) 
 
62 (62.0) 
 
62 (76.5) 
 
< 0.05 
Attended GDP within 12 months 
positive finding (n(%)) 
 
68 (68.0) 
 
70 (86.4) 
 
< 0.01 
Reason for last visit (n(%)) * 
  
 
N/A 35 (35.0) 7 (9.1) 
< 0.001 
 
Check-up 38 (38.0) 55 (71.4) 
Emergency 14 (14.0) 6 (7.8) 
Restoration 3 (3.0) 5 (6.5) 
Periodontal therapy 1 (1.0) 3 (3.9) 
other 9 (9.0) 1 (1.3) 
Frequency of tooth-brushing (n(%))** 
  
 
<1/day 7 (7.0) 2 (2.4) 
< 0.001 1/day 29 (29.9) 5 (6.0) 
2/day 60 (60.0) 68 (81.9) 
>2/day 4 (4.0) 8 (9.6) 
 
Frequency of interproximal (n(%))** 
  
 
never 65 (65.0) 30 (36.1) < 0.001 
1/wk 10 (10.0) 14 (16.9) 
 
>3/wk 25 (25.0) 39 (47.0) 
 
P-values were determined using chi-squared test for discrete variables. * n=100 diabetic 
subjects, n=77 non-diabetics subjects. ** n=100 diabetic subjects, n=83 non-diabetics 
subjects.
   
Table 4.8  Oral health behaviour data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic (n=101) Non-diabetic (n=83) p-value 
 
Healthy  
(n=14) 
Gingivitis  
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
Attends GDP regularly–positive finding(n(%)) 12 (85.7) 19 (48.7) 31 (64.6) 10 (62.5) 9 (47.4) 43 (89.6) < 0.001 
Attended GDP within 12 months-positive finding (n(%)) 11 (78.6) 23 (59.0) 34 (70.8) 13 (81.3) 10 (52.6) 47 (97.9) < 0.001 
Reason for last visit (n(%)) * 
       
N/A 3 (21.4) 16 (41.0) 16 (33.3) 1 (6.3) 5 (26.3) 1 (2.1) 
 
Check-up 8 (57.1) 11 (28.2) 19(39.6) 10 (62.5) 5 (26.3) 40 (83.3) 
 
Emergency 2 (14.3) 7 (17.9) 5 (10.4) 2 (12.5) 1 (5.2) 3 (6.25) < 0.001 
Restoration 1 (7.1) 1 (2.6) 1 (2.1) 1 (6.3) 3 (15.8) 1 (2.1) 
 
Periodontal 0 (0) 0 (0) 1 (2.1) 0 (0) 0 (0) 3(6.25) 
 
Other 0 (0%) 3 (7.7) 6 (12.5) 0 (0) 1 (5.2) 0 (0) 
 
Frequency of tooth-brushing (n(%)) ** 
       
<1/day 0 (0) 3 (7.7) 4 (8.3) 1 (6.3) 0 (0) 1 (2.1) 
 
1/day 2 (14.3) 15 (38.5) 12 (25.0) 0 (0) 1 (5.2) 4 (8.3) < 0.01 
2/day 11 (78.6) 19 (48.7) 30 (62.5) 14 (87.5) 18 (90.5) 36 (76.1) 
 
>2/day 1 (7.1) 1 (2.6) 2 (4.2) 1(6.3) 0 (0) 7 (14.6) 
 
Frequency of inter-proximal cleaning (n(%)) ** 
       
never 5 (35.7) 30 (76.9) 30 (62.5) 2 (12.5) 9 (47.4) 19 (39.6) 
 
1/wk 6 (42.9) 1 (2.6) 3 (6.3) 3 (18.8) 6 (31.6) 5 (10.4) < 0.001 
>3/wk 3 (21.4) 7 (17.9) 15 (31.3) 11 (68.8) 4 (21.1) 24 (50.0) 
 
P-values were determined using chi-squared test for discrete variables. * n= 14 diabetic subjects with healthy periodontal tissues, n=38 diabetic subjects 
with gingivitis, n=48 diabetic subjects with periodontitis, n=14 non-diabetic subjects with healthy periodontal tissues, n=15 non-diabetic subjects with 
gingivitis, n=48 non-diabetic subjects with periodontitis. ** n= 14 diabetic subjects with healthy periodontal tissues, n=38 diabetic subjects with 
gingivitis, n=48 diabetic subjects with periodontitis, n=16 non-diabetic subjects with healthy periodontal tissues, n=19 non-diabetic subjects with 
gingivitis, n=48 non-diabetic subjects with periodontitis.
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Figure 4.5  Categorisation using attendance at a GDP of subjects within groups 
based on periodontal and diabetes status 
 
Stacked bar chart of subjects categorised based on regular attendance at a GDP for D/H 
patients (regular attender at GDP  n=12, irregular attender at GDP n= 2), D/G patients 
(regular attender at GDP  n=19, irregular attender at GDP n= 19), D/P patients (regular 
attender at GDP  n=31, irregular attender at GDP n=17), ND/H patients (regular 
attender at GDP  n=10, irregular attender at GDP n=6), ND/G patients (regular attender 
at GDP  n=9, irregular attender at GDP n=8) ND/P patients (regular attender at GDP  
n=43, irregular attender at GDP n=5). 
 
 Attends GDP regularly,     Irregular attender at GDP        
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis  
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Figure 4.6  Categorisation using frequency of tooth-brushing of subjects within 
groups based on periodontal and diabetes status 
 
 
Stacked bar chart of subjects categorised based on frequency of tooth brushing for D/H 
patients (once per day  n= 2, twice per day n= 11, > twice per day n= 1), D/G patients (< 
once per day  n=3, once per day  n= 15, twice per day n=19 , > twice per day n=1), D/P 
patients (< once per day  n=4, once per day  n=12 , twice per day n= 30, > twice per day 
n=2), ND/H patients (< once per day  n=1, twice per day n=14 , > twice per day n=1), 
ND/G patients (once per day  n=1 , twice per day n=18) ND/P patients (< once per day  
n=1, once per day  n=4 , twice per day n= 36, >twice per day n=7). 
 
 Tooth-brushing < once per day        Tooth-brushing once per day   
 Tooth-brushing twice per day         Tooth-brushing > twice per day   
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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4.2.5 Pre-treatment clinical biochemistry data 
Table 4.9 summarises the pre-treatment clinical biochemistry data for diabetic 
patients and non-diabetic patients. Of note, when comparing the T2DM and the non-
diabetic groups there were significant differences for HbA1c, triglycerides, HDL, non-
HDL and cholesterol. Subjects with diabetes had significantly lower levels of HDL, 
non-HDL [3.2 (2.7-3.9) mmol/L] and total cholesterol [4.4 (3.9-5.3) mmol/L] compared 
to non-diabetics [4.1(3.5-4.6) mmol/L and 5.5 (5.0-6.1) mmol/L]. As would be 
expected, HbA1c was significantly higher subjects with diabetes [7.2 (6.5-8.9)%] 
compared to the non-diabetic group subjects [5.5 (5.3-5.7)%]. Levels of high sensitive 
CRP also appeared higher in subjects with T2DM [2.3 (0.9-4.5) mg/L] compared to 
non-diabetic subjects [1.9 (0.8-3.9) mg/L], however the difference failed to reach 
statistical significance (Table 4.9 and Figure 4.7).  
 Table 4.10 presents pre-treatment clinical biochemistry data following 
further categorisation of subjects based on their periodontal diagnosis and demonstrates 
that HbA1c, as expected, was significantly higher in diabetic subjects compared to the 
non-diabetic subjects regardless of periodontal condition.  Interestingly, when 
comparing groups in subjects with T2DM, HbA1c appeared higher in subjects with 
periodontitis [7.5 (6.7-9.2)%] compared to subjects with healthy periodontal tissues [6.4 
(5.9-9.0)%]. However, the Bonferroni-Holm correction of p-values for multiple 
comparison placed the critical p-value at 0.017, therefore, this difference was detected 
as trend (p=0.036) (Table 4.10). 
When comparing groups with different periodontal conditions, triglyceride 
levels were significantly higher in subjects with T2DM with healthy periodontal tissues 
[3.1 (2.2-3.9) mmol/L] and periodontitis [2.5 (1.7-4.2) mmol/L] compared to non-
diabetic subjects with healthy periodontal tissues [1.0 (0.8-2.7) mmol/L] and 
periodontitis [1.7 (1.2-2.7) mmol/L].  When considering subjects with T2DM, 
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triglyceride levels were significantly higher in those with healthy periodontal tissues 
[3.1 (2.2-3.9) mmol/L] compared to those with periodontitis [2.5 (1.7-4.2) mmol/L] and 
lower in those with gingivitis [1.8 (1.3-2.6) mmol/L] compared to those with 
periodontitis [2.5 (1.7-4.2) mmol/L] (Table 4.10).  
Following categorisation of data based on periodontal diagnosis, HDL levels 
were significantly lower in subjects with T2DM with healthy periodontal tissues [1.2 
(1.2-1.6) mmol/L], gingivitis [1.2 (1.3-2.6) mmol/L] and periodontitis [1.1 (1.0-1.3) 
mmol/L] compared to non-diabetic subjects with healthy periodontal tissues [1.7 (1.5-
2.0) mmol/L], gingivitis [1.5 (1.3-1.7) mmol/L] and periodontitis [1.4 (1.1-1.6) 
mmol/L]. In subjects with T2DM, HDL levels in subjects with healthy periodontal 
tissues [1.2 (1.2-1.6) mmol/L] appeared higher compared to subjects with periodontitis 
[1.1 (1.0-1.3) mmol/L]. However, the Bonferroni-Holm correction of p-values for 
multiple comparison placed the critical p-value at 0.017, therefore, the difference was 
detected as trend (p=0.04). Similarly, in non-diabetic subjects, HDL levels in subjects 
with healthy periodontal tissues [1.7 (1.5-2.0) mmol/L] appeared higher compared to 
subjects with periodontitis [1.4 (1.1-1.6) mmol/L]. However, the Bonferroni-Holm 
correction of p-values for multiple comparison placed the critical p-value at 0.017, 
therefore, the difference was detected as trend (p=0.021) (Table 4.10). 
Following categorisation of data based on periodontal diagnosis, non-HDL 
levels were significantly lower in T2DM subjects with gingivitis [3.0 (2.3-3.7) mmol/L] 
and periodontitis [3.3 (2.8-3.9) mmol/L] compared to the non-diabetic subjects with 
gingivitis [4.4 (3.8-4.7) mmol/L] and periodontitis [4.2 (3.6-4.6) mmol/L]. When 
considering subjects with T2DM, non-HDL levels were significantly higher in those 
with healthy periodontal tissues [4.3 (3.0-5.1) mmol/L] compared to those with 
gingivitis [3.0 (2.3-3.7) mmol/L]. Similarly, in subjects with T2DM, non-HDL levels in 
those with healthy periodontal tissues [4.3 (3.0-5.1) mmol/L] appeared higher compared 
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to subjects with periodontitis [3.3 (2.8-3.9) mmol/L]. However, the Bonferroni-Holm 
correction of p-values for multiple comparison placed the critical p-value at 0.025, 
therefore, this difference was detected as trend (p=0.04) (Tables 4.9 and 4.10). 
Following categorisation of data based on periodontal diagnosis, total-
cholesterol levels were significantly higher in T2DM subjects with healthy periodontal 
tissues [5.5 (4.3-6.4) mmol/L] compared to T2DM subjects with gingivitis [4.2 (3.7-5.9) 
mmol/L]. Similarly, in subjects with T2DM, total cholesterol levels appeared higher in 
subjects with healthy periodontal tissues [5.5 (4.3-6.4) mmol/L] compared to those with 
periodontitis [4.4 (4.0-5.3) mmol/L]. However, the Bonferroni-Holm correction of p-
values for multiple comparison placed the critical p-value at 0.025, therefore, this 
difference was detected as trend (p=0.026) (Tables 4.9 and 4.10). 
When considering hsCRP levels, subjects with T2DM and healthy periodontal 
tissues [2.4 (0.8-5.5) mg/L] had significantly higher  hsCRP levels than non-diabetic 
subjects with healthy periodontal tissues [0.6 (0.2-1.5) mg/L]. Also, in non-diabetic 
subjects, those with healthy periodontal tissues [0.6 (0.2-1.5) mg/L] had significantly 
lower hsCRP levels compared to subjects with gingivitis [2.3 (0.8-4.2) mg/L] or 
periodontitis [2.3 (1.1-4.3) mg/L]. However, in subjects with T2DM similar differences 
were not found when comparing subjects with healthy periodontal tissues [2.4 (0.8-5.5) 
mg/L], gingivitis [2.4 (1.0-4.4) mg/L] and periodontitis [2.1 (0.9-4.6) mg/L] (Table 
4.10). 
 
  
4  Results 137
 
Table 4.9  Pre-treatment clinical biochemistry data comparing subjects with 
and without T2DM 
 
 
Diabetics 
(n=99) 
Non-diabetics 
(n=79) p-value 
HbA1c (%) 7.2 (6.5-8.9) 5.5 (5.3-5.7) < 0.001 
Triglycerides (mmol/L) 2.3 (1.5-3.6) 1.6 (1.1-2.4) < 0.001 
HDL (mmol/L) 1.2 (1-1.4) 1.5 (1.2-1.8) < 0.001 
Non-HDL (mmol/L) 3.2 (2.7-3.9) 4.1 (3.5-4.6) < 0.001 
Total cholesterol (mmol/L) 4.4 (3.9-5.3) 5.5 (5.0-6.1) < 0.001 
High sensitive CRP (mg/L)* 2.3 (0.9-4.5) 1.9 (0.8-3.9) 0.25 
P-values determined using Mann Whitney-U tests as all variables are continuous non-
parametric. Median and IQR presented for this non-parametric data. *(92 T2DM and 71 
non-diabetic subjects) 
 
Figure 4.7  Pre-treatment serum levels of high sensitive CRP in subjects with 
T2DM and in non-diabetic subjects 
 
Boxplot of pre-treatment serum levels of high sensitive CRP in 92 T2DM and 71 non-
diabetic subjects. Statistics: Mann Whitney-U test (differences were non-significant). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
   
Table 4.10  Pre-treatment clinical biochemistry data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=99) Non-diabetic subjects (n=79) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=38) 
Periodontitis 
(n=47) 
Healthy 
(n=15) 
Gingivitis 
(n=17) 
Periodontitis 
(n=47) 
 
HbA1c (%) 6.4 (5.9-9.0) $ 7.0 (6.5-8.3) $ 7.5 (6.7-9.2) $ 5.5 (5.3-5.6) 5.7 (5.3-5.9) 5.5 (5.3-5.7) $< 0.001 
Triglycerides (mmol/L) 3.1 (2.2-3.9)#, $ 1.8 (1.3-2.6)† 2.5 (1.7-4.2) $ 1.0 (0.8-2.7) 1.7 (1.4-2.1) 1.7 (1.2-2.7) †,#,$< 0.05 
HDL (mmol/L) 1.2 (1.2-1.6) $ 1.2 (1.1-1.5) $ 1.1 (1.0-1.3) $ 1.7 (1.5-2.0)  1.5 (1.3-1.7) 1.4 (1.1-1.6) $< 0.05 
Non-HDL (mmol/L) 4.3 (3.0-5.1) # 3.0 (2.3-3.7) $ 3.3 (2.8-3.9) $ 3.5 (2.9-4.3) 4.4 (3.8-4.7) 4.2 (3.6-4.6) $,#< 0.05 
Total cholesterol (mmol/L) 5.5 (4.3-6.4) # 4.2 (3.7-5.0) $ 4.4 (4.0-5.3) $ 5.1 (4.7-6.0) 5.9 (5.1-6.3) 5.5 (5.0-6.1) #, $< 0.01 
High sensitive CRP (mg/L)* 2.4 (0.8-5.5) $ 2.4 (1.0-4.4) 2.1 (0.9-4.6) 0.6 (0.2-1.5) #,¶ 2.3 (0.8-4.2) 2.3 (1.1-4.3) $,#,¶< 0.05 
P-values were determined using Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-parametric variables (all data). Medians 
(IQR) are presented for this non-parametric data. *(n=13 diabetic subjects with healthy periodontal tissues, n=36 diabetic subjects with gingivitis, n=43 
diabetic subjects with periodontitis, n=15 non-diabetic subjects with healthy periodontal tissues, n=14 non-diabetic subjects with gingivitis, n=42 non-
diabetic subjects with periodontitis). 
 
$
 indicates a comparison within rows between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes group 
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4.2.6 Pre-treatment clinical periodontal data 
Table 4.11 summarises the clinical periodontal data for diabetic patients and 
non-diabetic patients before periodontal management. Of note, when comparing the 
T2DM and the non-diabetic groups, there were significant differences in mean PI, 
PESA, % sites with PD ≥6mm and % of sites with LOA ≥6mm. The subjects with 
T2DM had significantly higher PI [0.8 (0.6-1.0)mmol/L] compared to the non-diabetic 
subjects [0.6 (0.3-0.8)mmol/L]. Conversely, in subjects with T2DM, PESA [1038.9 
(817.9-1327.6) mm2] was significantly lower compared to non-diabetic subjects [1372.7 
(849.2-1801.0) mm2]. Furthermore, T2DM subjects had significantly fewer sites with 
PD ≥ 6 mm [0.0 (0.0-2.0)] and fewer sites with LOA ≥ 6 mm [0.7 (0.0-4.4)] compared 
to non-diabetic subjects [0.7 (0.0-11.3) and 3.2 (0.0-15.1) respectively] (Table 4.11). 
Table 4.12 presents pre-treatment clinical periodontal data following further 
categorisation of subjects based on their periodontal diagnosis. When considering levels 
of plaque control, PI was significantly higher in diabetic subjects with healthy 
periodontal tissues [0.4 (0.3-0.8)], gingivitis [0.9 (0.7-1.0)] and periodontitis [0.8 (0.6-
1.1)] compared to the non-diabetic subjects with healthy periodontal tissues [0.2 (0.0-
0.4)], gingivitis [0.6 (0.4-0.7)] and periodontitis [0.6 (0.4-0.8)].  When comparing the 
subjects with T2DM, PI was significantly higher in those with gingivitis [0.9 (0.7-1.0)] 
compared to those with healthy periodontal tissues [0.4 (0.3-0.8)]. Similarly, in subjects 
with T2DM, PI was significantly higher in those with periodontitis [0.8 (0.6-1.1)] 
compared to those with healthy periodontal tissues [0.4 (0.3-0.8)]. For non-diabetic 
subjects, PI was significantly higher in those with gingivitis [0.6 (0.4-0.7)] compared to 
those with healthy periodontal tissues [0.2 (0.0-0.4)]. Similarly, in non-diabetic 
subjects, PI was significantly higher in those with periodontitis [0.6 (0.4-0.8)].   
compared to those with healthy periodontal tissues [0.2 (0.0-0.4)] (Table 4.12 and 
Figure 4.8).   
4  Results 140
Table 4.12 presents pre-treatment clinical periodontal data following further 
categorisation of subjects based on their periodontal diagnosis. When considering levels 
of gingival inflammation, mGI was significantly higher in diabetic subjects with healthy 
periodontal tissues [0.8 (0.5-1.6)] and gingivitis [1.9 (1.3-2.5)] compared to the non-
diabetic subjects with healthy periodontal tissues [0.5(0.3-0.8)] and gingivitis [1.3 (0.8-
1.7)]. When comparing the subjects with T2DM, mGI was significantly higher in those 
with gingivitis [1.9 (1.3-2.5)] compared to those with healthy periodontal tissues [0.8 
(0.5-1.6)].  Similarly, in subjects with T2DM, mGI was significantly higher in those 
with periodontitis [2.0 (1.5-2.7)] compared to those with healthy periodontal tissues [0.8 
(0.5-1.6)]. For non-diabetic subjects, mGI was significantly higher in those with 
gingivitis [1.3 (0.8-1.7)] compared to those with healthy periodontal tissues [0.5 (0.3-
0.8)]. Similarly, in non-diabetic subjects, mGI was significantly higher in those with 
periodontitis [2.4 (2.0-2.7)] compared to those with healthy periodontal tissues [0.5 
(0.3-0.8)]. Additionally, in non-diabetic subjects mGI was significantly higher in the 
periodontitis group [2.4 (2.0-2.7)] compared to those with gingivitis [1.3 (0.8-1.7)] 
(Table 4.12 and Figure 4.9).  
When considering bleeding on probing, % BOP was significantly higher in 
diabetic subjects with healthy periodontal tissues [4.5 (0.7-13.1)%] and gingivitis [35.1 
(25.0-44.9)%] compared to the non-diabetic subjects with healthy periodontal tissues 
[0.7(0.0-2.6)%] and gingivitis [22.0 (17.3-32.6)%]. When comparing the subjects with 
T2DM, % BOP was significantly higher in those with gingivitis [35.1 (25.0-44.9)%] 
compared to those with healthy periodontal tissues [4.5 (0.7-13.1)%].  Similarly, in 
subjects with T2DM, % BOP was significantly higher in those with periodontitis [46.0 
(30.0-60.7)%] compared to those with healthy periodontal tissues [4.5 (0.7-13.1)%].   
For non-diabetic subjects, % BOP was significantly higher in those with gingivitis [22.0 
(17.3-32.6)%] compared to those with healthy periodontal tissues [0.7 (0.0-2.6)%]. 
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Similarly, in non-diabetic subjects, % BOP was significantly higher in those with 
periodontitis [43.0 (29.4-56.7)%] compared to those with healthy periodontal tissues 
[0.7 (0.0-2.6)%].  Additionally, in non-diabetic subjects % BOP was significantly 
higher in the periodontitis group [43.0 (29.4-56.7)%] compared to those with gingivitis 
[22.0 (17.3-32.6)%] (Table 4.12 and Figure 4.10). 
When considering probing depths, mean PD was significantly higher in diabetic 
subjects with healthy periodontal tissues [1.7 (1.6-1.8) mm] and gingivitis [2.1 (1.2-2.2) 
mm] compared to the non-diabetic subjects with healthy periodontal tissues [1.6 (1.5-
1.7) mm] and gingivitis [1.9 (1.8-2.1) mm]. When comparing the subjects with T2DM, 
mean PD was significantly higher in those with gingivitis [2.1 (1.2-2.2) mm] compared 
to those with healthy periodontal tissues [1.7 (1.6-1.8) mm]. Similarly, in subjects with 
T2DM, mean PD was significantly higher in those with periodontitis [2.8 (2.4-3.2) mm] 
compared to those with healthy periodontal tissues [1.7 (1.6-1.8) mm]. Additionally, in 
subjects with T2DM, mean PD was significantly higher in the periodontitis group [2.8 
(2.4-3.2) mm] compared to those with gingivitis [2.1 (1.2-2.2) mm]. For non-diabetic 
subjects, mean PD was significantly higher in those with gingivitis [1.9 (1.8-2.1) mm] 
compared to those with healthy periodontal tissues [1.6 (1.5-1.7) mm]. Similarly, in 
non-diabetic subjects, mean PD was significantly higher in those with periodontitis 
[2.9(2.5-3.5) mm] compared to those with healthy periodontal tissues [1.6(1.5-1.7) 
mm].  Additionally, in non-diabetic subjects mean PD was significantly higher in the 
periodontitis group [2.9(2.5-3.5) mm] compared to those with gingivitis [1.9(1.8-2.1) 
mm] (Table 4.12 and Figure 4.11).  
When considering the percentage of sites with PD  ≥ 4 mm, there was a 
significantly greater % in diabetic subjects with healthy periodontal tissues [0.7 (0.0-
1.7) %] compared to the non-diabetic subjects with healthy periodontal tissues [0.0 (0.0-
0.0) %]. When comparing the subjects with T2DM, % of sites with PD ≥ 4 mm was 
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significantly higher in those with gingivitis [3.6 (1.4-7.0) %] compared to those with 
healthy periodontal tissues [0.7 (0.0-2.7) %]. Similarly, in subjects with T2DM, % of 
sites with PD ≥ 4 mm was significantly higher in those with periodontitis [20.2 (12.7-
35.2) %] compared to those with healthy periodontal tissues [0.7 (0.0-1.7) %].  
Additionally, in subjects with T2DM, the % of sites with PD ≥ 4 mm was significantly 
higher in the periodontitis group [20.2 (12.7-35.2) %] compared to those with gingivitis 
[3.6 (1.4-7.0) %]. For non-diabetic subjects, % of sites with PD ≥ 4 mm was 
significantly higher in those with gingivitis [2.0 (0.6-5.1) %] compared to those with 
healthy periodontal tissues [0.0 (0.0-0.0) %]. Similarly, in non-diabetic subjects, % of 
sites with PD ≥ 4 mm was significantly higher in those with periodontitis [24.2 (18.0-
40.0) %] compared to those with healthy periodontal tissues [0.0 (0.0-0.0) %]. 
Additionally, in non-diabetic subjects % of sites with PD ≥ 4 mm was significantly 
higher in the periodontitis group [24.2 (18.0-40.0) %] compared to those with gingivitis 
[2.0 (0.6-5.1) %] (Table 4.12 and Figure 4.12).  
When considering the percentage of PD sites ≥5mm, there were no significant 
differences found in any periodontal category between T2DM and non-diabetic 
subjects. When comparing the subjects with T2DM, % of sites with PD ≥ 5 mm was 
significantly higher in those with gingivitis [0.0 (0.0-1.2) %] compared to those with 
healthy periodontal tissues [0.0 (0.0-0.0) %], although the clinical significance of this 
difference is likely to be minimal. Similarly, in subjects with T2DM, % of sites with PD 
≥ 5 mm was significantly higher in those with periodontitis [10.9 (8.1-18.2) %] 
compared to those with healthy periodontal tissues [0.0 (0.0-0.0) %]. Additionally, 
insubjects with T2DM, the % of sites with PD ≥ 5 mm was significantly higher in the 
periodontitis group [10.9 (8.1-18.2) %] compared to those with gingivitis [0.0 (0.0-1.2) 
%]. For non-diabetic subjects, % of sites with PD ≥ 5 mm was significantly higher in 
those with gingivitis [0.0 (0.0-0.0) %] compared to those with healthy periodontal 
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tissues [0.0 (0.0-0.0) %], although the clinical significance of this difference is likely to 
be minimal. Similarly, in non-diabetic subjects, % of sites with PD ≥ 5 mm was 
significantly higher in those with periodontitis [16.0 (8.0-30.8) %] compared to those 
with healthy periodontal tissues [0.0 (0.0-0.0) %]. Additionally, in non-diabetic subjects 
% of sites with PD ≥ 5 mm was significantly higher in the periodontitis group [16.0 
(8.0-30.8) %] compared to those with gingivitis [0.0 (0.0-0.0) %] (Table 4.12 and 
Figure 4.13).  
The percentage of PD sites ≥ 6 mm, was significantly lower in diabetic subjects 
with periodontitis [2.7 (0.7-7.1) %] compared to the non-diabetic subjects with 
periodontitis [8.7 (2.6-16.7) %]. When comparing the subjects with T2DM, % of sites 
with PD ≥ 6 mm was significantly higher in those with periodontitis [2.7 (0.7-7.1) %] 
compared to those with healthy periodontal tissues [0.0 (0.0-0.0) %]. Additionally, in 
subjects with T2DM, the % of sites with PD ≥ 6 mm was significantly higher in the 
periodontitis group [2.7 (0.7-7.1) %] compared to those with gingivitis [0.0 (0.0-0.0) 
%]. For non-diabetic subjects, % of sites with PD ≥ 6 mm was significantly higher in 
those with periodontitis [8.7 (2.6-16.7) %] compared to those with healthy periodontal 
tissues [0.0 (0.0-0.0) %]. Additionally, in non-diabetic subjects % of sites with PD ≥ 6 
mm was significantly higher in the periodontitis group [8.7 (2.6-16.7) %] compared to 
those with gingivitis [0.0 (0.0-0.0) %] (Table 4.12 and Figure 4.14).  
When considering loss of attachment, mean LOA was significantly higher in 
diabetic subjects with gingivitis [2.3 (2.1-2.4) mm] compared to the non-diabetic 
subjects with gingivitis [2.1 (2.0-2.3) mm].  When comparing the subjects with T2DM, 
mean LOA was significantly higher in those with gingivitis [2.3 (2.1-2.4)] compared to 
those with healthy periodontal tissues [1.9 (1.8-2.1)]. Similarly, in subjects with T2DM, 
mean LOA was significantly higher in those with periodontitis [3.1 (2.7-3.9)] compared 
to those with healthy periodontal tissues [1.9 (1.8-2.1)]. Additionally, in subjects with 
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T2DM, the mean LOA was significantly higher in the periodontitis group [3.1 (2.7-3.9)] 
compared to those with gingivitis [2.3 (2.1-2.4)]. For non-diabetic subjects, the mean 
LOA significantly higher in those with gingivitis [2.1 (2.0-2.3)] compared to those with 
healthy periodontal tissues [1.8 (1.6-2.0)]. Similarly, in non-diabetic subjects, mean 
LOA was significantly higher in those with periodontitis [3.4 (2.9-4.2)] compared to 
those with healthy periodontal tissues [1.8 (1.6-2.0)]. Additionally, in non-diabetic 
subjects mean LOA was significantly higher in the periodontitis group [3.4 (2.9-4.2)] 
compared to those with gingivitis [2.1 (2.0-2.3)] (Table 4.12). 
When considering the percentage of sites with LOA ≥ 4mm, there were no 
significant differences found in any periodontal category between T2DM and non-
diabetic subjects. When comparing the subjects with T2DM, the % of sites with LOA ≥ 
4 mm was significantly higher in those with gingivitis [5.8 (1.8-10.1) %] compared to 
those with healthy periodontal tissues [2.3 (0.5-6.1) %]. Similarly, in subjects with 
T2DM, the % of sites with LOA  ≥ 4 mm was significantly higher in those with 
periodontitis [32.0 (19.5-51.2) %] compared to those with healthy periodontal tissues 
[2.3 (0.5-6.1) %].  Additionally, in subjects with T2DM, the % of sites with LOA ≥ 4 
mm was significantly higher in the periodontitis group [32.0 (19.5-51.2) %] compared 
to those with gingivitis [5.8 (1.8-10.1) %]. For non-diabetic subjects, the % of sites with 
LOA ≥ 4 mm significantly higher in those with gingivitis [4.2 (0.7-8.2) %] compared to 
those with healthy periodontal tissues [1.0 (0.0-4.0) %]. Similarly, in non-diabetic 
subjects, the % of sites with LOA ≥ 4 mm was significantly higher in those with 
periodontitis [39.9(25.6-58.0) %] compared to those with healthy periodontal tissues 
[1.0(0.0-4.0) %]. Additionally, in non-diabetic subjects the % of sites with LOA ≥ 4 mm 
was significantly higher in the periodontitis group [39.9(25.6-58.0) %] compared to 
those with gingivitis [4.2(0.7-8.2) %] (Table 4.12).  
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When considering the percentage of LOA sites ≥ 5 mm, there were no 
significant differences found in any periodontal category between T2DM and non-
diabetic subjects. When comparing the subjects with T2DM, the % of sites with LOA ≥ 
5 mm was significantly higher in those with periodontitis [17.3 (10.6-31.7) %] 
compared to those with healthy periodontal tissues [0.5 (0.0-1.7) %]. Additionally, in 
subjects with T2DM, the % of sites with LOA ≥ 5 mm was significantly higher in the 
periodontitis group 17.3 (10.6-31.7) %] compared to those with gingivitis [0.8 (0.0-2.6) 
%]. For non-diabetic subjects, % of sites with LOA ≥ 5 mm was significantly higher in 
those with gingivitis [0.0 (0.0-1.6) %] compared to those with healthy periodontal 
tissues [0.0 (0.0-0.0) %], although the clinical significance of this difference is likely to 
be minimal. Similarly, in non-diabetic subjects, % of sites with LOA ≥ 5 mm was 
significantly higher in those with periodontitis [24.7 (14.5-37.2) %] compared to those 
with healthy periodontal tissues [0.0 (0.0-0.0) %]. Additionally, in non-diabetic subjects 
% of sites with LOA ≥ 5 mm was significantly higher in the periodontitis group [24.7 
(14.5-37.2) %] compared to those with gingivitis [0.0 (0.0-1.6) %] (Table 4.12).  
When considering the percentage of sites with LOA ≥ 6 mm, there was a 
significantly greater % in non-diabetic subjects with periodontitis [12.7 (6.0-25.6) %] 
compared to the diabetic subjects with and periodontitis [4.6 (1.2-13.3) %]. Conversely, 
there was a significantly greater % in diabetic subjects with gingivitis [0.0 (0.0-0.7) %] 
compared to the non-diabetic subjects with and gingivitis [0.0 (0.0-0.0) %]. When 
comparing the subjects with T2DM, the % of sites with LOA ≥ 6 mm was significantly 
higher in those with periodontitis [4.6 (1.2-13.3) %] compared to those with healthy 
periodontal tissues [0.0 (0.0-0.2) %]. Additionally, in subjects with T2DM, the % of 
sites with LOA ≥ 6 mm was significantly higher in the periodontitis group [4.6 (1.2-
13.3) %] compared to those with gingivitis [0.0 (0.0-0.7) %]. For non-diabetic subjects, 
% of sites with LOA ≥ 6 mm was significantly higher in those with periodontitis [12.7 
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(6.0-25.6) %] compared to those with healthy periodontal tissues [0.0 (0.0-0.0) %]. 
Additionally, in non-diabetic subjects % of sites with LOA ≥ 6 mm was significantly 
higher in the periodontitis group [12.7 (6.0-25.6) %] compared to those with gingivitis 
[0.0 (0.0-0.0) %] (Table 4.12).  
When considering periodontal epithelial surface area, PESA was a significantly 
greater in non-diabetic patients with periodontitis [1744.9±519.9 mm2] compared to 
diabetic subjects with periodontitis [1444.7±495.1 mm2]. When comparing the subjects 
with T2DM, the PESA was significantly higher in those with gingivitis [921.5±184.3 
mm2] compared to those with healthy periodontal tissues [698.5±197.3 mm2]. Similarly, 
in subjects with T2DM, the PESA was significantly higher in those with periodontitis 
[1444.7±495.1 mm2] compared to those with healthy periodontal tissues [698.5±197.3 
mm2].  Additionally, in subjects with T2DM, the PESA was significantly higher in the 
periodontitis group [1444.7±495.1 mm2] compared to those with gingivitis 
[921.5±184.3 mm2]. For non-diabetic subjects, the PESA was significantly higher in 
those with gingivitis [921.4±154.4 mm2] compared to those with healthy periodontal 
tissues [787.2±82.1 mm2]. Similarly, in non-diabetic subjects, the PESA was 
significantly higher in those with periodontitis [1744.9±519.9 mm2] compared to those 
with healthy periodontal tissues [787.2±82.1 mm2].  Additionally, in non-diabetic 
subjects the PESA was significantly higher in the periodontitis group [1744.9±519.9 
mm2] compared to those with gingivitis [921.4±154.4 mm2] (Table 4.12, Figure 4.15) 
When considering the periodontal surface area which was considered inflamed 
due to the presence of bleeding on probing, there was no significant differences in PISA 
were found in any periodontal category between T2DM and non-diabetic subjects. 
When comparing the subjects with T2DM, the PISA was significantly higher in those 
with gingivitis [342.4 (239.4-439.1) mm2] compared to those with healthy periodontal 
tissues [24.7 (0.0-89.8) mm2]. Similarly, in subjects with T2DM, the PISA was 
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significantly higher in those with periodontitis [683.0 (439.1-1085.5) mm2] compared to 
those with healthy periodontal tissues [24.7 (0.0-89.8) mm2]. Additionally, subjects with 
T2DM, the PISA was significantly higher in the periodontitis group [683.0 (439.1-
1085.5) mm2] compared to those with gingivitis [342.4 (239.4-439.1) mm2]. For non-
diabetic subjects, the PISA significantly higher in those with gingivitis [242.6 (195.6-
353.3) mm2] compared to those with healthy periodontal tissues [4.48 (0.0-23.2) mm2]. 
Similarly, in non-diabetic subjects, the PISA was significantly higher in those with 
periodontitis [897.3 (683.6-1232.9) mm2] compared to those with healthy periodontal 
tissues [4.48(0.0-23.2) mm2]. Additionally, in non-diabetic subjects the PISA was 
significantly higher in the periodontitis group [897.3(683.6-1232.9) mm2] compared to 
those with gingivitis [242.6(195.6-353.3) mm2] (Table 4.12 and Figure 4.16) 
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Table 4.11  Pre-treatment clinical periodontal data comparing subjects with and 
without T2DM 
 
 
Diabetic subjects 
(n=101) 
Non-diabetic 
subjects 
(n=83) 
p-value 
 
   
Month 0 mean mGI 1.9 (1.3-2.5) 1.8 (0.8-2.5) NS 
Month 0 mean PI 0.8 (0.6-1.0) 0.6 (0.3-0.8) < 0.001 
Month 0 BOP (%)  36.3 ±22.4 31.6 ±22.7 NS 
Month 0 mean PD (mm) 2.4 (2.0-2.8) 2.5 (1.8-3.1) NS 
Month 0 mean recession (mm) 0.3 (0.1-0.5) 0.3 (0.2-0.6) NS 
Month 0 mean LOA (mm) 2.7 (2.2-3.1) 2.9 (2.0-3.5) NS 
Month 0 PESA (mm2) 1038.9 (817.9-1327.6) 1372.7 (849.2-1801.0) < 0.05 
Month 0 PISA (mm2) 526.7 (201.1-746.8) 634.1 (145.3-963.0) NS 
Month 0 % PD sites ≥4mm 7.8 (2.2-18.5) 14.7 (0.6-31.3) NS 
Month 0 total assessed sites 150 (132.0-162.0) 156.0 (144.0-162.0) NS 
Month 0 % PD sites ≥5mm 2.9 (0.0-10.5) 5.6 (0.0-21.8) NS 
Month 0 % PD sites ≥6mm 0.0 (0.0-2.0) 0.7 (0.0-11.3) < 0.01 
Month 0 % LOA sites ≥4mm 12. (4.3-31.1) 17.9 (3.3-41.7) NS 
Month 0 % LOA sites ≥5mm 4.0 (0.68-16.2) 8.3 (0.0-27.9) NS 
Month 0 % LOA sites ≥6mm 0.7(0.0-4.4) 3.2 (0.0-15.1) < 0.05 
P-values determined using independent t-test for continuous parametric variables (% 
BOP) and Mann-Whitney U tests for the remaining continuous non-parametric 
variables. Means (±SD) are presented for parametric data and medians (IQR) are 
presented for non-parametric data. 
 
   
Table 4.12  Pre-treatment clinical periodontal data comparing groups based on diabetic status and periodontal diagnosis 
 
Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
Month 0 mean PI 0.4 (0.3-0.8) #,¶,$ 0.9 (0.7-1.0) $ 0.8 (0.6-1.1) $ 0.2 (0.0-0.4) #,¶ 0.6 (0.4-0.7) 0.6 (0.4-0.8) #,¶< 0.001 
$< 0.05 
Month 0 mean mGI 0.8 (0.5-1.6)#,¶,$ 1.9 (1.3-2.5)$ 2.0 (1.5-2.7) 0.5 (0.3-0.8)#,¶ 1.3 (0.8-1.7)† 2.4 (2.0-2.7) #,¶,†< 0.001 
$< 0.05 
Month 0 BOP (%) 4.5 (0.7-13.1) #,¶,$ 35.1(25.0-44.9) †,$ 46.0 (30.0-60.7) 0.7 (0.0-2.6) #,¶ 22.0 (17.3-32.6) † 43.0 (29.4-56.7) #,¶< 0.001 
†,$< 0.05 
Month 0 mean PD (mm) 1.7 (1.6-1.8) #,¶,$ 2.1(1.2-2.2) †,$ 2.8 (2.4-3.2) 1.6 (1.5-1.7) #,¶ 1.9 (1.8-2.1) † 2.9 (2.5-3.5) #,¶,†< 0.001 
$< 0.05 
Month 0 mean recession (mm) 0.3 (0.1-0.4) 0.2 (0.1-0.3) † 0.4 (0.3-0.7) 0.2 (0.1 0.4)¶ 0.2 (0.1-0.3) † 0.4 (0.2-0.9) †,¶< 0.01 
Month 0 mean LOA (mm) 1.9 (1.8-2.1) #,¶ 2.3 (2.1-2.4) †,$ 3.1 (2.7-3.9) 1.8 (1.6-2.0) #,¶ 2.1 (2.0-2.3) † 3.4 (2.9-4.2) #,¶,†< 0.001 
$< 0.05 
Month 0 PESA (mm2) 698.5±197.3#,¶ 921.5±184.3† 1444.7±495.1$ 787.2±82.1#,¶ 921.4±154.4† 1744.9±519.9 ¶,†< 0.001 
#,$< 0.01 
Month 0 PISA (mm2) 24.7 (0.0-89.8) #,¶ 342.4 (239.4-
439.1)† 
683.0 (439.1-1085.5) 4.48 (0.0-
23.2)#,¶ 
242.6 (195.6-
353.3)† 
897.3 (683.6-
1232.9) 
†,¶< 0.001 
Month 0 total sites assessed 150.0 (141.0-
159.0) 
150.0 (132.0-162.0) 150.0 (132.0-162.0) 156.0 (144.0-
156.0) 
150 (144.0-156.0) 156.0 (138.0-
162.0) 
NS 
Month 0 % PD sites ≥4mm 0.7 (0.0-1.7) #,¶,$ 3.6(1.4-7.0) † 20.2 (12.7-35.2) 0.0 (0.0-0.0) #,¶ 2.0 (0.6-5.1) † 24.2 (18.0-40.0) #,¶,$,†< 0.001 
Month 0 % PD sites ≥5mm 0.0 (0.0-0.0) #,¶ 0.0 (0.0-1.2) † 10.9 (8.1-18.2) 0.0 (0.0-0.0) #,¶ 0.0 (0.0-0.0) † 16.0 (8.0-30.8) #,¶ < 0.001 
†< 0.05 
Month 0 % PD sites ≥6mm 0.0 (0.0-0.0) ¶ 0.0 (0.0-0.0) † 2.7 (0.7-7.1) $ 0.0 (0.0-0.0) ¶ 0.0 (0.0-0.0) † 8.7 (2.6-16.7) ¶,†< 0.001 
$< 0.01 
 
   
 
     
continued over the page 
Continued from previous page 
Diabetic subjects (n=101) Non-diabetic subjects (n=83) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
Month 0 % LOA sites ≥4mm 2.3 (0.5-6.1) #,¶ 5.8 (1.8-10.1) † 32.0 (19.5-51.2) 1.0 (0.0-4.0) #,¶ 4.2 (0.7-8.2) † 39.9 (25.6-58.0) #< 0.05 
¶,†< 0.001 
Month 0 % LOA sites ≥5mm 0.5 (0.0-1.7) ¶ 0.8 (0.0-2.6) † 17.3 (10.6-31.7) 0.0 (0.0-0.0) #,¶ 0.0 (0.0-1.6) † 24.7 (14.5-37.2) #,¶,†< 0.05 
Month 0 % LOA sites ≥6mm 0.0 (0.0-0.2) ¶ 0.0 (0.0-0.7) †,$ 4.6 (1.2-13.3) $ 0.0 (0.0-0.0) ¶ 0.0 (0.0-0.0) † 12.7 (6.0-25.6) ¶,†< 0.001 
$< 0.05 
P-values were determined using chi-squared test for discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables and one way ANOVA test with post-hoc independent t-test for continuous parametric variables (PESA). Mean (±SD) is presented for 
parametric data and median (IQR) is presented for non-parametric data. 
 
$
 indicates a comparison within rows between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes groups
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Figure 4.8  Pre-treatment mean PI data comparing groups based on diabetic 
status and periodontal diagnosis 
 
Boxplots of pre-treatment mean PI data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=39, periodontitis n=47) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.9  Pre-treatment mean mGI data comparing groups based on diabetic 
status and periodontal diagnosis  
 
Boxplots of pre-treatment mean mGI data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=39, periodontitis n=47) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.10  Pre-treatment mean % BOP data comparing groups based on 
diabetic status and periodontal diagnosis 
 
 
Boxplots of pre-treatment % BOP data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=39, periodontitis n=47) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.11  Pre-treatment mean PD data comparing groups based on diabetic 
status and periodontal diagnosis 
 
Boxplots of pre-treatment mean PD data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=39, periodontitis n=45) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=18, periodontitis n=47). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.12  Pre-treatment data for the % of sites with PD ≥4mm comparing 
groups based on diabetic status and periodontal diagnosis 
 
Boxplots of pre-treatment data for the % of sites with PD ≥4mm in 98 T2DM subjects 
(healthy periodontal tissues n=14, gingivitis n=39, periodontitis n=45) and 81 non-
diabetic subjects (healthy periodontal tissues n=16, gingivitis n=18, periodontitis n=47). 
Statistics: Kruskal-Wallis with Mann Whitney-U post hoc test *<0.05, **p<0.01, 
***p<0.001(according to periodontal status within T2DM or non-diabetic group); § 
p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups within the 
corresponding periodontal status). ○ outlier more than 3 times the IQR from the box 
boundaries, ● outlier more than 1.5 but less than 3 times the IQR from the box 
boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Graph 4.13  Pre-treatment data for the % of sites with PD ≥5mm comparing 
groups based on diabetic status and periodontal diagnosis 
 
 
Boxplots of pre-treatment data for the % of sites with PD ≥5mm in 98 T2DM subjects 
(healthy periodontal tissues n=14, gingivitis n=39, periodontitis n=45) and 81 non-
diabetic subjects (healthy periodontal tissues n=16, gingivitis n=18, periodontitis n=47). 
Statistics: Kruskal-Wallis with Mann Whitney-U post hoc test *<0.05, **p<0.01, 
***p<0.001(according to periodontal status within T2DM or non-diabetic group); § 
p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups within the 
corresponding periodontal status). ○ outlier more than 3 times the IQR from the box 
boundaries, ● outlier more than 1.5 but less than 3 times the IQR from the box 
boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.14  Pre-treatment data for the % of sites with PD ≥6mm comparing 
groups based on diabetic status and periodontal diagnosis 
 
 
 
Boxplots of pre-treatment data for the % of sites with PD ≥6mm in 98 T2DM subjects 
(healthy periodontal tissues n=14, gingivitis n=39, periodontitis n=45) and 81 non-
diabetic subjects (healthy periodontal tissues n=16, gingivitis n=18, periodontitis n=47). 
Statistics: Kruskal-Wallis with Mann Whitney-U post hoc test *<0.05, **p<0.01, 
***p<0.001(according to periodontal status within T2DM or non-diabetic group); § 
p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups within the 
corresponding periodontal status). ○ outlier more than 3 times the IQR from the box 
boundaries, ● outlier more than 1.5 but less than 3 times the IQR from the box 
boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.15  Pre-treatment PESA data comparing groups based on diabetic 
status and periodontal diagnosis 
 
 
Boxplots of pre-treatment PESA data in 97 T2DM subjects (healthy periodontal tissues 
n=14, gingivitis n=39, periodontitis n=44) and 81 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=18, periodontitis n=47). Statistics: ANOVA with 
independent sample t-test post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 4.16  Pre-treatment PISA data comparing groups based on diabetic status 
and periodontal diagnosis 
 
 
Boxplots of pre-treatment PISA data in 97 T2DM subjects (healthy periodontal tissues 
n=14, gingivitis n=39, periodontitis n=44) and 81 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=18, periodontitis n=47). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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4.3 Discussion 
In Western developed countries, the prevalence of T2DM is closely linked to 
socio-economic status, with diabetic individuals more likely to live in deprived areas of 
the UK (Ismail et al., 1999; Evans et al., 2000). Within the present study, subjects’ 
socio-economic status was assessed using IMD.  A number of indicators, covering a 
range of economic, social and housing issues are combined to produce a single IMD in 
each small area in England. Each area can then be ranked relative to one another 
according to their level of deprivation. In the current study the IMD rank differed 
significantly between the T2DM subjects [9198 (3384-21930)] and the non-diabetic 
subjects [18213 (7658-25035)] (p < 0.001), with diabetic subjects living in areas ranked 
higher for IMD. This corroborates previous research (Ismail et al., 1999; Evans et al., 
2000), and shows that within the North East of England, individuals with T2DM live in 
more deprived areas compared to non-diabetic subjects.   
Smoking is a recognised risk factor for periodontal disease (Tomar and Asma, 
2000). Interestingly, there was a 9% prevalence of current smokers in the present study 
in both the T2DM and non-diabetic groups. This is markedly lower than the 21% 
prevalence rate for smoking in England (Robinson and Harris, 2011). Subjects’ past 
experience of healthcare could impact on smoking habits. Smoking cessation is an 
integral part of the management of T2DM (NICE, 2008) and a key part of the oral 
health advice provided to patients by the oral health profession. The lower prevalence of 
current smoking in the present study compared to that found in the general population 
could reflect the impact of smoking cessation advice previously received as part of 
either their diabetes management and/or their oral healthcare. Furthermore, the subjects 
participating in this study have actively opted in, indicating the presence of a healthcare 
seeking behaviour that may not be reflected in the general population of England.  
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Previous research has also shown that smokers are up to 4 times more likely to 
have periodontal disease compared with non-smokers with length of smoking history 
and number of cigarettes smoked per day being important factors to consider (Tomar 
and Asma, 2000; Calsina et al., 2002). The importance of smoking history in the 
development of periodontitis is highlighted in the current study with pack years, 
regardless of diabetes status, being lowest in subjects with healthy periodontal tissues 
and highest in subjects with periodontitis, although the differences failed to reach 
statistical significance. 
Previous research has clearly demonstrated that obesity is a powerful risk factor 
for T2DM (Chan et al., 1994), with general obesity, as measured by BMI strongly 
predicting the risk of T2DM (Wang et al., 2005). It has also been said that the leading 
cause for developing insulin resistance is obesity (Kahn et al., 2006). Patients with 
T2DM had significantly higher BMI [32.6 (29.8-36.0) kg/m2] compared to the non-
diabetic patients [27.3 (25.0-29.5) kg/m2] (p < 0.001). Furthermore, the T2DM group 
contained a higher proportion of obese (43%) and morbidly obese (31%) subjects 
compared to 11% and 13% in the non-diabetic group, respectively. 
Cross-sectional studies have demonstrated a positive association between 
periodontal disease and obesity (Pischon et al., 2007). Interestingly, in the current study, 
BMI was significantly higher in non-diabetic subjects with periodontitis [28.1 (25.2-
32.0)] compared to non-diabetic subjects with healthy periodontal tissues [24.7 (23.1-
27.7)] (p < 0.05). Similarly, in subjects with T2DM, with the BMI appeared higher in 
the periodontitis group [33.0 (29.9-36.5)] compared to the group with healthy periodontal 
tissues [31.2 (24.5-34.6)], although the difference failed to reach significance. Therefore, 
the current study would appear to support data from a recent meta-analysis that, 
notwithstanding the limitations stated by the authors, provided evidence of a greater 
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mean CAL among obese individuals and a higher BMI among periodontal patients 
(Chaffee and Weston, 2010). 
T2DM and hypertension are commonly associated conditions, both of which 
carry an increased risk of cardiovascular and renal disease (Garcia et al., 1974; Turner 
et al., 1998b). The prevalence of hypertension in T2DM is higher than that in the 
general population, especially in younger patients (HDS, 1993). Tight control of BP in 
hypertensive patients with T2DM has been shown to provide a 24% reduction in 
diabetic complications and a 32% reduction in deaths related to diabetes (Turner et al., 
1998a) and this is now reflected within national UK guidelines for the management of 
T2DM (NICE, 2008). However, despite the clear guidance for the intensive 
management of hypertension in subjects with T2DM, the present study demonstrates 
that systolic BP is significantly higher in subjects with T2DM [146.9±21.2 mmHg] 
compared to non-diabetic subjects [136.6±18.9 mmHg] (p<0.001). Despite clinical trials 
having convincingly demonstrated that  intensive treatment of hypertension among 
patients with diabetes reduces diabetic complications and deaths related to diabetes 
(Turner et al., 1998a) the mean BP for subjects with T2DM included in this study was 
147±21 mmHg /81(74-90) mmHg which is above the target (140/80 mmHg) set out 
within UK management guidelines for T2DM (NICE, 2008). This supports previous 
research that consistently found that most diabetic patients do not achieve recommended 
levels of blood pressure control (Martin et al., 1995; Harris, 2000). A lack of 
medication intensification by clinicians in hypertensive subjects with T2DM is 
recognised as a major factor in patients not achieving the recommended BP targets 
(Berlowitz et al., 2003) although, the reasons why clinicians are not more aggressively 
managing hypertension in patients with T2DM remains unclear. However, the 
implications for patients with T2DM not achieving adequate blood pressure control 
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remain significant, placing them at an increased risk of life limiting diabetic 
complications, such as CVD (Turner et al., 1998b). 
In patients with T2DM, the risk of diabetic complications is strongly associated 
with hyperglycaemia, with reductions in HbA1c leading to a reduced the risk of 
developing diabetic complications (UKPDS, 1998a). Each 1% reduction in mean 
HbA1c has been shown to be associated with reductions in risk of 21% for diabetic 
complications (Stratton et al., 2000). Such data have been influential in the development 
of management guidelines for T2DM, which advocate using dietary and lifestyle 
interventions with  medication, as required, to achieve and maintain the ideal target 
HbA1c level of 6.5% or less (NICE, 2008). Interestingly, in the current study, only 
26.3% of subjects met the HbA1c target of 6.5% set out in the UK T2DM management 
guidelines (NICE, 2008). The most recent National Diabetes Audit for 2009-2010 
showed that 66.5% of people with T2DM were achieving a HbA1c of 7.5% or less 
(National Diabetes Audit, 2011), however, disappointingly, the % of subjects achieving 
the optimal target of 6.5% for T2DM set by NICE was not published , although it is 
reasonable to propose the % of subjects would be less than 66.5%. Although the 
benefits of more intensive management in preventing or delaying the development and 
progression of diabetic complications are well documented, achieving an ideal HbA1c 
has to be balanced against the risk of hypoglycaemic episodes. Previous research has 
shown that subjects who receive intensive management of hyperglycemia, such as 
through the use of insulin, have more hypoglycaemic episodes than subjects not 
receiving intensive management of blood glucose (UKPDS, 1998a). Risk of 
hypoglycaemic episodes may be one reason why subjects are not intensively managed 
to achieve an ideal HbA1c target of 6.5%. 
Research shows that a deterioration of insulin secretion over time is the usual 
course in most patients with T2DM, and many patients will have deficient insulin 
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secretion after 10 years of diabetes (Wallace and Matthews, 2002). The rate of 
deterioration in diabetes control is around 1.5% HbA1c per 10 years and it thought to be 
a result of a decline in β-cell function (Home, 2008b). Patients with a longer history of 
T2DM may therefore find it more difficult to achieve adequate blood glucose control 
and potentially they are exposed for a greater length of time to diabetes related risk 
factors. In this study, subjects with gingivitis [6.0 (3.0-13.0 years] or periodontitis [7.0 
(3.0-10.0) years] presented with a significantly longer history of diabetes compared to 
those with healthy periodontal tissues [2.5 (1.0-5.0) years] (p < 0.05) (Table 4.4). 
Furthermore, there were significant differences in the proportions of subjects meeting 
the UK target for glycaemic control of HbA1c ≤ 6.5 %, with a higher proportion of 
subjects with healthy periodontal tissues meeting the target (64.3%) and progressively 
fewer subjects reaching this target in the gingivitis (26.3%) and periodontitis groups 
(14.9%) respectively (Table 4.4 and Figure 4.4). There were also significant differences 
in the proportions of subjects with specific management regimes with a higher 
proportion of subjects with healthy periodontal tissues being managed by dietary 
intervention alone (42.9%) and progressively fewer subjects being managed by diet 
alone in the gingivitis (12.8%) and periodontitis (8.5%) groups, respectively. 
Conversely, a higher proportion of subjects with periodontitis (29.8%) required insulin 
and there were progressively fewer subjects requiring insulin in the gingivitis (17.9%) 
and healthy periodontal tissues (0.0%) groups respectively (Table 4.4). 
Taken collectively, this highlights that the deterioration in glycaemic control 
appears to be mirrored by worsening periodontal health. Thus, as with other diabetes 
complications, the duration of diabetes and the degree of glycaemic control would 
appear to be important factors in the deterioration of periodontal health. The 2 way 
relationship between T2DM and periodontal disease could provide an explanation for 
this. T2DM or specifically hyperglycaemia may modify inflammatory processes 
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contributing to local dysregulated immune-inflammatory responses, causing increased 
periodontal destruction and likewise, inflammatory changes within the periodontal 
tissues may impact on glycaemic control and the systemic health of those with T2DM. 
However, the influence of health behaviours on both T2DM and periodontal disease 
should also not be overlooked. For example, the levels of compliance with health care 
behaviours required to achieve good glycaemic control are likely to be mirrored in the 
quality of oral hygiene practices achieved. Thus the relationship between T2DM and 
periodontal disease could be a reflection of healthcare behaviours.  
In the current study, 1/3 of the T2DM subjects had at least one diabetic 
complication. Previous research demonstrates more cardiovascular complications in 
T2DM subjects with periodontitis compared to T2DM subjects without periodontitis  
(Jansson et al., 2006). In the current study, a higher proportion of subjects reporting a 
diabetic complication was seen in subjects with periodontitis [35.4%] and gingivitis 
[35.9%] compared to subjects with healthy periodontal tissues [14.3%], although the 
difference failed to reach statistical significance. Within the literature, epidemiological 
data suggest a link between periodontitis and an increased risk of cardiovascular events 
(Humphrey et al., 2008). Similarly, the association between T2DM and CVD is well 
known (Stratton et al., 2000) as is the association between T2DM and periodontal 
diseases (Taylor, 2001). However, the nature of the associations between these three 
diseases remains unclear, with periodontitis, CVD and T2DM all sharing a number of 
risk factors. Common pathological mechanisms could result in increased susceptibility 
to these three diseases, however interventional trials are required to clarify the 
relationship between periodontal disease, cardiovascular disease and T2DM.  
When considering patient care pathways within diabetes management, it is 
interesting to note that in the current study, 95% of subjects with T2DM had received 
examinations of their feet and eyes within the past 12 months. This clearly demonstrates 
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the robust patient pathway that exists for screening for diabetic complications. 
However, the same is not true of screening for oral complications of T2DM, with as 
many as 1/3 of subjects with T2DM in this study reporting not seeing a dentist in the 
past 12 months. Thus, a regular opportunity for the screening of oral complications in 
this disease susceptible population is clearly being lost. 
The current study demonstrates that, compared to the non-diabetic group, the 
T2DM group had a higher number of subjects who presented with clinically detectable 
dry mouth.  This supports previous research demonstrating a higher prevalence of 
xerostomia in patients with T2DM compared to non-diabetic subjects, with polyuria and 
medications being cited as the potential causes of dry mouth in subjects with T2DM 
(Sandberg et al., 2000; Hintao et al., 2007; Borges et al., 2010).  
Furthermore, in agreement with previous research, in the T2DM group in this 
current study, the percentage of subjects with at least one carious tooth was over 4 times 
greater in subjects with T2DM (21%) compared to non-diabetic subjects (4.9%) (p < 
0.05) (Sandberg et al., 2000; Hintao et al., 2007). The most recent UK Adult Dental 
Health Survey showed that in the general population just under 1/3 of dentate adults 
(31%) had obvious tooth decay (Steele and O’ Sullivan, 2011), which is higher than for 
subjects within the current study. However, given the cumulative nature of dental 
disease and the potential of caries to cause pain and sepsis, it is disappointing that, 
within the current study, subjects with T2DM appear to be 4 times more likely to be 
experiencing dental caries. This is particularly relevant given the importance of diet and 
nutrition for subjects with T2DM. Possible reasons for this difference could include 
differences in diet, although as part of the management of T2DM patients are actively 
advised to limit their intake of carbohydrates, which is also an important message for 
caries prevention. The differences may also be a reflection of the recruitment strategy 
for the current study in which subjects with T2DM were recruited from databases of 
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T2DM patients held in both primary and secondary care settings whereas non-diabetic 
patients were recruited from either those referred from general dental practice into the 
restorative department within the School of Dental Sciences or patients seen on student 
treatment clinics within the School of Dental Sciences.  
Previous research has demonstrated that the attitudes towards oral health of 
patients with diabetes are poor in comparison with the findings from surveys of the 
general population (Allen et al., 2008). Other studies have reported on the dental care 
habits of subjects with T2DM both with and without periodontal disease, but providing 
no comparison with non-diabetic subjects (Jansson et al., 2006). In this current study, 
the T2DM group reported poorer oral health behaviours (including attendance at a 
dentist and oral hygiene practices) compared to the non-diabetic group. T2DM subjects 
reported a less favourable pattern of attendance at the GDP, with 62% of T2DM 
subjects regularly attending and 68% attending in the past 12 months compared to 77% 
and 86%, respectively, for non-diabetic subjects. This supports previous reports that 
70% T2DM subjects have attended a dentist in the past 12 months (Jansson et al., 
2006). The current study showed that T2DM subjects reported less favourable oral 
hygiene practices, with 64% of T2DM subjects toothbrushing at least twice a day, 30% 
once a day, 7% less than once a day and 25% cleaning interproximally more than 3 
times a week compared to 92%, 5%, 2% and 47% respectively for non-diabetic subjects. 
This supports reports that approximately 90% of  subjects with T2DM toothbrush at 
least once a day but is not in agreement with reports that 51% of subjects with T2DM 
clean interproximally more than 3 times a week (Jansson et al., 2006). Interestingly, 
attendance pattern and tooth brushing frequency  in the T2DM subjects from this study 
were comparable with findings from the general UK population, with the UK Adult 
Dental Health Survey (Steele and O’ Sullivan, 2011) reporting that 61% of the general 
population attend a dentist regularly and 75% clean at least twice a day. In contrast, the 
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attendance patterns and tooth brushing frequency in the non-diabetic subjects included 
in the current study appear to be more favourable than that of the general UK 
population.  
Possible reasons for more favourable oral health behaviours in the non-diabetic 
subjects compared to either the T2DM subjects or data from the general population 
could reflect the recruitment strategy used in the current study, with the non-diabetic 
subjects being recruited from patients referred from general dental practice or from 
patients seen on student treatment clinics within the School of Dental Sciences and 
therefore likely to be motivated, oral health seeking individuals, that have previously 
received oral hygiene advice. On the other hand, when considering the reasons for the 
poorer oral health behaviours in the T2DM group compared to the non-diabetic group 
seen in this current study, it is important to recognise that given the potential severe and 
life threatening complications of diabetes, oral problems may not be a major priority for 
this group of patients. Furthermore, in the current study, patients were not matched 
based on regular attendance at a dentist or deprivation. This could introduce a potential 
bias in oral health behaviours, in that 77% of non-diabetics as compared to 62% of 
diabetics reported attending a dentist regularly and the T2DM subjects lived in more 
deprived areas than the non-diabetic subjects. It is not unreasonable to think that regular 
attenders at a dentist would have better oral health knowledge and thus more favourable 
oral health behaviours. Furthermore, answers to questions may be subject to recall bias 
due to participants giving socially acceptable responses to questions pertaining to oral 
health behaviours (Allen et al., 2008).  
 Interestingly, the current study demonstrates that, compared to the non-diabetic 
group, subjects with T2DM had lower total cholesterol and lower non-HDL, which are 
both considered indicators of risk for CVD. Potentially, this reflects the UK  
management guidelines for T2DM which recommends dietary advice to optimise blood 
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lipid profile and the use of lipid lowering therapy to reduce CVD risk in T2DM subjects 
(NICE, 2008). Therefore, it is feasible that the T2DM subjects in the current study are 
receiving more aggressive management of CVD risks factors than the non-diabetic 
subjects. In this current study, 72% of subjects with T2DM were taking lipid lowering 
medication; however, comparable data for non-diabetic subjects were not collected in 
this study. Within the published literature, the few studies that present blood lipid 
profiles in patients with diabetes and periodontal disease use fasting samples (Cutler et 
al., 1999a; Kardesler et al., 2010), thus preventing a direct comparison with values 
obtained in this current study (which used non-fasting samples). One study found no 
significant differences in total cholesterol, triglycerides and low density lipoprotein 
levels between subjects with T2DM and non-diabetic subjects (Kardesler et al., 2010). 
This was not supported by data from the current study that found T2DM subjects had 
significantly higher triglyceride levels and significantly lower levels of HDL, non-HDL 
and total cholesterol compared to non-diabetic subjects. Another study demonstrated a 
trend for increased levels of triglyceride in subjects with T2DM compared to non-
diabetic subjects (Cutler et al., 1999a), thus supporting data from the current study. 
Currently the data regarding levels of hsCRP in patients with T2DM and 
periodontitis is limited (Correa et al., 2010; Kardesler et al., 2010). One study reported 
no significant difference in hsCRP levels between subjects with T2DM and non-diabetic 
subjects (Kardesler et al., 2010) although a lack of a non-diabetic group in a different 
study prevents a similar comparison (Correa et al., 2010). In the current study, levels of 
hsCRP appeared higher in subjects with T2DM [2.3(0.9-4.5) mg/L] compared to non-
diabetic subjects [1.9(0.8-3.9) mg/L], however the difference failed to reach statistical 
significance (Table 4.10 and Figure 4.6). Due to the wide variation seen in hsCRP 
levels, further studies with larger sample sizes would be required to clarify whether 
CRP levels are actually higher in subjects with T2DM compared to non-diabetic 
4  Results 170
subjects. Interestingly, when subjects were further categorised based on periodontal 
status, subjects with T2DM and healthy periodontal tissues [2.4(0.8-5.5) mg/L] had 
significantly higher hsCRP levels than non-diabetic subjects with the same periodontal 
status [0.6(0.2-1.5) mg/L] (p < 0.05), potentially supporting published evidence that 
demonstrates the association between elevated systemic inflammation and the 
development of T2DM (Bertoni et al., 2010). Evidence from a meta-analysis also that 
demonstrated that CRP is consistently elevated in patients with periodontitis compared 
to patient with healthy periodontal tissues (Paraskevas et al., 2008). This was confirmed 
in the current study, which showed that in non-diabetic subjects, those with healthy 
periodontal tissues [0.6(0.2-1.5) mg/L] had significantly lower hsCRP levels compared 
to subjects with gingivitis [2.3(0.9-4.6) mg/L] or periodontitis [2.4(0.8-5.5) mg/L] (p < 
0.05). However, in subjects with T2DM, similar differences were not found when 
comparing subjects with healthy periodontal tissues [2.4(0.8-5.5) mg/L], gingivitis 
[2.4(1.0-4.4) mg/L] and periodontitis [2.1(0.9-4.6) mg/L]. Perhaps the raised 
background levels of CRP seen in subjects with T2DM masks any differences in CRP 
levels caused by inflammation in the periodontal tissues. The assessment of systemic 
inflammation in the current study, did not however, take into account the potential 
impact of medication on systemic inflammation. For example, as part of the 
management of CVD risk, statins have been shown to lower LDL and also reduce CRP 
levels, with both mechanisms contributing independently to CVD risk reduction 
(Devaraj et al., 2007; Ridker and Silvertown, 2008). 
This study showed that, as expected, HbA1c was higher in the T2DM group 
compared to non-diabetic group (Table 4.10). Previous research demonstrated higher 
HbA1c levels were found in subjects with poorer periodontal health (Jansson et al., 
2006; Chen et al., 2010). This current study found a trend for a higher HbA1c level in 
T2DM subjects with periodontitis [7.5 (6.7-9.2)%] compared to T2DM subjects with 
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healthy periodontal tissues [6.4 (5.9-9.0)%]. Given both the variability of HbA1c seen 
in subjects with T2DM and the statistical requirement to correct the p-values to 
compensate for multiple comparisons, the numbers of subjects included in this study 
were too small to clarify the relationship of HbA1c and periodontal status.   
When the HbA1c level for T2DM subjects with periodontitis was compared to 
that reported in previous research, it would appear comparable to some studies (Kiran et 
al., 2005; Chen et al., 2010) but lower than other studies (Correa et al., 2010). 
Interestingly, some studies categorised T2DM subjects based on glycaemic control with 
the T2DM subjects with periodontitis in our study having a HbA1c level that was lower 
than the ‘poorly controlled group’ and higher than the ‘well controlled group’ used in 
previous studies (Dag et al., 2009; Kardesler et al., 2010). Given the proposed interplay 
between hyperglycaemia and inflammatory mediators (Stumvoll et al., 2005), it could 
be viewed as important to ensure that HbA1c levels are consistent in all studies. 
However, limiting inclusion of T2DM subjects into studies based on their HbA1c value 
would reduce how accurately results can be generalised to the T2DM population as a 
whole. Stratification of subjects based on their HbA1c levels could be used; however 
adequate numbers of subjects would be required in each category of HbA1c. 
Stratification of subjects based on HbA1c was not built into the recruitment strategy for 
the current study and to prevent low n values in groups, data were not subsequently 
stratified when the data was analysed.  
Previous epidemiological evidence has reported an increased prevalence and 
severity of periodontal disease in subjects with T2DM compared to non-diabetic 
subjects (Shlossman et al., 1990; Sandberg et al., 2000; Mattout et al., 2006; Moles, 
2006). In more recent interventional studies evaluating the response to periodontal 
therapy, the pre-treatment periodontal condition of subjects with and without diabetes 
was well matched (Dag et al., 2009; Kardesler et al., 2010) or the T2DM subjects had 
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higher levels of BOP and mean PD (Correa et al., 2008). In the current study, when 
exploring the pre-treatment periodontal status of subjects with T2DM in comparison to 
those without diabetes, no significant difference was found in the mean PD for subjects 
with T2DM and periodontitis [2.8 (2.4-3.2) mm] compared to non-diabetic subjects 
with periodontitis [2.9 (2.5-3.5) mm]. Interestingly, the mean PD data from this current 
study are comparable to data from some previous studies (Kiran et al., 2005; Dag et al., 
2009) but are lower than data from other studies (Correa et al., 2008; Kardesler et al., 
2010), indicating potential variations in extent of periodontal disease between different 
studies. However, only one previous study supplemented the mean PD data with data on 
the % of sites with advanced periodontal disease, showing that when considering the % 
of PD sites ≥ 7 mm, the differences between subjects with T2DM [9.0 (1.0-22.0)%] and 
non-diabetic subjects [5.5 (3.0-14.0)%] were found not be significant (Correa et al., 
2008). Periodontal disease rarely affects all parts of the periodontium equally and mean 
PD provides only a crude description of the PD found in each subject. Therefore, the 
use of mean PD, without additional data on the % of sites with advanced periodontal 
disease, is a limitation of all other studies in this field of work. In the current study, the 
% of PD sites ≥ 6 mm was significantly lower in subjects with T2DM and periodontitis 
[2.7 (0.7-7.1)%] compared to non-diabetic subjects with periodontitis [8.7 (2.6-16.7)%] 
(p < 0.01), indicating more severe periodontal disease was present in non-diabetic 
subjects compared to subjects with T2DM (Table 4.14 and Figure 4.13). This may 
reflect the differences in the recruitment pools used for diabetic and non-diabetic 
subjects in the current study. As previously described, T2DM subjects were recruited 
from medical databases of T2DM patients held in both primary and secondary care 
settings whereas the non-diabetic subjects were recruited from patients referred from 
general dental practice or from patients seen on student treatment clinics within the 
School of Dental Sciences. Although, diabetic and non-diabetic subjects were matched 
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based on their periodontal diagnosis, the extent of periodontal disease was not however 
considered in this process. This is a limitation of the current study and highlights a need 
to stratify periodontal case selection based on extent and severity of disease to ensure 
more robust matching of groups with regards to periodontal status in future studies. 
In the current study, exploration of the data relating to gingival inflammation 
indicates different patterns for subjects with T2DM compared to non-diabetic subjects, 
with significantly higher levels of mGI and % BOP in subjects with T2DM and healthy 
tissues [0.8 (0.5-1.6) and 4.5 (0.7-13.1)] or gingivitis [1.9 (1.3-2.5) and 35.1 (25.0-
44.9)] compared to non-diabetic subjects with healthy periodontal tissues [0.5 (0.3-0.8) 
and 0.7 (0.0-2.6)] and gingivitis [1.3 (0.8-1.7) and 22.0 (17.3-32.6)] (p < 0.05) (Table 
4.12 and Figure 4.8 and 4.9). This supports data from previous studies that demonstrate 
significantly higher levels of gingival inflammation in subjects with T2DM compared to 
non-diabetic subjects (Lu and Yang, 2004; Campus et al., 2005; Mattout et al., 2006; 
Correa et al., 2008). A potential explanation for the higher levels of gingival 
inflammation seen in subjects with T2DM is that the increased gingival inflammation is 
a manifestation of the upregulated systemic inflammation seen in diabetes. In the 
current study, the same pattern of increased gingival inflammation in subjects with 
T2DM compared to non-diabetic subjects is not replicated in subjects with periodontitis. 
There were no significant differences in % BOP and mGI in subjects with T2DM and 
periodontitis [46.0 (30.0-60.7) and 2.0 (1.5-2.7)] compared to non-diabetic subjects with 
periodontitis [43.0 (29.4-56.7) and 2.4 (2.0-2.7)]. It is not unreasonable to presume that 
the more severe periodontal disease present in non-diabetic subjects compared to 
subjects with T2DM likely masked the presence of a higher background level of 
gingival inflammation in subjects with T2DM with periodontitis compared to non-
diabetic subjects who had periodontitis. 
4  Results 174
In previously published research, both PESA and PISA have been used to 
investigate the condition of the periodontal tissues (Nesse et al., 2008; Nesse et al., 
2009). Using measurements for LOA and recession at 6 sites per tooth, the surface area 
of the periodontium is calculated, taking into account variations in the root surface area 
of each tooth, and PESA (mm2) is the sum value for the periodontal surface area for the 
whole mouth. To calculate the surface area of inflamed periodontal tissue, the 
periodontal surface area for each tooth is multiplied by the proportion of sites around 
the tooth affected by BOP, and PISA (mm2) is the sum value for the periodontal 
inflamed surface area for the whole mouth. 
In the current study, PESA is able to represent key aspects of the PD data, 
highlighting differences in PD between subjects with difference periodontal status. For 
example, when comparing the subjects with T2DM, the PESA was significantly higher 
in those with gingivitis [921.5±184.3 mm2] compared to those with healthy periodontal 
tissues [698.5±197.3 mm2] (p < 0.01), the PESA was significantly higher in the 
periodontitis group [1444.7±495.1 mm2] compared to those with gingivitis 
[921.5±184.3 mm2] (p < 0.001) and the PESA was significantly higher in those with 
periodontitis [1444.7±495.1 mm2] compared to those with healthy periodontal tissues 
[698.5±197.3 mm2] (p < 0.001). Similarly, for non-diabetic subjects, the PESA 
significantly higher in those with gingivitis [921.4±154.4 mm2] compared to those with 
healthy periodontal tissues [787.2±82.1] mm2 (p < 0.01), the PESA was significantly 
higher in the periodontitis group [1744.9±519.9 mm2] compared to those with gingivitis 
[921.4±154.4 mm2] (p < 0.001) and the PESA was significantly higher in those with 
periodontitis [1744.9±519.9 mm2] compared to those with healthy periodontal tissues 
[787.2±82.1 mm2] (p < 0.001) (Table 4.14, Figure 4.14). Furthermore, the present study 
demonstrated that PESA was more sensitive than the mean PD data in detecting the 
presence of advanced periodontal disease. PESA was significantly greater in non-
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diabetic subjects with periodontitis [1744.9±519.9 mm2] compared to subjects with 
T2DM and periodontitis [1444.7±495.1 mm2] (p < 0.01). This supports the significantly 
greater % of PD sites ≥6mm in non-diabetic subjects [8.7 (2.6-16.7)%] compared to 
subjects with T2DM [2.7 (0.7-7.1)%] (p < 0.01). Thus, PESA was able to detect the 
more advanced periodontal disease present in the non-diabetic subjects compared to 
subjects with T2DM. Conversely, when considering mean PD data, no significant 
differences were demonstrated between non-diabetic subjects [2.9 (2.4-3.2) mm] and 
non-diabetic subjects [2.9 (2.5-3.5) mm], highlighting that mean PD fails to detect the 
differences in PD that were present. In the current study, PESA not only supports the 
conventional PD data, but is also able to better indicate the extent and severity of the 
periodontal disease present (Table 4.12). 
PISA incorporates both periodontal surface area and BOP data into a single 
variable. In the current study, PISA was able to represent key differences between 
subjects with difference periodontal status. For example, when comparing the subjects 
with T2DM, the PISA was significantly higher in those with gingivitis [342.4 (239.4-
439.1) mm2] compared to those with healthy periodontal tissues [24.7 (0.0-89.8) mm2] 
(p < 0.001), the PISA was significantly higher in the periodontitis group [683.0 (439.1-
1085.5) mm2] compared to those with gingivitis [342.4 (239.4-439.1) mm2] (p < 0.001) 
and the PISA was significantly higher in those with periodontitis [683.0 (439.1-1085.5) 
mm2] compared to those with healthy periodontal tissues [24.7 (0.0-89.8) mm2] (p < 
0.001). Similarly, for non-diabetic subjects, the PISA was significantly higher in those 
with gingivitis [242.6 (195.6-353.3) mm2] compared to those with healthy periodontal 
tissues [4.48 (0.0-23.2) mm2] (p < 0.001), the PISA was significantly higher in the 
periodontitis group [897.3 (683.6-1232.9) mm2] compared to those with gingivitis 
[242.6 (195.6-353.3) mm2] (p < 0.001) and the PISA was significantly higher in those 
with periodontitis [897.3 (683.6-1232.9) mm2] compared to those with healthy 
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periodontal tissues [4.48(0.0-23.2) mm2] (p < 0.001) (Table 4.14, Figure 4.14). PISA 
was greater in non-diabetic subjects with periodontitis [897.3 (683.6-1232.9) mm2] 
compared to subjects with T2DM and periodontitis [683.0 (439.1-1085.5) mm2], 
however, the differences failed to reach significance. Thus, although PISA showed a 
similar pattern, it was not able to confirm (with statistical significance) the significantly 
greater % of PD sites ≥ 6 mm in non-diabetic subjects [8.7 (2.6-16.7)%] compared to 
subjects with T2DM [2.7 (0.7-7.1) %] (p < 0.01). This indicates that the incorporation 
of BOP into PISA makes it less sensitive than PESA in detecting differences in the 
extent and severity of periodontal disease as defined by PD. However, given that BOP 
data remains key in the clinical assessment of inflammation in the periodontal tissues, it 
would be appropriate to present both PESA and PISA when evaluating the clinical 
periodontal status. 
 
Summary of key findings from chapter 4 
• Subjects with T2DM had significantly higher BMI compared to the non-diabetic 
subjects and systolic BP was significantly higher in subjects with T2DM compared 
to non-diabetic subjects. 
• Subjects with gingivitis or periodontitis presented with a significantly longer history 
of diabetes compared to those with healthy periodontal tissues and fewer reached the 
UK target for HbA1c. Also, insulin was required in a higher proportion of subjects 
with periodontitis compared to those with healthy periodontal tissues. 
• 95% of subjects with T2DM had received examinations of their feet and eyes within 
the past 12 months. However, 1/3 of subjects with T2DM had not seen a dentist in 
the past 12 months. 
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• Subjects with T2DM had a significantly higher % of subjects with dry mouth 
compared to those without diabetes. Also, the percentage of subjects with at least one 
carious tooth was over 4 times greater in subjects with T2DM compared to non-
diabetic subjects. 
• The T2DM group reported poorer oral health behaviours (including attendance at a 
dentist and oral hygiene practices) compared to the non-diabetic group. 
• Levels of cholesterol and non-HDL were significantly lower in subjects with T2DM 
compared to non-diabetic subjects.  
• Levels of hsCRP appeared higher in subjects with T2DM compared to non-diabetic 
subjects, however the difference failed to reach statistical significance. Also, in non-
diabetic subjects hsCRP was significantly lower in those with healthy periodontal 
tissues compared to subjects with gingivitis or periodontitis. 
• A trend for higher HbA1c in T2DM subjects with periodontitis compared to T2DM 
subjects with healthy periodontal tissues was seen. 
• No significant difference was found in the mean PD for subjects with T2DM and 
periodontitis compared to non-diabetic subjects with periodontitis. However, the % 
of PD sites ≥ 6 mm was significantly lower in subjects with T2DM and periodontitis 
compared to non-diabetic subjects with periodontitis. 
• Higher levels of gingival inflammation were seen in subjects with T2DM and 
gingivitis compared to non-diabetic subjects with gingivitis, although this difference 
is not replicated in subjects with periodontitis. 
• PESA is able to represent key aspects of the PD data, highlighting differences in PD 
between subjects with different periodontal status and detecting differences in the 
extent and severity of periodontal disease between T2DM and non-diabetic subjects. 
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Chapter 5 Analysis of pre-treatment local and systemic 
cytokine levels in patients with T2DM 
5.1 Introduction 
A number of prospective studies  have demonstrated an association between 
higher circulating levels of inflammatory mediators, such as IL-6 and CRP, and the 
development of T2DM (Pradhan et al., 2001; Spranger et al., 2003b; Bertoni et al., 
2010). This relationship between inflammation and T2DM is mediated through 
adiposity, insulin resistance and β-cell dysfunction (Donath et al., 2003; Pickup, 2004). 
 In the pathogenesis of periodontal disease, the importance of the host response 
and the production of inflammatory cytokines is well recognised. Research has 
demonstrated elevated inflammatory cytokine levels in tissue and GCF samples in 
disease compared to health (Stashenko et al., 1991b; Irwin and Myrillas, 1998; 
Engebretson et al., 2002; Lin et al., 2005; Zhong et al., 2007) with reductions following 
successful periodontal management (Engebretson et al., 2002). Published data on 
circulating levels of inflammatory cytokines in periodontitis are currently very limited 
(Marcaccini et al., 2009; Sun et al., 2009), as are data for salivary levels of 
inflammatory cytokines in periodontitis (Miller et al., 2006; Gursoy et al., 2009; Teles 
et al., 2009; Costa et al., 2010).  
Clearly, inflammatory cytokines contribute to the pathogenesis of both T2DM 
and periodontitis. Alterations in immunologically active molecules as a result of T2DM 
have the potential to influence the cytokine network within the periodontium and thus 
contribute to local periodontal tissue destruction. Furthermore, inflammation within the 
periodontium has the potential to contribute to the systemic inflammatory burden and 
thus influence the pathogenic mechanisms present in T2DM.  It is therefore surprising 
that, until very recently, relatively few studies had investigated the role of inflammatory 
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cytokines in patients with T2DM and periodontal disease (Cutler et al., 1999a; 
Engebretson et al., 2007; Correa et al., 2008; Dag et al., 2009; Correa et al., 2010; 
Kardesler et al., 2010; Santos et al., 2010).  
5.2 Results 
5.2.1 Analysis of local and systemic cytokine levels before periodontal 
management 
5.2.1.1 Analysis of pre-treatment serum cytokine levels in T2DM and non-
diabetic patients with or without periodontal disease 
Table 5.1 and Figure 5.1 show that before periodontal treatment, the levels of 
TNF-α, IL-1β and INF-γ in serum were significantly higher in subjects with T2DM 
[7.45 (5.07-9.23) pg/ml, 0.18 (0.01-0.37) pg/ml and 1.35 (0.66-2.50) pg/ml] compared 
to non-diabetic subjects [5.25 (3.15-7.69) pg/ml, 0.04 (0.00-0.10) pg/ml and 0.78 (0.43-
1.88) pg/ml] (p<0.01). However, caution must be used when interpreting these results 
given that serum levels of IL-1β and INF-γ for both groups are around the lower limits 
of detection for the assay used (Table 5.1 and Figure 5.1).  
Table 5.2 presents serum cytokine concentrations before periodontal treatment 
following further categorisation of subjects based on their periodontal diagnosis. When 
considering IL-6 levels in serum, there were no significant differences found in any 
periodontal category between T2DM and non-diabetic subjects. When comparing the 
subjects with T2DM, serum IL-6 appeared higher in those with gingivitis [1.33 (0.42-
2.65) pg/ml] compared to those with healthy periodontal tissues [0.50 (0.33-0.81) 
pg/ml]. However, the Bonferroni-Holm correction of p-values for multiple comparisons 
placed the critical p-value at 0.017, therefore, this difference was detected as trend 
(p=0.018). Likewise, when comparing the subjects with T2DM, serum IL-6 appeared 
higher in those with gingivitis [1.33 (0.42-2.65) pg/ml] compared to those with 
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periodontitis [0.51 (0.34-1.50) pg/ml]. However, the Bonferroni-Holm correction of p-
values for multiple comparisons placed the critical p-value at 0.025, therefore, this 
difference was detected as trend (p=0.041). Furthermore, in subjects with T2DM, serum 
IL-6 levels were not significantly different in those with healthy periodontal tissues 
[0.50 (0.33-0.81) pg/ml] compared to those with periodontitis [0.51 (0.34-1.50) pg/ml]. 
In non-diabetic subjects, serum IL-6 levels were not significantly different in those with 
healthy periodontal tissues [0.69 (0.43-1.11) pg/ml], gingivitis [0.75 (0.41-1.42) pg/ml] 
and periodontitis [0.59 (0.32-0.93) pg/ml] (Table 5.2).  
When considering serum TNF-α, the levels were significantly higher in diabetic 
subjects with periodontitis [7.10 (3.25-9.30) pg/ml] compared to the non-diabetic 
subjects with periodontitis [3.44 (2.34-7.24) pg/ml] (p <0.05). However, there were no 
significant differences in serum TNF-α levels in those with gingivitis or healthy 
periodontal tissues when comparing T2DM and non-diabetic subjects. In subjects with 
T2DM, serum TNF-α levels were not significantly different in those with healthy 
periodontal tissues [8.02 (6.34-9.24) pg/ml], gingivitis [7.69 (5.62-9.26) pg/ml] and 
periodontitis [7.10 (3.25-9.30) pg/ml]. For non-diabetic subjects, serum TNF-α was 
significantly higher in those with periodontally healthy tissues [6.28 (4.4-8.81) pg/ml] 
compared to those with periodontitis [3.44 (2.34-7.24) pg/ml] (p < 0.05). Also, in non-
diabetic subjects, serum TNF-α was significantly higher in those with gingivitis [6.39 
(5.21-8.03) pg/ml] compared to those with periodontitis [3.44 (2.34-7.24) pg/ml] (p < 
0.05). However, in non-diabetic subjects, there were no significant differences in serum 
TNF-α between those with healthy periodontal tissues [6.28 (4.4-8.81) pg/ml] and those 
with gingivitis [6.39 (5.21-8.03) pg/ml] (Table 5.2). 
When considering serum IL-1β, the level was significantly higher in diabetic 
subjects with healthy periodontal tissues, gingivitis and periodontitis [0.28 (0.09-0.40) 
pg/ml, 0.24 (0.04-0.40) pg/ml] and 0.08 (0.00-0.34) pg/ml] compared to non-diabetic 
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subjects with healthy periodontal tissues, gingivitis and periodontitis respectively [0.09 
(0.06-0.14) pg/ml, 0.09 (0.02-0.20) pg/ml and 0.00 (0.00-0.48) pg/ml] (p < 0.05). In 
subjects with T2DM, serum IL-1β levels were not significantly different in those with 
healthy periodontal tissues [0.28 (0.09-0.40) pg/ml], gingivitis [0.24 (0.04-0.40) pg/ml] 
and periodontitis [0.08 (0.00-0.34) pg/ml]. For non-diabetic subjects, serum IL-1β was 
significantly higher in those with periodontally healthy tissues [0.09 (0.06-0.14) pg/ml] 
compared to those with periodontitis [0.00 (0.00-0.05) pg/ml] (p <0.001). Also, in non-
diabetic subjects, serum IL-1β was significantly higher in those with gingivitis [0.09 
(0.02-0.20) pg/ml] compared to those with periodontitis [0.00 (0.00-0.05) pg/ml] (p < 
0.001).  However, in non-diabetic subjects, there were no significant differences in 
serum IL-1β between those with healthy periodontal tissues [0.09 (0.06-0.14) pg/ml] 
and those with gingivitis [0.09 (0.02-0.20) pg/ml]. Caution must however, be used when 
interpreting these results given that serum levels of IL-1β for all subjects were around 
the lower limits of detection for the assay used (Table 5.2). 
When considering serum IFN-γ, the level was significantly higher in diabetic 
subjects with gingivitis and periodontitis [1.74 (0.77-5.80) pg/ml and 1.09 (0.56-2.50) 
pg/ml] compared to the non-diabetic subjects with gingivitis and periodontitis [0.79 
(0.58-2.67) pg/ml and 0.57 (0.26-1.33) pg/ml] (p < 0.05). In subjects with T2DM, serum 
IFN-γ levels were not significantly different in those with healthy periodontal tissues 
[1.19 (0.71-1.62) pg/ml], gingivitis [1.74 (0.77-5.80) pg/ml] and periodontitis [1.09 
(0.56-2.50) pg/ml]. For non-diabetic subjects, serum IFN-γ was significantly higher in 
those with periodontally healthy tissues [1.78 (0.67-3.64) pg/ml] compared to those 
with periodontitis [0.57 (0.26-1.33) pg/ml] (p < 0.01). However, in non-diabetic 
subjects, there were no significant differences in serum IFN-γ between those with 
healthy periodontal tissues [1.78 (0.67-3.64) pg/ml] and gingivitis [0.79 (0.58-2.67) 
pg/ml]. Likewise, in non-diabetic subjects, there were no significant differences in 
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serum IFN-γ between those with gingivitis [0.79 (0.58-2.67) pg/ml] and periodontitis 
[0.57 (0.26-1.33) pg/ml]. Caution must however be used when interpreting these results 
given that serum levels of INF-γ for some subjects are around the lower limits of 
detection for the assay used (Table 5.2). 
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Table 5.1:  Serum cytokine concentrations before periodontal treatment in 
T2DM patients and non-diabetic patients 
 
 
 
Diabetic subjects 
(n=99) 
Non-diabetic subjects 
(n=79) p-value 
  
   
IL-6 (pg/ml) 0.64 (0.37-1.86) 0.63 (0.39-1.03) NS 
TNF-α (pg/ml) 7.45 (5.07-9.23) 5.25 (3.15-7.69) <0.01 
IL-1β (pg/ml) 0.18 (0.01-0.37) 0.04 (0.00-0.10) <0.001 
IFN-γ (pg/ml) 1.35 (0.66-2.50) 0.78 (0.43-1.88) <0.01 
 
   
P-values determined using Mann-Whitney U tests for continuous non-parametric 
variables and median (IQR) is presented for this non-parametric data. 
 
 
  
5  Results 184
Figure 5.1 Pre-treatment serum levels of IL-6, TNF-α, IL-1β and IFN-γ in 
subjects with T2DM and in non-diabetic subjects 
 
 
 
 
 
Boxplots of pre-treatment serum levels of IL-6, TNF-α, IL-1β and IFN-γ in 99 T2DM 
and 79 non-diabetic subjects. Statistics: Mann Whitney-U test * p<0.05, **p<0.01, 
***p<0.001. ○ outlier more than 3 times the IQR from the box boundaries, ● outlier 
more than 1.5 but less than 3 times the IQR from the boundaries. 
 
** 
*** *** 
   
Table 5.2  Pre-treatment serum cytokine data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=98) Non-diabetic subjects (n=79) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=38) 
Periodontitis 
(n=46) 
Healthy 
(n=15) 
Gingivitis 
(n=19) 
Periodontitis 
(n=45) 
 
 
       
IL-6 (pg/ml) 0.50 (0.33-0.81) 1.33 (0.42-2.65) 0.51 (0.34-1.50) 0.69 (0.43-1.11) 0.75 (0.41-1.42) 0.59 (0.32-0.93) NS  
TNF-α (pg/ml) 8.02 (6.34-9.24) 7.69 (5.62-9.26) 7.10 (3.25-9.30)$ 6.28 (4.4-8.81)¶ 6.39 (5.21-8.03)† 3.44 (2.34-7.24) ¶,†,$≤0.05 
IL-1β (pg/ml) 0.28 (0.09-0.40)$ 0.24 (0.04-0.40)$ 0.08 (0.00-0.34)$ 0.09 (0.06-0.14)¶ 0.09 (0.02-0.20)† 0.00 (0.00-0.05) ¶,†≤0.001 
$
≤0.05 
IFN-γ (pg/ml) 1.19 (0.71-1.62) 1.74 (0.77-5.80)$ 1.09 (0.56-2.50)$ 1.78 (0.67-3.64)¶ 0.79 (0.58-2.67) 0.57 (0.26-1.33) ¶≤0.01 
$
≤0.05 
 
       
P-values were determined using Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-parametric variables (all data). Median 
(IQR) is presented for this non-parametric data.  
 
$
 indicates a comparison within row between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes group 
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5.2.1.2 Analysis of pre-treatment saliva cytokine levels in T2DM and non-diabetic 
patients with or without periodontal disease 
Table 5.3 and Figure 5.2 show that before periodontal treatment, the levels of 
TNF-α, IL-1β and INF-γ in saliva were significantly higher in non-diabetic subjects 
[2.59 (1.40-3.98) pg/ml, 46.00 (22.00-90.43) pg/ml and 1.48 (0.64-2.12) pg/ml] 
compared to subjects with T2DM [1.38 (0.53-2.70) pg/ml, 26.95 (12.08-59.90) pg/ml 
and 0.81 (0.35-1.34) pg/ml] (p < 0.01). Also, the levels of salivary IL-6 were higher in 
the non-diabetic subjects [2.18 (0.89-5.72) pg/ml] compared to the subjects with T2DM 
[1.74 (0.72-4.18) pg/ml], although this difference was detected as a trend (p=0.065). 
Caution must, however, be used when interpreting these results for salivary levels of IL-
6 and IFN-γ as some data are around the lower limits of detection for the assays used 
(Table 5.3 and Figure 5.2).  
Table 5.4 presents saliva cytokine levels before periodontal treatment following 
further categorisation of subjects based on their periodontal diagnosis. When 
considering IL-6 levels in saliva, there were no significant differences found in any 
periodontal category between T2DM and non-diabetic subjects. In subjects with T2DM, 
levels of IL-6 in saliva were significantly higher in those with periodontitis [2.29 (1.27-
4.83) pg/ml] compared to those with healthy periodontal tissues [0.80 (0.25-3.25) 
pg/ml] (p < 0.05). In subjects with T2DM, levels of IL-6 in saliva showed no significant 
differences in those with gingivitis [1.37 (0.65-3.84) pg/ml] compared to healthy 
periodontal tissues. Likewise in subjects with T2DM, levels of IL-6 in saliva showed no 
significant differences those with gingivitis [1.37 (0.65-3.84) pg/ml] compared to those 
with periodontitis [2.29 (1.27-4.83) pg/ml]. In non-diabetic subjects, saliva IL-6 levels 
were not significantly different in those with healthy periodontal tissues [2.13 (1.27-
4.83) pg/ml], gingivitis [1.85 (0.85-4.07) pg/ml] and periodontitis [2.41 (0.95-7.26) 
pg/ml]. Caution must be used when interpreting the results for salivary levels of IL-6 as 
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data for some subjects are around the lower limits of detection for the assay used (Table 
5.4). 
When considering saliva TNF-α, the level was significantly higher in non-
diabetic subjects with gingivitis and periodontitis [2.30 (1.55-4.08) pg/ml and 2.59 
(1.18-3.97) pg/ml] compared to subjects with T2DM and gingivitis and periodontitis 
[1.17 (0.52-2.04) pg/ml and 1.58 (0.61-3.08) pg/ml] (p < 0.05). However, no significant 
differences were found in levels of TNF-α in saliva between non-diabetic subjects with 
healthy periodontal tissues [2.79 (1.63-4.54) pg/ml] and diabetic subjects with healthy 
periodontal tissue [2.26 (0.42-4.29) pg/ml]. In subjects with T2DM, there were no 
significant differences in saliva TNF-α levels between those with healthy periodontal 
tissues [2.26 (0.42-4.29) pg/ml], gingivitis [1.17 (0.52-2.04) pg/ml] and periodontitis 
[1.58 (0.61-3.08) pg/ml]. For non-diabetic subjects, there were no significant 
differences in saliva TNF-α levels between those with healthy periodontal tissues [2.79 
(1.63-4.54) pg/ml], gingivitis [2.30 (1.55-4.08) pg/ml] and periodontitis [2.59 (1.18-
3.97) pg/ml] (Table 5.2). 
When considering IL-1β in saliva, the level was significantly higher in non-
diabetic subjects with gingivitis and periodontitis [43.00 (24.70-93.70) pg/ml and 62.60 
(39.20-97.10) pg/ml] compared to subjects with T2DM and gingivitis and periodontitis 
[16.70 (7.99-49.60) pg/ml and 38.65 (20.45-68.28) pg/ml] (p < 0.05). However, no 
significant differences were found in levels of IL-1β between non-diabetic subjects with 
healthy periodontal tissues [17.60 (14.20-31.95) pg/ml] and diabetic subjects with 
healthy periodontal tissue [14.20 (3.26-43.50) pg/ml]. In subjects with T2DM, levels of 
IL-1β in saliva was significantly higher in those with periodontitis [38.65 (20.45-68.28) 
pg/ml] compared to those with healthy periodontal tissues [14.20 (3.26-43.50) pg/ml] 
(p< 0.05). Similarly, in subjects with T2DM, levels of IL-1β in saliva were significantly 
higher in those with periodontitis [38.65 (20.45-68.28) pg/ml] compared to those with 
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gingivitis [16.70 (7.99-49.60) pg/ml] (p < 0.05). However, in subjects with T2DM, no 
significant differences in the levels of IL-1β in saliva were seen in those with gingivitis 
[16.70 (7.99-49.60) pg/ml] compared to healthy periodontal tissues [14.20 (3.26-43.50) 
pg/ml]. In non-diabetic subjects, levels of IL-1β in saliva were significantly higher in 
those with periodontitis [62.60 (39.20-97.10) pg/ml] compared to those with healthy 
periodontal tissues [17.60 (14.20-31.95) pg/ml] (p < 0.05). Similarly, in non-diabetic 
subjects, levels of IL-1β in saliva were significantly higher in those with gingivitis 
[43.00 (24.70-93.70) pg/ml] compared to those with healthy periodontal tissues [17.60 
(14.20-31.95) pg/ml] (p < 0.01).  In non-diabetic subjects, no significant differences in 
the levels of IL-1β in saliva were seen in those with gingivitis [43.00 (24.70-93.70) 
pg/ml] compared to those with periodontitis [62.60 (39.20-97.10) pg/ml] Therefore, for 
both T2DM and non-diabetic subjects, IL-1β levels in saliva increased as the 
periodontal status worsened (Table 5.4).  
When considering IFN-γ in saliva, the levels were significantly higher in non-
diabetic subjects with healthy periodontal tissues, gingivitis and periodontitis [1.74 
(0.46-2.09) pg/ml, 1.07 (0.53-1.65) pg/ml and 1.55 (0.86-2.24) pg/ml] compared to 
diabetic subjects with healthy periodontal tissues, gingivitis and periodontitis 
respectively [0.58 (0.17-1.51) pg/ml, 0.64 (0.34-0.98) pg/ml and 0.86 (0.47-1.60) 
pg/ml] (p < 0.05). In subjects with T2DM, there were no significant differences in saliva 
IFN-γ levels between those with healthy periodontal tissues [0.58 (0.17-1.51) pg/ml], 
gingivitis [0.64 (0.34-0.98) pg/ml] and periodontitis [0.86 (0.47-1.60) pg/ml]. For non-
diabetic subjects, there were no significant differences in saliva IFN-γ levels between 
those with healthy periodontal tissues [1.74 (0.46-2.09) pg/ml], gingivitis [1.07 (0.53-
1.65) pg/ml] and periodontitis [1.55 (0.86-2.24) pg/ml]. However, caution must be used 
when interpreting the results for salivary levels of IFN-γ as data for some subjects are 
around the lower limits of detection for the assay used (Table 5.4). 
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Table 5.3  Saliva cytokine concentrations before periodontal treatment in 
T2DM patients and non-diabetic patients 
 
 
 
Diabetic subjects 
(n=101) 
Non-diabetic subjects 
(n=83) p-value 
 
   
IL-6 (pg/ml) 1.74 (0.72-4.18) 2.18 (0.89-5.72) 0.065 
TNF-α (pg/ml) 1.38 (0.53-2.70) 2.59 (1.40-3.98) <0.001 
IL-1β (pg/ml) 26.95 (12.08-59.90) 46.00 (22.00-90.43) <0.01 
IFN- (pg/ml) 0.81 (0.35-1.34) 1.48 (0.64-2.12) <0.001 
 
   
P-values determined using Mann-Whitney U tests for continuous non-parametric 
variables and median (IQR) is presented for this non-parametric data. 
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Figure 5.2 Pre-treatment saliva levels of IL-6, TNF-α, IL-1β and IFN-γ in 
subjects with T2DM and in non-diabetic subjects 
 
  
 
  
 
Boxplots of pre-treatment saliva levels of IL-6, TNF-α, IL-1β and IFN-γ in 100 T2DM 
and 80 non-diabetic subjects. Statistics: Mann Whitney-U test * p<0.05, **p<0.01, 
***p<0.001. ○ outlier more than 3 times the IQR from the box boundaries, ● outlier 
more than 1.5 but less than 3 times the IQR from the boundaries. 
*** 
** *** 
   
Table 5.4  Pre-treatment saliva cytokine data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=100) Non-diabetic subjects (n=80) p-value 
 
Healthy 
(n=13) 
Gingivitis 
(n=39) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=45) 
 
 
       
IL-6 (pg/ml) 0.80 (0.25-3.25) ¶ 1.37 (0.65-3.84) 2.29 (1.27-4.83) 2.13 (1.27-4.83) 1.85 (0.85-4.07) 2.41 (0.95-7.26) ¶<0.05 
TNF-α (pg/ml) 2.26 (0.42-4.29) 1.17 (0.52-2.04)$ 1.58 (0.61-3.08)$ 2.79 (1.63-4.54) 2.30 (1.55-4.08) 2.59 (1.18-3.97) $<0.05 
IL-1β (pg/ml) 14.20 (3.26-43.50) ¶ 16.70 (7.99-49.60)†,$ 38.65 (20.45-68.28) $ 17.60 (14.20-31.95)#, 
¶
 
43.00 (24.70-93.70) 62.60 (39.20-97.10) ¶,†,$<0.05 
#<0.01 
IFN-γ (pg/ml) 0.58 (0.17-1.51)$ 0.64 (0.34-0.98)$ 0.86 (0.47-1.60)$ 1.74 (0.46-2.09) 1.07 (0.53-1.65) 1.55 (0.86-2.24) $<0.05 
 
       
P-values were determined using Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-parametric variables (all data). Median 
(IQR) is presented for this non-parametric data.  
 
$
 indicates a comparison within row between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes group 
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5.2.1.3 Analysis of pre-treatment GCF cytokine levels in T2DM and non-diabetic 
patients with or without periodontal disease 
Table 5.5 shows that before periodontal treatment, no significant differences in 
the levels of IL-6, TNF-α and IL-1β in GCF were found in subjects with T2DM [1.50 
(0.65-3.88) pg/ml, 3.03 (1.66-6.04) pg/ml and 202.80 (90.76-420.09) pg/ml] compared to 
non-diabetic subjects [1.74 (0.76-3.08) pg/ml, 3.09 (1.66-5.88) pg/ml and 205.25 (83.78-
537.00) pg/ml]. A trend for higher GCF levels of IFN-γ in the non-diabetic group [2.62 
(1.01-5.66) pg/ml] compared to the T2DM group [1.66 (0.71-4.58) pg/ml] was 
demonstrated (p=0.08). However, caution must be used when interpreting the results for 
GCF levels of IFN-γ as data were around the lower limits of detection for the assay used 
(Table 5.5). 
Table 5.6 presents GCF cytokine levels before periodontal treatment following 
further categorisation of subjects based on their periodontal diagnosis. When considering 
IL-6 levels in GCF, there were no significant differences found in any periodontal 
category between T2DM and non-diabetic subjects. In subjects with T2DM, the levels of 
IL-6 in GCF appeared to be higher in those with periodontitis [1.97 (0.98-5.17) pg/ml] 
compared to those with healthy periodontal tissues [0.99 (0.48-2.25) pg/ml]. However, 
the Bonferroni-Holm correction of p-values for multiple comparisons placed the critical 
p-value at 0.017, therefore, this difference was detected as trend (p=0.037). Furthermore, 
apparent differences in GCF IL-6 levels between those with healthy periodontal tissues 
[0.99 (0.48-2.25) pg/ml] and gingivitis [1.44 (0.53-3.61) pg/ml] and between those with 
gingivitis [1.44 (0.53-3.61) pg/ml] and periodontitis [1.97 (0.98-5.17) pg/ml] failed to 
reach statistical significance. In non-diabetic subjects, levels of IL-6 in GCF was 
significantly higher in those with periodontitis [2.25 (1.12-3.37) pg/ml] compared to 
those with healthy periodontal tissues [1.00 (0.26-2.69) pg/ml] (p < 0.05). Similarly, in 
non-diabetic subjects, levels of IL-6 in GCF were significantly higher in those with 
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periodontitis [2.25 (1.12-3.37) pg/ml] compared to those with gingivitis [0.90 (0.39-2.12) 
pg/ml] (p < 0.05). In non-diabetic subjects, no significant difference was detected 
between those with gingivitis and those with healthy periodontal tissues (Table 5.6 and 
Figure 5.3). 
When considering TNF-α levels in GCF, there were no significant differences 
found in any periodontal category between T2DM and non-diabetic subjects. In subjects 
with T2DM, the levels of TNF-α in GCF were significantly higher in those with 
periodontitis [4.16 (2.7-6.69) pg/ml] compared to those with gingivitis [2.28 (1.30-3.06) 
pg/ml]. However, in subjects with T2DM, the apparent differences in GCF TNF-α levels 
between those with healthy periodontal tissues [1.32 (0.05-7.20) pg/ml] and periodontitis 
[4.16 (2.7-6.69) pg/ml] and between those with gingivitis [2.28 (1.30-3.06) pg/ml] and 
healthy periodontal tissues [1.32 (0.05-7.20) pg/ml] failed to reach statistical 
significance. In non-diabetic subjects, levels of TNF-α in GCF were significantly higher 
in those with periodontitis [4.49 (2.55-7.04) pg/ml] compared to those with healthy 
periodontal tissues [1.83 (1.23-2.90) pg/ml] (p < 0.01). Similarly, in non-diabetic 
subjects, levels of IL-6 in GCF were significantly higher in those with periodontitis [2.25 
(1.12-3.37) pg/ml] compared to those with gingivitis [0.90 (0.39-2.12) pg/ml] (p < 0.01) 
(Table 5.6 and Figure 5.4). 
When considering IL-1β levels in GCF, there were no significant differences 
found in any periodontal category between T2DM and non-diabetic subjects. In subjects 
with T2DM, the levels of IL-1β in GCF were significantly higher in those with gingivitis 
[173.41 (77.60-268.19) pg/ml] compared to those with healthy periodontal tissue [84.95 
(40.66-130.61) pg/ml] (p < 0.05). Likewise, in subjects with T2DM, the levels of IL-1β 
in GCF were significantly higher in those with periodontitis [344.33 (156.16-572.50) 
pg/ml] compared to those with periodontal healthy tissues [84.95 (40.66-130.61) pg/ml] 
(p < 0.001). Furthermore, in subjects with T2DM, the levels of IL-1β in GCF were 
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significantly higher in those with periodontitis [344.33 (156.16-572.50) pg/ml] compared 
to those with gingivitis [173.41 (77.60-268.19) pg/ml] (p < 0.001). In non-diabetic 
subjects, the levels of IL-1β in GCF were significantly higher in those with gingivitis 
[116.25 (56.50-176.53) pg/ml] compared to those with healthy periodontal tissue [54.26 
(25.79-100.65) pg/ml] (p< 0.05). Likewise, in non-diabetic subjects, the levels of IL-1β 
in GCF were significantly higher in those with periodontitis [413.38 (213.84-770.56) 
pg/ml] compared to those with periodontal healthy tissues [54.26 (25.79-100.65) pg/ml] 
(p < 0.001). Furthermore, in non-diabetic subjects, the levels of IL-1β in GCF were 
significantly higher in those with periodontitis [413.38 (213.84-770.56) pg/ml] compared 
to those with gingivitis [116.25 (56.50-176.53) pg/ml] (p < 0.001). Therefore, for both 
T2DM and non-diabetic subjects, IL-1β levels in GCF increased as the periodontal status 
worsened (Table 5.6 & Figure 5.5). 
When considering IFN-γ in GCF, the levels were significantly higher in non-
diabetic subjects with periodontitis [4.40 (2.18-7.09) pg/ml] compared to diabetic 
subjects with periodontitis [2.51 (1.11-5.24) pg/ml] (p < 0.05). However, no significant 
differences were found in IFN-γ levels in GCF between T2DM and non-diabetic subjects 
for those with healthy periodontal tissues or gingivitis. In subjects with T2DM, levels of 
IFN-γ in GCF appeared higher in those with periodontitis [2.51 (1.11-5.24) pg/ml] 
compared to those with healthy periodontal tissues [0.53 (0.34-5.76) pg/ml]. However, 
the Bonferroni-Holm correction of p-values for multiple comparisons placed the critical 
p-value at 0.025, therefore, this difference was detected as trend (p=0.032). In subjects 
with T2DM, levels of IFN-γ in GCF appeared higher in those with periodontitis [2.51 
(1.11-5.24) pg/ml] compared to those with gingivitis [2.17 (0.65-2.50) pg/ml]. However, 
the Bonferroni-Holm correction of p-values for multiple comparisons placed the critical 
p-value at 0.017, therefore, this difference was detected as trend (p=0.018). In non-
diabetic subjects, levels of IFN-γ were significantly higher in those with periodontitis 
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[4.40 (2.18-7.09) pg/ml] compared those with healthy periodontal tissues [0.72 (0.58-
2.16) pg/ml] (p < 0.001). Likewise, in non-diabetic subjects, levels of IFN-γ were 
significantly higher in those with periodontitis [4.40 (2.18-7.09) pg/ml] compared to 
those with gingivitis [1.85 (1.01-2.44) pg/ml] (p < 0.001). However, caution must be 
used when interpreting the results for GCF levels of IFN-γ as some data for all groups 
were around the lower limits of detection for the assay used (Table 5.6 and Figure 5.6). 
When considering GCF volume, the volume was significantly higher in diabetic 
subjects with gingivitis [0.44±0.23 µl] compared to non-diabetic subjects with gingivitis 
[0.28(±0.15) µl] (p < 0.01). However, no significant differences were found in GCF 
volume between T2DM and non-diabetic subjects for those with healthy periodontal 
tissues or periodontitis. In subjects with T2DM, the GCF volumes were significantly 
higher in those with gingivitis [0.44±0.23 µl] compared to those with healthy periodontal 
tissue [0.27±0.11 µl] (p < 0.01). Likewise, in subjects with T2DM, GCF volume was 
significantly higher in those with periodontitis [0.53±0.23 µl] compared to those with 
healthy periodontal tissues [0.27±0.11 µl] (p < 0.001). However, in subjects with T2DM 
the apparent difference in GCF volume between those with gingivitis [0.44±0.23 µl] and 
periodontitis [0.53±0.23 µl] failed to reach statistical significance. In non-diabetic 
subjects, the GCF volumes were significantly higher in those with periodontitis 
[0.53±0.25 µl] compared to those with healthy periodontal tissue [0.21±0.10 µl] (p < 
0.01).  Likewise, in subjects with T2DM, GCF volume was significantly higher in those 
with periodontitis [0.53±0.25 µl] compared to those with gingivitis [0.28±0.15 µl] (p < 
0.001). However, in non-diabetic subjects, the difference in GCF volume between those 
with healthy periodontal tissues [0.21±0.10 µl] and gingivitis [0.28±0.15 µl] failed to 
reach statistical significance. Overall, for both T2DM and non-diabetic subjects, GCF 
volume increased as the periodontal status worsens (Table 5.6). 
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Table 5.5  Pre-treatment GCF cytokine concentrations and volume in T2DM 
patients and non-diabetic patients 
 
 
 
Diabetics (n=100) Non-diabetics (n=83) p-value 
   
 
GCF Vol  (µl) 0.43 (0.29-0.58) 0.35 (0.21-0.60) NS 
 
   
IL-6 (pg/ml) 1.50 (0.65-3.88) 1.74 (0.76-3.08) NS 
TNF-α (pg/ml) 3.03 (1.66-6.04) 3.09 (1.66-5.88) NS 
IL-1β (pg/ml) 202.80 (90.76-420.09) 205.25 (83.78-537.00) NS 
IFN-γ (pg/ml) 1.66 (0.71-4.58) 2.62 (1.01-5.66) NS 
 
   
P-values determined using Mann-Whitney U tests for continuous non-parametric 
variables and median (IQR) is presented for this non-parametric data. 
    
Table 5.6  Pre-treatment GCF volume and GCF cytokine data comparing groups based on diabetic status and periodontal diagnosis 
 
 
Diabetic subjects (n=100) Non-diabetic subjects (n=83) p-value 
 
Healthy 
(n=14) 
Gingivitis 
(n=38) 
Periodontitis 
(n=48) 
Healthy 
(n=16) 
Gingivitis 
(n=19) 
Periodontitis 
(n=48) 
 
 
       
GCF Vol (µl) 0.27 (±0.11)#,¶ 0.44 (±0.23)$ 0.53 (±0.23) 0.21 (±0.10)¶ 0.28 (±0.15)† 0.53 (±0.25) #,$<0.01 
¶,†<0.001 
IL-6 (pg/ml) 0.99 (0.48-2.25) 1.44 (0.53-3.61) 1.97 (0.98-5.17) 1.00 (0.26-2.69)¶ 0.90 (0.39-2.12)† 2.25 (1.12-3.37) ¶,†<0.05 
TNF-α (pg/ml) 1.32 (0.05-7.20) 2.28 (1.30-3.06)† 4.16 (2.7-6.69) 1.83 (1.23-2.90)¶ 2.23 (1.66-4.30)† 4.49 (2.55-7.04) ¶,†<0.01 
IL-1β (pg/ml) 84.95 (40.66-
130.61)#,¶ 
173.41 (77.60-
268.19)† 
344.33 (156.16-
572.50) 
54.26 (25.79-
100.65)#,¶ 
116.25 (56.50-176.53)† 413.38 (213.84-
770.56) 
#<0.05 
¶,†<0.001 
IFN-γ (pg/ml) 0.53 (0.34-5.76) 2.17 (0.65-2.50) 2.51 (1.11-5.24)$ 0.72 (0.58-2.16)¶ 1.85 (1.01-2.44)† 4.40 (2.18-7.09) ¶,†<0.001 
$<0.05 
 
       
P-values were determined using chi-squared test for discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables and one way ANOVA test with post-hoc independent t-test for continuous parametric variables (GCF vol). Mean (±SD) is presented 
for parametric data and median (IQR) is presented for non-parametric data. 
 
$
 indicates a comparison within row between diabetics and non-diabetic group with the same periodontal diagnosis 
#
 indicates a comparison within rows between periodontally healthy and gingivitis groups within either diabetes or non-diabetes groups 
¶
 indicates a comparison within rows between periodontally healthy and periodontitis groups within either diabetes or non-diabetes groups 
†
 indicates a comparison within rows between gingivitis and periodontitis groups within either diabetes or non-diabetes group 
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Figure 5.3   Pre-treatment GCF levels of IL-6 comparing groups based on 
diabetic status and periodontal diagnosis 
 
 
Boxplots of pre-treatment GCF IL-6 data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=38, periodontitis n=48) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more that 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 5.4  Pre-treatment GCF levels of TNF-α comparing groups based on 
diabetic status and periodontal diagnosis 
 
Boxplots of pre-treatment GCF TNF-α data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=38, periodontitis n=48) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more that 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 5.5  Pre-treatment GCF levels of IL-1β comparing groups based on 
diabetic status and periodontal diagnosis 
 
 
Boxplots of pre-treatment GCF IL-1β data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=38, periodontitis n=48) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more that 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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Figure 5.6  Pre-treatment GCF levels of IFN-γ comparing groups based on 
diabetic status and periodontal diagnosis 
 
 
Boxplots of pre-treatment GCF IFN-γ data in 100 T2DM subjects (healthy periodontal 
tissues n=14, gingivitis n=38, periodontitis n=48) and 83 non-diabetic subjects (healthy 
periodontal tissues n=16, gingivitis n=19, periodontitis n=48). Statistics: Kruskal-Wallis 
with Mann Whitney-U post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
periodontal status within T2DM or non-diabetic group); § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups within the corresponding periodontal status). ○ 
outlier more that 3 times the IQR from the box boundaries, ● outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries. 
 
D/H:  T2DM and healthy periodontal tissues 
D/G:  T2DM and gingivitis 
D/P:   T2DM and periodontitis 
ND/H: Non-diabetic subjects with healthy periodontal tissues 
ND/G: Non-diabetic subjects with gingivitis 
ND/P: Non-diabetic subjects with periodontitis 
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5.2.2 Exploration of the associations between clinical periodontal 
parameters, cytokine levels and clinical markers of diabetes 
control and inflammation 
5.2.2.1 The relationship of HbA1c and hsCRP with clinical periodontal 
parameters 
Pre-treatment levels of HbA1c and hs-CRP were investigated for correlations 
with mGI, BOP, mean PD, PESA and PISA. Correlations were first undertaken for all 
subjects and then repeated taking diabetes status into account (Tables 5.7, 5.8 and 5.9).   
When considering all subjects (diabetic and non-diabetic), a significant negative 
correlation was demonstrated between HbA1c levels and PESA (Spearman’s ρ =-0.17, 
p<0.05). All other correlations between HbA1c levels and mGI, BOP, mean PD and 
PISA were non-significant (Table 5.7). In subjects with T2DM and for non-diabetic 
subjects, no significant correlations were found between levels of HbA1c and mGI, 
BOP, mean PD, PESA and PISA (Tables 5.8 and 5.9). 
When considering all subjects (diabetic and non-diabetic), significant positive 
correlations were demonstrated between hsCRP levels and mGI (Spearman’s ρ =0.24, 
p<0.05) and mean PD (Spearman’s ρ =0.16, p<0.05). All other correlations between 
hsCRP levels and BOP, PESA and PISA were non-significant (Table 5.7). When the 
data were split according to diabetes status, no significant correlations were found 
between levels of hsCRP and mGI, BOP, mean PD, PESA and PISA in subjects with 
T2DM (Table 5.8). However, in non-diabetic subjects, significant positive correlations 
were shown between hsCRP levels and mGI (Spearman’s ρ= 0.23, p<0.05), BOP 
(Spearman’s ρ= 0.26, p<0.05), mean PD (Spearman’s ρ= 0.26, p<0.01) and PISA 
(Spearman’s ρ= 0.27, p<0.05) (Table 5.9).  
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Table 5.7 Correlations between HbA1c and hsCRP levels and clinical 
periodontal parameters for all subjects 
 
 
 
Table 5.8 Correlations between HbA1c and hsCRP levels and clinical 
periodontal parameters for T2DM subjects 
 
 
 
 
 
Table 5.9 Correlations between HbA1c and hsCRP levels and clinical 
periodontal parameters for non-diabetic subjects 
 
 
 
 
 
Tables show Spearman rank correlation coefficients with colour indicates strength of 
correlation: small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) (Cohen, 
1988). *p<0.001, †p<0.01, ‡ p<0.05. 
 
  
Clinical parameters Spearman rank Correlation Co-efficient 
HbA1c (%) Hs CRP (mg/L) 
mGI 0.05 0.24† 
BOP (%) 0.04 0.15 
Mean PD (mm) -0.05 0.16‡ 
PESA (mm2) -0.17‡ -0.01 
PISA (mm2) 0.04 -0.09 
Clinical parameters Spearman rank Correlation Co-efficient 
HbA1c (%) Hs CRP (mg/L) 
mGI 0.03 -0.07 
BOP (%) -0.02 -0.14 
Mean PD (mm) -0.21 -0.05 
PESA (mm2) 0.06 -0.17 
PISA (mm2) 0.10 -0.11 
Clinical parameters Spearman rank Correlation Co-efficient 
HbA1c (%) Hs CRP (mg/L) 
mGI 0.03 0.23‡ 
BOP (%) -0.06 0.26‡ 
Mean PD (mm) -0.07 0.26‡ 
PESA (mm2) -0.05 0.17 
PISA (mm2) -0.04 0.27‡ 
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5.2.2.2 The relationship of HbA1c and hsCRP levels with cytokine levels in 
serum, saliva and GCF  
Pre-treatment levels of HbA1c and hs-CRP were investigated for correlations 
with levels of IL-6, TNF-α, IL-1β and IFN-γ in serum, saliva and GCF. Correlations 
were first undertaken for all subjects and then repeated taking diabetes status into 
account (Tables 5.10, 5.11 and 5.12). 
When considering all subjects (diabetic and non-diabetic), significant positive 
correlations were demonstrated between HbA1c levels and serum levels of IL-6 
(Spearman’s ρ =0.16, p<0.05), TNF-α (Spearman’s ρ =0.18, p<0.05) and IL-1β 
(Spearman’s ρ =0.21, p<0.01) and all other correlations between HbA1c levels and 
serum cytokines were non-significant (Table 5.10).  In subjects with T2DM only, a 
significant negative correlation was demonstrated between HbA1c levels and serum IL-
1β levels (Spearman’s ρ =-0.26,p<0.05) and all other correlations between HbA1c 
levels and serum cytokines were non-significant (Table 5.11).   In non-diabetic subjects, 
no significant correlations between levels of HbA1c and serum levels of IL-6, TNF-α, 
IL-1β and IFN-γ were found (Table 5.12). 
 Additionally, in all subjects, significant negative correlations were 
demonstrated between HbA1c levels and saliva levels of TNF-α (Spearman’s ρ =-0.18, 
p<0.05) and IFN-γ (Spearman’s ρ =-0.15, p<0.05) and all other correlations between 
HbA1c levels and saliva cytokines were non-significant (Table 5.10). In subjects with 
T2DM only, a significant positive correlation was demonstrated between HbA1c levels 
and saliva levels of IL-1β (Spearman’s ρ =-0.27,p<0.05) and IFN-γ (Spearman’s ρ 
=0.20, p<0.01) and all other correlations between HbA1c levels and saliva cytokines 
were non-significant (Table 5.11). In non-diabetic subjects, no significant correlations 
between levels of HbA1c and saliva levels of IL-6, TNF-α, IL-1β and IFN-γ were found 
(Table 5.12).  
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Furthermore, in all subjects and when the data were split according to diabetes 
status,  no significant correlations between levels of HbA1c and GCF levels of IL-6, 
TNF-α, IL-1β and IFN-γ were found (Tables 5.10, 5.11 and 5.12). 
When considering all subjects, and following categorisation according to 
diabetes status, no significant correlations between levels of hsCRP and serum or saliva 
levels of IL-6, TNF-α, IL-1β and IFN-γ were found (Tables 5.10, 5.11 and 5.12). When 
considering cytokine levels in GCF, no significant correlations between levels of hsCRP 
and GCF levels of IL-6, TNF-α, IL-1β and IFN-γ were found when all subjects or 
subjects with T2DM alone were considered. In non-diabetic subjects, a significant 
positive correlation was demonstrated between hsCRP levels and GCF levels of IL-1β 
(Spearman’s ρ =-0.32, p<0.01) (Tables 5.10, 5.11 and 5.12). 
 
    
Table 5.10  Correlations between HbA1c and hsCRP levels and cytokine levels in serum, saliva and GCF for all subjects 
 
 
Table 5.11  Correlations between HbA1c and hsCRP levels and cytokine levels in serum, saliva and GCF for T2DM subjects 
 
Table 5.12  Correlations between HbA1c and hsCRP levels and cytokine levels in serum, saliva and GCF for non-diabetic subjects 
Tables show correlation coefficients: small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) (Cohen, 1988) *p<0.001, †p<0.01, ‡ p<0.05
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
HbA1c (%) 0.16‡ 0.18‡ 0.21† 0.15 -0.72 -0.18‡ -0.10 -0.15‡ 0.05 0.001 0.00 -0.14 
hsCRP (mg/L) 0.10 -0.09 0.04 0.13 0.58 -0.01 0.06 0.07 0.02 0.05 0.15 0.10 
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
HbA1c (%) 0.09 -0.08 -0.26‡ -0.15 0.14 0.18 0.27† 0.20† 0.16 0.19 0.11 0.06 
hsCRP (mg/L) 0.09 -0.15 0.78 0.04 0.07 0.03 0.06 0.10 -0.08 -0.02 -0.01 -0.03 
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
HbA1c (%) 0.18 0.03 0.10 0.09 -0.06 0.06 0.02 0.13 -0.15 -0.17 -0.03 -0.10 
hsCRP (mg/L) 0.15 -0.12 -0.15 0.18 0.06 -0.02 -0.10 0.07 0.16 0.16 0.32† 0.21 
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5.2.2.3 The relationship of cytokine levels in serum, saliva and GCF with clinical 
periodontal parameters 
Pre-treatment levels of inflammatory cytokines in serum, saliva and GCF were 
investigated for correlations with mGI, BOP, mean PD, PESA and PISA. Correlations 
were first undertaken for all subjects (Table 5.13) and then repeated taking diabetes 
status into account (Tables 5.14 and 5.15). A series of scatter plots were used to 
graphically present correlations of BOP, mean PD, PESA and PISA with IL-6, TNF-α, 
IL-1β and IFN-γ in serum, saliva and GCF (Figure 5.7 to 5.18) 
When considering all subjects, a significant negative correlations was 
determined between TNF-α levels in serum and mean PD (Spearman’s ρ= -0.15, 
p<0.05) and PESA (Spearman’s ρ= -0.18, p<0.05). A significant negative correlation 
was also determined between IL-1β levels in serum and mean PD (Spearman’s ρ= -0.26, 
p<0.001), PESA (Spearman’s ρ= -0.30, p<0.001) and PISA (Spearman’s ρ= -0.26, 
p<0.001) (Table 5.13 and Figure 5.8). When the data were split according to diabetes 
status, similar negative correlations between clinical periodontal parameters and serum 
TNF-α and IL-1β were demonstrated in non-diabetic subjects but no such correlations 
were demonstrated in T2DM subjects (Tables 5.14 and 5.15). Caution must however be 
used when interpreting these results given that serum levels of the cytokines measured 
are around the lower limits of detection for the assay used. 
When considering all subjects, significant positive correlations were determined 
between IL-6 levels in saliva and mGI (Spearman’s ρ= 0.35, p<0.001), BOP 
(Spearman’s ρ= 0.25, p<0.01), mean PD (Spearman’s ρ= 0.20, p<0.01) and PESA 
(Spearman’s ρ= 0.24, p<0.001) and PISA (Spearman’s ρ= 0.27, p<0.001) (Table 5.13 
and Figure 5.11). Similarly, significant positive correlations were determined between 
IL-1β levels in saliva and mGI (Spearman’s ρ= 0.35, p<0.001), mean PD (Spearman’s 
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ρ= 0.40, p<0.001) and PESA (Spearman’s ρ= 0.46, p<0.001) and PISA (Spearman’s ρ= 
0.45, p<0.001) (Table 5.13 and Figure 5.13). When the data were split according to 
diabetes status, similar positive correlations between clinical periodontal parameters and 
saliva IL-6 and IL-1β levels were also demonstrated in non-diabetic and T2DM subjects 
(Tables 5.14 and 5.15).  
When considering all subjects, significant positive correlations were 
demonstrated between IL-6 levels in GCF and mGI (Spearman’s ρ= 0.30, p<0.001), 
BOP (Spearman’s ρ= 0.37, p<0.001), mean PD (Spearman’s ρ= 0.35, p<0.001) and 
PESA (Spearman’s ρ= 0.32, p<0.001) and PISA (Spearman’s ρ= 0.39, p<0.001) (Table 
5.13 and Figure 5.15).  Similarly, significant positive correlations were also 
demonstrated between TNF-α levels in GCF and mGI (Spearman’s ρ= 0.23, p<0.01), 
BOP (Spearman’s ρ= 0.30, p<0.001), mean PD (Spearman’s ρ= 0.40, p<0.001) and 
PESA (Spearman’s ρ= 0.35, p<0.001) and PISA (Spearman’s ρ= 0.38, p<0.001) (Table 
5.13 and Figure 5.16). Additionally, significant positive correlations were also between 
IL-1β levels in GCF and mGI (Spearman’s ρ= 0.51, p<0.001), BOP (Spearman’s ρ= 
0.58, p<0.001), mean PD (Spearman’s ρ= 0.66, p<0.001) and PESA (Spearman’s ρ= 
0.59, p<0.001) and PISA (Spearman’s ρ= 0.66, p<0.001) (Table 5.10 and Figure 5.17). 
Furthermore, significant positive correlations were shown between IFN-γ levels in GCF 
and mGI (Spearman’s ρ= 0.33, p<0.001), BOP (Spearman’s ρ= 0.31, p<0.001), mean 
PD (Spearman’s ρ= 0.46, p<0.001) and PESA (Spearman’s ρ= 0.42, p<0.001) and PISA 
(Spearman’s ρ= 0.47, p<0.001) (Table 5.13 and Figure 5.18). When the data were split 
according to diabetes status, similar positive correlations between clinical periodontal 
parameters and GCF IL-6, TNF-α, IL-1β and IFN-γ levels were also demonstrated in 
non-diabetic and T2DM subjects, although the correlations were smaller in magnitude 
in the T2DM subjects (Tables 5.14 and 5.15). 
 
 Table 5.13  Relationships among clinical periodontal parameters and cytokine levels in serum, saliva and GCF for all subjects 
 
 
 
 
 
 
 
 
 
Table 5.14  Relationships among periodontal clinical parameters and cytokine levels in serum, saliva and GCF for T2DM subjects 
 
  
 
 
 
 
 
Table 5.15  Relationships among periodontal biochemistry parameters and cytokine levels in serum, saliva and GCF for non-diabetic subjects 
 
 
 
 
 
 
 
Tables show correlation coefficients: small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) (Cohen, 1988) *p<0.001, †p<0.01, ‡ p<0.05,
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
mGI -0.04 -0.08 -0.02 -0.10 0.35* 0.13 0.35* 0.10 0.30* 0.23† 0.51* 0.33* 
BOP (%) -0.04 -0.09 -0.09 0.05 0.25† -0.07 0.35 0.04 0.37* 0.30* 0.58* 0.31* 
Mean PD (mm) -0.08 -0.15‡ -0.26* -0.13 0.20† -0.05 0.40* 0.13 0.35* 0.40* 0.66* 0.46* 
PESA (mm2) -0.11 -0.18‡ -0.30* -0.17‡ 0.24* 0.07 0.46* 0.20† 0.32* 0.35* 0.59* 0.42* 
PISA (mm2) -0.03 -0.13 -0.26* -0.10 0.27* 0.01 0.45* 0.12 0.39* 0.38* 0.66* 0.47* 
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
mGI 0.02 0.09 0.17 0.06 0.42* 0.25‡ 0.32† 0.17 0.24‡ 0.18 0.38* 0.24‡ 
BOP (%) 0.17 0.09 -0.05 0.22‡ 0.28† -0.29 0.30† 0.10 0.32† 0.19 0.48* 0.31† 
Mean PD (mm) 0.06 0.07 -0.18 0.08 0.24‡ 0.01 0.38* 0.24‡ 0.27† 0.28† 0.56* 0.35† 
PESA (mm2) -0.00 0.01 -0.19 0.02 0.26‡ 0.11 0.40* 0.24‡ 0.26‡ 0.24‡ 0.49* 0.27† 
PISA (mm2) 0.10 0.06 -0.18 0.81 0.30† 0.04 0.40* 0.14 0.34† 0.25‡ 0.55* 0.34† 
Clinical Parameters 
Spearman Rank Correlation Co-efficient 
Serum cytokines Saliva cytokines GCF cytokines 
IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ IL-6 TNF-α IL-1β IFN-γ 
mGI -0.00 -0.42* -0.31† -0.34† 0.31† 0.12 0.47* 0.10 0.34† 0.29† 0.61* 0.47* 
BOP (%) -0.18 -0.43* -0.37†- -0.21 0.26‡ -0.13 0.50* 0.06 0.44* 0.45* 0.69* 0.53* 
Mean PD (mm) -0.22 -0.41* -0.47* -0.31† 0.14 -0.09 0.48* 0.06 0.42* 0.53* 0.72* 0.60* 
PESA (mm2) -0.19 -0.36† -0.41* -0.27‡ 0.17 -0.06 0.50* 0.09 0.41* 0.48* 0.67* 0.59* 
PISA (mm2) -0.19 -0.38† -0.44* -0.25‡ 0.25‡ 0.00 0.56* 0.09 0.56* 0.51* 0.72* 0.59* 
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Figure 5.7 The relationship of serum IL6 with clinical periodontal parameters 
in all subjects 
 
 
 
Figure shows Spearman correlation of serum IL-6 concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
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Figure 5.8 The relationship of serum TNF-α with clinical periodontal 
parameters in all subjects 
 
 
 
Figure shows Spearman correlation of serum TNF-α concentrations with BOP (%), 
mean PD (MM), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ 
non-diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of 
a significant correlation. 
 
 
  
Spearman’s ρ= -0.18  
p<0.05 
Spearman’s ρ= -0.15 
p<0.05 
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Figure 5.9 The relationship of serum IL-1β with clinical periodontal 
parameters in all subjects 
 
 
 
Figure shows Spearman correlation of serum IL-1β concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
  
Spearman’s ρ= -0.30  
p<0.001 
Spearman’s ρ= -0.26  
p<0.001 
Spearman’s ρ= -0.26  
p<0.001 
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Figure 5.10 The relationship of serum IFN-γ with clinical periodontal 
parameters in all subjects 
 
 
 
Figure shows Spearman correlation of serum IFN-γ concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
 
 
  
Spearman’s ρ= -0.17  
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Figure 5.11 The relationship of saliva IL-6 with clinical periodontal parameters 
in all subjects 
 
  
 
  
Figure shows Spearman correlation of saliva IL-6 concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
  
Spearman’s ρ= 0.25  
p<0.01 
Spearman’s ρ= 0.24  
p<0.001 
Spearman’s ρ= 0.27  
p<0.001 
Spearman’s ρ= 0.20  
p<0.01 
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Figure 5.12 The relationship of saliva TNF-α with clinical periodontal 
parameters in all subjects 
 
  
 
  
Figure shows Spearman correlation of saliva TNF-α concentrations with BOP (%), 
mean PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ 
non-diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of 
a significant correlation. 
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Figure 5.13 The relationship of saliva IL-1β with clinical periodontal parameters 
in all subjects 
 
  
 
  
Figure shows Spearman correlation of saliva IL-1β concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
 
  
Spearman’s ρ= 0.40  
p<0.001 
Spearman’s ρ= 0.46  
p<0.001 
Spearman’s ρ= 0.45  
p<0.001 
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Figure 5.14 The relationship of saliva INF-γ with clinical periodontal parameters 
in all subjects 
 
 
 
 
Figure shows Spearman correlation of saliva IFN-γ concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
  
Spearman’s ρ= 0.20  
p<0.01 
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Figure 5.15 The relationship of GCF IL-6 with clinical periodontal parameters 
in all subjects 
 
  
 
Figure shows Spearman correlation of GCF IL-6 concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
 
  
Spearman’s ρ= 0.37  
p<0.001 
Spearman’s ρ= 0.35  
p<0.001 
Spearman’s ρ= 0.32  
p<0.001 
Spearman’s ρ= 0.39  
p<0.001 
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Figure 5.16 The relationship of GCF TNF-α with clinical periodontal parameters 
in all subjects  
 
 
 
 
Figure shows Spearman correlation of GCF TNF-α concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
  
Spearman’s ρ= 0.30  
p<0.001 
Spearman’s ρ= 0.40  
p<0.001 
Spearman’s ρ= 0.35  
p<0.001 
Spearman’s ρ= 0.38  
p<0.001 
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Figure 5.17 The relationship of GCF IL-1β with clinical periodontal parameters 
in all subjects  
 
  
 
 
 
Figure shows Spearman correlation of GCF IL-1β concentrations with BOP (%), mean 
PD (mm), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
  
Spearman’s ρ= 0.58  
p<0.001 
Spearman’s ρ= 0.66  
p<0.001 
Spearman’s ρ= 0.59  
p<0.001 
Spearman’s ρ= 0.66  
p<0.001 
5  Results 221
 
Figure 5.18 The relationship of GCF IFN-γ with clinical periodontal parameters 
in all subjects 
 
  
 
  
Figure shows Spearman correlation of GCF IFN-γ concentrations with BOP (%), mean 
PD (MM), PESA (mm2) and PISA (mm2) in all subjects ● T2DM subjects and ○ non-
diabetic subjects (n=182). The addition of a trend-line demonstrates the presence of a 
significant correlation. 
 
 
Spearman’s ρ= 0.31  
p<0.001 
Spearman’s ρ= 0.46  
p<0.001 
Spearman’s ρ= 0.42  
p<0.001 
Spearman’s ρ= 0.47  
p<0.001 
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5.2.3 PISA as a predictor of periodontal status  
The potential of PISA in predicating gingivitis or periodontitis was assessed in 
multinomial logistic regression models. Periodontal status (periodontal health, gingivitis 
or periodontitis) was assigned as the dependent variable, using periodontal health as the 
reference category. All tests were conducted on measurements taken before periodontal 
treatment and groups were not divided according to diabetic status. In a multinomial 
logistic regression model, PISA was identified as a predicator of the periodontal status 
with PISA being a significant predicator of gingivitis (p < 0.01) and periodontitis (p < 
0.01). 
5.2.4 Inflammatory cytokine levels in GCF as predictors of PISA 
The potential of GCF IL-6, TNF-α, IL-1β and IFN-γ as predictors of PISA was 
assessed in linear regression models. PISA was assigned as the dependent variable and 
GCF IL-6, TNF-α, IL-1β and IFN-γ were assigned as the independent variables. All 
tests were conducted on measurements taken before periodontal treatment and groups 
were not divided according to diabetic status. In linear regression models, GCF IL-1β 
and IFN-γ concentrations were determined as significant predicators of PISA (p < 
0.001). A trend for GCF TNF-α concentration as a predicator of PISA was noted (p = 
0.089), however, GCF IL-6 concentration was not a predictor for PISA (p = 0.125). 
5.2.5 Inflammatory cytokine levels in saliva as predictors of PISA 
The potential of saliva IL-6 and IL-1β as predictors of PISA was assessed in 
linear regression models. PISA was assigned as the dependent variable and saliva IL-6 
and IL-1β were assigned as the independent variables. All tests were conducted on 
measurements taken before periodontal treatment and groups were not divided 
according to diabetic status. No significant correlations had been demonstrated of saliva 
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TNF-α and IFN-γ with PISA, thus the potential of saliva TNF-α and IFN-γ as predictors 
of PISA was not assessed. In linear regression models, saliva IL-1β (p < 0.001) and IL-6 
(p < 0.05) concentrations were determined as significant predicators of PISA.  
5.3 Discussion 
Cytokine levels in serum 
Previous research has demonstrated an association between higher circulating 
levels of inflammatory mediators and the development of T2DM, with significantly 
higher levels of CRP, IL-6 and TNF-α found in subjects with T2DM compared to non-
diabetic subjects (Pradhan et al., 2001; Spranger et al., 2003b; Bertoni et al., 2010). The 
current study supports this, with levels of TNF-α, IL-1β and INF-γ in serum being 
significantly higher in subjects with T2DM [7.45 (5.07-9.23) pg/ml, 0.18 (0.01-0.37) 
pg/ml and 1.35 (0.66-2.50) pg/ml] compared to non-diabetic subjects [5.25 (3.15-7.69) 
pg/ml, 0.04 (0.00-0.10) pg/ml and 0.78 (0.43-1.88) pg/ml] (p < 0.01) (Table 5.1). 
Similarly, following further categorisation of the serum cytokine data based on 
periodontal status, serum TNF-α, IL-1β and IFN-γ  levels were significantly higher in 
diabetic subjects with periodontitis [7.10 (3.25-9.30) pg/ml, 0.08 (0.00-0.34) pg/ml and 
1.09 (0.56-2.50) pg/ml] compared to non-diabetic subjects with periodontitis [3.44 
(2.34-7.24) pg/ml, 0.00 (0.00-0.48) pg/ml and 0.57 (0.26-1.33) pg/ml] (p < 0.05). 
Again, this corroborates previous research showing significantly higher circulating 
levels of inflammatory mediators, such as CRP, IL-6 and TNF-α in subjects with T2DM 
compared to non-diabetic controls (Pradhan et al., 2001; Spranger et al., 2003b; Bertoni 
et al., 2010).   
Currently, data on serum cytokine levels in subjects with T2DM and periodontitis 
are limited. One study showed no significant difference in pre-treatment serum TNF-α 
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levels between subjects with poorly controlled T2DM [12.44±5.27 pg/ml], well 
controlled T2DM [9.92±3.33 pg/ml] and non-diabetic subjects [10.42±4.80 pg/ml] (Dag 
et al., 2009). Similarly, another study showed no significant difference in serum TNF-α 
or IL-6 levels between subjects with T2DM and non-diabetic subjects. Unfortunately, 
however, detailed evaluation of the data from this study is precluded due to a lack of 
numerical values within the publication, with the authors presenting serum cytokine 
levels in graphs alone (Kardesler et al., 2010). Data from the present study, with levels 
of TNF-α, IL-1β and INF-γ in serum being significantly higher in subjects with T2DM 
[7.45 (5.07-9.23) pg/ml, 0.18 (0.01-0.37) pg/ml and 1.35 (0.66-2.50) pg/ml] compared 
to non-diabetic subjects [5.25 (3.15-7.69) pg/ml, 0.04 (0.00-0.10) pg/ml and 0.78 (0.43-
1.88) pg/ml] (p < 0.01), do not support the data from these two previously published 
studies. Another previously published study presents plasma levels of IL-6, TNF-α, IL-
1β and IFN-γ in subjects with T2DM and periodontitis [2.1±0.3 pg/ml, 0.3±0.3 pg/ml, 
0.3±0.3 pg/ml and 2.8±1.3 pg/ml] (O'Connell et al., 2008). However, a lack of a non-
diabetic group prevents a comparison of levels in subjects with and without T2DM from 
being made. Furthermore, the use of plasma (not serum) prevents a direct comparison to 
data from the current study. Similarly, a further study, also presents plasma levels of IL-
6 and TNF-α in subjects with T2DM and periodontitis [3.1 (2.1-4.2) pg/ml and 5.6 (4.3-
7.4) pg/ml], although again a lack of a non-diabetic group prevents a comparison of 
levels in subjects with and without T2DM from being made and again the use of plasma 
(not serum) prevents a direct comparison to data from the current study (Correa et al., 
2010). Taken collectively, data from the current study along with previously published 
data suggest that subjects with T2DM have higher circulating levels of some 
inflammatory cytokines. A further study, within the general medical literature, 
evaluated hsCRP levels and serum levels of IL-1β, IL-6 and TNF-α in 89 patients with 
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T2DM (periodontal status unknown) finding low levels of IL-1β [0.5 (0.3-0.8) pg/ml] 
and IL-6 [7.0 (3.5-12.1) pg/ml] and undetectable levels of TNF-α in serum (Castoldi et 
al., 2007). 
Published data demonstrated that in non-diabetic subjects, serum IL-6 levels 
were significantly higher in the periodontitis group compared to the control group 
without periodontitis, although the authors only present this difference graphically and 
do not report the numerical values (Marcaccini et al., 2009). In another study, the level 
of plasma IL-6 in patients with aggressive periodontitis (1.20 pg/ml) was significantly 
higher than that in subjects without periodontitis (0.08 pg/ml) (Sun et al., 2009) . In a 
further small study, serum levels of IL-1β were evaluated, but in many of the subjects 
with periodontitis and the majority of subjects without periodontitis, no IL-1β was 
measureable in serum (Mengel et al., 2002). Interestingly, in this current study it would 
appear the reverse is true, with serum TNF-α levels, IL-1β and IFN-γ in non-diabetic 
subjects being significantly lower in those with periodontitis [3.44 (2.34-7.24) pg/ml, 
0.00 (0.00-0.48) pg/ml and 0.57 (0.26-1.33) pg/ml] compared to those with healthy 
periodontal tissues [6.28 (4.4-8.81) pg/ml, 0.09 (0.06-0.14) pg/ml and 1.78 (0.67-3.64) 
pg/ml] and no significant difference in serum IL-6 levels in non-diabetic subjects with 
periodontitis [0.59 (0.32-0.93) pg/ml] compared to non-diabetic subjects with healthy 
periodontal tissues [0.69 (0.43-1.11) pg/ml]. Interestingly, in the current study, 
differences in serum cytokine levels between subjects with and without periodontitis 
were not seen in subjects with T2DM. For example, in subjects with T2DM, serum IL-
6, TNF-α levels, IL-1β and IFN-γ were not significantly different in subjects with 
periodontitis [0.51 (0.34-1.50) pg/ml, 7.10 (3.25-9.300 pg/ml, 0.08 (0.00-0.34) pg/ml 
and 1.09 (0.56-2.50) pg/ml] compared to those with healthy periodontal tissues [0.50 
(0.33-0.81) pg/ml, 8.02 (6.34-9.24) pg/ml, 0.28 (0.09-0.40) pg/ml and 1.19 (0.71-1.62) 
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pg/ml]. Published studies, investigating the circulating levels of inflammatory cytokines 
in subjects with T2DM have not included subjects without periodontitis (O'Connell et 
al., 2008; Dag et al., 2009; Correa et al., 2010; Kardesler et al., 2010), therefore, no 
comparison can be made with the data from the current study which assessed serum 
cytokine levels in diabetic subjects both with and without periodontitis. Overall it would 
however appear that data from the current study doesn’t support the hypothesis that 
subjects with periodontitis have higher levels of systemic inflammation compared to 
subjects without periodontitis. The variations seen in the presented serum cytokine 
levels and the lack of agreement between the data from the current study and published 
research could be due to heterogeneity of methodology. Differences in analytical 
techniques, storage of samples and case definition of periodontitis may all impact on the 
data that are presented. Additionally, the low levels of cytokines present in serum which 
are around the lower limit of detection for assays used, lead to larger intra- and inter- 
study variations. Large variations, coupled with small sample sizes have the potential to 
produce a greater number of chance findings. Therefore, to clarify the role of circulating 
inflammatory cytokines in the relationship between T2DM and periodontitis, further, 
well designed, studies of adequate power are required. 
Cytokine levels in Saliva 
 Recently, a small number of studies have investigated inflammatory cytokine 
levels in saliva in subjects with and without periodontitis (Miller et al., 2006; Gursoy et 
al., 2009; Teles et al., 2009; Costa et al., 2010). One previous study demonstrated 
significantly higher levels of IL-1β in saliva from subjects with periodontitis 
[665.7±267.5 pg/ml] compared to those without periodontitis [467.8±279.8 pg/ml] 
(Gursoy et al., 2009). Another study also found significantly higher levels of IL-1β in 
saliva from subjects with periodontitis [753.7±1022.4 pg/ml] compared to those without 
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periodontitis [212.8±167.4 pg/ml] (Miller et al., 2006). This increase in IL-1β levels in 
saliva with the development of periodontitis is supported by data from the current study, 
which show in non-diabetic subjects, levels of IL-1β in saliva were significantly higher 
in those with periodontitis [62.60 (39.20-97.10) pg/ml] compared to those with healthy 
periodontal tissues [17.60 (14.20-31.95) pg/ml] (p <0.01) and similarly in subjects with 
T2DM, levels of IL-1β in saliva were significantly higher in those with periodontitis 
[38.65 (20.45-68.28) pg/ml] compared to those with healthy periodontal tissues [14.20 
(3.26-43.50) pg/ml] (p < 0.05) (Table 5.4). Previous studies have also demonstrated 
elevated levels in saliva of IL-6 in subjects with periodontitis compared to those without 
periodontitis (Costa et al., 2010), although numerical values were not published, with 
differences presented graphically. A different study however, found no significant 
differences in IL-6 and TNF-α levels in saliva in subjects with periodontitis [3.6±5.9 
pg/ml and 2.9±4.0 pg/ml] compared to control subjects without periodontitis [3.1±3.6 
pg/ml and 2.7±2.8 pg/ml] (Gursoy et al., 2009). In the current study subjects with 
T2DM and periodontitis have significantly higher levels of IL-6 in saliva [2.29 (1.27-
4.83) pg/ml] compared to those with healthy periodontal tissues [0.80 (0.25-3.25) 
pg/ml] (p < 0.05), although the pattern was not replicated in non-diabetic subjects, with 
no significant differences found in saliva IL-6 levels between those with healthy 
periodontal tissues [2.13 (1.27-4.83) pg/ml] and periodontitis [2.41 (0.95-7.26) pg/ml]. 
In a further published study, a number of inflammatory cytokines in saliva were 
quantified using a multiplex bead immunoassay, demonstrating no significant 
differences between periodontitis and periodontally healthy groups with regards to 
levels of IL-6, TNF-α, IL-1β and IFN-γ (Teles et al., 2009). Unfortunately, however, 
detailed evaluation of the data from this study is precluded due to a lack of numerical 
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values within the publication, with the authors presenting saliva cytokine levels in 
graphs alone.  
 Currently, there is very little published research investigating the role of 
inflammatory cytokines in saliva in subjects with T2DM and periodontitis. One small 
study found no significant differences in IL-6 levels in saliva when subjects with T2DM 
and periodontitis (n=24) were compared to non-diabetic subjects with periodontitis 
(n=24) (Costa et al., 2010), although again numerical values were not presented. This 
lack of difference in IL-6 levels in saliva between subjects with and without T2DM was 
not supported in the current study. Comparing all non-diabetic subjects (n=101) with all 
subjects with T2DM (n=83), data from the current study showed the levels of salivary 
IL-6 were higher in the non-diabetic subjects [2.18 (0.89-5.72) pg/ml] compared to the 
subjects with T2DM [1.74 (0.72-4.18) pg/ml], although this difference was detected as a 
trend (p=0.065) (Table 5.3). Furthermore, in the current study, the levels of TNF-α, IL-
1β and INF-γ in saliva were significantly higher in non-diabetic subjects [2.59 (1.40-
3.98) pg/ml, 46.00 (22.00-90.43) pg/ml and 1.48 (0.64-2.12) pg/ml] compared to 
subjects with T2DM [1.38 (0.53-2.70) pg/ml, 26.95 (12.08-59.90) pg/ml and 0.81 (0.35-
1.34) pg/ml] (Table 5.3). One explanation for the higher levels of salivary cytokine in 
non-diabetic subjects compared to subjects with T2DM seen in the current study is the 
greater severity and extent of periodontitis seen in non-diabetic subjects compare to 
subjects with T2DM, indicated by significantly greater PESA and % of sites with PD  ≥ 
6 mm [1372.7 (849.2-1801.0) mm2 and 0.7(0.0-11.3)%] compared to subjects with 
T2DM [1038.9(817.9-1327.6) mm2 and 0.0(0.0-0.2)%] (Table 4.12). This clinical 
difference between subjects with and without diabetes most probably reflect the 
differences in the recruitment pools used for diabetic and non-diabetic subjects in the 
current study and although, diabetics and non-diabetic subjects were matched based on 
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their periodontal diagnosis, the extent of periodontal disease was not however 
considered in this process.  
 Following further categorisation of subjects based on their periodontal 
diagnosis, the current study demonstrated that TNF-α, IL-1β and IFN-γ in saliva, were 
significantly higher in non-diabetic subjects with periodontitis [2.59 (1.18-3.97) pg/ml, 
62.60 (39.20-97.10) pg/ml and 1.55 (0.86-2.24) pg/ml] compared to subjects with 
T2DM and periodontitis [1.58 (0.61-3.08) pg/ml, 38.65 (20.45-68.28) pg/ml and 
0.86(0.47-1.60) pg/ml] (p < 0.05) (Table 5.4). Similarly, TNF-α, IL-1β and IFN-γ in 
saliva, were significantly higher in non-diabetic subjects with gingivitis [2.30 (1.55-
4.08) pg/ml, 43.00 (24.70-93.70) pg/ml and 1.07 (0.53-1.65) pg/ml] compared to 
subjects with T2DM and gingivitis [1.17 (0.52-2.04) pg/ml, 16.70 (7.99-49.60) pg/ml 
and 0.64 (0.34-0.98) pg/ml] (p < 0.05) (Table 5.4). For subjects with periodontitis, a 
possible explanation for this is that the non-diabetic group had a significantly greater 
PESA and % of sites with PD ≥6mm [1744.9± and 8.7(2.6-16.7)] and compared to 
subjects with T2DM [1444.7±495.1 and 2.7(0.7-7.1)]. This indicates that more severe 
periodontal disease was present in non-diabetic subjects compared to subjects with 
T2DM and most likely reflects the differences in the recruitment pools used for diabetic 
and non-diabetic subjects in the current study and a lack of stratified periodontal case 
selection based on extent and severity of disease when matching T2DM and non-
diabetic subjects (Table 4.13 and Figures 4.13 & 4.14). However, no such differences in 
these clinical PD parameters were demonstrated between the T2DM and non-diabetic 
groups with gingivitis (Table 4.13 and Figures 4.13 & 4.14). Additionally, the higher 
levels of salivary cytokines seen in non-diabetic subjects with gingivitis compared to 
subjects with T2DM with gingivitis do not appear to reflect the levels of local 
inflammation, as assessed by mGI and % BOP, which show significantly higher levels 
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in T2DM with gingivitis [1.9 (1.3-2.5) and 35.1 (25.0-44.9)] compared to non-diabetic 
subjects with gingivitis [1.3 (0.8-1.7) and 22.0 (17.3-32.6)] (Table 4.13 and Figures 4.8 
and 4.9). 
Overall, data from the current study and published research suggest that salivary 
levels of IL-1β and possibly IL-6 increase with the development of periodontitis. This 
would suggest that select salivary biomarkers may reflect periodontal status. However, 
this pattern is not universally demonstrated and a lack of clarity remains regarding the 
effect of periodontitis on levels of other inflammatory cytokines in saliva, with further 
studies required to clarify this. 
There are numerous possible explanations for the variations seen in the salivary 
cytokine levels within currently available data. It is wise to remember that the 
periodontium will not be the sole source of inflammatory cytokines found in saliva, 
with the salivary glands and oral mucosa possible contributors to the levels of cytokines 
found in saliva. Heterogeneity of methodology between studies is another possible 
explanation for variations in cytokine levels, with differences in analytical techniques, 
sampling techniques, storage of samples and case definition of periodontitis all 
potentially impacting on the data that are presented. Additionally, some inflammatory 
cytokines were present in saliva at low levels which are around the lower limit of 
detection for assays used and thus leading to larger intra- and inter- study variations. 
This coupled with the small sample sizes, used in previous studies, have the potential to 
produce a greater number of chance findings. Therefore, to clarify the role of circulating 
inflammatory cytokines in the relationship between T2DM and periodontitis, further, 
well designed, studies of adequate power are required. One specific limitation in the 
current study is the technique used to sample saliva. This involved an oral rinse using 
10ml of saline and this consequently diluted the sa
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potential to take already low levels of inflammatory cytokine nearer to or below the 
lower level of detection for the assay used and thus increasing the variability in the data. 
Additionally, because the actual volume of whole saliva in each sample is not known, it 
is not possible to clarify the levels of dilution each sample underwent, causing greater 
and unpredictable variation in salivary cytokine data. 
Cytokine levels in GCF 
 The current study showed no significant differences in GCF levels of the IL-6, 
TNF-α, IL-1β and IFN-γ, between T2DM subjects [1.50 (0.65-3.88 pg/ml, 3.03 (1.66-
6.04) pg/ml, 202.80 (90.76-420.09) pg/ml and 1.66 (0.71-4.58) pg/ml] and non-diabetic 
subjects [1.74 (0.76-3.08 pg/ml, 3.09 (1.66-5.88) pg/ml, 205.25 (83.78-537.00) pg/ml 
and 2.62(1.01-5.66) pg/ml]. Furthermore, following categorisation of subjects based on 
periodontal status, the apparent higher levels of in GCF levels of IL-6, TNF-α and IL-1β 
in non-diabetic subjects with periodontitis [2.25 (1.12-3.37) pg/ml, 4.49 (2.55-7.04) 
pg/ml and 413.38 (213.84-770.56) pg/ml] compared to subjects with T2DM and 
periodontitis [1.97 (0.98-5.17) pg/ml, 4.16 (2.7-6.69) pg/ml and 344.33 (156.16-572.50) 
pg/ml] did not reach significance. Only, GCF IFN-γ levels were significantly higher in 
non-diabetic subjects with periodontitis [4.40 (2.18-7.09) pg/ml] compared to T2DM 
subjects with periodontitis [2.51 (1.11-5.24) pg/ml] (p < 0.05). The higher levels, albeit 
non-significant, of GCF cytokines in non-diabetic subjects with periodontitis compared 
to subjects with T2DM and periodontitis, may well be a reflection of the more severe 
periodontal disease that was present in non-diabetic subjects compared to subjects with 
T2DM (Table 4.13). However, the large variations in GCF cytokine levels seen in the 
present study provide a possible reason for the lack of significant differences in GCF 
cytokine levels between diabetic and non-diabetic subjects with periodontitis. An 
additional reason for a lack of difference may be due to a higher levels of background 
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inflammation present in the periodontium of subjects with T2DM, as possibly indicated 
by the higher, albeit non significant, levels of IL-6, TNF-α, IL-1β and IFN-γ in GCF in 
subjects with T2DM and gingivitis [1.44 (0.53-3.61) pg/ml, 2.28 (1.30-3.06) pg/ml, 
173.41 (77.60) pg/ml and 2.17 (0.65-2.50) pg/ml] compared to non-diabetic subjects 
with gingivitis [0.90 (0.39-2.12) pg/ml, 2.23 (1.66-4.30) pg/ml, 116.25 (56.50-176.53) 
pg/ml and 1.85 (1.01-2.44) pg/ml] (Table 5.6). 
 To date, there are a limited number of published studies that investigated GCF 
cytokine levels in subjects with T2DM and periodontitis compared to non-diabetic 
subjects with periodontitis. One study demonstrated higher levels of GCF IL-6 in 
T2DM subjects with periodontitis compared to non-diabetic subjects with periodontitis 
(Kardesler et al., 2011). Unfortunately, however, detailed evaluation of the data from 
this study is precluded due to a lack of numerical values within the publication, with the 
authors presenting serum cytokine levels in graphs alone. This is not replicated in the 
current study, which found no significant difference in GCF levels of IL-6 in subjects 
with T2DM and periodontitis [1.97 (0.98-5.17) pg/ml] compared to non-diabetic 
subjects with periodontitis [2.25 (1.12-3.37) pg/ml]. Another published study showed 
no differences in pre-treatment GCF IL-1β levels between T2DM subjects with 
periodontitis [140.9 (106.0-177.7) pg/ml] and non-diabetic subjects with periodontitis 
[159.6 (145.71-197.1) pg/ml] (Correa et al., 2008), supporting data in the current study 
which found no significant difference in the pre-treatment GCF levels of IL-1β in 
subjects with T2DM and periodontitis [344.33 (156.16-572.50) pg/ml] compared to 
non-diabetic subjects with periodontitis [413.38 (213.84-770.56) pg/ml].  
There are additional studies that have investigated GCF cytokine levels in 
subjects with well and poorly controlled T2DM; however a lack of a non-diabetic group 
for comparison is a limitation to these studies (Engebretson et al., 2007; Santos et al., 
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2010). One study showed higher GCF IL-1β levels in subjects with poorly controlled 
T2DM [89.0 (61.7-116.3) pg/ml] compared to those with well controlled T2DM [49.1 
(18.3-80) pg/ml] (Engebretson et al., 2004). Another study demonstrated higher levels 
of GCF IFN-γ in well controlled compared to poorly controlled T2DM subjects, but no 
differences in GCF TNF-α in well controlled compared to poorly controlled T2DM 
subjects (Santos et al., 2010), although numerical values were not published and the 
data were presented graphically. In the current study, T2DM subjects were not sub-
divided based on level of control thus preventing direct comparison to these previous 
studies (Engebretson et al., 2004; Santos et al., 2010).  
Heterogeneity of methodology between studies is a possible explanation for the 
variations in GCF cytokine levels seen both within the published literature and also 
compared to the current study. Differences in analytical techniques, GCF sampling 
techniques, methods for elution of GCF cytokines from Periopapers, storage of samples 
and case definition of periodontitis could all potentially impact on the data that is 
presented. Specifically, when considering the method used for eluting the cytokines in 
GCF from the Periopapers, a wide variety of protocols are used within studies. In one 
study, for example, 5 or 6 GCF Periopaper samples were pooled into 1 tube containing 
1ml of PBS, followed by 40 minutes of standing and then centrifugation at 3000 g for 
10 minutes before storing within a freezer at -70oC (Correa et al., 2008). Another study 
placed each GCF Periopaper sample into a tube containing 250 µl of PBS containing 
protease inhibitor, followed by ‘vortexing’ for 30 seconds and then centrifugation for 5 
minutes before storing within a freezer at -20oC (Santos et al., 2010). By comparison, a 
different study placed each GCF Periopaper sample into 500 µl of PBS followed by 
shaking for 45 minutes before storing within a freezer at -40oC (Kardesler et al., 2011). 
As demonstrated in the verification studies conducted within the current study (Table 
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3.2), both the methodology for elution and the volumes of solution into which the GCF 
cytokines are eluted has an impact on the recoverability of cytokines from Periopapers 
(Table 3.2). Consequently, a lack of consistency within the literature for the elution of 
GCF cytokines from Periopapers will increase inter-study variations in GCF cytokine 
levels and thus prevent clear conclusions regarding the role of GCF cytokines in 
subjects with T2DM and periodontitis from being made. 
Currently, there are no published data comparing GCF cytokine levels in T2DM 
subjects with and without periodontitis. However, previously research has investigated 
GCF levels of key inflammatory mediators in periodontitis in systemically healthy 
subjects, showing increased levels of IL-1β in GCF from subjects with periodontitis 
(Preiss and Meyle, 1994; Figueredo et al., 1999; Engebretson et al., 2002; Zhong et al., 
2007)  and elevated IL-6 levels in GCF from diseased sites compared with control 
samples (Mogi et al., 1999; Lin et al., 2005). Data from another study, in subjects 
without systemic conditions such as T2DM, demonstrated that subjects with 
periodontitis had significantly higher levels of GCF IL-1β compared to periodontally 
healthy subjects (Teles et al., 2010). Furthermore, data from a further small study using 
a site based analysis of multiple cytokines, demonstrated that only IL-1β and IL-1α 
differed when healthy and diseased sites were compared, with higher levels for both 
mediators in diseased sites (Thunell et al., 2010). The current study supports previous 
data, with elevated levels of pro-inflammatory cytokines in GCF in subjects with 
periodontitis compared to subjects with healthy periodontal tissues. For example, in 
non-diabetic subjects, levels of IL-6, TNF-α, IL-1β and IFN-γ in GCF were 
significantly higher in those with periodontitis [2.25 (1.12-3.37) pg/ml, 4.49 (2.55-7.04) 
pg/ml, 413.38 (213.84-770.56) pg/ml and 4.40 (2.18-7.09) pg/ml] compared to those 
with healthy periodontal tissues [1.00 (0.26-2.69) pg/ml, 1.83 (1.23-2.90) pg/ml, 54.26 
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(25.79-100.65) pg/ml and 0.72 (0.58-2.16) pg/ml]. In subjects with T2DM, the pattern is 
still present but less clear, with significantly higher levels of IL-1β in GCF being 
significantly higher in those with periodontitis [344.33 (156.16-572.50) pg/ml] 
compared to those with healthy periodontal tissue [84.95 (40.66-130.61) pg/ml]. In 
subjects with T2DM, the higher levels of IL-6, TNF-α and IFN-γ in GCF in those with 
periodontitis [1.97 (0.98-5.17) pg/ml, 4.16 (2.7-6.69) pg/ml and 2.51 (1.11-5.24) pg/ml] 
compared to those with healthy periodontal tissues [0.99 (0.48-2.25) pg/ml, 1.32 (0.05-
7.20) pg/ml] and 0.53 (0.34-5.76) pg/ml] were detected as trends (Table 5.6 and Figures 
5.3 to 5.6).  
Furthermore, data from the current study demonstrates that GCF IL-1β is a 
promising indicator of periodontal disease, reflecting not only difference between 
subjects with healthy periodontal tissues and periodontitis, but also differences between 
subjects with healthy periodontal tissues and gingivitis and likewise between subjects 
with gingivitis and periodontitis. This corroborates data from previous studies which 
demonstrates elevated GCF IL-1β and IL-6 from diseased periodontal sites compared to 
healthy sites (Mogi et al., 1999; Lin et al., 2005; Thunell et al., 2010). However, these 
studies evaluating GCF cytokine levels in periodontitis, all presented data in a site 
specific manner. Interestingly, one additional study shows clinically healthy sites from 
subjects with periodontitis had higher levels of IL-1β than clinically healthy sites from 
periodontally healthy subjects (Teles et al., 2010), highlighting that the case definition 
on a subject levels may affect local site specific cytokine levels. To date, there remains 
a lack of published data of GCF cytokine levels for subjects with or without 
periodontitis. 
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Relationship between HbA1c,  hsCRP levels and periodontal parameters 
In one previously published study, a dose-response relationship was shown 
between PISA and HbA1c in subjects with T2DM, indicating that PISA was a predictor 
significantly associated with HbA1c levels (Nesse et al., 2009). However, a number of 
other studies, collecting full mouth periodontal data in subjects with T2DM and 
periodontitis and undertaking correlation tests, did not report significant correlations 
between HbA1c levels and clinical periodontal parameters (Engebretson et al., 2007; 
Dag et al., 2009; Costa et al., 2010; Santos et al., 2010). In line with this, the current 
study found no significant correlations between HbA1c and mGI, %BOP, mean PD and 
PISA. A significant negative correlation was demonstrated between HbA1c and PESA 
(Spearman’s ρ=-0.17, p<0.05). However, given that the correlation was small and is not 
supported by other correlations, it is likely this was simply a chance finding. One 
potential explanation of the lack of correlation found within the current study and 
previous studies is that, in addition to the inflammatory burden from periodontal 
disease, many conditions potentially impact on glycaemic control, including obesity and 
duration of diabetes. Therefore, variations in HbA1c, unrelated to the periodontal 
condition, prevent the correlation tests in these relatively small studies from detecting 
possible associations between worsening glycaemic control and increased periodontal 
severity that have been previously demonstrated in epidemiological studies (Taylor, 
2001). 
 Given that CRP has been shown to be elevated in subjects with T2DM (Bertoni 
et al., 2010) and in subjects with periodontitis (Paraskevas et al., 2008) and considering 
the importance of inflammation in the proposed mechanism linking T2DM and 
periodontitis, it is surprising that data evaluating hsCRP in patients with T2DM and 
periodontitis are currently very limited (Correa et al., 2010; Kardesler et al., 2010) . 
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Therefore, in subjects with T2DM, correlations between hsCRP levels and clinical 
periodontal parameters have yet to be explored within the published literature. In a 
recent study of systemically healthy patients with and without periodontitis, a 
significant positive correlation was demonstrated between log serum IL-6 levels and 
mean PD (r=0.39, p=0.000) and mean LOA (r=0.42, p=0.000) (Sun et al., 2009). In the 
current study, significant positive correlations were demonstrated between hsCRP, mGI 
(Spearman’s ρ =0.24, p<0.05) and mean PD (Spearman’s ρ =0.16, p<0.05), when all 
subjects were considered (Table 5.7). Interestingly, when the data was split according to 
diabetes status, no significant correlations between hsCRP and the clinical periodontal 
parameters were found in subjects with T2DM (Table 5.8), whereas, in non-diabetic 
subjects, significant positive correlations were shown between hsCRP and mGI 
(Spearman’s ρ= 0.23, p<0.05), BOP (Spearman’s ρ= 0.26, p<0.05), mean PD 
(Spearman’s ρ= 0.26, p<0.01) and PISA (Spearman’s ρ= 0.27, p<0.05) (Tables 5.9). 
Overall, these data would suggest that increasing severity and extent of periodontitis are 
associated with increasing levels of systemic levels of inflammation, as indicated by 
hsCRP. One possible explanation for this is that as the inflammatory burden from the 
periodontium increases, so do systemic levels of inflammation. This is supported by 
previous estimates that the cumulative size of all periodontal lesions in patients with 
untreated severe periodontitis may amount to 20cm2 (Loos, 2005). A potential 
explanation for the lack of significant correlations in T2DM subjects is that perhaps the 
systemic condition of T2DM subjects, such as obesity, concurrent CVD or the routine 
use of statin medication, may mask the relationship between the periodontal condition 
and hs-CRP levels in subjects with T2DM. It must also be remembered that although 
the correlations demonstrated between hsCRP and clinical periodontal parameters were 
significant, they were small in magnitude. 
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Relationship between HbA1c, hsCRP and inflammatory cytokines 
Currently, there are limited published data exploring the relationship between 
HbA1c and levels of inflammatory cytokines in GCF in subjects with T2DM. In one 
study evaluating GCF levels of TNF-α, INF-γ, IL-4, IL-17 and IL-23 in subjects with 
T2DM, a significant positive correlation was demonstrated between GCF TNF-α, IL-4 
and IL-17 levels and HbA1c (r=0.25; p<0.05,  r=0.41; p<0.001 and r=0.50; p<0.001 
respectively) and significant negative correlations between GCF levels of IFN-γ and 
HbA1c (r=-0.06; p<0.001) (Santos et al., 2010). In a further study of subjects with 
T2DM and periodontitis, HbA1c was significantly correlated with GCF IL-1β levels 
(r=0.371, p=0.01) (Engebretson et al., 2004). Furthermore, this study identified HbA1c 
as an independent predictor of high GCF IL-1β and demonstrated that patients with 
HbA1c > 8% had significantly higher mean GCF IL-1β levels than patients with HbA1c 
< 8% (Engebretson et al., 2004). In the current study, similar correlations between 
levels of inflammatory cytokines in GCF and HbA1c levels were not replicated, such 
that no significant correlations between levels of HbA1c and GCF levels of IL-6, TNF-
α, IL-1β and IFN-γ were found, either when all subjects were considered or when 
subjects were split based on diabetes status (Table 5.7, 5.8 and 5.9). However, the 
significant correlations demonstrated in previous research between HbA1c and GCF 
cytokines are small in magnitude (Engebretson et al., 2004; Santos et al., 2010) and so 
it is not necessarily surprising that data from the current study failed to corroborate 
these findings. Other studies evaluating both GCF cytokine levels and HbA1c do not 
present correlation data and this could either due correlations not being undertaken or, 
due to publication bias, non-significant correlations were not reported within the 
publications (Correa et al., 2008; Kardesler et al., 2011). 
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Currently, there is one published study exploring the relationship between 
HbA1c and levels of inflammatory cytokines in saliva in subjects with T2DM, 
demonstrating a positive correlation between salivary IL-6 levels and HbA1c levels in 
subjects with T2DM (r=0.60; p<0.01) (Costa et al., 2010). This suggests that increasing 
levels of salivary IL-6 are associated with poorer glycaemic control, as indicated by 
increasing HbA1c levels. This was not, however, supported by data from the current 
study, which failed to demonstrate a correlation between levels of IL-6 in saliva and 
HbA1c. In fact, significant negative correlations between HbA1c levels and saliva 
levels of TNF-α (r=-0.18, p<0.05) and IFN-γ (r=-0.15, p<0.05) were demonstrated in 
the present study in all subjects. The current study did, however, demonstrate a 
significant positive correlation between HbA1c levels and saliva levels of IL-1β in 
subjects with T2DM (r=0.27, p<0.05) and IFN-γ (r=0.20, p<0.010). The inconsistency 
between previous research and the current study could be due to the variation in HbA1c 
levels and levels of cytokines in saliva coupled with the relatively small sample size 
used, both of which would increase the likelihood of chance findings.  
 Within the current literature, there is one published study exploring the 
correlations between circulating cytokine levels and HbA1c levels in subjects with 
T2DM and periodontitis, demonstrating there was no significant positive correlation 
found between plasma TNF-α levels and HbA1c (r=0.10, p=0.50) (Engebretson et al., 
2007). Within the general medical literature however, a previous study evaluating the 
relationship between circulating levels of IL-6 and HbA1c demonstrated that a 
significant positive correlation was demonstrated between serum Il-6 levels and HbA1c 
levels (β=0.58, p=0.04) (Kado et al., 1999). This is supported by data from the current 
study that demonstrates significant positive correlations between HbA1c and serum 
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levels of IL-6 (Spearman’s ρ =0.16, p<0.05), TNF-α (Spearman’s ρ =0.18, p<0.05) and 
IL-1β (Spearman’s ρ =0.21, p<0.01) when all subjects are considered. 
 In subjects with T2DM and periodontitis, the relationship between hsCRP levels 
and inflammatory cytokines has yet to be explored within the published literature. In a 
recent study, of systemically healthy patients with and without periodontitis, no 
significant correlations were demonstrated between serum IL-6 and hsCRP in patients 
with and without periodontitis (Marcaccini et al., 2009), which is surprising given that 
circulating IL-6 is reported as a major regulator of CRP production (Yudkin et al., 
2000). A further study, within the general medical literature, evaluated correlations 
between hsCRP levels and serum levels of IL-1β, IL-6 and TNF-α and reported no 
significant correlations between hsCRP and serum levels of IL-1β, IL-6 and TNF-α 
(Castoldi et al., 2007). This is supported in the current study that shows no significant 
correlations between levels of hsCRP and serum levels of IL-6, TNF-α, IL-1β and IFN-
γ. Overall, in the current study, therefore, systemic or local level inflammatory 
cytokines do not appear related to either HbA1c (a marker of glycaemic control) or 
hsCRP (a biomarker of systemic inflammation). 
Correlations between periodontal parameters and cytokine levels in saliva & GCF   
 Previous published research has begun to explore the relationship between 
clinical periodontal parameters and levels of inflammatory cytokines in GCF in subjects 
with T2DM. One study demonstrates that levels of GCF IL-1β were associated with 
increasing CAL in subjects with T2DM (Engebretson et al., 2007). In another study, 
levels of IL-1β in GCF showed significant correlations between PD, CAL and BOP in 
subjects with T2DM (Engebretson et al., 2004). However, one further study in subjects 
with T2DM failed to show a significant correlation between levels of TNF-α, INF-γ, IL-
4, IL-17 and IL-23 in GCF and mean PD or mean LOA  (Santos et al., 2010). Recently, 
5  Results 241
an additional study, evaluating GCF levels of IL-1β in systemically healthy subjects 
with and without periodontitis, demonstrated significant positive correlations between 
levels of IL-1β in GCF and mean PD (r=0.75, p<0.001), % BOP (r=0.75, p<0.001) 
(Teles et al., 2010). The previously demonstrated correlations between GCF levels of 
inflammatory cytokines and clinical periodontal parameters are corroborated in the 
current study, which found that significant positive correlations were consistently 
demonstrated between mGI, BOP, mean PD, PESA and PISA and GCF levels of IL-6 
(Table 5.13 and Figure 5.13), TNF-α (Table 5.13 and Figure 5.16), IL-1β (Table 5.10 
and Figure 5.17) and IFN-γ (Table 5.13 and Figure 5.18). This suggests that as the 
clinical periodontal measurements increase, the levels IL-6, TNF-α, IL1β and IFN-γ in 
GCF also increase.  
One study evaluating levels of IL-1β in saliva in subjects with and without 
periodontitis demonstrated significant positive correlations between levels of Il-1β in 
saliva and BOP (r=0.41, p=0.001), the % of sites with PD ≥4mm (r=0.53, p=0.0001) 
and the % of sites with PD ≥5mm (r=0.53, p=0.0001) (Miller et al., 2006). This was 
supported in another study that reported significant correlations with salivary IL-1β 
levels and clinical periodontal measurements, although a failure to report the correlation 
coefficients limits interpretation. (Tobon-Arroyave et al., 2008). Furthermore, logistic 
regression analysis showed that salivary IL-1β was associated in a dose-response 
manner with advanced periodontitis (Gursoy et al., 2009). A further study however, 
used correlations to explore associations between the levels of salivary cytokines and 
clinical periodontal parameters in subjects with and without periodontitis, but failed to 
demonstrate a significant correlation between salivary IL-1β and BOP, mean PD or 
mean LOA (Teles et al., 2009). In the current study, significant positive correlations 
were determined between mGI, %BOP, PESA and PISA and levels in saliva of IL-6 
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(Table 5.13 and Figure 5.11) and IL-1β (Table 5.13 and Figure 5.13). This suggests that 
as the clinical periodontal measurements increase, the levels IL-6 and IL1β in saliva 
also increase. 
 Overall, it would appear that increases in the severity and extent of periodontitis 
are associated with increasing levels of IL-1β, α-TNF- and IL-6 in GCF (Table 5.13), 
supporting the recognised key role of these pro-inflammatory cytokines within the 
pathogenesis of periodontitis (Kinane et al., 2011; Preshaw and Taylor, 2011). 
Furthermore, this situation is mirrored in saliva, with increasing levels of IL-1β and IL-
6 being associated with increasing severity and extent of periodontitis (Table 5.13), 
suggest that cytokines produced within the periodontal tissues are also present in saliva. 
On the whole, the correlations were smaller in magnitude for T2DM subjects compared 
to non-diabetic subjects (Tables 5.14 and 5.15) perhaps highlighting that within this 
current study, non-diabetic subjects with periodontitis had a greater extent of disease 
compared to T2DM subjects with periodontitis.  
Correlations between periodontal parameters and cytokine levels in serum  
 A previous study, evaluating levels of TNF-α, IFN-γ (along with other 
cytokines) in subjects with T2DM and non-diabetic subjects, demonstrated a significant 
positive correlation between TNF-α levels in serum and PD (r=0.55, p=0.033) and GI 
(r=0.70, p=0.003) (Dag et al., 2009). However, in a further study of subjects with 
T2DM, the picture is less clear, with log transformed data for TNF-α levels in plasma 
demonstrating a  positive correlation with CAL (r=0.40, p=0.009) but not mean PD 
(r=0.28, p=0.07) or BOP (r=0.30, p=0.053) (Engebretson et al., 2007). In a different 
study of 84 patients with periodontitis and 65 patients without periodontitis, significant 
positive correlations were demonstrated between log transformed data for serum IL-6 
levels and mean PD (r=0.39, p=0.000) and mean LOA (r=0.42, p=0.000) (Sun et al., 
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2009). In a further study of 25 patients with periodontitis and 20 patients without 
periodontitis, a significant positive correlation was see between serum IL-6 and mean 
PD (r=0.31, p<0.025) (Marcaccini et al., 2009). However, this was not supported by 
data from the current study, which failed to demonstrate significant correlations 
between IL-6 levels in serum and clinical periodontal parameters, and found significant 
negative correlations between serum levels of TNF-α, IL-1β and clinical periodontal 
parameters when all subjects are considered. It is difficult to provide an explanation as 
to why the increases in the severity and extent of periodontitis appeared to be associated 
with decreasing circulating levels of TNF-α, IL-1β. However, given that it is not a 
consistent finding, it could potentially be a chance finding. To clarify the relationship 
between circulating inflammatory cytokines and periodontitis in subjects with T2DM, 
further studies of adequate power are required. 
Inflammatory cytokines in GCF and saliva as predictors of periodontal status 
 Currently, large variations exist within the literature regarding the definition and 
classification of periodontal disease within research (Preshaw, 2009). Current 
classifications of periodontitis fail to quantify the amount of inflamed periodontal tissue 
which is required to accurately describe the inflammatory burden posed by 
periodontitis. PISA has recently been developed to describe the quantity of inflamed 
periodontal tissue (Nesse et al., 2008). PISA, calculated using LOA, recession and BOP, 
is reported to reflect the surface area of bleeding pocket epithelium (mm2). Whilst 
theoretically PISA appears to be offer a better method of classifying periodontitis, there 
remains a need to assess the validity of PISA to ensure it correlates with conventional 
measures of periodontal disease. This was confirmed in the current study, in which a 
multinomial logistic regression model identified PISA as a predictor of periodontal 
status, with PISA being a significant predictor of gingivitis and periodontitis. 
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 The identification of biomarkers that would effectively identify subjects with 
periodontitis would facilitate better patient management. In the current study, linear 
regression models demonstrated GCF IL-1β and GCF IFN-γ levels were significant 
predictors of PISA and a trend for GCF TNF-α levels as a predictor of PISA was noted. 
Likewise, salivary IL-6 and IL-1β levels were determined as significant predictors of 
PISA. Therefore, these findings confirm that increased levels of these local 
inflammatory cytokines predict higher PISA and more advanced disease, and 
conversely lower levels of these cytokines predict lower PISA and less advanced 
disease. 
Interestingly, in a recent study, a dose-response relationship was identified 
between PISA and HbA1c in T2DM subjects, with multiple linear regression analyses 
demonstrating PISA was a predictor significantly associated with HbA1c (Nesse et al., 
2009). In contrast, the current study found no correlation between PISA and HbA1c for 
T2DM subjects (Table 5.7) and thus a regression analysis was not performed. 
Interestingly, the median (IQR) for PISA in the published study was 151 (39-307) mm2 
in comparison to 417 (195-733) mm2 for T2DM subjects in the current study, indicating 
a greater severity of periodontal disease in the current study.  
 
Summary of key findings from chapter 5 
• Serum levels of TNF-α, IL-1β and IFN-γ were significantly higher in subjects with 
T2DM compared to non-diabetic subjects. Furthermore, serum levels of TNF-α, IL-
1β and IFN-γ were significantly higher in T2DM subjects with periodontitis 
compared to non-diabetic subjects with periodontitis. 
• In non-diabetic subjects, serum TNF-α, IL-1β and IFN-γ were significantly higher 
in those with healthy periodontal tissues compared to subjects with periodontitis. 
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• In both diabetic and non-diabetic subjects, IL-1β in saliva was significantly higher 
in subjects with periodontitis compared to those with healthy periodontal tissues. 
Also, in subjects with T2DM, IL-6 in saliva was significantly higher in subjects 
with periodontitis compared to those with healthy periodontal tissues. 
• TNF-α, IL-1β and IFN-γ in saliva was significantly higher in non-diabetic subjects 
compared to subjects with T2DM. Furthermore, compared to subjects with T2DM 
and periodontitis, non-diabetic subjects with periodontitis had significantly higher 
levels of TNF-α, IL-1β and IFN-γ in saliva. 
• No significant differences in GCF IL-6, TNF-α, IL-1β and IFN-γ were found 
between subjects with T2DM and non-diabetic subjects. 
• Non-diabetic subjects with periodontitis had apparently higher levels of GCF IL-6, 
TNF-α and IL-1β compared to T2DM subjects with periodontitis, although the 
differences failed to reach statistical significance. 
• T2DM subjects with gingivitis had apparently higher levels of GCF IL-6, IL-1β and 
IFN-γ compared to non-diabetic subjects with gingivitis, although the differences 
failed to achieve statistical significance.  
• In both diabetic and non-diabetic subjects, IL-1β in GCF was significantly higher in 
subjects with periodontitis compared to those with healthy periodontal tissues.  
• Levels of IL-6, TNF-α and IFN-γ in GCF were significantly higher in non-diabetic 
subjects with periodontitis compared to non-diabetics with healthy periodontal 
tissues. Similarly, in subjects with T2DM the same differences in GCF levels of IL-
6, TNF-α and IFN-γ were detected as trends.  
• When all subjects were considered, significant positive correlations were found 
between hsCRP and mGI and mean PD. Furthermore, in non-diabetic subjects, 
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significant positive correlations were found between hsCRP and mGI, % BOP, 
mean PD and PISA. However, no significant correlations were demonstrated 
between hsCRP and serum levels of IL-6, IL-1β, TNF-α and IFN-γ. 
• Significant positive correlations were consistently demonstrated between mGI, 
mean PD, PESA and PISA and GCF levels of IL-6, TNF-α and IL-1β. Furthermore, 
GCF levels of IL-1β and IFN-γ were significant predictors of PISA and a trend for 
GCF TNF-α levels as a predictor of PISA was noted. 
• Significant positive correlations were found between mGI, %BOP, PESA and PISA 
and saliva levels of IL-6 and IL-1β. Furthermore, salivary levels of IL-6 and IL-1β 
were significant predictors of PISA. 
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Chapter 6 Response to non-surgical management in 
subjects with T2DM and the impact on 
markers of diabetes control and local and 
systemic cytokine levels 
6.1 Introduction 
 The role of inflammatory cytokines in the pathogenesis of periodontal disease  
is well recognised (Preshaw and Taylor, 2011). Likewise, inflammatory cytokines are 
key players in the relationship between inflammation and T2DM. Cytokines, such as 
TNF-α, IL-1β and IL-6, contribute to the development of T2DM through obesity, 
insulin resistance and β-cell dysfunction (Donath et al., 2003; Pickup, 2004; Wellen 
and Hotamisligil, 2005).  
In recent years, a number of controlled interventional studies have confirmed 
positive clinical periodontal treatment outcomes following NSM in patients with 
T2DM (Stewart et al., 2001; Kiran et al., 2005; Promsudthi et al., 2005; Jones et al., 
2007; Correa et al., 2008; O'Connell et al., 2008; Dag et al., 2009; Kardesler et al., 
2010; Kardesler et al., 2011). Overall, clinical treatment outcomes assessed in these 
studies  include reduction in probing depths, gain in clinical attachment and reduction 
in bleeding on probing (Cobb, 2002). More recently, composite assessments have also 
been used to evaluate the periodontal condition of patients, incorporating within a 
numerical score, both periodontal epithelial surface area and BOP (Nesse et al., 2008) 
and thus providing an evaluation of the inflammatory burden produced from the 
periodontium. 
In addition to the observational evidence highlighting the relationship between 
periodontal disease and T2DM, increasing numbers of interventional studies have been 
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conducted to explore the effects of periodontal disease on glycaemic control in patients 
with diabetes. However, consideration of intervention studies both controlled (Stewart 
et al., 2001; Kiran et al., 2005; Promsudthi et al., 2005; Jones et al., 2007; O'Connell 
et al., 2008) and non-controlled (Grossi et al., 1997; Iwamoto et al., 2001) 
demonstrated inconsistent results regarding the impact of periodontal management on 
HbA1c. Furthermore, 2 meta-analyses have also been conducted in an attempt to 
clarify whether periodontal treatment has an effect on glycaemic control (Janket et al., 
2005; Darre et al., 2008). However, the situation remains unclear, with  one previous 
meta-analysis producing a significant reduction in HbA1c (Darre et al., 2008)  whilst 
another gave a non-significant reduction in HbA1c (Janket et al., 2005). In the most 
recent meta-analysis, when compared against no treatment or usual treatment, NSM 
gave a statistically significant 0.40% HbA1c reduction (p=0.04) (Simpson et al., 
2010). 
Research demonstrates an association between raised serum lipids and 
periodontitis (Cutler et al., 1999b; Losche et al., 2000; Noack et al., 2000; Fentoglu et 
al., 2009; Fentoglu et al., 2010). Given that hyperlipidemia has been described as one 
of the factors associated with diabetes-induced immune cell alterations (Iacopino and 
Cutler, 2000), it is surprising that only a few studies have investigated the effect of 
improved periodontal health on serum lipid profiles in subjects with T2DM (Christgau 
et al., 1998; Kiran et al., 2005; Kardesler et al., 2010) .  
It is increasingly recognised that inflammation plays a role in the development 
of T2DM. CRP production is part of the non-specific acute-phase response to 
inflammation, infection and tissue damage (Pepys and Hirschfield, 2003). A recent 
systematic review concluded that there was strong evidence from cross-sectional 
studies that plasma CRP was elevated in periodontitis affected subjects compared with 
controls (Paraskevas et al., 2008). Furthermore, studies have begun to describe the 
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effect of reducing periodontal inflammation on CRP and circulating inflammatory 
cytokine levels (Ide et al., 2003; D'Aiuto et al., 2004; Marcaccini et al., 2009). In 
subjects with T2DM, CRP has been proposed as a cardiovascular risk marker (Pfutzner 
and Forst, 2006) as well as a useful marker in predicting the risk of developing T2DM 
(Freeman et al., 2002; Duncan et al., 2003). Despite the importance of inflammation in 
both T2DM and periodontitis, few studies have investigated the effect of improved 
periodontal health on CRP levels in subjects with T2DM (Christgau et al., 1998; 
Correa et al., 2010; Kardesler et al., 2010). 
Recently, studies have begun to investigate the role of inflammatory cytokines 
in patients with T2DM and periodontal disease (Cutler et al., 1999a; Engebretson et 
al., 2007; Correa et al., 2008; Dag et al., 2009; Correa et al., 2010; Kardesler et al., 
2010; Santos et al., 2010) and more specifically the impact of periodontal management 
on cytokine levels in patients with T2DM and periodontitis (Correa et al., 2008; Dag et 
al., 2009; Correa et al., 2010; Kardesler et al., 2010; Santos et al., 2010; Kardesler et 
al., 2011). Although such studies have begun to elucidate the role of inflammatory 
cytokines within patients with T2DM and periodontitis, differences in sampling and 
analytical techniques, inconsistencies in the selection of cytokines investigated, small 
sample sizes and lack of non-diabetic control groups currently prevents clear 
conclusions from being made. 
6.2 Results 
6.2.1 Changes in BMI, blood pressure and medical history following 
non-surgical periodontal management (NSM) 
Table 6.1 and Figure 6.1 summarise the BMI data following non-surgical 
periodontal management for patients with T2DM and periodontitis and non-diabetic 
patients with periodontitis. Of note, BMI was significantly higher in patients with 
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T2DM at each time point. Also, within the subjects with T2DM, BMI showed a 
significant reduction from a pre-treatment level [33.0 (29.9-36.5) kg/m2] to month 6 
[31.0 (27.6-34.8) kg/m2] and month 12 months [31.6 (28.7-34.5) kg/m2] after NSM 
(Table 6.1 and Figure 6.1). Table 6.1 also presents the number of subjects within each 
BMI category and shows that at month 6 and month 12 post-treatment, there was a 
reduction in the number of obese and morbidly obese individuals seen, without any 
concurrent increase in number of subjects classified as normal and overweight. This 
would suggest that the apparent reduction in BMI seen in patients with T2DM 
following NSM is not due to actual weight loss, but rather as a result of drop-out of 
obese and morbidly obese subjects (Table 6.1).  
Table 6.2 and Figure 6.2 presents blood pressure data following NSM for 
patients with T2DM and periodontitis and non-diabetic patients with periodontitis. No 
significant differences between T2DM patients and non-diabetic patients were found at 
any time point and no significant changes were found following NSM (Table 6.2 and 
Figure 6.2). 
Interestingly, from data collected at month 12, it would appear that there were 
minimal changes to the medical care for subjects over the study period. Out of the 29 
T2DM subjects and 37 non-diabetic subjects reviewed at month 12, a change in 
medical history was reported in only 4 (13.8%) and 1 (2.7%) of subjects respectively. 
   
Table 6.1 BMI data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
P-values were determined using chi-squared test for discrete variable, Friedman test with Wilcoxon post hoc test for continuous parametric variable 
compared over time and Mann-Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data are 
non-parametric. 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups 
 
 
 
Pre-treatment 
 
 
Month 6 
 
Month 12 
 
p-value 
 T2DM subjects 
(n=48) 
Non-diabetic 
subjects 
(n= 46) 
T2DM 
subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 22) 
T2DM 
subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 37) 
 
 
BMI (kg/m2) 
 
33.0 (29.9-36.5) 
¶,†,$
 
 
28.1 (25.1-
32.0) 
 
31.0 (27.6-
34.8)$ 
 
25.9 (23.9-
30.3) 
 
31.6 (28.7-
34.5)$ 
 
28.0 (25.1-
32.9) 
 
¶,†,$
 <0.05 
BMI status (n(%))        
Normal weight (18.5-
24.9) 
3 (6.3) 10 (21.7) 2 (6.9) 8 (36.4) 2 (6.9) 8 (21.6)  
Overweight (25.0-29.9) 9 (18.8) 23 (50.0) 8 (27.6) 8 (36.4) 9 (31.0) 18 (70.3) NS 
Obese (30.0-34.9) 20 (41.7) 5 (10.9) 12 (41.4) 3 (13.6) 13 (44.8) 3 (78.4)  
Morbidly obese (>35.0) 16 (33.3) 8 (17.4) 7 (24.1) 3 (13.6) 5 (17.2) 8 (21.6)  
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Figure 6.1  BMI in subjects with periodontitis pre- and post NSM for both 
T2DM and non-diabetic subjects  
 
 
 
Boxplots of BMI pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=48, month 6 n=29, month 12 n=29) and non-diabetic 
subjects (pre-treatment n=46, month 6 n=22, month 12 n=37). Statistics: Friedman test 
with Wilcoxon post hoc test  *<0.05, **p<0.01, ***p<0.001(according to time within 
T2DM or non-diabetic group); Mann-Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 
(T2DM versus non-diabetic groups at each time point). ○ outlier more than 3 times the 
IQR from the box boundaries, ● outlier more than 1.5 but less than 3 times the IQR 
from the box boundaries. 
  
§ 
* 
* 
§ § 
  
Table 6.2  Blood pressure data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-Whitney U 
test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data are non-parametric. 
 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups 
 
 
 
 
 
Pre-treatment 
 
 
Month 6 
 
Month 12 
 
p-value 
 T2DM subjects 
(n=48) 
Non-diabetic 
subjects 
(n= 46) 
T2DM subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 22) 
T2DM subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 36) 
 
 
 Systolic BP 
 
144.0 (127.3-
159.8) 
 
143.0 (127.5-
153.0) 
 
148.0 (135.5-
155.5) 
 
137.5 (128.5-
156.3) 
 
144.0 (135.5-
155.5) 
 
141.5 (134.3-
152.8) 
 
NS 
 Diastolic BP 
 
79.5 (74.0-88.8) 83.0 (76.3-94.5) 77.0 (74.0-84.0) 86.0 (75.8-92.0) 77.0 (74.5-90.5) 85.0 (77.0-90.0) NS 
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Figure 6.2  Blood pressure in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
 
Boxplots of systolic and diastolic BP pre- and post NSM in subjects with periodontitis 
in both T2DM subjects (pre-treatment n=48, month 6 n=29, month 12 n=29) and non-
diabetic subjects (pre-treatment n=46, month 6 n=22, month 12 n=36). Statistics: 
Friedman test with Wilcoxon post hoc test  *<0.05, **p<0.01, ***p<0.001(according 
to time within T2DM or non-diabetic group); Mann-Whitney U test § p<0.05, §§ 
p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time point). ○ outlier 
more than 3 times the IQR from the box boundaries, ● outlier more than 1.5 but less 
than 3 times the IQR from the box boundaries. 
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6.2.2 Changes in HbA1c, hsCRP and lipids following non-surgical 
periodontal management 
Table 6.3 and Figures 6.3 to 6.8 summarise the clinical biochemistry data 
following NSM for patients with T2DM and periodontitis and non-diabetic patients 
with periodontitis. As expected, at each time point, % HbA1c was significantly higher 
in patients with T2DM compared to non-diabetic subjects. In T2DM patients, pre-
treatment % HbA1c levels [7.5 (6.7-9.2)%] showed a reduction at month 3 [7.05 (6.6-
9.5)%] and month 12 [7.1 (6.6-7.4)%], which is a reduction of 0.455 and 0.40% 
respectively. The reductions in HbA1c did not however reach statistical significance.  
When considering levels of triglycerides, subjects with T2DM had significantly 
higher levels compared to non-diabetic subjects at pre-treatment, month 3 and month 
12. Also, compared to pre-treatment levels, triglyceride levels showed no significant 
changes following NSM in either subjects with T2DM or non-diabetic subjects at any 
time-point (Table 6.3 and Figure 6.4). For levels of HDL, non-diabetic subjects had 
significantly higher levels compared to subjects with T2DM, at each time point. Also, 
compared to pre-treatment levels, HDL levels showed no significant changes 
following NSM in either subjects with T2DM or non-diabetic subjects at any time-
point (Table 6.3 and Figure 6.5). For levels of non-HDL, non-diabetic subjects had 
significantly higher levels compared to subjects with T2DM, at each time point. Also, 
in non-diabetic subjects, non-HDL levels demonstrated a significant reduction between 
pre-treatment [4.2 (3.6-4.6) mmol/L] and 6 month [4.0 (3.2-4.6) mmol/L]. For levels 
of total cholesterol, non-diabetic subjects had significantly higher levels compared to 
subjects with T2DM, at each time point. Also, in non-diabetic patients, a reduction was 
demonstrated in cholesterol levels between pre-treatment [5.5 (5.0-6.1) mmol//L] and 
6 month [5.3 (4.9-6.0) mmol/L], although following the Bonferroni-Holm correction 
of p-values for multiple comparisons placed the critical p-value at 0.017, therefore, this 
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difference was detected as a trend (p=0.05) (Table 6.3 and Figure 6.7). For hsCRP 
levels, no significant differences between T2DM patients and non-diabetic patients 
were found at any time point. Also, in subjects with T2DM, hsCRP levels 
demonstrated a non-significant reduction between pre-treatment [2.1 (0.9-4.6) mg/L] 
and month 12 [1.5 (0.7-3.1) mg/L], which is a reduction of 0.6 mg/L. Similarly, in 
non-diabetic subjects hsCRP levels demonstrated a non-significant reduction between 
pre-treatment [2.3 (1.1-4.3) mg/L] and month 12 [1.6 (0.7-2.9) mg/L], which is a 
reduction of 0.7 mg/L, however both these reductions failed to reach statistical 
significance (Table 6.3 and Figure 6.8).  
Table 6.4 presents the number of subjects within each category of glycaemic 
control. It shows that at month 12 post-treatment, there was a reduction in the number 
subjects categorised as having good glycaemic control, a reduction in the number 
subjects categorised as having poor glycaemic control and an increase in the number of 
subjects categorised as having moderate glycaemic control. This would suggest that 
the apparent reduction in HbA1c levels seen in subjects with T2DM following NSM is 
not a result of drop out of subjects but is more likely due to actual improvements in 
glycaemic control. 
Following stratification of the data based on subjects’ initial level of glycaemic 
control, Table 6.5 summarises the HbA1c levels following NSM for patients with 
T2DM and periodontitis. In T2DM patients with poorer initial glycaemic control, as 
indicated by HbA1c ≥ 7.5%, there was a 1.9 % reduction in HbA1c levels from pre-
treatment [9.2 (8.3-10.2)%] to month 12 [7.3 (7.1-8.7)%], although, the reduction did 
not reach statistical significance. Figure 6.9 shows a line and scatter plot of HbA1c 
levels for individual subjects with T2DM and periodontitis at pre-treatment and month 
12, with the lines highlighting that for the majority of subjects, a reduction in % 
HbA1c was demonstrated over this time period. Figures 6.10 and 6.11 presents the 
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same data as line and scatter plots following stratification based on subjects’ initial 
level of glycaemic control. Interestingly, of those subjects with an initial HbA1c of 
7.5% or greater, the majority show a reduction in HbA1c at month 12. In contrast, 
subjects with an initial HbA1c of less that 7.5% show a less clear response in HbA1c 
at month 12, with HbA1c levels for some subjects increasing and some decreasing 
(Figures 6.10 and 6.11).  
 
   
Table 6.3  Clinical biochemistry data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-
Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data is non-parametric. 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
#
 indicates a comparison within rows between pre-treatment and month 3 within either T2DM or non-diabetic groups 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups 
 Pre-treatment Month 3 Month 6 Month 12  
 T2DM 
subjects 
(n=47) 
Non-diabetic 
subjects 
(n= 48) 
T2DM 
subjects 
(n=36) 
Non-diabetic 
subjects 
(n= 42) 
T2DM 
subjects 
(n=35) 
Non-diabetic 
subjects 
(n= 39) 
T2DM subjects 
(n=27) 
Non-diabetic 
subjects 
(n= 33) 
p-value 
 
HbA1c (%) 
 
7.5 (6.7-9.2)$ 
 
5.5 (5.3-5.7) 
 
7.05 (6.6-9.5)$ 
 
5.6 (5.4-5.7) 
 
7.6 (6.7-9.4)$ 
 
5.4 (5.4-5.7) 
 
7.1 (6.6-7.4)$ 
 
5.5 (5.4-5.7) 
 
$
 <0.001 
Triglycerides 
(mmol/L) 
2.5 (1.7-4.2)$ 1.7 (1.2-2.7) 2.4 (1.4-3.4)$ 1.6 (1.1-2.2) 2.3 (1.4-3.2) 1.6 (1.1-2.5) 2.0 (1.4-2.8)$ 1.5 (1.1-1.9) $ <0.05 
HDL (mmol/L) 1.1 (1.0-1.3)$ 1.4 (1.1-1.6) 1.1 (1.0-1.4)$ 1.5 (1.2-1.8) 1.2 (1.0-1.4)$ 1.4 (1.2-1.8) 1.1 (1.0-1.2)$ 1.4 (1.1-1.7) $<0.01 
Non-HDL 
(mmol/L) 
3.3 (2.8-3.9)$ 4.2 (3.6-4.6)¶ 2.9 (2.3-3.5)$ 4.0 (3.6-4.7) 3.1 (2.5-3.6)$ 4.0 (3.2-4.6) 2.7 (2.3-3.4)$ 4.1 (3.5-4.8) ¶<0.01, 
$<0.01 
Cholesterol 
(mmol/L) 
4.4 (4.0-5.3)$ 5.5 (5.0-6.1)¶ 4.0 (3.6-5.1)$ 5.5 (4.9-6.3) 4.4 (3.6-4.8)$ 5.3 (4.9-6.0) 3.9 (3.4-4.8)$ 5.5 (4.9-6.3) ¶<0.05, 
$<0.01 
Hs-CRP (mg/L) 2.1 (0.9-4.6) 2.3 (1.1-4.3) 2.0 (1.1-5.1) 1.8 (0.8-3.1) 2.0 (0.8-4.6) 1.7 (0.9-3.2) 1.5 (0.7-3.1) 1.6 (0.7-2.9) NS 
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Figure 6.3  HbA1c levels in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
 
Boxplots of HbA1c levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 n=27) 
and non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, month 
12 n=33). Statistics: Friedman test with Wilcoxon post hoc test  *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
 
 
 
 
§§§ 
§§§ 
§§§ 
§§§ 
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Figure 6.4  Triglyceride levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
 
Boxplots of triglyceride levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 n=27) and 
non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, month 12 
n=33). Statistics: Friedman test with Wilcoxon post hoc test  *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
  
§ 
§ 
§ 
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Figure 6.5  HDL levels in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
Boxplot of HDL levels pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 n=27) and non-
diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, month 12 n=33). 
Statistics: Friedman test with Wilcoxon post hoc test  *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
  
§§ 
§§ 
§§ §§ 
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Figure 6.6  Non-HDL levels in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
 
Boxplots of non-HDL levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 n=27) and 
non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, month 12 
n=33). Statistics: Friedman test with Wilcoxon post hoc test  *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
  
§§ 
§§ 
§§ §§ 
** 
6  Results 263
 
Figure 6.7  Total cholesterol levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
 
Boxplots of total cholesterol levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 
n=27) and non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, 
month 12 n=33). Statistics: Friedman test with Wilcoxon post hoc test  *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier 
more than 1.5 but less than 3 times the IQR from the box boundaries. 
 
  
* 
§§ §§ 
§§ 
§§ 
6  Results 264
 
Figure 6.8  HsCRP levels in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
 
Boxplots of hsCRP levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=47, month 3 n=36, month 6 n=35, month 12 n=27) and 
non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=39, month 12 
n=33). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
   
Table 6.4 Glycaemic control in T2DM subjects with periodontitis pre- and post NSM  
 Pre-treatment 
(n=47) 
 
Month 3 
(n=36) 
Month 6 
(n=35) 
Month 12 
(n=27) 
p-value 
 
Glycaemic control categories (n(%)) 
 
 
 
 
 
 
 
 
 
 
Good (<7.0%) 18 (38.3) 15 (41.7) 17 (48.6) 7 (25.9) 
NS Moderate (7.0-8.5%) 12 (25.5) 7 (19.4) 3 (8.6) 16 (59.3) 
Poor (>8.5%) 17 (36.2) 14 (38.9) 15 (42.9) 4 (14.8) 
Glycaemic control target met (≤6.5%) 
(n(%)) 
 
7 (14.9) 9 (25.0) 7 (20.0) 6 (22.2) NS 
P-values were determined using chi-squared test for discrete variable. 
 
  
   
Table 6.5  HbA1c in T2DM subjects pre- and post NSM categorised on initial HbA1c level 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-Whitney U 
test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data are non-parametric. Subjects with initial 
HbA1c≥ (pre-treatment n=24, month 3 n=17, month 6 n=18 and month 12 n=13) and initial HbA1c <7.5% (pre-treatment n=23, month 3 n=18, month 6 
n=16, and month 12 n=14) 
 
$
 indicates a comparison at a specific time point between rows   
#
 indicates a comparison between pre-treatment and month 3 within rows 
¶
 indicates a comparison between pre-treatment and month 6 within rows 
†
 indicates a comparison between pre-treatment and month 12 within 
 
Initial HbA1c 
 
Pre-treatment 
 
 
Month 3 
 
Month 6 
 
Month 12 
 
p-value 
 
>7.5% 
 
9.2 (8.3-10.2)$ 
 
9.5 (8.4-9.8)$ 
 
9.2 (7.8-9.9)$ 
 
7.3 (7.1-8.7) $ 
 
$ <0.01 
<7.5% 
 
6.7 (6.2-6.9) 6.8 (6.2-7.0) 6.8 (6.1-6.9) 6.7 (6.2-7.2)  
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Figure 6.9  HbA1c levels in individual subjects with periodontitis and T2DM 
pre-treatment and month 12 
Hb
A1
c 
(%
)
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6
8
10
12
14
16
 
Line and scatter plot of HbA1c levels for individual subjects with T2DM and 
periodontitis at pre-treatment (n=47) and month 12 (n=27). Lines highlight the 
direction of change of HbA1c. 
  
Month 12 Pre-treatment 
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Figure 6.10  HbA1c levels in individual subjects with periodontitis and T2DM 
pre-treatment and month 12 with initial HbA1c ≥7.5% 
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Line and scatter plots of HbA1c levels for individual subjects with T2DM and 
periodontitis and with initial HbA1c levels ≥7.5%: pre-treatment (n=24) and month 12 
(n=13). Lines highlight the direction of change of HbA1c. 
Figure 6.11  HbA1c levels in individual subjects with periodontitis and T2DM 
pre-treatment and month 12 with initial HbA1c <7.5% 
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Line and scatter plots of HbA1c levels for individual subjects with T2DM and 
periodontitis and with initial HbA1c levels <7.5%: pre-treatment (n=23) and month 12 
(n=14). Lines highlight the direction of change of HbA1c. 
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6.2.3 Changes in clinical periodontal data following non-surgical 
periodontal management 
Table 6.6 and Figures 6.12 to 6.20 summarises the clinical periodontal data 
following non-surgical periodontal management for patients with T2DM and 
periodontitis and non-diabetic patients with periodontitis.  
When considering the % of sites exhibiting BOP, no significant differences in 
% BOP were found between subjects with T2DM and non-diabetic subjects at any 
time point. Also, in subjects with T2DM, compared to pre-treatment levels [46.0 (30.0-
60.7)%], % BOP showed significant reductions following NSM at 3 months [18.5 
(8.8-38.0)%], 6 months [15.3 (8.3-39.6)%] and 12 months [17.6 (6.5-28.4)%]. 
Similarly, in non-diabetic subjects, compared to pre-treatment levels [43.0 (29.4-
56.7)%], % BOP showed significant reductions following NSM at 3 months [14.5 
(10.3-27.0)%], 6 months [14.7 (7.2-25.0)%] and 12 months [10.0 (5.1-24.2)%] (Table 
6.6 and Figure 6.12).  
For gingival inflammation, no significant differences in mGI were found 
between subjects with T2DM and non-diabetic subjects at any time point. Also, in 
subjects with T2DM, compared to pre-treatment levels [2.0 (1.5-2.7)], mGI showed 
significant reductions following NSM at 3 months [1.4 (0.7-2.0)], 6 months [1.5 (0.9-
2.0)] and 12 months [1.3 (0.8-1.7)]. Similarly, in non-diabetic subjects, compared to 
pre-treatment levels [2.4 (2.0-2.7)], mGI showed significant reductions following 
NSM at 3 months [1.6 (0.9-2.2)], 6 months [1.5 (0.7-2.0)] and 12 months [1.4 (0.9-
2.3)] (Table 6.6 and Figure 6.13). 
When considering plaque levels, subjects with T2DM had significantly higher 
PI at pre-treatment [0.8 (0.5-1.1)], month 3 [0.5 (0.3-0.7)], month 6 [0.6 (0.3-0.8)] and 
month 12 [0.5 (0.3-0.7)] compared to non-diabetic subjects at pre-treatment [0.6 (0.4-
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0.8)], month 3 [0.3 (0.1-0.6)], month 6 [0.3 (0.1-0.6)] and month 12 [0.4 (0.2-0.8)]. 
When the impact of the pre-treatment difference between subjects with T2DM and 
non-diabetic subjects was taken into account, the differences found between subjects 
with T2DM and non-diabetic subjects at month 3, month 6 and month 12 failed to 
reach significance. In subjects withT2DM, compared to pre-treatment levels [0.8 (0.5-
1.1)], PI showed significant reductions following NSM at 3 months [0.5 (0.3-0.7)], 6 
months [0.6 (0.3-0.8)] and 12 months [0.5 (0.3-0.7)]. Similarly, in non-diabetic 
subjects, compared to pre-treatment levels [0.6 (0.4-0.8)], PI showed significant 
reductions following NSM at 3 months [0.3 (0.1-0.6)], 6 months [0.3 (0.1-0.6)] and 12 
months [0.4 (0.2-0.8)] (Table 6.6 and Figure 6.14). 
For mean PD, no significant differences were found between subjects with 
T2DM and non-diabetic subjects at any time point. In subjects withT2DM, compared 
to pre-treatment levels [2.8 (2.4-3.2) mm], mean PD showed significant reductions 
following NSM at 3 months [2.4 (2.2-2.9) mm], 6 months [2.2 (2.0-2.7) mm] and 12 
months [2.2 (1.9-2.8) mm]. Similarly, in non-diabetic subjects, compared to pre-
treatment levels [2.9 (2.5-3.5) mm], mean PD showed significant reductions following 
NSM at 3 months [2.6 (2.2-2.9) mm], 6 months [2.5 (2.1-2.9) mm] and 12 months [2.3 
(1.9-2.7) mm] (Table 6.6 and Figure 6.15). 
For mean LOA, no significant differences were found between subjects with 
T2DM and non-diabetic subjects at any time point. In subjects withT2DM, compared 
to pre-treatment levels [3.1 (2.8-3.9) mm], mean LOA showed significant reductions 
following NSM at 3 months [3.0 (2.6-3.6) mm], 6 months [2.8 (2.4-3.7) mm] and 12 
months [2.8 (2.4-3.6) mm]. Similarly, in non-diabetic subjects, compared to pre-
treatment levels [3.4 (2.9-4.2) mm], mean LOA showed significant reductions 
following NSM at 3 months [3.3 (2.8-3.9) mm], 6 months [3.1 (2.6-4.1) mm] and 12 
months [3.1 (2.5-3.7) mm] (Table 6.6). 
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For the % of PD sites ≥ 5 mm, at pre-treatment, despite the apparent higher % 
of PD sites ≥ 5 mm recorded in non-diabetic subjects [16.0 (8.0-30.8)%] compared to 
subjects with T2DM [10.9 (8.1-18.2)%], the difference failed to reach statistical 
significance. After treatment, the % of PD sites ≥ 5 mm were significantly higher in 
non-diabetic subjects at month 3 [10.1 (5.8)%] and month 6 [9.0 (3.2-19.5)%] 
compared to subjects with T2DM at month 3[5.3 (1.8-9.9)%] and month 6 [5.3 (1.9-
9.7)%]. When the impact of the pre-treatment difference between subjects with T2DM 
and non-diabetic subjects was taken into account, the differences found between 
subjects with T2DM and non-diabetic subjects at month 3 and month 6 failed to reach 
significance. In subjects with T2DM, compared to pre-treatment levels [10.9 (8.1-
18.2)%], % of PD sites ≥5mm showed significant reductions following NSM at 3 
months [5.3 (1.8-9.9)%], 6 months [5.3 (1.9-9.7)%] and 12 months [3.0 (0.9-8.9)%]. 
Similarly, in non-diabetic subjects, compared to pre-treatment levels [16.0 (8.0-
30.8)%], % of PD sites ≥5mm showed significant reductions following NSM at 3 
months [10.1 (5.8-19.0)%], 6 months [9.0 (3.2-19.5)%] and 12 months [3.2 (1.3-
13.4)%] (Table 6.6 and Figure 6.16).  
When considering periodontal surface area, pre-treatment PESA was 
significantly higher in non-diabetic subjects [1711.0 (1439.4-2096.5) mm2] compared 
to subjects with T2DM [1401.5 (1144.3-1733.7) mm2]. At month 3, 6 and 12, non-
diabetic subjects had apparently higher PESA compared to non-diabetic subjects, 
however the differences failed to reach statistical significance. In subjects withT2DM, 
compared to pre-treatment levels [1401.5 (1144.3-1733.7) mm2 ], PESA showed 
significant reductions following NSM at 3 months [1238.2 (1092.4-1543.9) mm2], 6 
months [1159.7 (1010.1-509.0) mm2] and 12 months [1181.3 (930.3-1374.7) mm2 ]. 
Similarly, in non-diabetic subjects, compared to pre-treatment levels [1711.0 (1439.4-
2096.5) mm2], PESA showed significant reductions following NSM at 3 months 
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[1464.2 (1192.0-1686.2) mm2], 6 months [1402.9 (1139.8-1698.3) mm2] and 12 
months [1260.2 (983.7-1566.8) mm2] (Table 6.6 and Figure 6.17). 
For PISA, no significant differences were found between subjects with T2DM 
and non-diabetic subjects at any time point. In subjects withT2DM, compared to pre-
treatment levels [683.0 (439.1-1085.5) mm2], PISA showed significant reductions 
following NSM at 3 months [339.0 (145.4-688.3) mm2], 6 months [340.1 (101.0-
628.1) mm2 ] and 12 months [216.5 (87.1-539.4) mm2]. Similarly, in non-diabetic 
subjects, compared to pre-treatment levels [897.3 (683.6-1232.9) mm2], PISA showed 
significant reductions following NSM at 3 months [299.4 (159.5-536.5) mm2], 6 
months [262.6 (89.0-514.8) mm2] and 12 months [215.1 (62.5-520.3) mm2] (Table 6.6 
and Figure 6.18). 
Table 6.7 and Figures 6.19 and 6.20 summarises the % of sites displaying a 
reduction in PD or LOA for patients with T2DM and periodontitis and non-diabetic 
patients with periodontitis. When considering the % of sites demonstrating a reduction 
in PD of ≥ 2 mm during the 0 to 3 month period, no significant differences were found 
when comparing subjects with T2DM [11.0 (5.3-17.2)%] and non-diabetic subjects 
[12.3 (8.3-20.8)%]. Similarly, during the 0 to 6 month period, no significant 
differences were found in the number of sites demonstrating a reduction in PD of 
≥2mm when comparing subjects with T2DM [12.2 (9.3-19.1)%] and non-diabetic 
subjects [14.0 (9.3-19.4)%]. Likewise, during the 0 to 12 month period, no significant 
differences were found in the % of sites demonstrating a reduction in PD of ≥ 2 mm 
when comparing subjects with T2DM [13.6 (10.5-24.0)%] and non-diabetic subjects 
[18.0 (10.2-23.2)%] (Table 6.7 and Figure 6.19). 
When considering the % of sites demonstrating a reduction in PD of ≥ 3 mm 
during the 0 to 3 month period, no significant differences were found when comparing 
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subjects with T2DM [3.3 (1.0-6.6)%] and non-diabetic subjects [4.3 (2.4-8.3)%]. 
Similarly, during the 0 to 6 month period, no significant differences were found in the 
% of sites demonstrating a reduction in PD of ≥ 3 mm when comparing subjects with 
T2DM [4.7 (2.8-8.3)%] and non-diabetic subjects [5.1 (2.9-10.4)%]. Likewise, during 
the 0 to 12 month period, no significant differences were found in the % of sites 
demonstrating a reduction in PD of ≥ 3 mm when comparing subjects with T2DM [6.6 
(2.7-11.4)%] and non-diabetic subjects [6.0 (3.8-11.7)%] (Table 6.7 and Figure 6.20). 
 
 
 
   
Table 6.6  Clinical periodontal data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
 
 
 
Pre-treatment 
 
 
Month 3 
 
Month 6 
 
Month 12 
 
 T2DM subjects 
(n=47) 
Non-diabetic 
subjects 
(n= 48) 
T2DM subjects 
(n=37) 
Non-diabetic 
subjects 
(n= 42) 
T2DM 
subjects 
(n=35) 
Non-diabetic 
subjects 
(n= 40) 
T2DM subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 37) 
p-value 
BOP (%) 46.0 (30.0-
60.7)#,¶,† 
43.0 (29.4-
56.7)#,¶,† 
18.5 (8.8-38.0) 14.5 (10.3-
27.0) 
15.3 (8.3-39.6) 14.7 (7.2-
25.0) 
17.6 (6.5-28.4) 10.0 (5.1-24.2) #,¶,†<0.001 
mGI 2.0 (1.5-2.7)#,¶,† 2.4 (2.0-2.7)#,¶,† 1.4 (0.7-2.0) 1.6 (0.9-2.2) 1.5 (0.9-2.0) 1.5 (0.7-2.0) 1.3 (0.8-1.7) 1.4 (0.9-2.3) #,¶,†<0.001 
PI 0.8 (0.6-
1.1)#,¶,†,$ 
0.6 (0.4-0.8)#,¶,† 0.5 (0.3-0.7)$ 0.3 (0.1-0.6) 0.6 (0.3-0.8)$ 0.3 (0.1-0.6) 0.5 (0.3-0.7)$ 0.4 (0.2-0.8) #,¶<0.001 
†,$<0.05 
Mean PD (mm) 2.8 (2.4-3.2)#,¶,† 2.9 (2.5-3.5)#,¶,† 2.4 (2.2-2.9) 2.6 (2.2-2.9) 2.2 (2.0-2.7) 2.5 (2.1-2.9) 2.2 (1.9-2.8) 2.3 (1.9-2.7) #,¶,†<0.001 
Mean recession 
(mm) 
0.4 (0.3-0.7)#,¶,† 0.4 (0.2-0.9)#,¶,† 0.7 (0.4-0.8) 0.6 (0.3-1.0) 0.5 (0.4-0.8) 0.6 (0.3-1.0) 0.6 (0.4-0.9) 0.7 (0.4-1.2) #,¶,†<0.001 
Mean LOA 
(mm) 
3.1 (2.8-3.9)#,¶,† 3.4 (2.9-4.2)#,¶,† 3.0 (2.6-3.6) 3.3 (2.8-3.9) 2.8 (2.4-3.7) 3.1 (2.6-4.1) 2.8 (2.4-3.6) 3.1 (2.5-3.7) #,¶,†<0.001 
 
         
% PD sites 
≥5mm 
10.9 (8.1-
18.2)#,¶,† 
16.0 (8.0-
30.8)#,¶,† 
 
5.3 (1.8-9.9)$ 10.1 (5.8-
19.0) 
5.3 (1.9-9.7)$ 9.0 (3.2-19.5) 3.0 (0.9-8.9) 3.2 (1.3-13.4) #,¶,†<0.001 
 
       
Continued on next page 
   
 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-
Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data were non-parametric. 
 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
#
 indicates a comparison within rows between pre-treatment and month 3 within either T2DM or non-diabetic groups 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups 
  
Continued from previous page 
       
 
  
Pre-treatment 
 
 
 
Month 3 
 
 
 
Month 6 
 
 
 
Month 12 
 
 
 T2DM subjects 
(n=47) 
Non-diabetic 
subjects 
(n= 48) 
T2DM subjects 
(n=37) 
Non-diabetic 
subjects 
(n= 42) 
T2DM 
subjects 
(n=35) 
T2DM 
subjects 
(n=47) 
T2DM subjects 
(n=29) 
Non-diabetic 
subjects 
(n= 37) 
p value 
 
        
 
 
         
PESA (mm2) 1401.5 (1144.3-
1733.7)#,¶,† 
1711.0 (1439.4-
2096.5)#,¶,†,$ 
1238.2 (1092.4-
1543.9) 
1464.2 
(1192.0-
1686.2) 
1159.7 
(1010.1-509.0) 
1402.9 
(1139.8-
1698.3) 
1181.3 (930.3-
1374.7) 
1260.2 (983.7-
1566.8) 
#,¶,†<0.001 
$<0.01 
PISA (mm2) 683.0 (439.1-
1085.5)#,¶,† 
897.3 (683.6-
1232.9)#,¶,† 
339.0 (145.4-
688.3) 
299.4 (159.5-
536.5) 
340.1 (101.0-
628.1) 
262.6 (89.0-
514.8) 
216.5 (87.1-
539.4) 
215.1 (62.5-
520.3) 
 
#,¶,†<0.001 
 
   
       Table 6.7  The change in PD and LOA after NSM for both T2DM and non-diabetic subjects 
 0-3 months 0-6 months 0-12 months  
 T2DM subjects 
(n=36) 
Non-diabetic 
subjects 
(n= 41) 
T2DM subjects 
(n=35) 
Non-diabetic 
subjects 
(n= 40) 
T2DM subjects 
(n=28) 
Non-diabetic 
subjects 
(n= 37) 
p value 
 
       
% PD sites reduced ≥2mm 11.0 (5.3-17.2) 12.3 (8.3-20.8) 12.2 (9.3-19.1) 14.0 (9.3-19.4) 13.6 (10.5-24.0) 18.0 (10.2-23.2) NS 
% PD sites reduced ≥3mm 3.3 (1.0-6.6) 4.3 (2.4-8.3) 4.7 (2.8-8.3) 5.1 (2.9-10.4) 6.6 (2.7-11.4) 6.0 (3.8-11.7) NS 
% LOA sites reduced ≥2mm 11.1 (8.3-14.6) 11.7 (8.3-17.8) 13.8 (9.7-19.5) 12.6 (8.7-17.9) 15.5 (9.3-22.2) 14.2 (10.6-19.7) NS 
% LOA sites reduced ≥3mm 3.3 (0.8-5.6) 4.2 (2.4-7.8) 4.9 (1.9-6.8) 5.1 (2.6-9.4) 5.3 (1.9-8.3) 5.6 (2.9-8.3) NS 
        
 
P-values were determined using Mann-Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented 
as all the data were non-parametric. $ indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
  
6  Results 277
Figure 6.12  BOP in subjects with periodontitis pre- and post NSM for both 
T2DM and non-diabetic subjects  
 
 
 
Boxplots of % of sites showing BOP pre- and post NSM in subjects with periodontitis 
in both T2DM subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 
n=29) and non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, 
month 12 n=37). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier 
more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
*** 
*** 
*** 
*** 
*** 
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Figure 6.13 mGI in subjects with periodontitis pre- and post NSM for both 
T2DM and non-diabetic subjects  
 
 
Boxplots of mGI pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 n=29) and non-
diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, month 12 n=37). 
Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
*** 
*** 
*** 
*** 
*** 
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Figure 6.14  PI in subjects with periodontitis pre- and post NSM for both T2DM 
and non-diabetic subjects  
 
 
 
Boxplots of PI pre- and post NSM in subjects with periodontitis in both T2DM subjects 
(pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 n=29) and non-diabetic 
subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, month 12 n=37). Statistics: 
Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, ***p<0.001(according to 
time within T2DM or non-diabetic group); Mann-Whitney U test § p<0.05, §§ p<0.01, 
§§§p<0.001 (T2DM versus non-diabetic groups at each time point). ○ outlier more than 3 
times the IQR from the box boundaries, ● outlier more than 1.5 but less than 3 times the 
IQR from the box boundaries. 
  
*** 
*** 
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*** 
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Figure 6.15  Mean PD in subjects with periodontitis pre- and post NSM for both 
T2DM and non-diabetic subjects  
 
 
 
Boxplots of mean PD pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 n=29) and non-
diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, month 12 n=37). 
Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
*** 
*** 
*** 
*** 
*** 
*** 
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Figure 6.16  % of PD sites ≥5mm in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
 
 
Boxplots of % of PD sites ≥5mm pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 
n=29) and non-diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, 
month 12 n=37). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier 
more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
*** 
*** 
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*** 
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Figure 6.17  Mean PESA in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
 
Boxplots of PESA pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 n=29) and non-
diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, month 12 n=37). 
Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
*** 
*** 
*** 
*** 
*** 
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Figure 6.18  Mean PISA in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
 
Boxplots of PISA pre- and post NSM in subjects with periodontitis in both T2DM 
subjects (pre-treatment n=47, month 3 n=37, month 6 n=35, month 12 n=29) and non-
diabetic subjects (pre-treatment n=48, month 3 n=42, month 6 n=40, month 12 n=37). 
Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
*** 
*** 
*** 
*** 
*** 
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Figure 6.19  % of PD sites showing ≥ 2 mm reduction in subjects with 
periodontitis pre- and post NSM for both T2DM and non-diabetic 
subjects  
 
Boxplots of % of PD sites showing ≥ 2 mm reduction pre- and post NSM in subjects 
with periodontitis in both T2DM subjects (0-3 months n=36, 0-6 months n=35, 0-12 
months n=37) and non-diabetic subjects (0-3months n=41, 0-6 months n=40, 0-12 
months n=40). Statistics: Mann-Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM 
versus non-diabetic groups at each time point). ○ outlier more than 3 times the IQR 
from the box boundaries, ● outlier more than 1.5 but less than 3 times the IQR from the 
box boundaries. 
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Figure 6.20  % of PD sites showing ≥ 3 mm reduction in subjects with 
periodontitis pre- and post NSM for both T2DM and non-diabetic 
subjects  
 
Boxplots of % of PD sites showing ≥ 3 mm reduction pre- and post NSM in subjects 
with periodontitis in both T2DM subjects (0-3 months n=36, 0-6 months n=35, 0-12 
months n=37) and non-diabetic subjects (0-3months n=41, 0-6 months n=40, 0-12 
months n=40). Statistics: Mann-Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM 
versus non-diabetic groups at each time point). ○ outlier more than 3 times the IQR 
from the box boundaries, ● outlier more than 1.5 but less than 3 times the IQR from the 
box boundaries. 
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6.2.4 Changes in local and systemic cytokine data following non-
surgical periodontal management 
6.2.4.1 Serum cytokine data 
Table 6.8 and Figures 6.21 to 6.24 summarise the serum cytokine data following 
non-surgical periodontal management for patients with T2DM and periodontitis and 
non-diabetic patients with periodontitis.  
When considering levels of IL-6 in serum, no significant differences were found 
between subjects with T2DM and non-diabetic subjects at pre-treatment, month 3 or 
month 6. At month 12, subjects with T2DM had significantly higher levels of serum IL-
6 [0.91 (0.53-1.56) pg/ml] compared to non-diabetic subjects [0.61 (0.41-1.96) pg/ml]. 
Also, in subjects with T2DM and in non-diabetic subjects, no significant changes in 
serum IL-6 levels were demonstrated following NSM at any time-point. Furthermore, 
serum levels of IL-6 remained consistently around the lower limits of detection for the 
assay used (Table 6.8 and Figure 6.21).  
With regards to serum TNF-α, pre-treatment levels were significantly higher in 
subjects with T2DM [7.10 (3.25-9.30) pg/ml] compared to non-diabetic subjects [3.44 
(2.34-7.24) pg/ml]. However, at month 3 and 6, this situation reversed, with 
significantly higher levels of serum TNF-α levels in the non-diabetic subjects [6.43 
(3.16-9.13) pg/ml and 7.06 (5.59-8.79) pg/ml] compared to the subjects withT2DM 
[3.70 (2.21-6.72) pg/ml and 3.86 (2.15-7.33) pg/ml]. At month 12, No significant 
differences in serum TNF-α levels were found between subjects with T2DM and non-
diabetic subjects.  In subjects withT2DM, compared to pre-treatment levels [7.10 (3.25-
9.30) pg/ml], serum TNF-α levels, showed significant reductions following NSM at 3 
months [3.70 (2.21-6.72) pg/ml] and 6 months [3.86 (2.15-7.33) pg/ml], with a non-
significant increase being noted at month 12 [8.03 (5.28-9.62) pg/ml]. In non-diabetic 
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subjects, compared to pre-treatment levels [3.44 (2.34-7.24) pg/ml], serum TNF-α 
levels, showed significant increases following NSM at 6 months [7.06 (5.59-8.79) 
pg/ml] and 12 months [7.70 (6.71-10.20) pg/ml] (Table 6.8 and Figure 6.22). 
For levels of IL-1β in serum, no significant differences were found between 
subjects with T2DM and non-diabetic subjects at month 3 or month 6. However, pre-
treatment and at month 12, subjects with T2DM had significantly higher levels of serum 
IL-1β compared to non-diabetic subjects. In subjects withT2DM, compared to pre-
treatment levels [0.08 (0.00-0.34) pg/ml], serum IL-1β levels showed significant 
reductions following NSM at 3 months [0.00 (0.00-1.15) pg/ml], 6 months [0.00 (0.00-
0.13) pg/ml] and month 12 [0.04 (0.00-0.15) pg/ml]. In non-diabetic subjects, compared 
to pre-treatment levels, no changes in serum IL-1β was demonstrated at 6 and 12 
months. At month 3 [0.03 (0.00-0.09) pg/ml] an increase was found in IL-1β levels 
compared to pre-treatment levels [0.00 (0.00-0.05) pg/ml], however, the Bonferroni-
Holm correction of p-values for multiple comparisons placed the critical p-value at 
0.017, therefore, this difference was reported as a trend (p=0.027). Furthermore, serum 
levels of IL-1β remained consistently around the lower limits of detection for the assay 
used (Table 6.8 and Figure 6.23). 
For levels of IFN-γ in serum, no significant differences were found between 
subjects with T2DM and non-diabetic subjects at pre-treatment, month 3, month 6 and 
month 12. Also, in subjects with T2DM and in non-diabetic subjects, no significant 
changes in serum IFN-γ levels were seen following NSM at any time-point. 
Furthermore, serum levels of IFN-γ remained consistently around the lower limits of 
detection for the assay used (Table 6.8 and Figure 6.24).  
   
Table 6.8  Serum cytokine data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-
Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data were non-parametric. 
 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
#
 indicates a comparison within rows between pre-treatment and month 3 within either T2DM or non-diabetic groups 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups
 
 
 
Pre-treatment 
 
 
Month 3 
 
Month 6 
 
                  Month 12      
 T2DM 
subjects 
(n=46) 
Non-diabetic 
subjects 
(n= 45) 
T2DM 
subjects 
(n=32) 
Non-diabetic 
subjects 
(n= 38) 
T2DM 
subjects 
(n=30) 
Non-diabetic 
subjects 
(n= 38) 
T2DM 
subjects 
(n=26) 
Non-diabetic 
subjects 
(n= 34) 
p-value 
 
Serum IL-6 
(pg/ml) 
 
0.51 (0.34-
1.50) 
 
0.59 (0.32-
0.93) 
 
0.50 (0.33-
1.24) 
 
0.81 (0.41-
1.24) 
 
0.47 (0.29-
1.31) 
 
0.55 (0.35-
0.95) 
 
0.91 (0.53-
1.56)$ 
 
0.61 (0.41-
1.96) 
 
$<0.05 
 Serum TNF-α 
(pg/ml)  
7.10 (3.25-
9.30)#,¶,$ 
3.44 (2.34-
7.24)¶,† 
3.70 (2.21-
6.72)$ 
6.43 (3.16-
9.13) 
3.86 (2.15-
7.33)$ 
7.06 (5.59-
8.79) 
8.03 (5.28-
9.62) 
7.70 (6.71-
10.20) 
#,¶,$<0.05 
†<0.001 
Serum IL-1β 
(pg/ml) 
0.08 (0.00-
0.34)#,¶,†,$ 
0.00 (0.00-
0.05) 
0.00 (0.00-
1.15) 
0.03 (0.00-
0.09) 
0.00 (0.00-
0.13) 
0.00 (0.00-
0.07) 
0.04 (0.00-
0.15)$ 
0.00 (0.00-
0.00) 
#,¶,†<0.05 
$<0.001 
Serum IFN-γ 
(pg/ml) 
1.09 (0.56-
2.50)$ 
0.57 (0.26-
1.33) 
0.74 (0.39-
1.44) 
1.07 (0.27-
1.81) 
0.90 (0.19-
1.50) 
1.11 (0.33-
1.57) 
1.08 (0.83-
1.44) 
1.11 (0.65-
1.63) 
$<0.01 
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Figure 6.21  Serum IL-6 levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
 
Boxplots of serum IL-6 levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=46, month 3 n=32, month 6 n=30, month 12 n=26) 
and non-diabetic subjects (pre-treatment n=45, month 3 n=38, month 6 n=38, month 
12 n=34). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$ 
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Figure 6.22  Serum TNF-α levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects 
  
 
Boxplots of serum TNF-α levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=46, month 3 n=32, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=45, month 3 n=38, month 6 n=38, 
month 12 n=34). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$ 
$ 
$ 
* 
*** 
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Figure 6.23  Serum IL-1β levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
 
Boxplots of serum IL-1β levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=46, month 3 n=32, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=45, month 3 n=38, month 6 n=38, 
month 12 n=34). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
* 
* 
* 
$$$ 
$$$ 
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Serum 6.24  Serum IFN-γ levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
 
Boxplots of serum INF-γ levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=46, month 3 n=32, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=45, month 3 n=38, month 6 n=38, 
month 12 n=34). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries.
$$ 
6  Results 293
6.2.4.2 Saliva cytokine data 
Table 6.9 and Figures 6.28 to 6.28 summarise the saliva cytokine data following 
non-surgical periodontal management for patients with T2DM and periodontitis and 
non-diabetic patients with periodontitis.  
When considering Il-6 levels in saliva, no significant differences were found 
between T2DM and non-diabetic subjects, except at month 3, when non-diabetic 
subjects [1.96 (1.17-8.07) pg/ml] had significantly higher levels of IL-6 in saliva 
compared to subjects with T2DM [0.90 (0.43-3.79) pg/ml]. In subjects with T2DM, 
compared to pre-treatment levels, no changes in saliva IL-6 were demonstrated at 6 and 
12 months. In subjects with T2DM, at month 12 [4.06 (1.62-6.96) pg/ml] an apparent 
increase was found in IL-6 levels compared to pre-treatment levels [2.29 (1.27-4.83) 
pg/ml], however, the Bonferroni-Holm correction of p-values for multiple comparisons 
placed the critical p-value at 0.017, therefore, this difference was reported as a trend 
(p=0.04). In non-diabetic subjects, no significant changes in serum IL-6 levels were 
demonstrated following NSM at any time-point (Table 6.9 and Figure 6.25). 
With regards to saliva TNF-α, pre-treatment and month 3 levels were 
significantly higher in non-diabetic subjects [2.59 (1.18-3.97) pg/ml and 2.58 (1.62-
4.52) pg/ml] compared to subjects with T2DM [1.58 (0.61-3.08) pg/ml and 0.66 (0.26-
1.53) pg/ml]. At month 6 and month 12, no differences in saliva TNF-α levels were 
found between T2DM and non-diabetic subjects. In subjects withT2DM, compared to 
pre-treatment levels [1.58 (0.61-3.08) pg/ml], saliva TNF-α levels showed significant 
reductions following NSM at 3 months [0.66 (0.26-1.53) pg/ml], however conversely a 
significant increase was noted at month 12 [2.88 (1.25-4.32) pg/ml]. Similarly, in non-
diabetic subjects, compared to pre-treatment levels [2.59 (1.18-3.97) pg/ml], saliva 
TNF-α levels, showed a reduction at month 6 [1.59 (1.00-3.83) pg/ml], however, this 
change failed to reach statistical significance (Table 6.9 and Figure 6.26). 
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 With regards to saliva IL-1β, pre-treatment and month 3 levels were 
significantly higher in non-diabetic subjects [62.60 (39.20-97.10) pg/ml and 55.75 
(21.03-96.15) pg/ml] compared to T2DM subjects [38.65 (20.45-68.28) pg/ml and 
19.00 (6.96-50.55) pg/ml]. For T2DM subjects, compared to pre-treatment levels 
[38.65(20.45-68.28)], saliva IL-1β showed a reduction at month 3 [19.00 (6.96-50.55) 
pg/ml], however, the Bonferroni-Holm correction of p-values for multiple comparisons 
placed the critical p-value at 0.017, therefore, this difference was reported as a trend 
(p=0.043). In non-diabetic subjects, compared to pre-treatment levels [62.60 (39.20-
97.10) pg/ml], saliva IL-1β showed apparent reductions at month 3[55.75 (21.03-96.15) 
pg/ml], month 6 [38.55 (21.43-67.80) pg/ml] and month 12 [48.20 (27.10-86.20) 
pg/ml], although these differences failed to reach statistical significance. (Table 6.9 and 
figure 6.27). 
 For saliva IFN-γ, pre-treatment and month 3 levels, were significantly higher in 
non-diabetic subjects [1.55 (0.86-2.24) pg/ml and 1.26 (0.86-1.85) pg/ml] compared to 
subjects with T2DM [0.86 (0.47-1.60) pg/ml and 0.43 (0.25-0.78) pg/ml]. In subjects 
with T2DM, compared to pre-treatment [0.86 (0.47-1.60) pg/ml], saliva IFN-γ levels 
were significantly reduced at 3 months [0.43 (0.25-0.78) pg/ml], however conversely a 
significant increase was noted at month 12 [1.61 (1.03-2.69) pg/ml]. For non-diabetic 
subjects, compared to pre-treatment [1.55 (0.86-2.24) pg/ml], saliva IFN-γ levels were 
reduced at 6 months [0.83 (0.42-1.88) pg/ml], however, the Bonferroni-Holm correction 
of p-values for multiple comparisons placed the critical p-value at 0.017, therefore, this 
difference was reported as a trend (p=0.04) (Table 6.9 and Figure 6.28).
   
Table 6.9  Saliva cytokine data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-
Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data were non-parametric. 
 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
#
 indicates a comparison within rows between pre-treatment and month 3 within either T2DM or non-diabetic groups 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups 
 
 
 
Pre-treatment 
 
 
Month 3 
 
Month 6 
 
Month 12 
 
 T2DM 
subjects 
(n=48) 
Non-diabetic 
subjects 
(n= 43) 
T2DM 
subjects 
(n=33) 
Non-diabetic 
subjects 
(n= 39) 
T2DM 
subjects 
(n=30) 
Non-diabetic 
subjects 
(n= 38) 
T2DM 
subjects 
(n=26) 
Non-diabetic 
subjects 
(n= 35) 
p-value 
 
Saliva IL-6 
(pg/ml) 
 
2.29 (1.27-
4.83) 
 
2.41 (0.95-
7.29) 
 
0.90 (0.43-
3.79)$ 
 
1.96 (1.17-
8.07) 
 
1.59 (0.87-
4.35) 
 
1.48 (0.79-
3.21) 
 
4.06 (1.62-
6.96) 
 
1.68 (1.13-
3.42) 
 
$<0.05 
 Saliva TNF-
α (pg/ml) 
1.58 (0.61-
3.08)#,†,$ 
2.59 (1.18-
3.97) 
0.66 (0.26-
1.53)$ 
2.58 (1.62-
4.52) 
1.45 (0.93-
2.36) 
1.59 (1.00-
3.83) 
2.88 (1.25-
4.32) 
2.73 (1.41-
3.54) 
#,†,$<0.05 
Saliva IL-1β 
(pg/ml)  
38.65 (20.45-
68.28)$ 
62.60 (39.20-
97.10) 
19.00 (6.96-
50.55)$ 
55.75 (21.03-
96.15) 
32.45 (14.28-
88.40) 
38.55 (21.43-
67.80) 
64.60 (26.88-
121.50) 
48.20 (27.10-
86.20) 
$<0.05 
Saliva IFN-γ 
(pg/ml) 
 
0.86 (0.47-
1.60)#,†,$ 
1.55 (0.86-
2.24) 
0.43 (0.25-
0.78)$ 
1.26 (0.86-
1.85) 
0.88 (0.56-
1.64) 
0.83 (0.42-
1.88) 
1.61 (1.03-
2.69) 
1.30 (0.80-
1.96) 
†<0.001 
$,#<0.01 
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Figure 6.25  Saliva IL-6 levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
Boxplots of saliva IL-6 levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=48, month 3 n=33, month 6 n=30, month 12 n=26) 
and non-diabetic subjects (pre-treatment n=43, month 3 n=39, month 6 n=38, month 
12 n=35). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$ 
6  Results 297
Figure 6.26  Saliva TNF-α levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
 
Boxplots of saliva TNF-α levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=48, month 3 n=33, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=43, month 3 n=39, month 6 n=38, 
month 12 n=35). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$ 
$ 
* 
* 
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Figures 6.27  Saliva IL-1β levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
Boxplots of saliva IL-1β levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=48, month 3 n=33, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=43, month 3 n=39, month 6 n=38, 
month 12 n=35). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$ 
$ 
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Figure 6.28  Saliva IFN-γ levels in subjects with periodontitis pre- and post 
NSM for both T2DM and non-diabetic subjects  
 
Boxplots of saliva IFN-γ levels pre- and post NSM in subjects with periodontitis in 
both T2DM subjects (pre-treatment n=48, month 3 n=33, month 6 n=30, month 12 
n=26) and non-diabetic subjects (pre-treatment n=43, month 3 n=39, month 6 n=38, 
month 12 n=35). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, 
**p<0.01, ***p<0.001(according to time within T2DM or non-diabetic group); Mann-
Whitney U test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at 
each time point). ○ outlier more than 3 times the IQR from the box boundaries, ● 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries.
** 
*** 
$$ 
$$ 
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6.2.4.3 GCF cytokine data 
Table 6.10 and Figures 6.29 to 6.32 summarise the GCF cytokine data following 
non-surgical periodontal management for patients with T2DM and periodontitis and 
non-diabetic patients with periodontitis.  
When considering IL-6 levels in GCF, no significant differences were found 
between T2DM and non-diabetic subjects, except at month 6, when non-diabetic 
subjects [1.51 (0.94-2.34) pg/ml] had significantly higher levels of IL-6 in GCF 
compared to subjects with T2DM [0.89 (0.14-1.80) pg/ml]. In subjects with T2DM, 
compared to pre-treatment levels [1.97 (0.98-5.17) pg/ml], IL-6 in GCF showed 
significant reductions at month 3 [1.03 (0.51-2.70) pg/ml], month 6 [0.89(0.14-1.80)] 
and month 12 [1.03 (0.34-2.17) pg/ml]. In non-diabetic subjects, compared to pre-
treatment levels [2.25(1.12-3.37)] IL-6 in GCF showed significant reductions at month 
6 [1.51 (0.94-2.34) pg/ml] and non-significant reductions was also seen at month 3 
[1.96 (0.93-3.32) pg/ml] and month 12 [1.28 (0.56-3.77) pg/ml] (Table 6.10 and Figure 
6.29). 
For TNF-α levels in GCF, no significant differences were found between T2DM 
and non-diabetic subjects, except at month 6, when non-diabetic subjects [4.36 (2.21-
7.55) pg/ml] had significantly higher levels of IL-6 in GCF compared to subjects with 
T2DM [2.03 (0.65-3.80) pg/ml]. In subjects with T2DM, compared to pre-treatment 
levels [4.16 (2.72-6.69) pg/ml], TNF-α in GCF showed significant reductions at month 
3 [3.59 (1.28-10.37) pg/ml], month 6 [2.03 (0.65-3.80) pg/ml] and month 12 [1.74 
(0.96-3.45) pg/ml]. In non-diabetic subjects, compared to pre-treatment levels [4.49 
(2.55-7.04) pg/ml], saliva IL-1β showed apparent reduction at month 12 [2.35 (1.09-
3.55) pg/ml], although this difference failed to reach statistical significance (Table 6.10 
and Figure 6.30). 
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When considering IL-1β levels in GCF, no significant differences were found 
between T2DM and non-diabetic subjects at any time-points. In subjects with T2DM 
compared to pre-treatment levels [344.33 (156.16-572.50) pg/ml], IL-1β in GCF 
showed significant reductions at month 3 [180.05 (68.98-382.93) pg/ml], month 6 
[116.35 (48.71-206.56) pg/ml] and month 12 [175.65 (58.54-366.95) pg/ml]. Similarly, 
in non-diabetic subjects compared to pre-treatment levels [413.38 (213.83-770.56) 
pg/ml] IL-1β in GCF showed significant reductions at month 3 [166.25 (90.85-350.75) 
pg/ml], month 6 [150.60 (77.56-268.32) pg/ml] and month 12 [184.25 (77.51-291.71) 
pg/ml] (Table 6.10 and Figure 6.31). 
For IFN-γ levels in GCF, no significant differences were found between T2DM 
and non-diabetic subjects, except before treatment, when non-diabetic subjects [4.40 
(2.18-7.09) pg/ml] had significantly higher levels of INF-γ in GCF compared to subjects 
with T2DM [2.15 (1.11-5.24) pg/ml]. In subjects with T2DM, compared to pre-
treatment levels [2.15 (1.11-5.24) pg/ml], saliva IFN-γ showed a significant reduction at 
month 6 [0.85 (0.23-1.89) pg/ml] and a non-significant reduction at month 3 [1.29 
(0.35-3.46) pg/ml] and month 12 [1.62 (0.64-3.37) pg/ml]. In non-diabetic subjects, 
compared to pre-treatment levels [4.40 (2.18-7.09) pg/ml], saliva IFN-γ showed a 
significant reduction at month 3 [2.54 (0.92-4.87) pg/ml], month 6 [2.21 (1.41-4.23) 
pg/ml] and month 12 [1.43 (0.50-2.46) pg/ml] (Table 6.10 and Figure 6.32).
   
Table 6.10  GCF cytokine data in subjects with periodontitis pre- and post NSM for both T2DM and non-diabetic subjects 
 
P-values were determined using Friedman test with Wilcoxon post hoc test for continuous parametric variables compared over time and Mann-
Whitney U test for continuous non-parametric data compared at each time point. Median (IQR) is presented as all the data were non-parametric. 
$
 indicates a comparison within rows between of T2DM and non-diabetic groups at a specific time point 
#
 indicates a comparison within rows between pre-treatment and month 3 within either T2DM or non-diabetic groups 
¶
 indicates a comparison within rows between pre-treatment and month 6 within either T2DM or non-diabetic groups 
†
 indicates a comparison within rows between pre-treatment and month 12 within either T2DM or non-diabetic groups
 
 
 
Pre-treatment 
 
 
Month 3 
 
Month 6 
 
Month 12 
 
 T2DM 
subjects 
(n=48) 
Non-diabetic 
subjects 
(n= 47) 
T2DM 
subjects 
(n=35) 
Non-diabetic 
subjects 
(n= 38) 
T2DM 
subjects 
(n=36) 
Non-diabetic 
subjects 
(n= 38) 
T2DM 
subjects 
(n=28) 
Non-diabetic 
subjects 
(n= 36) 
p-value 
GCF vol (µl) 0.50 (0.38-
0.67)¶,# 
0.51(0.34-
0.68) 
0.29 (0.20-
0.46) 
0.46 (0.28-
0.59) 
0.41 (0.34-
0.53) 
0.34 (0.23-
0.66) 
0.40 (0.29-
0.58) 
0.43 (0.30-
0.64) 
¶,<0.01 
#,<0.001 
GCF IL-6 
(pg/ml) 
1.97 (0.98-
5.17)#,¶,† 
2.25 (1.12-
3.37)¶ 
1.03 (0.51-
2.70) 
1.96 (0.93-
3.32) 
0.89 (0.14-
1.80)$ 
1.51 (0.94-
2.34) 
1.03 (0.34-
2.17) 
1.28 (0.56-
3.77) 
¶,$<0.05 
#,†<0.001 
 GCF TNF-α 
(pg/ml)  
4.16 (2.72-
6.69)¶,† 
4.49 (2.55-
7.04)† 
3.59 (1.28-
10.37) 
4.82 (2.45-
7.56) 
2.03 (0.65-
3.80)$ 
4.36 (2.21-
7.55) 
1.74 (0.96-
3.45) 
2.35 (1.09-
3.55) 
¶,†<0.001 
GCF IL-1β 
(pg/ml) 
344.33 
(156.16-
572.50)#,¶,† 
413.38 
(213.83-
770.56)#,¶,† 
180.05 (68.98-
382.93) 
166.25 (90.85-
350.75) 
116.35 (48.71-
206.56) 
150.60 (77.56-
268.32) 
175.65 (58.54-
366.95) 
184.25 (77.51-
291.71) 
¶<0.001 
#,†<0.01 
GCF IFN-γ 
(pg/ml) 
2.51 (1.11-
5.24)¶,$ 
4.40 (2.18-
7.09)#,¶,† 
1.29 (0.35-
3.46) 
2.54 (0.92-
4.87) 
0.85 (0.23-
1.89)$ 
2.21 (1.41-
4.23) 
1.62 (0.64-
3.37) 
1.43 (0.50-
2.46) 
¶,$<0.05 
†,#<0.01 
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Figure 6.29 GCF IL-6 levels in subjects with periodontitis pre- and post NSM for 
both T2DM and non-diabetic subjects  
 
Boxplots of GCF IL-6 levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=48, month 3 n=35, month 6 n=36, month 12 n=28) and 
non-diabetic subjects (pre-treatment n=47, month 3 n=38, month 6 n=38, month 12 
n=36). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
*** 
* 
*** 
$$ 
* 
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Figure 6.30  GCF TNF-α levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
Boxplots of GCF TNF-α levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=48, month 3 n=35, month 6 n=36, month 12 n=28) and 
non-diabetic subjects (pre-treatment n=47, month 3 n=38, month 6 n=38, month 12 
n=36). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
$$$ 
*** 
*** 
*** 
* 
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Figure 6.31  GCF IL-1β levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
Boxplots of GCF IL-1β levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=48, month 3 n=35, month 6 n=36, month 12 n=28) and 
non-diabetic subjects (pre-treatment n=47, month 3 n=38, month 6 n=38, month 12 
n=36). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
  
** 
*** 
** 
** 
*** 
** 
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Figure 6.32  GCF IFN-γ levels in subjects with periodontitis pre- and post NSM 
for both T2DM and non-diabetic subjects  
 
 
Boxplots of GCF IFN-γ levels pre- and post NSM in subjects with periodontitis in both 
T2DM subjects (pre-treatment n=48, month 3 n=35, month 6 n=36, month 12 n=28) and 
non-diabetic subjects (pre-treatment n=47, month 3 n=38, month 6 n=38, month 12 
n=36). Statistics: Friedman test with Wilcoxon post hoc test *<0.05, **p<0.01, 
***p<0.001(according to time within T2DM or non-diabetic group); Mann-Whitney U 
test § p<0.05, §§ p<0.01, §§§p<0.001 (T2DM versus non-diabetic groups at each time 
point). ○ outlier more than 3 times the IQR from the box boundaries, ● outlier more 
than 1.5 but less than 3 times the IQR from the box boundaries. 
 
 
 
 
 
 
  
* 
* 
*** 
* 
$ $ 
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6.3 Discussion 
Changes in BMI 
In this study, it is clear that obesity, as defined by BMI, is closely linked to the 
presence of T2DM. At each time point, BMI was significantly higher in subjects with 
T2DM compared to non-diabetic subjects (Table 6.1 and Figure 6.1). Similarly, a 
greater proportion of subjects classified as obese and morbidly obese were found in the 
T2DM group compared to the non-diabetic group at each time point (Table 6.1). This 
reflects previous research that clearly demonstrates obesity as a risk factor for T2DM 
(Lundgren et al., 1989; Chan et al., 1994; Carey et al., 1997; Wang et al., 2005). 
Furthermore, in the present study, subjects with T2DM show a significant reduction in 
BMI from pre-treatment [33.0 (29.9-36.5) kg/m2] to month 6 [31.0 (27.6-34.8) kg/m2] 
and month 12 [31.6 (28.7-34.5) kg/m2]. However, further analysis of the number of 
subjects within each BMI category at each time point suggests there is potentially a 
higher drop-out of obese and morbidly obese subjects compared to the non-obese 
subjects, perhaps contributing to the apparent reduction in BMI seen in subjects with 
T2DM following periodontal management. It is therefore difficult to draw clear 
conclusions about actual weight loss following periodontal treatment, however, the 
impact of periodontal treatment on weight reduction is unlikely to be significant. 
Changes in biochemistry data 
Within T2DM subjects, the risk of diabetic complications is strongly associated 
with previous hyperglycaemia and a 1% reduction in HbA1c has been associated with a 
21% risk reduction in diabetic complications (Stratton 2000). In the present study pre-
treatment HbA1c levels [7.5 (6.7-9.2)%] showed a reduction at month 3 [7.05 (6.6-
9.5)%] and month 12 [7.1 (6.6-7.4)%], which is a reduction of 0.45% and 0.40% 
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respectively, although these reductions did not reach statistical significance (Table 6.3 
and Figure 6.3). This is in line with past studies (Promsudthi et al., 2005; Jones et al., 
2007; Correa et al., 2010).  In one study, pre-treatment HbA1c levels [8.98±0.88%] 
showed a non-significant decrease in HbA1c at 3 months [8.79±1.24%] in subjects 
receiving periodontal treatment (n=27)  and a non-significant rise from pre-treatment 
[9.17±1.02%] to month 3 [9.28±1.50%] in subjects receiving no treatment (n=25) 
(Promsudthi et al., 2005). In a larger RCT, at 4 months no significant differences in the 
change in HbA1c was showed when subjects receiving periodontal treatment (n=83) 
were compared against untreated subjects (n=82), such that, the mean HbA1c change in 
the treatment group was -0.65% compared to -0.51% in the untreated group (Jones et 
al., 2007). However, other studies suggest that control of periodontal infection 
significantly does improve metabolic control (Stewart et al., 2001; Rodrigues et al., 
2003; Kiran et al., 2005; O'Connell et al., 2008; Kardesler et al., 2011). In one such 
study,  pre-treatment HbA1c levels [7.31±0.74%] showed a significant decrease at 3 
months [6.51±0.80%] in subjects receiving periodontal treatment (n=22)  and a non-
significant rise from pre-treatment [7.00±0.72%] to month 3 [7.31±2.08%] in subjects 
receiving no treatment (n=22) (Kiran et al., 2005). Interestingly, the 0.45 % and 0.40% 
reductions in HbA1c seen in this study following NSM are comparable to data from the 
most recent meta-analysis which showed that when compared against no treatment or 
usual treatment, NSM gave a statistically significant 0.40% HbA1c reduction (p=0.04) 
(Simpson et al., 2010). Within the current study, at month 12 there was a reduction in 
the number of T2DM subjects categorised as having poor glycaemic along with a 
concurrent increase in the number of subjects categorised as having moderate glycaemic 
control, making it unlikely that the reduction in HbA1c seen at month 12 was due to 
drop of subjects categorised as having poor glycaemic control.   
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In some studies, changes in HbA1c data following periodontal management 
were assessed separately in well controlled and poorly controlled T2DM patients (Dag 
et al., 2009; Kardesler et al., 2010; Santos et al., 2010), with one study demonstrating 
significant reductions only in well controlled T2DM subjects (Dag et al., 2009), another 
study demonstrating significant reductions only in poorly controlled T2DM subjects 
(Kardesler et al., 2010) and a further study showing no change in HbA1c in either group 
(Santos et al., 2010). In our study, in T2DM patients with poorer initial glycaemic 
control, as indicated by HbA1c ≥ 7.5%, there was a 1.9 % reduction in HbA1c levels 
from pre-treatment [9.2 (8.3-10.2)%] to month 12 [7.3 (7.1-8.7)%], although, the 
reduction did not reach statistical significance. Stratification of subjects based on 
HbA1c was not built into the recruitment strategy for the current study and to prevent 
low n values in groups, data were not subsequently stratified when analyses were 
performed. 
Taken collectively, data from this present study and previous studies would 
appear to support that non-surgical periodontal management can produce an overall 
positive effect on glycaemic control. However, this would need to be confirmed in an 
interventional study with sufficient number of subjects to account for variations inherent 
in HbA1c between patients. Additionally, the method of periodontal therapy used in the 
future studies should also be carefully considered. In some of previous studies 
evaluating the impact of periodontal therapy on HbA1c, the NSM was supplemented 
with local (Iwamoto et al., 2001) or systemic (O'Connell et al., 2008) antibiotic 
administration. In this regard it is important to highlight the fact that tetracycline and its 
derivatives may act directly on insulin production (Qin et al., 2002) and thus some of 
the reductions of HbA1c following therapy  in some studies could be due to the 
antibiotic per se not only due to improvements in periodontal health. Also, the current 
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mainstay of periodontal management, particularly in the UK, is non-surgical 
management and given there is insufficient evidence to recommend the routine use of 
systemic antibiotics in the treatment of periodontitis (Sanz and Teughels, 2008), the 
method of periodontal therapy used in research should reflect this and thus allow 
generalisation of the results to the general population. 
Data from the present study showed that, at each time point, HDL, non-HDL 
and total cholesterol were significantly higher in non-diabetic subjects compared to 
subjects with T2DM (Table 6.3). This is not surprising, given that the management of 
raised levels of serum lipids is a key priority within the national management guidelines 
for T2DM (NICE, 2008). Conversely, levels of triglycerides were significantly higher in 
subjects with T2DM compared to non-diabetic subjects at pre-treatment, month 3 and 
month 12. Caution must, however, be used when interpreting this result given that the 
serum samples taken as part of this study were not fasting samples, and food intake can 
lead to sharp rises in triglycerides levels. Potentially, T2DM subjects may have 
demonstrated raised levels of triglycerides due to more regular eating patterns. 
However, this cannot be confirmed within the present study as data regarding dietary 
intake were not collected. Data from the present study did not however, confirm 
previous research. One study found no significant differences between T2DM (well and 
poorly controlled) and non-diabetic subjects at any time points, except for LDL which 
was lower in well controlled T2DM compared to poorly controlled T2DM patients 
(Kardesler et al., 2010) and another study found no differences in triglyceride and total 
cholesterol when diabetic subjects were compared to non-diabetic subjects (Christgau et 
al., 1998).  
The present study also assessed the effect of improved periodontal health on 
serum lipid profiles in subjects with T2DM and periodontitis, however, no changes 
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were demonstrated in levels of triglycerides, HDL, non-HDL and total cholesterol 
following NSM (Table 6.3). This corroborates data from previous studies that 
demonstrated minimal changes in lipid profiles in subjects withT2DM following NSM 
(Christgau et al., 1998; Kiran et al., 2005; Kardesler et al., 2010). Given that most 
T2DM subjects are likely to already receive intensive management of raised serum lipid 
levels as part of their T2DM management, the scope for further improvements in serum 
lipid profiles as a result of improved periodontal health is likely to be minimal. 
Interestingly, in the current study, a significant reduction in non-HDL and total 
cholesterol was demonstrated in non-diabetic subjects 6 months after treatment (Table 
6.3). This supported a recent small study of subjects with hyperlipidemia and 
periodontitis that found that significant reductions in LDL and total cholesterol were 
demonstrated after NSM (Fentoglu et al., 2010). Given the potential role of serum lipids 
in the relationship between systemic disease and periodontitis (Iacopino and Cutler, 
2000), further studies are required to clarify the effect of periodontal healing on lipid 
profiles in subjects with and without diabetes. 
Data from the present study demonstrated a reduction in hsCRP levels at month 
12 compared to pre-treatment levels in subjects with T2DM (2.1 (0.9-4.6) mg/L to 
1.5(0.7-3.1) mg/L and non-diabetic subjects (2.3 (1.1-4.3) mg/L to 1.6 (0.7-2.9) mg/L, 
however, the reductions failed to reach statistical significance (Table 6.3 and Figure 
6.8). This is in line with previous studies that demonstrated similar non-significant 
reductions in hsCRP following periodontal therapy in T2DM subjects (Christgau et al., 
1998; Correa et al., 2010; Kardesler et al., 2010). The wide variations in CRP levels 
seen in the current study are likely to be due to the non-specific nature of CRP as 
marker of systemic inflammation. In addition to T2DM and periodontitis, many other 
systemic conditions may impact upon CRP levels and transient increases in CRP can 
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occur with acute illness and thus a single measurement may not represent the true basal 
levels of CRP. Although at recruitment stage, patients with serious systemic illnesses 
were excluded from the study, extending exclusion criteria has to be weighed up against 
the effect it will have on recruitment of subjects and how effectively the research results 
can then be generalised to larger populations. Therefore, to clarify the effect of 
periodontal healing on systemic CRP levels in subjects with T2DM, it would be more 
appropriate to account for the variations seen in CRP by using the data generated from 
this and other studies to estimate, more accurately, the number of subjects required in a 
future studies.  
Changes in Periodontal parameters 
The significant reductions in all clinical periodontal parameters (BOP, mGI, PI, 
mean PD, PESA, PISA, % PD sites ≥5mm) at each post- treatment follow-up time 
point, in both diabetic and non-diabetic subjects, indicate that non-surgical periodontal 
treatment was effective and this post-treatment response was maintained for 12 months 
following initial treatment. Furthermore, in addition to the significant reductions in all 
clinical periodontal parameters seen in both T2DM and non-diabetic patients, few 
differences were found when comparing between groups each time point, confirming 
that NSM was effective regardless of diabetes status. This is in line with data from 
previous research that demonstrates significant improvements in clinical periodontal 
parameters following periodontal management in subjects with T2DM (Rodrigues et al., 
2003; Kiran et al., 2005; Correa et al., 2008; O'Connell et al., 2008; Dag et al., 2009; 
Correa et al., 2010; Kardesler et al., 2010; Santos et al., 2010; Kardesler et al., 2011).  
Previously, in a number of small studies, the clinical periodontal response to 
different treatment therapies has been investigated in subjects with T2DM (Rodrigues et 
al., 2003; O'Connell et al., 2008; Correa et al., 2010). One study of subjects with T2DM 
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and periodontitis (n=23) showed after NSM, compared to pre-treatment levels of BOP 
[90.4±10.5%], mean PD [4.2±1.0 mm], mean CAL [5.4±1.3 mm], % PD sites ≥ 5 mm 
[38.0±22.8 %] significant reductions were seen at 3 months post treatment in BOP 
[28.9±16.5%], mean PD [2.8±0.4 mm], mean CAL [4.6±1.1 mm], % PD sites ≥ 5 mm 
[7.5±6.8%] (Correa et al., 2010). Another small study of 30 T2DM subjects comparing 
the effect of 2 periodontal treatment therapies showed significant improvements in 
periodontal parameters at the 3 month follow up (Rodrigues et al., 2003). In the NSM 
group, pre-treatment mean PD [2.7±0.7 mm] and BOP [38±13%] were significantly 
reduced at month 3 with mean PD [1.9±0.4 mm] and BOP [15±9%] being recorded. In 
the group receiving NSM plus antibiotics, pre-treatment mean PD [3.2±0.8 mm] and 
BOP [32±15%] were significantly reduced at month 3 with mean PD [2.3±0.5 mm] and 
BOP [11±7%] being recorded. Furthermore, a comparison between the groups also 
failed to demonstrate significant differences in any of the clinical outcomes (Rodrigues 
et al., 2003). A further small study of 30 T2DM subjects comparing 2 periodontal 
treatment therapies showed significant improvements in periodontal parameters at the 3 
month follow-up (O'Connell et al., 2008). Once again, in the NSM group, pre-treatment 
mean PD [2.9±0.8 mm], number of PD sites ≥ 6 mm [12.6±14.1] and BOP 
[49.1±18.5%] were significantly reduced at month 3 with mean PD [2.1.9±0.3 mm], 
number of PD sites ≥6mm [3.7±2.6] and BOP [14.2±12.5%] being recorded. In the 
group receiving NSM plus antibiotics, pre-treatment mean PD [3.0±0.5mm], number of 
PD sites ≥6mm [7.5±5.2] and BOP [51.3±14.9%] were significantly reduced at month 3 
with mean PD [1.9±0.3mm], number of PD sites ≥6mm [2.5±0.7] and BOP [8.9±4.8%] 
being recorded (O'Connell et al., 2008). In a further study, 44 T2DM subjects were 
randomised to the treatment group, who received non-surgical periodontal management 
(n=22) or the control group that had no periodontal treatment (n=22) (Kiran et al., 
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2005). At the 3 month time-point mean PD [2.3±0.5], mean LOA [3.2±1.1] and BOP 
[54.4±18.8], showed a significant improvement compared to pre-treatment mean PD 
[1.8±0.3], mean LOA [2.8±1.0] and BOP [23.9±12.7] in the treatment group but not in 
the control group (Kiran et al., 2005). 
Overall, data from these studies demonstrate a good clinical response to 
periodontal therapy in subjects with T2DM and this is in line with data from the current 
study which shows that in subjects with T2DM compared to pre-treatment levels BOP 
[46.0(30.0-60.7)], mean PD [2.8(2.4-3.2)], mean LOA [3.1(2.8-3.9)] and % of PD sites 
≥5mm [10.9(8.1-18.2)] were significantly reduced at month 3 with BOP [18.5(8.8-
38.0)] mean PD [2.4(2.2-2.9)], mean LOA [3.0(2.6-3.6)] and % of PD sites ≥5mm 
[5.3(1.8-9.9)]. However, the lack of a non-diabetic group for comparison is a limitation 
of these previous studies and prevents conclusions from being made regarding the 
clinical periodontal response to NSM in subjects with T2DM compared to non-diabetic 
subjects. Furthermore, many of these studies relied on mean PD and mean CAL data to 
describe the clinical response within the periodontal tissues. Means fail to present data 
about the either the % or number of sites with deeper PD sites or the % of sites 
displaying a reduction in PD and thus conclusions about the severity and extent of 
periodontal disease in each group and how this changes with periodontal treatment 
cannot be made.  
A number of small studies have also investigated the clinical periodontal 
response to non-surgical periodontal therapy in subjects with T2DM compared to non-
diabetic subjects (Correa et al., 2008; Dag et al., 2009; Kardesler et al., 2010; Kardesler 
et al., 2011). In a study of 23 subjects with T2DM and periodontitis and 26 non-diabetic 
subjects with periodontitis, both groups showed significant improvements in the clinical 
periodontal parameters after NSM. Therefore, in subjects with T2DM, pre-treatment 
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BOP [94.4 (80.0-100.0)%], mean PD [3.8 (3.4-5.3)mm] and mean LOA [5.4 (4.4-
6.4)mm] showed a significant reduction at 90 day after NSM to BOP [25.6 (17.9-
32.7)%], mean PD [2.7 (2.4-3.0)mm] and mean LOA [4.9 (3.7-5.3)mm]. Likewise, in 
non-diabetic subjects pre-treatment BOP [74.8 (65.4-89.1)%], mean PD [3.6 (3.2-4.0) 
mm] and mean LOA [4.5 (3.8-5.1) mm] showed a significant reduction at 90 day after 
treatment BOP [14.0 (9.1-19.2)%], mean PD [2.4 (2.3-2.6) mm] and mean LOA [3.7 
(3.5-4.5) mm] (Correa et al., 2008). Another study of 20 subjects with T2DM and 22 
non-diabetic patients all with periodontitis showed similar improvements in clinical 
periodontal variables at month 1 and month 3 after NSM. In subjects with T2DM, pre-
treatment data [mean PD 3.9±0.5 mm, mean LOA 4.3±0.9 mm, PI 99.7±1.2 and BOP 
84.5±10.3%] showed significant improvements at month 1 [mean PD 3.0±0.8 mm, 
mean LOA 4.1±1.0 mm, PI 38.3±9.5 and BOP 32.5±10.7%] and month 3 [mean PD 
2.9±0.6 mm, mean LOA 4.1±0.9 mm, PI 39.8±16.3 and BOP 31.5±10.5%]. Also in 
non-diabetic subjects pre-treatment data [mean PD 3.9±0.5 mm, mean LOA 4.2±0.6 
mm, PI 95.5±9.4 and BOP 67.2±13.5%] showed significant improvements at month 1 
[mean PD 2.8±0.4 mm, mean LOA 3.5±0.6 mm, PI 48.7±5.6 and BOP 31.5±8.5 %] and 
month 3 [mean PD 2.7±0.3 mm, mean LOA 3.5±0.6 mm, PI 38.9±9.2 and BOP 
30.1±8.5%] (Kardesler et al., 2011). 
In 2 further studies, the subjects with T2DM were also stratified based on initial 
glycaemic control (Dag et al., 2009; Kardesler et al., 2011). In one of these studies of 
13 well controlled and 12 poorly controlled patients with T2DM and periodontitis and 
15 non-diabetic patients with periodontitis, there were similar improvements in clinical 
periodontal variables at month 1 and month 3 after NSM. Therefore, in well controlled 
T2DM subjects pre-treatment data [PD 3.7±0.4 mm, PI 97.4±5.4% and BOP 
81.5±7.9%] showed significant improvements at month 1 [PD 2.7±0.4 mm, PI 
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37.9±11.1% and BOP 26.3±10.4%] and month 3 [PD 2.8±0.4 mm, PI 35.6±8.7% and 
BOP 25.4±6.9%]. Likewise in poorly controlled T2DM subjects, pre-treatment data [PD 
4.1±1.0 mm, PI 99.7±1.2% and BOP 86.0±12.3%] showed significant improvements at 
month 1 [PD 3.0±0.8 mm, PI 43.3±9.5 % and BOP 36.8±9.8 %] and month 3 [PD 3.1 
±0.6 mm, PI 44.2±6.3 % and BOP 40.6±8.2 %]. Also in non-diabetic subjects, pre-
treatment data [PD 3.9±0.6 mm, PI 95.5±9.4% and BOP 78.8±16.5%] showed 
significant improvements at month 1 [PD 2.8±0.4 mm, PI 46.7±8.9 % and BOP 
31.8±11.5%] and month 3 [PD 2.7±0.3 mm, PI 39.5±13.5% and BOP 28.1±9.2%]. 
When the groups were compared, no significant differences were demonstrated at any 
of the time points, except at month 1 and 3 subjects with poorly controlled T2DM 
patients demonstrating significantly higher BOP than the other 2 groups (Kardesler et 
al., 2010). In the other study, 15 well controlled and 15 poorly controlled patients with 
T2DM and periodontitis and 15 non-diabetic patients with periodontitis showed similar 
improvements in clinical periodontal variables at month 3 after NSM. Therefore, in well 
controlled T2DM subjects pre-treatment data [mean PD 2.7±0.5 mm, mean LOA 
4.3±0.8 mm, PI 1.8±0.7 and GI 1.0±0.3] showed significant improvements at month 3 
[mean PD 2.3±0.4 mm, mean LOA 3.0±0.8 mm, PI 0.2±0.1 and GI 0.1±0.1]. Likewise 
in poorly controlled T2DM subjects, pre-treatment data [mean PD 2.8±0.7 mm, mean 
LOA 4.3±1.0 mm, PI 2.1±0.7 and GI 1.3±0.4] showed significant improvements at 
month 3 [mean PD 2.4±0.6 mm, mean LOA 3.0±0.8 mm, PI 0.3±0.2 and GI 0.1±0.1]. 
Also in non-diabetic subjects pre-treatment data [mean PD 2.6±0.4 mm, mean LOA 
4.3±0.6 mm, PI 2.3±0.5 and GI 1.2±0.4] showed significant improvements at month 3 
[mean PD 2.4±0.7 mm, mean LOA 2.9±0.6 mm, PI 0.2±0.3 and GI 0.1±0.03] (Dag et 
al., 2009). 
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Collectively, the data from previous research indicates that NSM was equally as 
effective in subjects with T2DM subjects as in non-diabetic subjects. This is in line with 
data from the current study which showed similar improvements in clinical periodontal 
variables at month 3, month 6 and month 12 after NSM. For example, in subjects with 
T2DM, pre-treatment data [mean PD 2.8 (2.4-3.2) mm, mean LOA 3.1 (2.8-3.9) mm, PI 
0.8 (0.5-1.1) and BOP 46.0 (30.0-60.7)%] showed significant improvements at month 3 
[mean PD 2.4 (2.2-2.9) mm, mean LOA 3.0 (2.6-3.6) mm, PI 0.5 (0.3-0.7) and BOP 
18.5(8.8-38.0) %], month 6 [mean PD 2.2 (2.0-2.7) mm, mean LOA 2.8 (2.4-3.7) mm, 
PI 0.6 (0.3-0.8) and BOP 15.3 (8.3-39.6) %] and month 12 [mean PD 2.2 (1.9-2.8) mm, 
mean LOA 2.8 (2.4-3.6) mm, PI 0.5 (0.3-0.7) and BOP 17.6 (6.5-28.4) %]. Likewise, in 
non-diabetic subjects pre-treatment data [mean PD 2.9 (2.5-3.5) mm, mean LOA 3.5 
(2.9-4.2) mm, PI 0.6 (0.4-0.8) and BOP 43.0 (29.4-56.7) %] showed significant 
improvements at month 3 [mean PD 2.6 (2.2-2.9) mm, mean LOA 3.3 (2.8-3.9) mm, 
PI0.3 (0.1-0.6) and BOP 14.5 (10.3-27.0) %], month 6 [mean PD 2.5 (2.1-2.9) mm, 
mean LOA 3.1 (2.6-4.1) mm, PI 0.3 (0.1-0.6) and BOP 14.7 (7.2-25.0) %] and month 
12 [mean PD 2.3 (1.9-2.7) mm, mean LOA 3.1 (2.5-3.7) mm, PI 0.4 (0.2-0.8) and BOP 
10.0 (5.1-24.2) %] (Table 6.6)  
Within the current study, when subjects with T2DM were compared to non-
diabetic subjects mean PD, mean LOA and BOP  showed no significant differences 
between groups at any time point. This corroborates data from 1 previous study that 
showed no significant differences between subjects with and without T2DM at either 
time points (Dag et al., 2009). However, the current study does not support data from 2 
previous studies that showed significantly higher BOP, mean PD and mean LOA in 
subjects with T2DM compared to non-diabetic subjects both before and after NSM 
(Correa et al., 2008) and significantly higher BOP, mean PD measurements and mean 
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LOA in subjects with T2DM compared to non-diabetic subjects at various time points 
within the study (Kardesler et al., 2011). Furthermore, within the present study, despite 
the reductions in PI seen in both T2DM and non-diabetic subjects, PI was significantly 
higher in T2DM subjects compared to non-diabetic subjects at each time point, 
indicating poorer oral care or increased plaque accumulation in T2DM subjects. This is 
in line with a previous study which demonstrated better improvements in plaque levels, 
gingival inflammation and BOP within the non-diabetic subjects compared to the 
T2DM subjects (Correa et al., 2008). Caution must, however, be used when interpreting 
this result given the limitation that PI data, from the current study, do not represent full 
mouth assessments, but rather PI scores from 6 sites on 4 target teeth within each 
subject. The higher PI level in T2DM may, however represent a surrogate marker for 
poorer lifestyle and general health management, or how living with T2DM may 
negatively impact on a patient’s motivation for optimal oral hygiene, given the patient’s 
other competing healthcare needs.  
Taken collectively, previous research and data from the current study show that 
NSM lead to significant improvements in the clinical periodontal status both in subjects 
with and without T2DM (Correa et al., 2008; Dag et al., 2009; Kardesler et al., 2010; 
Kardesler et al., 2011). However, in the majority of previous studies evaluating the 
clinical response to NSM in subjects with T2DM, the review period is 3 months (Kiran 
et al., 2005; Correa et al., 2008; O'Connell et al., 2008; Dag et al., 2009; Kardesler et 
al., 2010; Kardesler et al., 2011) with only one previously published study using a 6 
month follow-up period (Santos et al., 2010). Therefore conclusions from the currently 
published literature regarding the effect of NSM on clinical periodontal health are 
limited to the short term. From the current literature, no conclusions can be made about 
long term clinical response to periodontal therapy in subjects with T2DM. Given that 
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periodontitis is a chronic condition, the lack of data beyond 3 months is a limitation. 
Within the current study, the clinical periodontal response to NSM was monitored at 
months 3, 6 and 12 and, compared to pre-treatment data. Significant improvements were 
demonstrated at each time point for both T2DM subjects and non-diabetic subjects 
(Table 6.6).   
Furthermore, previously published studies describe the clinical periodontal 
response to NSM in subjects with T2DM using mean PD, mean LOA and % BOP 
(Kiran et al., 2005; O'Connell et al., 2008; Dag et al., 2009; Kardesler et al., 2010; 
Santos et al., 2010; Kardesler et al., 2011). Whilst means provide a useful summary of 
the data, they provide no specific information about the extent and severity of the 
periodontitis. Only two previous studies supplemented the mean clinical data with data 
about the % of sites affected by specific probing depths (Correa et al., 2008; Correa et 
al., 2010).  Therefore, one study showed that in subjects with T2DM, the % PD sites 
≥7mm at pre-treatment [9.0 (1.0-22.0)%] was significantly reduced 90 days after NSM 
[0.0 (0.0-1.0)%]. Likewise, in non-diabetic subjects, the % PD sites ≥7mm at pre-
treatment [5.5 (3.0-14.0)%] were significantly reduced 90 days after to  [0.0 (0.0-0.0)%] 
(Correa et al., 2008). Additionally, another study showed that in subjects with T2DM, 
the % PD sites ≥5mm at pre-treatment [38.0±22.8%] was significantly reduced at 3 
months after NSM [7.5±6.8%]. Data from the current study shows that in subjects with 
T2DM, the % of PD sites ≥ 5 mm at pre-treatment [10.9 (8.1-18.2)%] was significantly 
reduced at month 3 [5.3 (1.8-9.9)%], month 6 [5.3 (1.9-9.7)%] and month 12 [3.0 (0.9-
8.9)%]. Similarly, in non-diabetic subjects, the % of PD sites ≥ 5 mm at pre-treatment 
[16.0 (8.0-30.8)%] was significantly reduced at month 3 [10.1 (5.8-19.0)%], month 6 
[9.0 (3.2-19.5)%] and month 12 [3.2 (1.3-13.4)%] (Table 6.6). At pre-treatment, there 
was an apparently higher % of PD sites ≥ 5 mm recorded in non-diabetic subjects [16.0 
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(8.0-30.8)%] compared to subjects with T2DM [10.9 (8.1-18.2)%], although the 
difference failed to reach significance. After treatment, the % of PD sites ≥ 5 mm were 
significantly higher in non-diabetic subjects at month 3 [10.1 (5.8)%] and month 6 [9.0 
(3.2-19.5)%] compared to subjects with T2DM at month 3[5.3 (1.8-9.9)%] and month 6 
[5.3 (1.9-9.7)%]. When the impact of the pre-treatment difference between subjects with 
T2DM and non-diabetic subjects was taken into account, the differences found between 
subjects with T2DM and non-diabetic subjects at month 3 and month 6 failed to reach 
significance (Table 6.6). 
In an attempt to more fully describe the clinical impact of NSM in subjects with 
T2DM compared to non-diabetic subjects data relating to the % of sites displaying 
changes in PD and LOA were also presented in the present study (Table 6.7). For 
example, in subjects with T2DM, the % of PD sites that reduced by ≥ 2 mm from pre-
treatment to month 3 was [11.0 (5.3-17.2)%], from pre-treatment to month 6 was [12.0 
(9.3-19.1)%] and from pre-treatment to month 12 was [13.6 (10.5-24.0)%].  Likewise in 
non-diabetic subjects, the % of PD sites that reduced by ≥ 2 mm from pre-treatment to 
month 3 was [12.3 (8.3-20.8)%], from pre-treatment to month 6 was [14.0 (9.3-19.4)%] 
and from pre-treatment to month 12 was [18.0 (10.2-23.2)%]. When the changes in 
subjects with T2DM were compared to those in non-diabetic subjects, despite the 
apparently higher % of reducing sites shown in non-diabetic subjects, no significant 
differences were identified for any time period (Table 6.7). Given that previous research 
has demonstrated that greater reductions in PD are seen in deeper pockets (Cobb, 2002), 
it is not unreasonable to propose that the more severe periodontal disease present in the 
non-diabetic subjects compared to subjects with T2DM (Table 4.14) has led to the 
apparently higher % of PD sites reducing by ≥ 2 mm seen in non-diabetic subjects 
compared to subjects with T2DM. 
6  Results 321
As previously shown within this current study, PESA data were able to detect 
subtle differences in PD data that mean PD data failed to detect (Table 4.14). 
Furthermore, in the current study, PISA appears to reflect both PD and BOP data within 
a composite measure (Table 4.14). Given that inflammation within the periodontium has 
the potential to contribute to the systemic inflammatory burden and thus influence the 
pathogenic mechanisms present in T2DM, both PESA and PISA data have been used in 
this study to describe the clinical response to NSM. In subjects with T2DM, pre-
treatment data [PESA 1401.5 (1144.3-1733.7) mm2 and PISA 683.0 (439.1-1085.5) 
mm2] showed significant reductions at month 3 [PESA 1238.2 (1092.4-1543.9) mm2 
and PISA 339.0 (145.4-688.3) mm2], month 6 [PESA 1159.7 (1010.1-509.0) mm2 and 
PISA 340.1 (101.0-628.1) mm2] and month 12 [PESA 1181.3 (930.3-1374.7) mm2] and 
PISA 216.5 (87.1-539.4) mm2]. Similarly, in non-diabetic subjects, pre-treatment data 
[PESA 1711.0 (1439.4-2096.5) mm2 and PISA 897.3 (683.6-1232.9) mm2] showed 
significant reductions at month 3 [PESA 1464.2 (1192.0-1686.2) mm2 and PISA 299.4 
(159.5-536.5) mm2], month 6 [PESA 1402.9 (1139.8-1698.3) mm2 and PISA 262.6 
(89.0-514.8) mm2] and month 12 [PESA 1260 (983.7-1566.8) mm2 and PISA 215.1 
(62.5-520.3) mm2]. Also, when subjects with T2DM were compared to non-diabetic 
subjects PESA and PISA showed no significant differences between groups at any time 
point (Table 6.6). It would appear therefore, that in this study, PESA and PISA data 
support the mean clinical data, demonstrating improvements in clinical periodontal 
variables at month 3, month 6 and month 12 after NSM that were similar in subjects 
with and without diabetes. Currently, published data relating to PESA and PISA is 
cross-sectional, with no published studies currently using PESA to describe the impact 
of NSM upon the health of the clinical periodontal tissues.  
Changes in serum cytokines 
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Previous studies have begun to describe the effect of reducing periodontal 
inflammation on circulating inflammatory cytokine levels (Ide et al., 2003; D'Aiuto et 
al., 2004; Marcaccini et al., 2009), however, until recently few studies had evaluated the 
impact of periodontal therapy on circulating levels of inflammatory cytokines in 
subjects with T2DM (Iwamoto et al., 2001; O'Connell et al., 2008; Dag et al., 2009; 
Correa et al., 2010; Kardesler et al., 2010).  
In the current study, in subjects with T2DM and non-diabetic subjects, pre-
treatment levels of IL-6 [0.51 (0.35-1.50) pg/ml and 0.59 (0.32-0.93) pg/ml] showed no 
significant changes after NSM (Table 6.8). This does not support results from some 
previous studies in subjects with T2DM, which show significant reductions in serum IL-
6 from pre-treatment level [2.1±0.3pg/ml] to 3 months post-treatment [1.1±0.2pg/ml] 
(O'Connell et al., 2008) or apparent reductions in pre-treatment IL-6 levels [3.1 (2.1-
4.2) pg/ml] to month 3 [2.3 (1.2-4.5) pg/ml], although the changes failed to reach 
statistical significance (Correa et al., 2010). An additional study showed that in subjects 
with well controlled T2DM, pre-treatment levels of serum IL-6 were significantly 
reduced at month 1 and 3 post-treatment and non-diabetic subjects also showed a 
significant reduction in serum IL-6 levels at month 3, with poorly controlled T2DM 
subjects also demonstrating non-significant reductions at month 1 and 3 (Kardesler et 
al., 2010). Interestingly, within the current study, serum levels of IL-6 remained 
consistently around the lower limits of detection for the assay used, at a lower level than 
reported in previous studies (O'Connell et al., 2008; Correa et al., 2010; Kardesler et al., 
2010). 
Within the present study, serum TNF-α pre-treatment levels [7.10 (3.25-9.30) 
pg/ml] in subjects withT2DM showed significant reductions at 3 months [3.70 (2.21-
6.72) pg/ml] and 6 months [3.86 (2.15-7.33) pg/ml] (Table 6.8). This is in line with a 
6  Results 323
previous study which shows pre-treatment serum TNF-α levels (9.2±3.33 pg/ml) and 
(12.44±5.27 pg/ml) showed significant reductions at 3 months after NSM (7.75±2.52 
pg/ml) and (10.25±3.68 pg/ml), in subjects with well controlled and poorly controlled 
T2DM respectively (Dag et al., 2009). In another study, in subjects with T2DM, serum 
TNF-α levels showed a significant reduction from pre-treatment [3.77±1.03pg/ml] to 1 
month post-treatment [3.28±0.86 pg/ml] (Iwamoto et al., 2001). In a separate study in 
subjects with T2DM, pre-treatment plasma levels of TNF-α [5.6 (4.3-7.4) pg/ml] 
showed a significant reduction at 3 months post-treatment [4.8 (2.7-6.7) pg/ml] (Correa 
et al., 2010). However, a further study failed to showed a significant change in serum 
TNF-α level from pre-treatment [0.0±0.3 pg/ml] to 3 months after NSM [0.0±0.2 pg/ml] 
(O'Connell et al., 2008). In the current study however, non-diabetic subjects shows 
significant increases at 6 months [7.06 (5.59-8.79) pg/ml] and 12 months [7.70 (6.71-
10.20) pg/ml] compared to pre-treatment serum TNF-α levels [3.44 (2.34-7.24) pg/ml] 
(Table 6.8). This is not supported by data from previous studies which show, in non-
diabetic subjects, either reductions in serum TNF-α levels from pre-treatment 
(10.42±4.80pg/ml) to 3 months after NSM (7.72±4.53pg/ml)] (Dag et al., 2009) or no 
significant changes after NSM (Ide et al., 2003; Kardesler et al., 2010). Possible reasons 
for the relatively low pre-treatment TNF-α levels in serum being measured in non-
diabetic subjects could include seasonal variations in room temperature that occurred 
during the quantification assays. Interestingly, the majority of non-diabetic patients 
were recruited within a short period of time, whereas recruitment of subjects with 
T2DM was slower and therefore spread over a longer period. However, as part of this 
study data about the timing of blood sampling and serum cytokine analysis has not been 
recorded and thus clear conclusions about the impact of seasonal temperature variations 
cannot be made. 
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Overall, data from previous studies and the current study would appear to 
suggest that in T2DM, a reduction in periodontal inflammation may be associated with 
a reduction in serum TNF-α, which is potentially an important finding given the role of 
inflammatory cytokines in the pathogenesis of T2DM and modulation of glycaemic 
control. However, when comparing the pre-treatment levels from published studies as 
well as from the current study, there are clear variations in the levels of TNF-α 
presented. The use of different assays could potentially account for some of these 
variations. Additionally, some studies used serum samples whilst others used plasma 
samples for quantifying circulating cytokine levels, with the possibility of the release of 
blood cell contents potentially contributing to the level of cytokines in plasma samples, 
providing another source for inter-study variations in cytokine levels. 
Changes in cytokines in saliva 
Despite the recognition that saliva has the potential to provide important 
complimentary information with regards to diagnosis and monitoring of periodontitis 
(Miller et al., 2010), there is currently limited published longitudinal data evaluating the 
impact of NSM on inflammatory cytokines in saliva (Sexton et al., 2011).  
In the present study, both non-diabetic subjects and subjects with T2DM showed 
that pre-treatment IL-6 levels in saliva [2.29 (1.27-4.38) pg/ml and 2.41 (0.95-7.29) 
pg/ml] did not change significantly after NSM (Table 6.9). Although pre-treatment 
levels of IL-6 in saliva appear similar to previously published data in systemically 
healthy subjects with periodontitis [3.6±5.9pg/ml] (Gursoy et al., 2009), there are 
currently no published longitudinal data, investigating the impact of NSM on levels of 
IL-6 in saliva. 
6  Results 325
In the current study, in subjects with T2DM, pre-treatment levels of TNF-α in 
saliva [1.58 (0.61-3.08) pg/ml] were significantly reduced at month 3 [0.66 (0.26-1.53) 
pg/ml], although at month 12 the level was significantly increased [2.88 (1.25-4.32) 
pg/ml]. In non-diabetic subjects, compared to pre-treatment levels of TNF-α in saliva 
[2.59 (1.18-3.97) pg/ml] no significant changes were detected after NSM (Table 6.9). In 
comparison, one study evaluating changes in levels of TNF-α in saliva in systemically 
healthy subjects with periodontitis, reported significant reductions in TNF-α in saliva at 
month 4 in subjects receiving OHI alone and subjects receiving NSM, although 
numerical values were not published and the data were presented graphically, 
preventing a direct comparison with data from the current study (Sexton et al., 2011).  
Additionally, in the present study, in subjects with T2DM, pre-treatment levels 
of IL-1β in saliva [38.65 (20.45-68.28) pg/ml] were reduced at month 3 [19.00 (6.96-
50.55) pg/ml] (detected as a trend following correction of p-values for multiple 
comparisons), although there was a non-significant increase at month 12 [64.60 (26.88-
121.50) pg/ml]. In non-diabetic subjects, compared to pre-treatment levels [62.60 
(39.20-97.10) pg/ml], saliva IL-1β showed apparent reduction at month 6 [38.55 (21.43-
67.80) pg/ml] and month 12 [48.20 (27.10-86.20) pg/ml], although these differences 
failed to reach statistical significance (Table 6.9). In comparison, one study evaluating 
changes in levels of IL-1β in saliva in systemically healthy subjects with periodontitis 
reported significant reductions in IL-1β in saliva at month 4 in subjects receiving OHI 
alone and in subjects receiving NSM, although numerical values were not published and 
the data were presented graphically, preventing a direct comparison with data from the 
current study (Sexton et al., 2011). 
Finally, in the current study, in subjects with T2DM pre-treatment levels of IFN-
γ in saliva [0.86(0.47-1.60)pg/ml] were significantly reduced at month 3 [0.43 (0.25-
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0.78) pg/ml], although there was a significant increase at month 12 [1.61 (1.03-2.69) 
pg/ml]. In non-diabetic subjects, compared to pre-treatment levels [1.55 (0.86-2.24) 
pg/ml], saliva IFN-γ showed reductions at month 6 [0.83 (0.42-1.88) pg/ml] (detected as 
a trend following correction of p-values for multiple comparisons) (Table 6.9). 
However, levels of IFN-γ in saliva remained consistently around the lower limits of 
detection for the assay used and currently no published data is available for comparison. 
Overall, data from previous studies and the current study would appear to 
suggests that in subjects with periodontitis, a reduction in periodontal inflammation may 
be associated with a reductions in levels of TNF-α and IL-1β in saliva (Sexton et al., 
2011). This would suggest that selected salivary biomarkers may reflect the clinical 
response to periodontal therapy. However, further longitudinal studies would be 
required to clarify this. 
Changes in cytokines in GCF 
In subjects with T2DM, the current study demonstrated that pre-treatment GCF 
levels of IL-6 [1.97 (0.98-5.17) pg/ml] reduced significantly at month 3 [1.03 (0.51-
2.70) pg/ml], month 6 [0.89 (0.14-1.80)pg/ml] and month 12 [1.03 (0.34-2.17)pg/ml]. 
Also pre-treatment GCF levels of TNF-α [4.16 (2.72-6.69) pg/ml] also reduced 
significantly at month 3 [3.59 (1.28-10.37) pg/ml], month 6 [2.03 (0.65-3.80) pg/ml] 
and month 12 [1.74(0.96-3.45)pg/ml]. Similarly, pre-treatment GCF levels of IL-1β 
[344.33 (156.16-572.50) pg/ml] reduced significantly at month 3 [180.05 (68.98-
382.93) pg/ml], month 6 [116.35 (48.71-206.56) pg/ml] and month 12 [175.65 (58.54-
366.95) pg/ml]. Also, in T2DM subjects, the pre-treatment GCF level of IFN-γ [2.51 
(1.11-5.24) pg/ml] also showed a significant reduction but only at month 6 [0.85 (0.23-
1.89) pg/ml].  
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In non-diabetic subjects, the current study demonstrated that pre-treatment GCF 
levels of IL-1β [413.38 (213.83-770.56) pg/ml] reduced significantly at month 3 
[166.25 (90.85-350.75) pg/ml], month 6 [150.60 (77.56-268.32) pg/ml] and month 12 
[184.25 (77.51-291.71) pg/ml]. Also, pre-treatment GCF levels of IFN-γ [4.40 (2.18-
7.09) pg/ml] reduced significantly at months 3 [2.54 (0.92-4.87) pg/ml], month 6 [2.21 
(1.41-4.23) pg/ml] and month 12 [1.43 (0.50-2.46) pg/ml]. Also in non-diabetic 
subjects, pre-treatment GCF levels of IL-6 [2.25 (1.12-3.37) pg/ml] reduced 
significantly at month 6 [1.51 (0.94-2.34) pg/ml] and pre-treatment levels of TNF-α 
[4.49 (2.55-7.04) pg/ml] reduced significantly at month 12 [2.35 (1.09-3.55) pg/ml]. 
Overall, in both T2DM and non-diabetic subjects, reductions in GCF levels of these 4 
selected pro-inflammatory cytokines would appear to mirror the improvements in 
periodontal health seen within this study following periodontal therapy.  
Currently published data investigating the changes in pro-inflammatory 
cytokines levels in GCF following non-surgical periodontal therapy in T2DM subjects 
is limited to three studies (Correa et al., 2008; Kardesler et al., 2010; Santos et al., 
2010). In one study, the impact of NSM on levels of IL-1β was assessed in patients with 
(n=23) and without (n=26) T2DM (Correa et al., 2008). After treatment, a significant 
improvement in clinical periodontal parameters in both groups was accompanied by 
significant reductions in GCF volume and the total amount of IL-1β (Correa et al., 
2008). In another study, the periodontal treatment effects on GCF IL-6 levels in T2DM 
(n=20) and non-diabetic subjects (n=22) were evaluated (Kardesler et al., 2011). At 3 
months post-treatment, reductions in the total amount of GCF IL-6 were demonstrated 
graphically in both T2DM and non-diabetic subjects, however, these reductions failed to 
reach significance and this studies did not publish the actual values for the cytokine 
levels pre- and post-treatment, making interpretation of the results difficult (Kardesler et 
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al., 2011). In a further study, the response of TNF-α, IFN-γ, IL-4 and IL-17 in GCF was 
assessed in patients with well controlled T2DM (n=18) and in patients with poorly 
controlled T2DM (n=20) (Santos et al., 2010), showing no significant changes in the 
total amounts of TNF-α, IFN-γ, IL-4 and IL-17 in GCF at 3 and 6 months post-
treatment. Again, failure to publish the actual values for the cytokine levels pre- and 
post-treatment makes the interpretation of the results difficult. Furthermore, a lack of 
non-diabetic subjects limits possible conclusions about the response in subjects with 
T2DM compared to non-diabetic subjects.  
Given the paucity of the available data regarding changes in GCF cytokines 
following NSM in subjects with T2DM, it’s worthwhile comparing data from the 
present study to studies evaluating the cytokine response to periodontal therapy, in 
systemically healthy subjects (Engebretson et al., 2002; Thunell et al., 2010).  A follow-
up study of systemically healthy subjects (n=29) showed that following non-surgical 
periodontal treatment, in patients with mild to moderate periodontitis and in patients 
with severe periodontitis the IL-1β levels in GCF were reduced 2 weeks post-treatment 
(Engebretson et al., 2002). However, at 6 months, the significant post-treatment 
reduction in GCF IL-1β levels was maintained only in patients with mild-moderate 
periodontal disease, with IL-1β returning to baseline levels in patients with severe 
disease (Engebretson et al., 2002). In a more recent study, a multiplex immunoassay 
was used to evaluate the effect of periodontal therapy on a range of 22 GCF mediators, 
including IL-1β, IL-6, TNF-α and IFN-γ in a small number of systemically healthy 
subjects (n=6) (Thunell et al., 2010). Following periodontal therapy, significant 
reductions were detected in 13 of the 16 detectable cytokines, including IL-1β, IL-6 and 
IFN-γ. However, interestingly, TNF-α was not found to be detectable in the GCF 
samples taken in this study. 
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Overall, data from previous studies and the current study would appear to 
suggest that in subjects with periodontitis, regardless of diabetes status, a reduction in 
periodontal inflammation may be associated with a reductions in levels of IL-1β, and 
possibly IL-6, TNF-α and IFN-γ in GCF (Engebretson et al., 2002; Correa et al., 2008; 
Thunell et al., 2010). Notwithstanding the differences in storage and elution protocols 
used within this field of research, data would suggest that in subjects with and without 
T2DM, selected GCF biomarkers may reflect the clinical response to periodontal 
therapy. However, further longitudinal studies, using standardized protocols for GCF 
sampling, elution and storage, would be required to clarify this. 
 
Summary of key findings from chapter 6 
• At each time point BMI was significantly higher in subjects with T2DM 
compared to non-diabetic subjects. Also, in subjects with T2DM a significant 
reduction in BMI was seen following NSM. 
• In subjects with T2DM, HbA1c showed 0.45% and 0.40% reductions at month 3 
and month 12 respectively, although these reductions did not reach statistical 
significance. 
• At each time point HDL, non-HDL and cholesterol was significantly higher in 
non-diabetic subjects compared to subjects with T2DM. Also, in non-diabetic 
subjects a significant reduction in non-HDL and cholesterol was seen 6 months 
after NSM. 
• In both diabetic and non-diabetic subjects reductions in hsCRP were seen 12 
months after NSM, although these reductions did not reach statistical significance. 
6  Results 330
• In both diabetic and non-diabetic subjects significant reductions in % BOP, mGI, 
PI, mean PD, mean LOA, PESA and PISA were seen at 3, 6 and 12 months after 
NSM. Furthermore, mGI, % BOP, mean PD, mean LOA, PESA and PISA showed 
no significant differences between subjects with T2DM and non-diabetic subjects 
at any time point.  
• In both diabetic and non-diabetic subjects significant reductions in % PD sites ≥ 5 
mm were seen at 3, 6 and 12 months after NSM. Taking into account the pre-
treatment difference in % PD sites ≥ 5 mm, the differences between subjects with 
T2DM and non-diabetic subjects at month 3 and month 6 failed to reach 
significance. 
• The % of PD sites that reduced by ≥ 2 mm and ≥ 3 mm appeared higher in non-
diabetic subjects compared to subjects with T2DM, although the differences failed 
to reach statistical significance.  
• In subjects with T2DM serum TNF-α was significantly reduced 3 and 6 months 
after NSM. Conversely, in non-diabetic subjects serum TNF-α was significantly 
increased at 6 and 12 months after NSM. 
• In subjects with T2DM a reduction in IL-1β in saliva was seen at 3 months after 
NSM was detected as a trend. In non-diabetic subjects reductions in IL-1β in 
saliva were seen at 6 and 12 months, although these differences failed to reach 
statistical significance. 
• In both diabetic and non-diabetic subjects significant reductions in IL-1β in GCF 
were seen at 3, 6 and 12 months after NSM. Similarly, reductions in TNF-α and 
IL-6 in GCF were seen after NSM, although not at every time point. 
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Chapter 7 General Discussion 
Diabetes is widely accepted as a major public health problem, associated with 
reduced life expectancy, increased morbidity and increased mortality (IDF, 2006; 
Mulnier et al., 2006; Dale et al., 2008). Between 2007 and 2025, the global predicted 
growth is 55% (IDF, 2006) and a recent UK health survey projects a 98% increase in 
the rate of obesity related diabetes by 2050 (Brown et al., 2010). As a risk factor for 
periodontal disease, T2DM is associated with an increased incidence and severity of 
periodontal disease, with the risk for developing periodontitis being greater if diabetes 
control is poor (Nelson et al., 1990; Emrich et al., 1991; Taylor et al., 1998a; Tsai et al., 
2002; Moles, 2006).  Furthermore, evidence suggests that those with moderate levels of 
periodontal disease have a 2-fold increased risk for developing T2DM (Demmer et al., 
2008) and diabetics with severe periodontal disease are six times more likely to have 
poor glycaemic control (Taylor et al., 1996), highlighting a possible bi-directional 
relationship between these two disease. Given the predicated future increase in diabetes 
and the likely impact on the future prevalence of periodontal disease, understanding the 
mechanistic connections between the two diseases is of increasing importance to health 
care. 
In this study, subjects with gingivitis or periodontitis presented with a 
significantly longer history of diabetes compared to those with healthy periodontal 
tissues. Furthermore, a higher proportion of subjects with healthy periodontal tissues 
(64.3%) was found to meet the UK target for glycaemic control (HbA1c ≤ 6.5%) and 
progressively fewer subjects reached this target in the gingivitis (26.3%) and 
periodontitis (14.9%) groups, respectively. There was also a higher proportion of 
subjects with healthy periodontal tissues being managed by dietary intervention alone 
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and progressively fewer in the gingivitis and periodontitis groups, respectively. 
Conversely, a higher proportion of subjects with periodontitis (29.8%) required insulin, 
with progressively fewer subjects requiring insulin in the gingivitis (17.9%) and healthy 
periodontal tissues (0.0%) groups, respectively. Taken collectively, these findings 
highlight that the deterioration in glycaemic control appears to be mirrored by 
worsening periodontal health and that, as with other diabetes complications, the 
duration of diabetes and the degree of glycaemic control (UKPDS, 1998b) would appear 
to be important factors in the development of periodontitis in subjects with T2DM 
Within T2DM subjects, the risk of diabetic complications is strongly associated 
with previous hyperglycaemia and a 1% reduction in HbA1c has been associated with a 
21% risk reduction in diabetic complications (Stratton 2000). Consequently, national 
guidelines have therefore set an ideal target HbA1c of 6.5%, and recommend the use of 
dietary and lifestyle interventions, with medications, as required, to achieve and 
maintain this target HbA1c levels (NICE, 2008). A number of previous studies have 
investigated the impact of periodontal treatment on glycaemic control in subjects with 
T2DM (Stewart et al., 2001; Kiran et al., 2005; Promsudthi et al., 2005; Jones et al., 
2007; O'Connell et al., 2008) and meta-analyses of data from smaller interventional 
studies have concluded that periodontal treatment could improve glycaemic control 
(Darre et al., 2008; Simpson et al., 2010), with NSM producing a statistically 
significant 0.40% HbA1c reduction (p=0.04) when compared to no treatment or usual 
treatment (Simpson et al., 2010). Interestingly, a similar magnitude of change in HbA1c 
was demonstrated in the present study which showed that after NSM, in subjects with 
T2DM, HbA1c was reduced by 0.45% and 0.40% at month 3 and month 12 
respectively, although in the current study these reductions did not reach statistical 
significance. Given the potential for successful periodontal treatment to contribute to a 
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positive effect on glycaemic control, is it surprising that as yet, the maintenance of oral 
health does not currently feature within national management guidelines for T2DM 
(NICE, 2008).  It is hoped that the data from this study will contribute to future meta-
analyses to investigate this issue further. 
It is increasingly recognised that inflammation plays a role in the development 
of diabetes and the association between elevated systemic inflammation and the 
development of T2DM has been previously demonstrated (Bertoni et al., 2010). In 
subjects with T2DM, CRP has been proposed as a cardiovascular risk marker (Pfutzner 
and Forst, 2006) as well as a useful marker in predicting the risk of developing T2DM 
(Freeman et al., 2002; Duncan et al., 2003). In the current study, levels of hsCRP 
appeared higher in subjects with T2DM [2.3 (0.9-4.5) mg/l) compared to non-diabetic 
subjects [1.9 (0.8-3.9) mg/l), although the difference failed to achieve statistical 
significance. Interestingly, when subjects were further categorised based on periodontal 
status, subjects with T2DM and healthy periodontal tissues had significantly higher 
hsCRP [2.4 (0.8-5.5) mg/l) than non-diabetic subjects with healthy periodontal tissues 
[0.6 (0.2-1.5) mg/l). Evidence from a previously published meta-analysis also 
demonstrated that CRP is elevated in patients with periodontitis (Paraskevas et al., 
2008) and this was confirmed in the current study, which showed that in non-diabetic 
subjects, hsCRP was significantly lower in those with healthy periodontal tissues [0.6 
(0.2-1.5) mg/l) compared to subjects with gingivitis [2.3 (0.8-4.2) mg/l] or periodontitis 
[2.3 (1.1-4.3) mg/l], although in subjects with T2DM, similar differences in hsCRP 
were not found. This might be because the impact of T2DM on CRP levels outweighs 
any impact of periodontal inflammation. Furthermore, previous studies have 
demonstrated that reduction in CRP levels follows periodontal management (D'Aiuto et 
al., 2004; Marcaccini et al., 2009), although this is not a universal finding in the 
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literature (Ide et al., 2003), and the most recent meta-analysis concluded that moderate 
evidence exists for an effect of periodontal therapy in lowering the levels of CRP 
(Paraskevas et al., 2008). Within the current study, the effect of NSM on CRP levels 
was investigated in subjects with T2DM. In both diabetic and non-diabetic subjects non-
significant reductions in hsCRP were seen 12 months after NSM, confirming data from 
previous studies that also demonstrate non-significant reductions in hsCRP in subjects 
with T2DM (Christgau et al., 1998; Correa et al., 2010; Kardesler et al., 2010). The 
wide variations in CRP levels are likely to be due to the non-specific nature of CRP as a 
marker of inflammation and future studies investigating the impact of NSM on CRP 
levels in T2DM need to be adequately powered to account for such variation. 
Obesity is a powerful risk factor for T2DM (Chan et al., 1994), with BMI 
predicting the risk of T2DM (Wang et al., 2005) and obesity being proposed as the 
leading cause of insulin resistance (Kahn et al., 2006). The link between diabetes and 
obesity was demonstrated in the current study, which showed that, at each time point, 
subjects with T2DM had significantly higher BMI compared to the non-diabetic 
patients.  Furthermore, the T2DM group contained a higher proportion of obese (42.6 
%) and morbidly obese (30.7%) subjects compared to the non-diabetic group (10.8% 
and 13.3%, respectively). Interestingly, in subjects with T2DM a significant reduction 
in BMI was seen following NSM, although the contribution made by the higher drop 
out of obese and morbidly obese subjects seen over time makes it difficult to draw clear 
conclusions about actual weight loss following periodontal treatment.  
T2DM and hypertension are commonly associated conditions, both of which 
carry an increased risk of cardiovascular and renal disease (Garcia et al., 1974; Turner 
et al., 1998b). Despite evidence that tight control of BP in subjects with T2DM reduces 
diabetic complications (Turner et al., 1998a) and the clear guidance for the intensive 
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management of hypertension in subjects with T2DM (NICE, 2008), the present study 
demonstrates that systolic BP was significantly higher in subjects with T2DM (146.9 
mmHg) compared to non-diabetic subjects (136.6 mm Hg). This supports previous 
evidence showing higher prevalence of hypertension in T2DM patients than that 
observed in the general population (HDS, 1993).  
In subjects with T2DM, hyperlipidemia is a risk factor for CVD (NICE, 2008). 
Furthermore, an association between hyperlipidemia and periodontitis has previously 
been demonstrated (Cutler et al., 1999b; Losche et al., 2000; Noack et al., 2000; 
Fentoglu et al., 2009; Fentoglu et al., 2010) with hyperlipidemia described as one of the 
factors associated with diabetes-induced immune cell alterations (Iacopino and Cutler, 
2000). Data from the present study showed that levels of non-HDL and cholesterol were 
significantly higher in non-diabetic subjects compared to subjects with T2DM, although 
this is not surprising, given that the management of raised lipid levels is a key priority 
for diabetes management (NICE, 2008). In subjects with T2DM and periodontitis, no 
changes in lipid levels were demonstrated following NSM, corroborating data from 
previous studies (Christgau et al., 1998; Kiran et al., 2005; Kardesler et al., 2010) and 
perhaps reflecting that when raised serum lipid levels are already actively managed as 
part of T2DM treatment, further improvements are not gained through improvements in 
periodontal health. Interestingly, a significant reduction in non-HDL and cholesterol 
was seen 6 months after NSM in non-diabetic subjects, which supports data from a 
recent small study (Fentoglu et al., 2010), although an appropriately designed RCT 
would be required to confirm this. 
Previous epidemiological evidence has reported an increased prevalence and 
severity of periodontal disease in subjects with T2DM compared to non-diabetic 
subjects (Shlossman et al., 1990; Sandberg et al., 2000; Mattout et al., 2006; Moles, 
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2006). In more recent interventional studies evaluating the response to periodontal 
therapy, the pre-treatment periodontal condition of subjects with and without diabetes 
was well matched (Dag et al., 2009; Kardesler et al., 2010) or the T2DM subjects had 
higher levels of BOP and mean PD (Correa et al., 2008). In the current study, when 
exploring the pre-treatment periodontal status of subjects with T2DM in comparison to 
those without diabetes, no significant differences were found in the mean PD, mean 
recession and mean LOA in subjects with T2DM and periodontitis compared to non-
diabetic subjects with periodontitis. However, periodontal disease rarely affects all parts 
of the periodontium equally and whilst means provides a useful summary statistic of the 
data, they provide no specific information about the extent and severity of the 
periodontitis. In the current study, the percent of periodontal sites with PD ≥ 6 mm was 
significantly lower in subjects with T2DM and periodontitis compared to non-diabetic 
subjects with periodontitis, indicating more severe periodontal disease was present, at 
pre-treatment, in non-diabetic subjects compared to subjects with T2DM. This was 
contrary to previous epidemiological evidence (Shlossman et al., 1990; Sandberg et al., 
2000; Mattout et al., 2006; Moles, 2006) and was not replicated in the one previous 
study that supplemented the mean PD data with data on the percent of sites with 
advanced periodontal disease, and which showed no significant differences in the 
percent of periodontal sites with PD  ≥ 7 mm between subjects with T2DM and non-
diabetic subjects (Correa et al., 2008). This most probably reflects the differences in the 
recruitment pools used for diabetic and non-diabetic subjects in the current study (and 
must be regarded, unfortunately, as a weakness in this study) and highlights the need to 
stratify periodontal case selection based on extent and severity of disease to ensure more 
robust matching of groups with regards to periodontal status in future studies. 
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Given that inflammation within the periodontium has the potential to contribute 
to the systemic inflammatory burden (Loos, 2005) and thus influence the pathogenic 
mechanisms present in T2DM (Hotamisligil et al., 1996; Stumvoll et al., 2005), it is 
interesting to note that in the present study, higher levels of gingival inflammation were 
seen in subjects with T2DM and gingivitis compared to non-diabetic subjects with 
gingivitis, although this difference is not replicated in subjects with periodontitis. Given 
that periodontitis was more advanced in the non-diabetic group compared to the T2DM 
group, the gingivitis groups offer the potential to study in more detail the effect of 
diabetes on gingival/periodontal inflammation.  Given the tight criteria for defining 
gingivitis, the gingivitis patients in the T2DM and non-diabetic groups were very well 
matched from a clinical perspective.  These groups therefore offer utility to study the 
impact of diabetes on gingival inflammation. It is noteworthy that gingival 
inflammation was significantly higher in the T2DM group with gingivitis, compared to 
the non-diabetic patients with gingivitis, and this could possibly reflect up-regulated 
inflammation as a result of diabetes.  Interestingly, this concept is supported by the 
T2DM subjects with gingivitis having elevated levels of GCF IL-6 (1.44 (0.53-3.61) 
pg/ml), IL-1β (173.41 (77.60-268.19) pg/ml) and IFN-γ (2.17 (0.65-2.50) pg/ml) 
compared to the GCF levels of IL-6 (0.90 (0.39-2.12) pg/ml), IL-1β (116.25 (56.50-
176.53) pg/ml) and IFN-γ (1.85 (1.01-2.44) pg/ml) in the non-diabetic subjects with 
gingivitis, although these differences didn’t achieve statistical significance. 
The current study also showed that PESA was able to represent key aspects of 
the PD data, highlighting differences in PD between subjects with different periodontal 
status and detecting differences in the extent and severity of periodontal disease 
between T2DM and non-diabetic subjects. PISA also reflected the differences in 
periodontal case definitions within the current study and given that PISA incorporates 
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both BOP and PD data into a single variable, data from the present study confirms 
PESA and PISA as valuable measures of the extent of periodontal disease and the 
periodontal inflammatory burden (Nesse et al., 2008; Nesse et al., 2009). 
In the current study, both diabetic and non-diabetic subjects demonstrated 
significant reductions in % BOP, mGI, PI, mean PD, mean LOA, PESA and PISA at 3, 
6 and 12 months after NSM. Furthermore, when diabetic and non-diabetic subjects were 
compared at each time point, no significant differences were identified in mGI, % BOP, 
mean PD, mean LOA, PESA and PISA. This supports previous research that has 
demonstrated significant improvements in clinical periodontal parameters following 
periodontal management in subjects with T2DM (Rodrigues et al., 2003; Kiran et al., 
2005; Correa et al., 2008; O'Connell et al., 2008; Dag et al., 2009; Correa et al., 2010; 
Kardesler et al., 2010; Santos et al., 2010; Kardesler et al., 2011). In both diabetic and 
non-diabetic subjects, the current study also showed significant reductions in % PD sites 
≥ 5 mm at 3, 6 and 12 months after NSM, and taking into account the pre-treatment 
differences in % PD sites ≥ 5 mm, the differences between subjects with T2DM and 
non-diabetic subjects at month 3 and month 6 failed to reach statistical significance. 
This confirms previous research that demonstrates significant reductions in the % of PD 
sites exhibiting advanced disease following NSM in subjects with T2DM (Correa et al., 
2008; Correa et al., 2010). The present study also showed that the % of PD sites that 
reduced by ≥ 2 mm and ≥ 3 mm appeared higher in non-diabetic subjects compared to 
subjects with T2DM, although the differences failed to reach statistical significance. 
Given that greater reductions in PD are seen in deeper pockets after NSM (Cobb, 2002), 
the apparently higher % of PD sites reducing by ≥ 2 mm and ≥ 3 mm seen in the non-
diabetic subjects most probably reflects the increased severity of  periodontal disease 
seen in non-diabetic subjects at baseline. Overall, the current study confirms that NSM 
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is effective in managing periodontitis in subjects with T2DM, and highlights the need 
for robust patient pathways to ensure delivery and uptake of periodontal screening, 
supplemented with therapy as required, within this disease susceptible population 
In the current study, the group with T2DM contained a significantly higher 
percent of subjects with dry mouth compared to those without diabetes and the 
percentage of subjects with at least one carious tooth was over 4 times greater in 
subjects with T2DM compared to non-diabetic subjects, confirming data from previous 
studies that have highlighted poorer oral health in subjects with T2DM (Sandberg et al., 
2000; Hintao et al., 2007; Borges et al., 2010). Furthermore, in the present study, the 
T2DM group reported poorer oral health behaviours (including attendance at a dentist 
and oral hygiene practices) compared to the non-diabetic group. This corroborates 
previous research that demonstrates that the attitudes towards oral health of patients 
with diabetes are poor in comparison with findings from surveys of general populations 
(Allen et al., 2008). In the current study, 95% of subjects with T2DM had received 
examinations of their feet and eyes within the past 12 months, clearly demonstrating the 
robust patient pathways that exist for screening for diabetic complications such as 
retinopathy and peripheral vascular disease. However, the same is not true regarding 
screening for oral complications in subjects with T2DM, with as many as one third of 
subjects with T2DM in this study reporting not seeing a dentist in the past 12 months. 
This clearly demonstrates that the opportunity for screening for oral complications is 
not currently taken up by all subjects within this disease-susceptible population. Taken 
collectively, this emphasises the importance of considering oral health within a wider 
perspective of maintaining systemic health, and the need for more robust care pathways 
to ensure good oral health in disease susceptible patients. 
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The role of inflammatory cytokines in the pathogenesis of periodontal disease  is 
well recognised (Preshaw and Taylor, 2011). Likewise, inflammatory cytokines are key 
players in the relationship between inflammation and T2DM with cytokines, such as 
TNF-α, IL-1β and IL-6, contributing to the development of T2DM through obesity, 
insulin resistance and β-cell dysfunction (Donath et al., 2003; Pickup, 2004; Wellen and 
Hotamisligil, 2005). It is proposed that alterations in immunologically active molecules 
as a result of T2DM have the potential to influence the cytokine network within the 
periodontium and thus contribute to local periodontal tissue destruction (Preshaw et al., 
2007). Furthermore, inflammation within the periodontium has the potential to 
contribute to the systemic inflammatory burden present in T2DM (Loos, 2005; Nesse et 
al., 2009).  It is therefore surprising that, until very recently, relatively few studies have 
investigated the role of inflammatory cytokines in patients with T2DM and periodontal 
disease (Cutler et al., 1999a; Engebretson et al., 2007; Correa et al., 2008; Dag et al., 
2009; Correa et al., 2010; Kardesler et al., 2010; Santos et al., 2010).  
Previous research demonstrates significantly higher serum levels of IL-6 and 
TNF-α in subjects with T2DM compared to non-diabetic subjects (Pradhan et al., 2001; 
Spranger et al., 2003b; Bertoni et al., 2010) and this was supported in the current study, 
which showed significantly higher serum levels of TNF-α, IL-1β and IFN-γ in subjects 
with T2DM compared to non-diabetic subjects and significantly higher serum levels of 
TNF-α, IL-1β and IFN-γ in T2DM subjects with periodontitis compared to non-diabetic 
subjects with periodontitis. Interestingly, in the present study, in subjects with T2DM 
and periodontitis, serum TNF-α was significantly reduced 3 and 6 months after NSM, 
supporting previously published data demonstrating  short term reductions in circulating 
TNF-α after periodontal therapy in subjects with T2DM (Iwamoto et al., 2001; Correa 
et al., 2008; Dag et al., 2009). Given the role of TNF-α in the pathogenesis of T2DM, 
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reductions in circulating TNF-α following NSM may, in part, explain the improvements 
in glycaemic control seen in subjects with T2DM after periodontal therapy. Conversely, 
in the current study, serum TNF-α was significantly increased at 6 and 12 months after 
NSM in non-diabetic subjects, with relatively low pre-treatment serum TNF-α levels 
being demonstrated in these subjects, potentially contributing to this apparent increase 
after NSM. Additionally, it would appear that data from the current study don’t support 
the published evidence that subjects with periodontitis have higher levels of circulating 
inflammatory cytokines (Marcaccini et al., 2009; Sun et al., 2009) with significantly 
lower serum TNF-α, IL-1β and IFN-γ demonstrated in non-diabetic subjects with 
periodontitis compared to subjects with healthy periodontal tissues. However, low 
levels of cytokines present in serum (at the limits of detection of even the high 
sensitivity assay system used in this research), along with variations in levels, make it 
difficult to interpret results and prevent clear conclusions from being made. To clarify 
the role of circulating inflammatory cytokines in the relationship between T2DM and 
periodontitis, further studies with larger sample size would be required. 
Our understanding of the specific roles of cytokines in periodontal disease is 
deepest for pro-inflammatory cytokines, for example IL-1β, IL-6 and TNF-α (Preshaw 
and Taylor, 2011) and previous data demonstrated increased levels of IL-1β and IL-6 in 
GCF from subjects with periodontitis (Preiss and Meyle, 1994; Figueredo et al., 1999; 
Engebretson et al., 2002; Zhong et al., 2007) and in GCF sampled from diseased sites 
compared with healthy sites (Mogi et al., 1999; Lin et al., 2005; Thunell et al., 2010). 
This is supported by data from the present study which demonstrated significantly 
higher GCF IL-1β in diabetic subjects with periodontitis [344.33 (156.16-572-50) 
pg/ml] compared to those with those with gingivitis [173.41 (77.60-268.19) pg/ml) and 
also those with healthy periodontal tissues [84.95 (40.66-130.61) pg/ml]. Similarly, 
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significantly higher GCF IL-1β was demonstrated in non-diabetic subjects with 
periodontitis [413.38 (213.84-770.56) pg/ml] compared to those with those with 
gingivitis [116.25 (56.50-176.53) pg/ml) and also those with healthy periodontal tissues 
[54.26 (25.79-100.65) pg/ml]. Also in non-diabetic subjects, significantly higher levels 
of GCF IL-6, TNF-α and IFN-γ were demonstrated in subjects with periodontitis 
compared to those with healthy periodontal tissues and in subjects with T2DM the same 
differences were detected as a trend. This confirms the utility of GCF IL-6, TNF-α, 
INF-γ and particularly IL-1β as indicators of inflammatory status in the periodontal 
tissues. Additionally, the findings of elevated circulating levels of these cytokines in 
T2DM patients and the less clear-cut finding of elevated GCF cytokines in T2DM 
patients with gingivitis may be a reflection of the underlying alterations to inflammatory 
networks that result from the diabetic state.   
In the current study, no significant differences in GCF IL-6, TNF-α, IL-1β and 
IFN-γ levels were found between subjects with T2DM and non-diabetic subjects, and 
even following categorisation based on periodontal status, in non-diabetic subjects with 
periodontitis the apparently higher levels of GCF IL-6, TNF-α and IL-1β compared to 
T2DM subjects with periodontitis failed to reach statistical significance. This supports 
previous data that showed no differences in pre-treatment IL-1β levels between subjects 
with and without T2DM (Correa et al., 2008) but doesn’t support the findings of a 
further study that demonstrated higher levels of GCF IL-6 in T2DM subjects with 
periodontitis compared to non-diabetic subjects with periodontitis (Kardesler et al., 
2011). In the current study, the higher levels, albeit non-significant, of GCF cytokines in 
non-diabetic subjects with periodontitis compared to subjects with T2DM and 
periodontitis, may well be a reflection of the more severe periodontal disease that was 
present in non-diabetic subjects compared to the subjects with T2DM.  
7  General Discussion 343
The relationship between increasing levels of pro-inflammatory cytokines in 
GCF and the presence of periodontal disease is further supported by significant positive 
correlations that were consistently demonstrated in the current study between mGI, 
mean PD, PESA and PISA and GCF levels of IL-6, TNF-α and IL-1β. Furthermore, the 
current study also demonstrated that GCF levels of IL-1β and IFN-γ were significant 
predictors of PISA, and a trend for GCF TNF-α levels as a predictor of PISA was also 
noted. Data from the current study therefore corroborate published research that 
demonstrated significant positive correlations between GCF levels of IL-1β and clinical 
periodontal parameters in subjects with T2DM (Engebretson et al., 2004; Engebretson 
et al., 2007). 
Previous studies investigating the impact of periodontal therapy on GCF 
cytokine levels demonstrated significant reductions in GCF IL-1β, IL-6 and IFN-γ post-
treatment (Engebretson et al., 2002; Thunell et al., 2010). Additionally, in patients 
withT2DM, although one study demonstrated significant reductions in IL-1β (Correa et 
al., 2008), others showed a non-significant reduction in GCF IL-6 (Kardesler et al., 
2011) or no significant changes in GCF TNF-α after NSM (Santos et al., 2010). In the 
current study, GCF samples from both diabetic and non-diabetic subjects showed 
significant reductions in IL-1β at 3, 6 and 12 months after NSM. Similarly, reductions 
in TNF-α and IL-6 in GCF were seen after NSM, although not at every time point. 
Overall, in both T2DM and non-diabetic subjects, reductions in GCF levels of selected 
pro-inflammatory cytokines would appear to mirror improvements in periodontal health 
seen following NSM.  
It is now recognised that biomarkers in saliva have the potential to provide 
information to aid in the diagnosis and monitoring of periodontal disease (Miller et al., 
2010). Published data demonstrated higher levels of Il-1β in saliva from subjects with 
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periodontitis compared to those without periodontitis (Miller et al., 2006; Gursoy et al., 
2009), and this is mirrored in the current study which showed that IL-1β levels in saliva 
were significantly higher in subjects with periodontitis compared to those with healthy 
periodontal tissues, in both diabetic and non-diabetic subjects. This would suggest that 
levels of IL-1β in saliva reflect the periodontal status. Similarly, IL-6 in saliva was 
significantly higher in subjects with periodontitis compared to those with healthy 
periodontal tissues, but the picture is less clear with differences only demonstrated in 
subjects with T2DM. Interestingly, when pre-treatment levels of cytokines in saliva 
from subjects with T2DM were compared to levels from non-diabetic subjects, TNF-α, 
IL-1β and IFN-γ were significantly higher in non-diabetic subjects compared to subjects 
with T2DM, most likely reflecting the more severe periodontal disease present in the 
non-diabetic subjects compared to subjects with T2DM seen in the current study. 
Significant positive correlations were also found in the current study between mGI, % 
BOP, PESA and PISA and saliva levels of IL-6 and IL-1β. Furthermore, salivary levels 
of IL-6 and IL-1β were significant predictors of PISA. This corroborates published 
research that demonstrated significant positive correlations between levels of IL-1β in 
saliva and clinical periodontal parameters (Miller et al., 2006; Tobon-Arroyave et al., 
2008; Gursoy et al., 2009), and reflects the potential importance of saliva as a 
diagnostic fluid for periodontal disease. 
One previous study has demonstrated significant reductions in IL-1β in saliva 
after NSM (Sexton et al., 2011). In the present study, a reduction in IL-1β in saliva was 
detected as a trend at 3 months after NSM in subjects with T2DM, and non-significant 
reductions in IL-1β in saliva were seen at 6 and 12 months in non-diabetic subjects. 
Taken collectively, it would suggest that IL-1β may reflect the clinical response to 
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periodontal therapy, although clearly, further investigations are warrant to confirm 
whether IL-1β in saliva is a useful biomarker for periodontitis. 
In conclusion, the findings of the present study contribute to the knowledge of the 
clinical and biological response to periodontal therapy, both in diabetic and non-diabetic 
patients. Moreover, the current study highlights the importance of studying pro-
inflammatory cytokines in both periodontal disease and diabetes, and more specifically, 
pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β show potential as 
contributors to the pathogenic links between diabetes and periodontal disease, with the 
consideration of IL-1β in saliva and GCF as a prognostic marker for periodontitis in 
individuals with and without diabetes.  It is encouraging that a reduction in HbA1c was 
observed following periodontal therapy in the diabetic patient group, although this 
failed to achieve statistical significance.  Additional research is warranted to investigate 
this further, ensuring that groups are well matched for periodontal status. 
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